Familial hypercholesterolaemia: identification and management. Evidence reviews for case-finding, diagnosis and statin monotherapy by Pilling, S et al.
  
  
National Institute for Health and Care 
Excellence 
 
 
Document information (version number/stage of process) 
     
Familial 
hypercholesterolaemia: 
identification and management 
Evidence reviews for case-finding, 
diagnosis and statin monotherapy 
NICE guideline CG71  
Evidence reviews 
[November 2017] 
Final 
  
These evidence reviews were developed 
by NICE’s Guideline Updates Team 
Final 
 2 
 
  
 
Disclaimer 
Healthcare professionals are expected to take NICE clinical guidelines fully into account 
when exercising their clinical judgement. However, the guidance does not override the 
responsibility of healthcare professionals to make decisions appropriate to the circumstances 
of each patient, in consultation with the patient and, where appropriate, their guardian or 
carer. 
 
Copyright 
© NICE 2017. All rights reserved. Subject to Notice of rights. 
 
 
 3 
 
Clinical Guideline 71.1 (Familial Hypercholesterolaemia) 
 
Contents 
Clinical guidelines update .................................................................................................. 8 
1 Summary section.......................................................................................................... 9 
1.1 Update information ................................................................................................ 9 
1.2 Recommendations .............................................................................................. 10 
1.3 Patient-centred care ............................................................................................ 12 
1.4 Methods .............................................................................................................. 12 
2 Evidence review and recommendations: case-finding ............................................ 13 
2.1 Introduction ......................................................................................................... 13 
2.2 Review question .................................................................................................. 13 
2.3 Clinical evidence review ...................................................................................... 14 
2.3.1 Methods ................................................................................................... 14 
2.3.2 Results ..................................................................................................... 14 
2.4 Health economic evidence review (case finding) ................................................. 22 
2.4.1 Methods ................................................................................................... 22 
2.4.2 Results of the economic literature review ................................................. 25 
2.4.3 Economic modelling ................................................................................. 26 
2.5 Evidence statements ........................................................................................... 33 
2.5.1 Clinical evidence statement ...................................................................... 33 
2.5.2 Health economic evidence statements ..................................................... 35 
2.6 Evidence to recommendations ............................................................................ 35 
2.7 Recommendations .............................................................................................. 41 
2.8 Research recommendations ................................................................................ 42 
2.8.1 Using different thresholds of low-density lipoprotein cholesterol 
concentration in primary care case-finding ............................................... 42 
2.8.2 Evaluate the benefits of different search strategies in secondary care 
case finding .............................................................................................. 43 
2.8.3 Evaluate the efficacy of direct and indirect cascade testing ...................... 44 
3 Evidence review and recommendations: Diagnosis ................................................ 46 
3.1 Introduction ......................................................................................................... 46 
3.2 Review question .................................................................................................. 46 
3.3 Clinical evidence review ...................................................................................... 46 
3.3.1 Methods ................................................................................................... 46 
3.3.2 Results ..................................................................................................... 47 
3.4 Health economic evidence (diagnosis) ................................................................ 50 
3.4.1 Methods ................................................................................................... 50 
3.4.2 Results of the economic literature review ................................................. 50 
3.4.3 Economic modelling ................................................................................. 50 
3.5 Evidence statements ........................................................................................... 50 
 4 
 
3.5.1 Clinical evidence statements .................................................................... 50 
3.5.2 Health economic evidence statements ..................................................... 51 
3.6 Evidence to recommendations ............................................................................ 51 
3.7 Recommendations .............................................................................................. 53 
3.8 Research recommendations ................................................................................ 53 
3.8.1 Compare the Simon Broome criteria and the DLCN score in a 
prospective cohort of general population subjects. ................................... 53 
4 Evidence review and recommendations: Management (Statin monotherapy) ....... 55 
4.1 Introduction ......................................................................................................... 55 
4.2 Review question .................................................................................................. 55 
4.3 Clinical evidence review ...................................................................................... 55 
4.3.1 Methods ................................................................................................... 55 
4.3.2 Results ..................................................................................................... 55 
4.4 Health economic evidence (statin monotherapy) ................................................. 58 
4.4.1 Methods ................................................................................................... 58 
4.4.2 Results of the economic literature review ................................................. 58 
4.5 Evidence statements ........................................................................................... 58 
4.5.1 Clinical evidence statements .................................................................... 58 
4.5.2 Health economic evidence statements ..................................................... 59 
4.6 Evidence to recommendations ............................................................................ 60 
4.7 Recommendations .............................................................................................. 62 
4.8 Research recommendations ................................................................................ 63 
4.8.1 Long-term monitoring of sub-clinical atherosclerosis in children with FH 
who are treated with statin therapy ........................................................... 63 
5 References .................................................................................................................. 64 
5.1 Clinical studies .................................................................................................... 64 
5.1.1 Case finding ............................................................................................. 64 
5.1.2 Diagnosis ................................................................................................. 66 
5.1.3 Management (statin monotherapy) ........................................................... 67 
5.2 Economic studies ................................................................................................ 67 
5.2.1 Studies included in case finding review question ...................................... 67 
5.2.2 Economic modelling report ....................................................................... 68 
6 Glossary and abbreviations ....................................................................................... 70 
6.1 Glossary .............................................................................................................. 70 
6.2 Abbreviations ...................................................................................................... 71 
Appendices ........................................................................................................................ 73 
Appendix A: Standing Committee members and NICE teams .................................... 73 
A.1 Core standing members ............................................................................... 73 
A.2 Condition specific standing members ........................................................... 73 
A.3 Topic expert members .................................................................................. 73 
 5 
 
A.4 NICE project team ........................................................................................ 73 
A.5 Clinical guidelines update team .................................................................... 74 
Appendix B: Declarations of interest .......................................................................... 75 
Appendix C: Review protocol ..................................................................................... 76 
C.1 Case finding ................................................................................................. 76 
C.2 Diagnosis...................................................................................................... 80 
C.3 Management (statin monotherapy) ............................................................... 84 
Appendix D: Search strategy ..................................................................................... 91 
D.1 Case-finding ................................................................................................. 91 
D.2 Diagnosis...................................................................................................... 92 
D.3 Management (statin monotherapy) ............................................................... 94 
Appendix E: Review flowchart.................................................................................... 96 
E.1 Case-finding ................................................................................................. 96 
E.2 Diagnosis...................................................................................................... 96 
E.3 Management (statin monotherapy) ............................................................... 97 
Appendix F: Excluded studies.................................................................................... 98 
F.1 Case finding ................................................................................................. 98 
F.2 Diagnosis.................................................................................................... 102 
F.3 Management (statin monotherapy) ............................................................. 106 
Appendix G: Evidence tables ................................................................................... 109 
G.1 Case finding ............................................................................................... 109 
G.1.1 Cascade testing ............................................................................ 109 
G.1.2 Primary care ................................................................................. 129 
G.1.3 Secondary care ............................................................................. 140 
G.2 Diagnosis.................................................................................................... 168 
G.3 Management (statin monotherapy) ............................................................. 170 
Appendix H: Forest plots .......................................................................................... 174 
H.1 Case finding ............................................................................................... 174 
H.2 Diagnosis.................................................................................................... 174 
H.3 Management (statin monotherapy) ............................................................. 179 
Appendix I: GRADE profiles ................................................................................... 183 
I.1 Case-finding ............................................................................................... 183 
I.1.1 Cascade testing ............................................................................ 183 
I.1.2 Primary care ................................................................................. 185 
I.1.3 Secondary care ............................................................................. 186 
I.2 Diagnosis.................................................................................................... 189 
I.3 Management (statin monotherapy) ............................................................. 191 
Appendix J: Economic search strategy .................................................................... 193 
J.1 Case finding ............................................................................................... 193 
J.2 Diagnosis.................................................................................................... 198 
 6 
 
J.3 Management (statin monotherapy) ............................................................. 200 
Appendix K: Economic review flowchart .................................................................. 203 
K.1 Case finding ............................................................................................... 203 
K.2 Diagnosis.................................................................................................... 204 
K.3 Management (statin monotherapy) ............................................................. 204 
Appendix L: Economic excluded studies ................................................................. 205 
L.1 Case finding ............................................................................................... 205 
L.2 Diagnosis.................................................................................................... 206 
L.3 Management (statin monotherapy) ............................................................. 206 
Appendix M: Full economic evidence tables ............................................................. 207 
Appendix N: Quality assessment checklists for economic studies ............................ 220 
Appendix O: Cost-utility analysis of strategies to identify and diagnose familial 
hypercholesterolaemia ......................................................................... 228 
O.1 Introduction ................................................................................................. 228 
O.2 Model overview........................................................................................... 229 
O.2.1 Interventions ................................................................................. 229 
O.2.2 Population ..................................................................................... 230 
O.2.3 Pathways ...................................................................................... 230 
O.2.4 Structure ....................................................................................... 233 
O.2.5 Time horizon, perspective and discount rate ................................. 240 
O.2.6 Outcomes ..................................................................................... 240 
O.2.7 Assumptions ................................................................................. 240 
O.3 Input parameters ........................................................................................ 241 
O.3.1 Identification and diagnosis module .............................................. 241 
O.3.2 Long term costs and QALYs for treated and untreated polygenic 
hypercholesterolaemia .................................................................. 254 
O.3.3 Long term costs and QALYs for treated and untreated familial 
hypercholesterolaemia .................................................................. 256 
O.3.4 Expected long term costs and QALYs, FH and polygenic ............. 260 
O.3.5 Sensitivity analysis ........................................................................ 261 
O.3.6 Probabilistic sensitivity anlaysis .................................................... 262 
O.4 Results ....................................................................................................... 264 
O.4.1 Base case, total short term economic cost .................................... 269 
O.4.2 One way sensitivity analysis ......................................................... 274 
O.4.3 Detailed scenario analysis: Strategy 9, ensure everyone with high 
cholesterol in primary care are treated with lipid modification 
regardless of FH status (no genetic testing) .................................. 278 
O.4.4 Detailed scenario analysis: ‘Definite’ clinical assessments only 
referred for genetic testing ............................................................ 282 
O.4.5 Detailed scenario analysis: Alternative thresholds for searching 
primary care databases................................................................. 284 
O.4.6 Detailed scenario analysis: SAFEHEART Data ............................. 287 
 7 
 
O.4.7 Probabilistic sensitivity analysis .................................................... 289 
O.5 Discussion .................................................................................................. 292 
O.6 Conclusion .................................................................................................. 293 
O.6.1 Alternative thresholds for case-finding .......................................... 293 
 
 
 8 
 
Clinical guidelines update 
The NICE clinical guidelines update team update discrete parts of published clinical 
guidelines as requested by NICE’s Guidance Executive.  
Suitable topics for update are identified through the surveillance programme (see 
surveillance programme interim guide).  
These guidelines are updated using a standing committee of healthcare professionals, 
research methodologists and lay members from a range of disciplines and localities. For the 
duration of the update the 5 core standing members of the committee are usually joined by 
up to 5 condition specific standing members and by a further 5 additional members who are 
have specific expertise in the topic being updated, hereafter referred to as ‘topic expert 
members’.  
In this document where ‘the committee’ is referred to, this means the entire committee, both 
the standing members and topic expert members. 
Where ‘standing committee members’ is referred to, this means the core standing members 
of the committee only. 
Where ‘topic expert members’ is referred to this means the recruited group of members with 
topic expertise.  
Where ‘condition specific standing members’ are referred to, this means the condition 
specific standing members of the committee only.  
All of the standing members and the topic expert members are fully voting members of the 
committee. 
Details of the committee membership and the NICE team can be found in Appendix A:. The 
committee members’ declarations of interest can be found via Appendix B:.
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1 Summary section 
1.1 Update information 
The NICE guideline on familial hypercholesterolaemia (NICE clinical guideline CG71) was 
reviewed in June 2015 as part of NICE’s routine surveillance programme to decide whether it 
required updating. The surveillance report identified new evidence relating to the use of different 
methods for the identification of familial hypercholesterolaemia (FH), updated methods for 
diagnosing FH and more information on the cost effectiveness of statins in the treatment of FH. 
The full surveillance report can be found here. 
Some recommendations can be made with more certainty than others. The committee makes a 
recommendation based on the trade-off between the benefits and harms of an intervention, 
taking into account the quality of the underpinning evidence. For some interventions, the 
committee is confident that, given the information it has looked at, most people would choose 
the intervention. The wording used in the recommendations in this guideline denotes the 
certainty with which the recommendation is made (the strength of the recommendation). 
For all recommendations, NICE expects that there is discussion with the person about the risks 
and benefits of the interventions, and their values and preferences. This discussion aims to help 
them to reach a fully informed decision (see also ‘Patient-centred care’).  
Recommendations that must (or must not) be followed 
We usually use ‘must’ or ‘must not’ only if there is a legal duty to apply the recommendation. 
Occasionally we use ‘must’ (or ‘must not’) if the consequences of not following the 
recommendation could be extremely serious or potentially life threatening. 
Recommendations that should (or should not) be followed– a ‘strong’ recommendation 
We use ‘offer’ (and similar words such as ‘refer’ or ‘advise’) when we are confident that, for the 
vast majority of people, following a recommendation will do more good than harm, and be cost 
effective. We use similar forms of words (for example, ‘Do not offer…’) when we are confident 
that actions will not be of benefit for most people. 
Recommendations that could be followed 
We use ‘consider’ when we are confident that following a recommendation will do more good 
than harm for most people, and be cost effective, but other options may be similarly cost 
effective. The course of action is more likely to depend on the person’s values and preferences 
than for a strong recommendation, and so the healthcare professional should spend more time 
considering and discussing the options with the person. 
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1.2 Recommendations 
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1. Suspect familial hypercholesterolaemia (FH) as a possible diagnosis in adults 
with: 
 a total cholesterol level greater than 7.5 mmol/l and/or 
 a personal or family history of premature coronary heart disease1 (an 
event before 60 years in an index individual or first-degree relative). 
[2008, amended 2017] 
2. Systematically search primary care records for people: 
 younger than 30 years, with a total cholesterol concentration greater 
than 7.5 mmol/l and 
 30 years or older, with a total cholesterol concentration greater than 
9.0 mmol/l 
as these are the people who are at highest risk of FH. [2017] 
3. For people with a personal or family history of premature coronary heart 
disease1 (an event before 60 years in an index individual or first-degree relative), 
but whose total cholesterol is unknown, offer to measure their total cholesterol. 
[2017] 
4. Carry out cascade testing using DNA testing to identify affected first-and 
second-and, when possible, third-degree biological relatives of people with a 
genetic diagnosis of FH. [2017]  
5. In children aged 0-10 years at risk of FH because of one affected parent, offer a 
DNA test at the earliest opportunity. If testing of a child at risk has not been 
undertaken by the age of 10 years, offer an additional opportunity for a DNA 
test. [2017]  
6. Use the Simon Broome or Dutch Lipid Clinic Network (DLCN) criteria to make a 
clinical diagnosis of FH in primary care settings. This should be done by a 
healthcare professional competent in using the criteria. [2017] 
7. Refer the person to an FH specialist service for DNA testing if they meet the 
Simon Broome criteria for possible or definite FH, or they have a DLCN score 
greater than 5. [2017] 
8. Inform all people who have an identified mutation diagnostic of FH that they 
have an unequivocal diagnosis of FH even if their LDL-C concentration does not 
meet the diagnostic criteria (see recommendation 6). [2008, amended 2017] 
9. Offer a high-intensity statin with the lowest acquistion cost as the initial 
treatment for all adults with FH and aim for at least a 50% reduction in LDL-C 
concentration from the baseline measurement. [2017]  
10. Offer statins to children with FH by the age of 10 years or at the earliest 
opportunity thereafter. [2017] 
11. For children and young people with FH, consider a statin that is licensed for use 
in the appropriate age group. [2017] 
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1.3 Patient-centred care 
This guideline offers best practice advice on the care of people with familial 
hypercholesterolaemia. 
People have the right to be involved in discussions and make informed decisions about their 
care, as described in your care. 
NICE has also produced guidance on the components of good patient experience in adult NHS 
services. All healthcare professionals should follow the recommendations in Patient experience 
in adult NHS services.  
1.4 Methods 
This update was developed based on the process and methods described in the Developing 
NICE guidelines: the manual. Specific methods used in addressing each question are detailed 
in the respective evidence reviews and review protocols. 
                                               
1 angina, acute coronary syndrome, myocardial infarction, need for coronary artery bypass grafting, need for 
percutaneous coronary intervention and/or definite coronary artery disease on coronary angiography 
12. Statin therapy for children and young people should be initiated by a healthcare 
professional with expertise in treating children and young people with FH, and 
in a child-focused setting. [2008, amended 2017] 
13. Coronary heart disease risk estimation tools, such as QRISK2 and those based 
on the Framingham algorithm, should not be used because people with FH are 
already at a high risk of premature coronary heart disease. [2008, amended 
2017] 
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2 Evidence review and recommendations: 
case-finding 
2.1 Introduction 
Familial Hypercholesterolaemia (FH) is characterised by an inherited genetic defect (or 
mutation) which causes a high cholesterol concentration from birth. This may lead to early 
development of atherosclerosis and coronary heart disease. Familial hypercholesterolaemia has 
an autosomal dominant pattern of inheritance; siblings and children of people with FH have a 
50% risk of inheriting FH.  
The combination of tests used to identify individuals with FH depends upon whether the 
diagnosis is of an individual with FH from a registry or database or identifying FH in relatives of 
an individual with FH (also known as index case) through cascade testing. Cascade testing is a 
mechanism for identifying people at risk of a genetic condition by a process of family tracing. 
Cascade testing can be direct or indirect: Direct cascade testing is where a healthcare 
professional makes direct contact with the relatives of the index case already diagnosed with (or 
identified as having ) FH; indirect cascade testing is where the index case contacts their own 
relatives themselves. 
Diagnosis of FH in an index individual can be based on the Simon Broome criteria, Dutch Lipid 
Network Criteria, MEDPED or LDL-cholesterol concentration. In families in which a mutation has 
been identified, the mutation and not LDL-C concentration should be used to identify affected 
relatives. Diagnosis of FH in a relative of the index case where a family mutation has not been 
identified is based on gender and age specific LDL-C criteria, (Appendix F of CG71). 
Identification by cholesterol levels alone is not always accurate and therefore DNA testing is the 
gold standard for identification of FH. 
Evidence from the surveillance review suggested that cascade testing may now be more cost-
effective than stated in the original guideline. The predicted improvement in cost effectiveness 
may be due to atorvastatin coming off patent, reduced costs of DNA testing and more people 
with FH being cared for in the community. It has been identified that the prevalence of FH 
appears to be higher than commonly reported, implying that there is even more under-diagnosis 
and under-treatment than previously thought, which in turn may have led to an underestimation 
of the benefits of cascade testing in the original guideline. 
 Cascade testing was recommended in the original guideline and was cost effective, but was not 
widely implemented. Therefore, there may now be other strategies which are more efficient and 
cost effective, and the evidence on this should be updated.  
2.2 Review question 
What is the clinical and cost-effectiveness of using the following strategies for identifying people 
with FH through: 
 Primary care electronic databases to identify people with 
o history of early myocardial infarction (MI) (<60 years) and hypercholesterolemia  
o family history of ischemic heart disease and hypercholesterolemia or;  
 Secondary care electronic databases  
o within cardiac care facilities or cardiac investigation units to identify people with history of 
early MI (<60 years) and hypercholesterolemia or  
 14 
 
o within pathology departments to identify people through pathology databases with history 
of early MI (<60 years) and hypercholesterolemia  
 Direct and Indirect cascade testing (including reverse cascade testing)? 
2.3 Clinical evidence review 
2.3.1 Methods 
This review was conducted according to the process outlined in the review protocol (see 
Appendix C.2), with the following exceptions: 
Results 
The results for diagnostic yield were reported as median values because the data was expected 
not to be normally distributed. Where 3 or more studies reported a diagnostic yield median and 
range were reported; where 2 studies reported diagnostic yield, only the range was reported. 
Where only a single study reported the diagnostic yield, the single outcome from that study is 
reported in the modified GRADE table and evidence statements. Where uptake rate is reported, 
the numerator is the number of people who underwent assessment or testing for FH, and the 
denominator is the number of people who were offered the opportunity to be tested for FH. 
Quality assessment 
As prospective or retrospective cohort studies were considered the most appropriate study 
types to answer this review question, the modified GRADE quality rating started at “high”, and 
was downgraded for any concerns about risk of bias (according to CASP cohort checklist), 
indirectness, inconsistency or imprecision (as detailed in the review protocol, appendix C1). 
Where case-series studies were included the quality rating started at very low. Imprecision 
could not be quantitatively assessed as only median and range values were reported; all 
outcomes were downgraded one level for imprecision due to the uncertainty caused by not 
being able to assess precision directly.  
2.3.2 Results 
A systematic search was conducted (see Appendix D.1) which identified 10,010 articles. The 
titles and abstracts were screened and 104 articles were identified as potentially relevant. Full-
text versions of these articles were ordered and reviewed against the criteria specified in the 
review protocol (see Appendix C.1). Of these, 64 were excluded as they did not meet the 
criteria and 40 studies (from 41 references) met the criteria and were included. Due to the 
publication of a study key to the review, an update search was undertaken to ensure the review 
was as up to date as possible. The update search retrieved 1,002 articles. The titles and 
abstracts were screened and 15 articles were identified as potentially relevant. Full-text versions 
of these articles were ordered and reviewed against the criteria specified in the review protocol 
(Appendix C.1). Of these, 12 were excluded as they did not meet the criteria and 3 studies met 
the criteria and were included. This resulted in a total of 43 included studies from 44 
publications. 
A review flowchart is provided in Appendix E.1, and the excluded studies (with reasons for 
exclusion) are shown in Appendix F.1. The included studies were categorised as follows: 
 Fourteen studies assessed cascade testing (7 used direct cascade testing only, 2 used 
indirect cascade testing only, 2 studies used a combination of both, and 3 did not report the 
specific method used),  
 Seven studies assessed primary care electronic database searching and  
 Twenty-two studies assessed secondary care electronic database searching.  
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There was variation in the methods used in each study to detect FH. Criteria used included:  
 Simon Broome criteria,  
 Medped criteria 
 Dutch Lipid Clinic Network (DLCN) Criteria and  
 DNA/molecular diagnosis.  
Studies which used DNA diagnosis differed in their methods of DNA testing and the mutations 
analysed. We only included studies of DNA testing if the DNA tests were for LDLR, APOB and 
PCSK9 mutations.  
The committee made a post-hoc decision that the interventions included in the primary care 
studies (n= 8) were too disparate to be pooled as they included a variety of database searching 
methodologies and differed in the diagnostic criteria for FH (and validation of those criteria). 
Therefore the evidence for this part of the review is presented in a narrative summary format. 
The committee also decided that the secondary care sources should be classed into distinct 
categories as follows: 
 Pathology databases,  
 Lipid clinics/registries,  
 Coronary care units/Myocardial Ischaemia National Audit Project (MINAP) and  
 Screening programs 
For a summary of the included studies please see Table 1, Table 2, Table 3 & Table 7 (for the 
full evidence tables and full GRADE profiles please see appendices G.1 and H.1). 
Table 1 Summary of included studies: Cascade testing 
Study 
reference 
(including 
study 
design) 
Study population Method Outcomes 
reported 
Comments 
Bell 2015 366 relatives of 100 
index patients 
Genetic cascade 
testing -direct 
Diagnostic yield  
Bhatnager 
2000 
259 probands + 285 
1st degree relatives 
Cascade 
screening -direct 
Diagnostic yield Included in CG71 
Hadfield 
2009 
931 index cases, 
2,292 living first 
degree relatives  
Cascade testing 
– direct and 
indirect 
Diagnostic yield  
Jannes 2015 248 index patients, 
394 relatives 
Cascade testing 
– direct and 
indirect 
Diagnostic yield 
Sensitivity and 
specificity of 
genetic vs DLCN 
and SB. 
 
Lee 1998 80 index patients 
and 200 relatives of 
probands, 50 
controls 
Cascade testing 
– method not 
reported  
Diagnostic yield  
Leren 2008 2,472 relatives of 
440 index patients 
Cascade testing -
indirect 
Diagnostic yield 
Sensitivity and 
specificity of GP 
diagnosis of FH 
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Study 
reference 
(including 
study 
design) 
Study population Method Outcomes 
reported 
Comments 
Marks 2006 227 index cases, 
1,075 first degree 
relatives 
Cascade testing -
indirect 
Diagnostic yield Included in CG71 
Muir 2010 353 relatives of 76 
index cases + 95 
people with a 
severe phenotype 
but no identified 
mutation 
Cascade testing-
Direct 
Diagnostic yield  
Taylor 1993 200 children Cascade testing 
– direct 
Diagnostic yield  
Thorsson 
2003 
2,201 living 
individuals in 4 
family clusters 
Cascade testing 
– direct 
Diagnostic yield Undertaken in Iceland, 
limited applicability in 
UK setting due to 
method of family tracing 
Umans-
Eckenhausen 
2002 
1,695 relatives of 
66 consecutive 
index patients 
Cascade testing 
– direct 
Diagnostic yield Only relatives of index 
cases included in study. 
Umans-
Eckenhausen 
2001 
5,442  Cascade testing 
using secondary 
care lipid clinic 
databases-direct 
Diagnostic yield 
Referral for 
treatment 
Included in CG71 
Relatives of 237 people 
Van Maarle 
2002 
677 consecutive 
patients 
Cascade testing 
– direct 
Diagnostic yield  
Vergotine 
2001 
790  Cascade testing-
method not 
reported 
Diagnostic yield Relatives of 379 index 
cases 
Table 2: Summary of included studies: Primary care electronic database 
Study 
reference 
(including 
study 
design) 
Study 
population 
Method Outcomes 
reported 
Comments 
Bell 2014b 153  Primary care  Diagnostic yield  
Gray 2008 12,100  Primary care 
database  
Sensitivity  
Diagnostic yield 
Included in CG71 
Green 2016 Approximately 
290,000  
Primary care 
database 
searching  
Diagnostic yield Patients registered with a 
GP 
Kirke 2015 2,762 GP and 
workplace 
assessment 
Diagnostic yield Also recruited population 
from pathology database; 
please see secondary care 
section for this information. 
Norsworthy 
2014 
617 Generation 
Scotland: 
Scottish family 
health study 
Diagnostic yield Primary health care data 
used. Database study (all 
others are primary 
research). 
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Study 
reference 
(including 
study 
design) 
Study 
population 
Method Outcomes 
reported 
Comments 
Qureshi 
2016 
821 Primary care; 
education of 
practice staff, 
electronic 
prompts and mail 
out 
Diagnostic yield Feasibility study. Also 
includes information on 
number of referrals to 
secondary care specialist 
Troeung 
2016 
3,708  Primary care 
database 
Diagnostic yield Comparison of electronic 
screening with GP manual 
search of records. 
Primary care narrative review 
One study based in Australia identified people at risk of having FH (either identified as having 
an elevated LDL-C level or identified from a GP database (using an unknown informatics tool -
search strategy not reported); From a total of 153 people identified as at high risk, a specialist 
identified 45 people as having clinical FH using DLCN criteria (≥6 [probable or definite]), and the 
GP identified 39 people as having clinical FH using DLCN criteria, representing a diagnostic 
yield of 29.4% (number needed to test [nnt=4]) for the specialist and 25.5% (nnt=4) for the GP. 
A subset of 30 people with DLCN ≥4 (from the 45 originally assessed by the lipid specialist 
using primary care data) underwent genetic testing for FH: 4 individuals were mutation positive, 
a diagnostic yield of 7.5% (nnt =8). The evidence was of low quality; the quality was 
downgraded due to the lack of detail about the informatics tool and search terms used within the 
GP database to identify people at risk of having FH and at what concentration of LDL-C was 
considered elevated. There was also no detail about the population of the GP database, so the 
diagnostic yield within the population could not be calculated. 
One study using a UK GP database with 12,100 people, searched computer records and notes 
(using key terms -read codes for IHD, lipid disorders and a search for statin and cholesterol 
>7.0 mmol/L) and identified 402 people with potential FH and a DLCN score was calculated for 
all those identified. The diagnostic yield from computer searches was 3.32% (nnt= 31). A GP 
and lipidologist manually viewed the data, notes and scores for each of the 402 patients; 12 
were diagnosed with definite FH (diagnostic yield 2.99%, nnt= 34), 8 were diagnosed with 
probable FH (diagnostic yield 1.99%, nnt= 51), and 47 as being possible FH (diagnostic yield 
11.69%, nnt= 9). The evidence was of low quality for the following reasons: no DNA testing was 
undertaken to confirm FH, therefore the diagnoses made using DLCN were not verified. 
Furthermore, the computer searches were undertaken using Read codes as search terms for 
IHD, lipid disorders, prescription for statins and cholesterol >7.0 mmol/L.  
One study using UK GP databases within Medway clinical commissioning group with 
approximately 199,000 people, searched computer records (using Audit+ software an FH audit 
tool developed and based on recommendations from CG71) people with elevated TC or LDL-C 
(defined as TC>7.5mmol/L or LDL-C >4.9mmol/L) were flagged. The GP received electronic 
prompts to consider FH diagnosis when the person next attended the clinic: This stage of the 
study identified 99 people with clinical FH according to Simon Broome criteria for possible FH, 
representing a diagnostic yield of 0.05% and nnt=2013. In the second part of the study, a nurse 
assessed those people at risk identified by the initial computer search, but who had not been 
assessed by a GP:(those with elevated TC and LDL-C but who had not been assessed by 
Simon Broome criteria). The records of 1,505 patients were reviewed and 334 were diagnosed 
with FH (diagnostic yield 22.2%, nnt= 5 in a targeted population): 192 with definite FH, DLCN >8 
(diagnostic yield 12.8%, nnt= 8), 83 with probable FH, DLCN 6-8 (diagnostic yield 5.5%, nnt= 
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18) and 59 with possible FH, DLCN 3-5 (diagnostic yield 3.9%, nnt= 25). The evidence was of 
low quality due to the fact that no DNA testing was undertaken to confirm genetic diagnosis of 
FH. In addition, those people identified as having FH through the Audit+ tool, only received a 
diagnosis of possible FH according to SB criteria, no further verification of the diagnosis was 
described.  
One study undertaken in Australia with 42,179 people using a GP practice register and 
workplace screening. People in the workplace completed a 5 question screening questionnaire 
to assess their CAD risk2. Participation was voluntary and people who identified 2 or more 
positive risk factors were contacted by the research nurse and offered a primary care 
assessment. GP database screening involved screening the electronic records of 2 private GP 
practices using the Canning tool (data extraction software). Criteria were: age 18-70, history of 
cardiac event <60 years, any CAD, diagnosis of lipid disorder, TC >7.5 mmol/L, LDL 
>4.0mmol/L or prescription for statins. Of the 42,179 people included 2,762 were invited for 
testing and 1,259 were assessed for FH (uptake rate of 45.6%). 35 of those tested were 
categorised as high risk of FH (DLCN score of >5, calculated by research nurse in face-face 
assessment); the diagnostic yield within the population was 0.083% (nnt= 1,205) and the 
diagnostic yield within the people tested was 2.77% (nnt= 36). 29 people (out of 35, uptake rate 
of 82.8%) went on the have DNA testing for FH; 3 people were positive for FH causing 
mutations (diagnostic yield 10.34%, nnt= 10). The evidence was of low quality because people 
in the workplace screening section of the study were volunteers and therefore this part of the 
study was susceptible to selection bias. 
One study undertaken in Scotland with 23,960 people where primary care databases were 
searched for people on the basis of TC and age thresholds (TC≥8mmol/L, any age; TC 8-
8.4mmol/L, aged ≤50; 7-7.9mmol/L, age ≤40; TC≥5.5mmol/L; TC 5.1-5.2 mmol/L) : 617 people 
were identified from these searches and were divided into 3 groups: high cholesterol (TC 
≥7mmol/L untreated), cholesterol therapy group (TC ≥5mmol/L and on lipid lowering therapy) 
and controls (people with TC 5.1-5.2 mmol/L). These 617 people underwent genetic testing and 
9 people had FH diagnosed (mutations in one of the 3 genes (LDLR, APOB, PCSK9), 
representing a diagnostic yield of 1.46% (nnt= 69). This study was of very low quality; this was a 
database study, not primary research and the population of this study was older (aged 35-65 
years) at recruitment. LDL-C concentration were not routinely collected, so recruitment was on 
the basis of TC and age only; this may identify a broader population of people than those truly 
at risk of FH. 
In one study with 3,708 people based in Australia an informatics tool (TARB-Ex) that identified 
components to calculate a DLCN score (TC and LDL-C concentration, statin prescription, family 
history and clinical history), was used to assess all active medical records retrospectively for risk 
of FH. Those identified at risk of FH (DLCN ≥5) through TARB-Ex were assessed by a GP and 
lipid specialist. This was compared against manual review of a subset of 360 patient records 
(those with high lipid level (TC ≥7.0mmol/L or LDL-C ≥4.0mmol/L) and on statin treatment at 
time of highest LDL-C reading). Electronic screening identified 32 people with DLCN ≥5, manual 
review follow up of electronic records identified 10 people with DLCN ≥5 (diagnostic yield in 
population 0.86% for electronic searching, 0.27% for manual follow up; nnt= 116 and 371 
respectively). In the subset of 360 people with high LDL or TC and statin treatment, who had a 
manual record search only, 22 people with DLCN ≥5 were identified (diagnostic yield 6.11%, 
nnt= 16.36). The study was of moderate quality: there was no genetic confirmation of diagnosis 
and the study was only carried out on active patients who had attended the surgery >3 times in 
the past 2 years. 
In one feasibility study with 35,438 people, based in UK general practices, 831 eligible patients 
were identified by electronic record screening for total cholesterol >7.5 mmol/L. The GPs 
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received an educational session, and opportunistic reminders were set up during consultation 
with the eligible patient or universal postal invitation. People fulfilling possible Simon Broome 
criteria were invited for GP assessment and referred for specialist diagnosis. 127 (15.3%) 
people were recruited and completed family history questionnaires. 86 (10.7%) through postal 
invitation and 41 (4.9%) through opportunistic consultation. The diagnostic yield for possible FH 
(Simon Broome criteria) was 25.6% (n=32) in primary care, nnt=1,107 in the whole population 
and 26 for eligible patients). Within 6 months of recruitment, 7 patients had specialist 
assessment confirming FH (secondary care diagnostic yield of 5.51%, nnt=5,063 and 119): 2 
patients with definite FH (28.6%) and 5 patients with possible FH (71.4%). The study was of low 
quality; there was no genetic confirmation of diagnosis and there was a low uptake rate of the 
intervention. 
Table 3: Summary of included studies: Secondary care pathology databases 
Study 
reference 
(including 
study 
design) 
Study 
population 
Method Outcomes 
reported 
Comments 
Bell 2012 
 
84,823  Assessment of 
FH cases in 
pathology 
laboratory 
database using 
Simon Broome, 
Medped and 
Dutch lipid 
criteria 
Diagnostic yield Second audit – see Hadfield 
2008 in excluded list 
84,832 people with 99,467 
LDL cholesterol 
measurements 
Bell 2014 
 
196  Pathology 
laboratory (case 
control; GP 
received a phone 
call from 
pathologist vs no 
phone call from 
pathologist) 
Diagnostic yield  
Kirke 2015 4,517 Data from 
pathology 
laboratory,  
Diagnostic yield Also recruited from GP 
practice and workplace; 
please see primary care 
section for these outcomes. 
Muir 2010 588 Pathology 
laboratory 
database; TC 
value >8.0 
mmol/L, lipid 
stigmata or 
family history 
CVD 
Diagnostic yield  
Table 4: Lipid clinics or registries 
Study 
reference 
(including 
study 
design) 
Study 
population 
Method Outcomes 
reported 
Comments 
Chung 1999 11  Patients with 
hyperlipidaemia 
Diagnostic yield  
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Study 
reference 
(including 
study 
design) 
Study 
population 
Method Outcomes 
reported 
Comments 
attending 
metabolic clinic  
Simon Broome 
criteria used to 
assess FH 
Clarke 2013 204 Lipid clinic 
registry.  
Comparison of 
diagnostic tools 
(SB, Dutch 
criteria) and 
additional 
stratification 
systems to 
improve 
identification of 
FH 
 
Sensitivity and 
specificity of 
DLNC and 
Simon Broome 
possible criteria 
to detect FH 
diagnosed 
according to 
definite Simon 
Broome criteria 
Outcomes reported for 
those with and without 
tendon xanthoma, with 
genetic FH 
Futema 
2013 
289  Lipid register. 
Secondary care 
Diagnostic yield People with definite or 
possible FH on lipid register 
Haralambos 
2015 
1,206 People with 
possible FH 
according to SB 
or DLCN criteria 
attending a lipid 
clinic. 
Diagnostic yield  
Heath 2001 227 + 141 People 
diagnosed with 
FH according to 
SB, lipid registry; 
referred from 
lipid clinic and 
GP. 
Secondary care 
Diagnostic yield 227 probands and 141 
family members 
Hu 2013 314 + 132 Secondary care 
– lipid clinics 
Diagnostic yield 314 first degree relatives 
and 132 possible index 
cases 
Medeiros 
2010/ 
Bourbon 
2007 
184 + 418 Lipid registry in 
Portugal. 
Secondary care 
Diagnostic yield 602 blood samples from 184 
index patients and 418 
relatives. Adults and 
children 
Taylor 2010 110  Lipid clinic. 
Secondary care 
Diagnostic yield 
using molecular 
testing 
People referred from adult 
or paediatric lipid clinics in 
the UK 
Widhalm 
2007 
263  Lipid clinic, 
Secondary care 
Diagnostic yield 
using genetic 
testing 
People attending lipid clinic 
at department of 
paediatrics, general 
hospital, university of 
Vienna. 
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Table 5: Coronary incident/ CCU 
Study 
reference 
(including 
study 
design) 
Study 
population 
Method Outcomes 
reported 
Comments 
Bates 2008 917  Coronary care 
patients/ CCU. 
 
Diagnostic yield DLNC used to diagnose FH 
De Backer 
2015 
7,044  CCU Diagnostic yield Patients from coronary care 
centres across Europe 
Nanchen 
2015 
4,778  People with ACS/ 
CCU setting 
Diagnostic yield Patients hospitalised with 
Acute coronary syndrome 
Pang 2015 175  coronary care 
unit setting 
Diagnostic yield People with early onset 
CAD 
Wald 2015 231 Young people 
with MI 
underwent 
molecular testing 
if TC >7 mmol/L. 
CCU setting 
Diagnostic yield, 
uptake rate 
People with MI admitted to 
hospital, UK 
Table 6: Screening (other) 
Study 
reference 
(including 
study 
design) 
Study 
population 
Method Outcomes 
reported 
Comments 
Besso 1999 9,673  Neonatal 
screening in 
secondary care 
setting 
Diagnostic yield  
Klancar 
2015 
272  Population 
screening in 
Slovenia -children 
with raised TC 
and/or family 
history premature 
cardiovascular 
events. 
Secondary care 
Diagnostic yield  
Laurie 2004 65  Population 
screening in NZ – 
no further detail. 
Secondary care 
Diagnostic yield  
Wald 2016 10,095 Screening 
children for FH 
during 
immunisations in 
primary care 
setting 
Diagnostic yield  
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2.4 Health economic evidence review (case finding) 
2.4.1 Methods 
Evidence of cost effectiveness 
The Committee is required to make decisions based on the best available evidence of both 
clinical and cost effectiveness. Guideline recommendations should be based on the expected 
costs of the different options in relation to their expected health benefits. 
Evidence on cost effectiveness related to the key clinical issues being addressed in the 
guideline update was sought. The health economist undertook: 
 a systematic review of the published economic literature; and 
 new cost-effectiveness analysis. 
Economic literature search 
A systematic literature search was undertaken to identify health economic evidence within 
published literature relevant to the review questions. The evidence was identified by 
conducting a broad search in the NHS Economic Evaluation Database (NHS EED) and the 
Health Technology Assessment database (HTA). The search also included Medline and 
Embase databases using an economic filter. Studies published in languages other than 
English were not reviewed. The search was conducted on 10 May 2016. The health 
economic search strategies are detailed in appendix J. 
The health economist also sought out relevant studies identified by the surveillance review or 
Committee members. 
Economic literature review 
The health economist: 
 Identified potentially relevant studies for each review question from the economic search 
results by reviewing titles and abstracts. Full papers were then obtained. 
 Reviewed full papers against pre-specified inclusion and exclusion criteria to identify 
relevant studies. 
 Critically appraised relevant studies using the economic evaluations checklist as specified 
in Developing NICE Guidelines: the manual. 
 Extracted key information about the studies’ methods and results into full economic 
evidence tables (appendix M). 
 Generated summaries of the evidence in economic evidence profiles. 
Inclusion and Exclusion criteria 
Full economic evaluations (studies comparing costs and health consequences of alternative 
courses of action: cost-utility, cost-effectiveness, cost-benefit and cost-consequence 
analyses) and comparative costing studies that address the review question in the relevant 
population were considered potentially includable as economic evidence. 
Studies that only reported burden of disease or cost of illness were excluded. Literature 
reviews, abstracts, posters, letters, editorials, comment articles, unpublished studies and 
studies not in English were excluded. 
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Remaining studies were prioritised for inclusion based on their relative applicability to the 
development of this guideline and the study limitations. For example, if a high quality, directly 
applicable UK analysis was available, then other less relevant studies may not have been 
included. Where selective exclusions occurred on this basis, this is noted in the excluded 
economic studies table (appendix L). 
For more details about the assessment of applicability and methodological quality see the 
economic evaluation checklist contained in Appendix H of Developing NICE Guidelines: the 
manual. 
Economic evidence profile 
The economic evidence profile summarises cost-effectiveness estimates. It shows an 
assessment of the applicability and methodological quality for each economic evaluation, 
with footnotes indicating the reasons for the assessment. These assessments were made by 
the health economist using the economic evaluation checklist from Appendix H of Developing 
NICE Guidelines: the manual. It also shows the incremental cost, incremental effect and 
incremental cost-effectiveness ratio for the base case analysis in the evaluation, as well as 
information about the assessment of uncertainty. 
The information contained in the economic evidence profile is explained in Table 7. 
Table 7: Explanation of fields used in the economic evidence profile 
Item Description 
Study This field is used to reference the study and provide basic details on the 
included interventions and country of origin. 
Applicability Applicability refers to the relevance of the study to specific review questions 
and the NICE reference case. Attributes considered include population, 
interventions, healthcare system, perspective, health effects and discounting. 
The applicability of the study is rated as: 
 Directly applicable – the study meets all applicability criteria or fails to meet 
one or more applicability criteria but this is unlikely to change the conclusions 
about cost effectiveness. 
 Partially applicable – the study fails to meet one or more applicability criteria 
and this could change the conclusions about cost effectiveness. 
 Not applicable – the study fails to meet one or more of the applicability 
criteria and this is likely to change the conclusions about cost effectiveness. 
Such studies would usually be excluded from the review. 
Limitations This field provides an assessment of the methodological quality of the study. 
Attributes assessed include the relevance of the model’s structure to the 
review question, timeframe, outcomes, costs, parameter sources, incremental 
analysis, uncertainty analysis and conflicts of interest. The methodological 
quality of the evaluation is rated as having: 
 Minor limitations – the study meets all quality criteria or fails to meet one or 
more quality criteria, but this is unlikely to change the conclusions about cost 
effectiveness. 
 Potentially serious limitations – the study fails to meet one or more quality 
criteria and this could change the conclusions about cost effectiveness 
 Very serious limitations – the study fails to meet one or more quality criteria 
and this is highly likely to change the conclusions about cost effectiveness. 
Such studies would usually be excluded from the review. 
Structure and 
time horizon 
This field contains particular issues that should be considered when 
interpreting the study, such as model structure and timeframe. 
Incremental cost 
effectiveness 
ratio (ICER) 
The incremental cost divided by the incremental effect which results in the cost 
per quality-adjusted life year gained (or lost). Negative ICERs are not reported 
as they could represent very different conclusions: either a decrease in cost 
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Item Description 
with an increase in health effects; or an increase in cost with a decrease in 
health effects. For this reason, the word ‘dominates’ is used to represent an 
intervention that is associated with decreased costs and increased health 
effects compared to the comparator, and the word ‘dominated’ is used to 
represent an intervention that is associated with an increase in costs and 
decreased health effects. 
Uncertainty A summary of the extent of uncertainty about the ICER. This can include the 
results of deterministic or probabilistic sensitivity analysis or stochastic 
analyses or trial data. 
Undertaking new health economic analysis 
As well as reviewing the published economic literature for each review question, new 
economic analysis was undertaken by the health economist.  
The following general principles were adhered to in developing the cost-effectiveness 
analysis: 
 Methods were consistent with the NICE reference case. 
 The Committee was involved in the design of the model, selection of inputs and 
interpretation of results. 
 Model inputs were based on the systematic review of the clinical literature supplemented 
with other published data sources where possible. 
 When published data were not available, Committee expert opinion was used to populate 
the model. 
 Model inputs and assumptions were reported fully and transparently. 
 The results were subject to sensitivity analysis and limitations were discussed. 
 The model was quality assured by another health economist within NICE’s Centre for 
Guidelines. 
Full methods for the cost-effectiveness analysis conducted for this guideline are described in 
appendix O. 
Cost-effectiveness criteria 
NICE’s report Social value judgements: principles for the development of NICE guidance 
sets out the principles that GDGs should consider when judging whether an intervention 
offers good value for money. In general, an intervention was considered to be cost effective if 
either of the following criteria applied (given that the estimate was considered plausible): 
 the intervention dominated other relevant strategies (that is, it was both less costly in 
terms of resource use and more clinically effective compared with all the other relevant 
alternative strategies), or 
 the intervention cost less than £20,000 per QALY gained compared with the next best 
strategy. 
If the Committee recommended an intervention that was estimated to cost more than 
£20,000 per QALY gained, or did not recommend one that was estimated to cost less than 
£20,000 per QALY gained, the reasons for this decision are discussed explicitly in the 
‘evidence to recommendations’ section of the relevant chapter, with reference to issues 
regarding the plausibility of the estimate or to the factors set out in Social value judgements: 
principles for the development of NICE guidance. 
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In the absence of economic evidence 
When no relevant economic studies were found from the economic literature review, and de 
novo modelling was not feasible or prioritised, the Committee made a qualitative judgement 
about cost-effectiveness by considering expected differences in resource use between 
options and relevant UK NHS unit costs, alongside the results of the clinical review of 
effectiveness evidence. The UK NHS costs reported in the guideline were those presented to 
the Committee and they were correct at the time recommendations were drafted; they may 
have been revised subsequently by the time of publication. However, we have no reason to 
believe they have been changed substantially. 
2.4.2 Results of the economic literature review 
A total of 1,012 articles were identified by the search with 990 being excluded based on their 
title and abstract and 22 full papers ordered. Of these a further 18 articles were excluded. An 
additional economic evaluation post-dating the search was identified by a member of the 
committee. Two of the remaining 5 articles related to the same study so 4 studies from 5 
articles were included in the economic systematic review. Table 8 contains the economic 
evidence profile for this review question summarising the results of the studies included in 
the systematic review, modelling conducted for the previous guideline and the economic 
model developed for the present update. Full economic evidence tables are contained in 
appendix M. 
The flowchart summarising the number of studies included and excluded at each stage of the 
review process can be found in appendix K. Appendix L contains a list of excluded studies 
and the reasons for their exclusion. The following discussion of the 4 included CUAs is 
summarised in Table 8. 
Kerr et al. (2017) investigated the cost effectiveness of genetic cascade testing from index 
cases with a confirmed monogenic mutation. Advantages of this analysis included using the 
modern testing pathway specified in the NICE quality standard based on recent 
developments in genetic testing, long term benefits and cost of treated and untreated FH 
based on the NICE lipid modification economic model, resource use based on actual FH 
services in the UK, and the use of HES data to extend the lipid modification model down to 
age 20. The study found that cascade testing was cost effective with an ICER of £5,806 per 
QALY. It was only partially applicable to the current decision-making context because it did 
not include case identification strategies. The study was assessed as having only minor 
methodological limitations, mainly related to a lack of reporting how the resources 
(particularly staff) supporting genetic testing were calculated and how gender specific risks 
were accounted for. There was also no probabilistic sensitivity analysis. 
Ademi et al. (2014) compared the cost effectiveness of cascade testing using genetic testing 
of the relatives of index cases compared with no cascade screening. They also investigated 
the cost effectiveness of cascade testing based on LDL-C thresholds but scant details are 
provided on this intervention and it was not included in incremental analysis. The decision 
tree and Markov model found that cascade testing using genetic testing was cost effective 
with an incremental cost effectiveness ratio of AUD$3,565 per QALY (2013) (£1,749 (2016)) 
with a 99% probability of being cost effective. The study was partially applicable to current 
decision-making purposes. Reasons for downgrading from directly applicable included it 
being based on the Australian health care system and it did not include interventions relevant 
to the update such as index case identification through searching databases. It had 
potentially serious methodological limitations such as a 10 year time horizon, effectiveness of 
cascade screening was based on a single centre associated with the authors, and 
inappropriate distributions were used to represent parameter uncertainty in the probabilistic 
sensitivity analysis. 
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Chen et al. (2015) investigated the cost effectiveness of genetic cascade screening and lipid 
cascade screening combined with a statin treatment adherence programme compared with 
lipid cascade screening alone. It found that genetic cascade screening was extendedly 
dominated. If the lipid cascade screening and adherence programme intervention was 
excluded due to irrelevance to the current decision-making context, genetic cascade 
screening had an incremental cost effectiveness ratio of US$519,813 (£376,138 (2016)) per 
QALY. At a willingness to pay threshold of US$150,000 per QALY, 99% of the simulated 
ICERs for lipid screening and adherence strategy vs. lipid screening were cost effective, and 
55% of those for genetic screening vs. lipid screening were cost effective. There are two key 
inputs that limit the generalisability of this study to the NHS. Firstly, the first year screening 
cost was US$5,528 (£4,000 (2016)) per person and this is likely to far exceed what is 
incurred by the NHS. In a sensitivity analysis, genetic cascade screening was found to have 
an ICER below US$150,000 (£108,540 (2016)) per QALY if the first year cost of genetic 
screening was reduced to US$1,830 (£1,324 (2016)) per person. It is likely that the cost of 
genetic screening is less than this in the UK. The second parameter that limited 
generalisability was the dose of 10mg for atorvastatin and treatment effect of 28% reduction 
in total cholesterol and 38% reduction in LDL cholesterol. A high-intensity statin is 
recommended to achieve a reduction of 50% from baseline in the original NICE guideline. 
Inappropriate distributions were used to represent parameter uncertainty in the probabilistic 
sensitivity analysis. Therefore, the quality assessment of this study found that it was partially 
applicable with potentially serious methodological limitations. 
NCCPC (2008) and Nherera et al (2011) developed an economic model to inform the original 
guideline on familial hypercholesterolaemia for NICE. Four strategies were compared in the 
analysis using a decision tree and Markov model framework: 
1. Cholesterol method – relatives diagnosed based on elevated LDL-C levels; 
2. DNA method – only people with an identified FH-causing mutation were included for 
cascade testing, with the relatives tested for the family mutation, and secondary 
cascading for those with the family mutation; 
3. DNA+DFH method – As per 2. DNA method, and in addition, in the relatives of definite 
familial hypercholesterolaemia index cases where no mutation can be found, cascade 
testing was undertaken using measures of LDL-C levels to identify affected relatives for 
treatments and for secondary cascading; 
4. DNA+DFH+PFH method – as per 2. DNA method, and in addition, cascade testing was 
undertaken in both definite familial hypercholesterolaemia and probable familial 
hypercholesterolaemia index cases using LCL-C measures.  
The analysis found that the DNA and DNA+DFH strategies were dominated by the 
cholesterol method. DNA+DFH+PFH had an ICER of £2,676 per QALY in the deterministic 
analysis and £3,666 per QALY in the probabilistic analysis making it the optimal strategy with 
100% probability that it was cost effective using a £20,000 per QALY cost-effectiveness 
threshold. This study is partially applicable to the decision-making of the current update 
because it did not include strategies on case identification in primary or secondary care.  
2.4.3 Economic modelling 
The full report of the economic model developed for this update is provided in appendix O. 
Economic modelling was prioritised for the area of case identification and diagnosis for the 
following reasons: 
 New recommendations for systematic case identification in primary care or secondary 
care were likely to involve a substantial resource impact. This was mainly due to the staff 
time required in primary care to undertake clinical assessment and refer patients to lipid 
clinics, and an increased demand for genetic testing. 
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 The cost effectiveness of new index case identification in primary care and secondary 
care has not been investigated in any of the studies identified in the economic review. 
 The cost of treatment (with atorvastatin) has decreased since the original guideline. 
 The cost of genetic testing has decreased since the original guideline. 
 The ability to differentiate between monogenic FH and polygenic hypercholesterolaemia 
due to developments in genetic testing is now an important part of the cascade testing 
pathway and its relative cost effectiveness. 
The following strategies were compared in the analysis: 
1. No case identification or cascade testing 
2. Genetic cascade testing of the relatives of people with a current clinical diagnosis of 
definite FH and a functional mutation in the LDLR, APOB or PCSK9 gene 
3. Primary care case identification, clinical assessment using the Simon Broome criteria, and 
cascade testing of the relatives of newly identified index cases; in addition to cascade 
testing from currently diagnosed index cases 
4. Primary care case identification, clinical assessment using the DLCN criteria, and cascade 
testing of the relatives of newly identified cases; in addition to cascade testing from 
currently diagnosed index cases 
5. Secondary care case identification, clinical assessment using the Simon Broome criteria, 
and cascade testing of the relatives of newly identified index cases; in addition to cascade 
testing from currently diagnosed index cases 
6. Secondary care case identification, clinical assessment using the DLCN criteria, and 
cascade testing of the relatives of new identified index cases; in addition to cascade 
testing from currently diagnosed index cases 
7. Primary care case identification, secondary care case identification, clinical assessment 
using the SB criteria, and cascade testing of the relatives of newly identified index cases; 
in addition to cascade testing from currently diagnosed index cases 
8. Primary care case identification, secondary care case identification, clinical assessment 
using the DLCN criteria, and cascade testing of the relatives of newly identified index 
cases; in addition to cascade testing from currently diagnosed index cases 
The diagnostic strategies were simulated via a decision tree, which determined the number 
of people with treated and untreated monogenic and polygenic hypercholesterolaemia that 
would enter the long term model and calculated the short term costs of case finding, 
appointments and genetic testing. The long term model calculated the relevant costs and 
QALYs for these four types of patients using an augmented version of the model produced 
for NICE’s guideline on Lipid Modification (CG181) in which relevant clinical and cost 
parameters were updated. 
This analysis confirmed that cascade testing is cost-effective and that the addition of primary 
care case identification strategies is highly cost-effective at an ICER of £1,572/QALY gained. 
The differences between the DLCN and Simon Broome (possible/probable+definite criteria) 
in terms of both costs and QALYs were extremely small although the Simon Broome was 
marginally more cost-effective. Secondary care case identification strategies in people with 
early MI was not cost effective with ICERs in the region of £70,000/QALY. A large number of 
parameters were varied in one-way sensitivity analysis with only a few having a material 
impact on the results. When a much higher (~3.3x the base case) prevalence of FH in the 
population with early MI was used, the addition of secondary care case identification became 
cost-effective.Secondary care case ID also became cost-effective in the sensitivity analysis 
where 12 relatives were assumed to be identified per new index case. Although this estimate 
has been used in prior analyses, the base case of 2.22 is based on the actual experiences of 
lipid services in the UK and thought to be a more realistic figure. The results of the model 
were robust to probabilistic sensitivity analysis with primary care case identification having a 
100% probability of being cost effective at a threshold of £20,000/QALY. 
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A scenario was examined where the stricter “definite only” criteria on the Simon Broome and 
DLCN were used and although this led to savings through less genetic testing, it also led to 
lower Net Monetary Benefit values so was considered cost-ineffective. 
The de novo analysis is directly applicable to the current decision-making context because it 
compares a range of case identification strategies with cascade testing alone. The analysis 
has potentially serious limitations due to the lack of robust data to inform the FH-specific 
adjustments made to the long term model, which is itself only indirectly relevant to the 
population under consideration. The results are, however, largely insensitive to even extreme 
variations in parameters.
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Table 8: Economic evidence profile (reverse chronological order) 
Study & 
country Strategies 
Applicabili
ty Limitations 
Structure & time 
horizon ICER Uncertainty 
NICE 
2017 
The following strategies 
were compared in the 
analysis: 
1. No case identification or 
cascade testing 
2. Genetic cascade testing 
of the relatives of people 
with a current clinical 
diagnosis of definite FH 
and a functional mutation in 
the LDLR, APOB or PCSK9 
gene 
3. Primary care case 
identification, clinical 
assessment using the 
Simon Broome criteria, and 
cascade testing of the 
relatives of newly identified 
index cases; in addition to 
cascade testing from 
currently diagnosed index 
cases 
4. Primary care case 
identification, clinical 
assessment using the 
DLCN criteria, and cascade 
testing of the relatives of 
newly identified cases; in 
addition to cascade testing 
from currently diagnosed 
index cases 
5. Secondary care case 
identification, clinical 
assessment using the 
Directly 
applicable 
Potentially 
serious 
limitations 
Decision tree with 
payoffs taken from 
lifetime Markov model 
Strategy 4 vs Strategy 2: 
£1,572/QALY 
Strategy 3 vs Strategy 4: 
£14,511/QALY 
Strategy 7 vs Strategy 3: 
£70,000/QALY 
All other strategies 
dominated or extendedly 
dominated in the base 
case. 
Extensive one-way 
sensitivity analysis was 
conducted. Model is only 
sensitive to somewhat 
extreme variation in the 
prevalence of FH in people 
with early MI and number of 
relatives approached for 
cascade testing. There is 
uncertainty with respect to 
the most realistic 
combination of 
assumptions that should 
form the base case in long 
term model, which itself is 
only indirectly relevant and 
doesn’t include any patients 
below age 40. 
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Study & 
country Strategies 
Applicabili
ty Limitations 
Structure & time 
horizon ICER Uncertainty 
Simon Broome criteria, and 
cascade testing of the 
relatives of newly identified 
index cases; in addition to 
cascade testing from 
currently diagnosed index 
cases 
6. Secondary care case 
identification, clinical 
assessment using the 
DLCN criteria, and cascade 
testing of the relatives of 
new identified index cases; 
in addition to cascade 
testing from currently 
diagnosed index cases 
7. Primary care case 
identification, secondary 
care case identification, 
clinical assessment using 
the SB criteria, and 
cascade testing of the 
relatives of newly identified 
index cases; in addition to 
cascade testing from 
currently diagnosed index 
cases 
8. Primary care case 
identification, secondary 
care case identification, 
clinical assessment using 
the DLCN criteria, and 
cascade testing of the 
relatives of newly identified 
index cases; in addition to 
cascade testing from 
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Study & 
country Strategies 
Applicabili
ty Limitations 
Structure & time 
horizon ICER Uncertainty 
currently diagnosed index 
cases 
Kerr et al. 
2017 
 Genetic cascade testing 
from index cases with 
confirmed monogenic 
mutation 
 Vs. no cascade testing 
Partially 
applicable 
Minor 
limitations 
 Decision tree and 
Markov model 
£5,806 per QALY  Results remain robust for 
one way sensitivity 
analysis of level of 
reduction in LDL-C, 
number of relatives 
cascade testing, 
compliance with lipid 
modification treatment 
and cost of Rosuvastatin 
and ezetimibe 
 No probabilistic sensitivity 
analysis 
Chen et 
al. 2015 
 
United 
States 
 Lipid cascade screening 
 Genetic cascade 
screening 
 Lipid cascade screening 
with an adherence 
programme to increase 
compliance with statin 
treatment 
Partially 
applicable 
Potentially 
serious 
limitations 
 Decision tree and 
Markov model 
 Lifetime  
 Cascade screening vs. 
lipid cascade 
screening: extendedly 
dominated 
 Lipid cascade 
screening with 
adherence programme 
vs. lipid cascade 
screening: 
US$12,223/QALY 
(£8,845 (2016)) 
Using a US$150,000 per 
QALY threshold 
(£108,540/QALY) 
 99% probability lipid 
cascade screening with 
adherence programme is 
cost effective compared 
with lipid cascade 
screening 
 55% probability that 
genetic cascade 
screening was cost 
effective compared with 
lipid cascade screening 
Ademi et 
al. 2014 
 
Australia 
 Cascade screening using 
genetic testing 
 no cascade screening 
(cascade screening using 
LDL-C thresholds was 
compared to no cascade 
Partially 
applicable 
Potentially 
serious 
limitations 
 Decision tree and 
Markov model 
 10 year time horizon 
AUD$3,565/QALY 
(£1,749.25 (2016)) 
 95% confidence interval 
$2,004 to $5,228 
 Cascade screening 99% 
probability of ICER less 
than AUD$50,000/QALY 
(£24,388/QALY) 
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Study & 
country Strategies 
Applicabili
ty Limitations 
Structure & time 
horizon ICER Uncertainty 
screening in a sensitivity 
analysis) 
NCCPC 
2008 
and 
Nherera et 
al. 2011 
(for NICE 
CG71) 
 
United 
Kingdom 
1. Cholesterol method 
2. DNA method 
3. DNA+DFH method 
4. DNA+DFH+PFH method 
Partially 
applicable 
Potentially 
serious 
limitations 
 Decision tree and 
Markov model 
 Lifetime 
Vs. cholesterol method: 
 DNA: dominated 
 DNA+DFH: dominated 
 DNA+DFH+PFH: 
£2,676/QALY 
100% probability that 
DNA+DFH+PFH is cost 
effective vs. cholesterol 
method using a 
£20,000/QALY threshold 
Additional details, such as the quality assessment of applicability and methodological limitations, are available in the full economic evidence tables, Appendix M. 
ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life year; LDL-C: low density lipoprotein cholesterol; DNA: deoxyribonucleic acid; DFH: definite familial 
hypercholesterolaemia; PFH: possible familial hypercholesterolaemia 
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2.5 Evidence statements 
2.5.1 Clinical evidence statement 
2.5.1.1 Cascade testing - clinical diagnosis 
Low to very low quality evidence from: 
 2 studies with 405 people found that direct cascade testing had a range of diagnostic 
yields for identification of clinically defined FH of 6 to 59%, with a number needed to test 
of 2 for the Simon Broome criteria and 17 for the Dutch Lipid Network Criteria (DLCN). 
 2 studies with 776 people found that indirect cascade testing had a range of diagnostic 
yields for identification of clinically defined FH of 30.5 to 37.9%, with a number needed to 
test of 3 for the Medped criteria and 3 for other non-standardised diagnostic criteria used 
to diagnose FH. 
 2 studies with 1,879 people found that a combination of indirect and direct cascade testing 
had a range of diagnostic yields for identification of clinically defined FH of 14.7 to 57.5%, 
with a number needed to test of 5 for the Simon Broome criteria and 2 for DLCN. 
2.5.1.2 Cascade testing - genetic diagnosis 
Moderate to very low quality evidence from: 
 5 studies with 7,144 people found that direct cascade testing had a median diagnostic 
yield for identification of genetically defined FH of 37.5% (range 11.4 to 51.4%), with a 
number needed to test of 3 (range 2 to 9). 
 1 study with 1,805 people found that indirect cascade testing had a diagnostic yield for 
identification of genetically defined FH of 44.8%, with a number needed to test of 3. 
 1 study with 642 people found that direct and indirect cascade testing had a diagnostic 
yield of 55.9%, with a number needed to test of 2. 
 2 studies with 2,910 people found that unknown methods of cascade testing had a 
diagnostic yield range of 32.8 to 33.9% with a number needed to test of 3. 
Cascade testing – uptake rate 
Low to very low quality evidence from: 
 3 studies with 1,557 people found a median uptake rate for index individuals for direct 
cascade testing of FH of 84.1% (range 69.1 to 98.9%). 
 2 studies with 626 people found uptake rates for relatives of index individuals for direct 
cascade testing of FH ranging from 84.1 to 98.9%. 
 1 study with 2,474 people found an uptake rate for relatives of index individuals for indirect 
cascade testing of FH of 73.0%. 
 1 study with 2,292 people foumd an uptake rate for relatives of index individuals for both 
indirect and direct cascade testing of FH of 65.2%. 
2.5.1.3 Primary care electronic databases 
Very low to moderate quality evidence was found from 6 studies which used distinct methods 
of case finding within primary care. The studies varied as to whether DLCN or Simon Broome 
criteria were used, and whether the scores were verified. Four studies with 339,642 people 
found that searching primary care electronic databases had a median diagnostic yield for 
identification of FH of 0.178% (range 0.083 to 3.9%), with a number needed to test of 563 
(range 116 to 1,250) using the Simon Broome (n=2) or DLCN (n=3) criteria. Five studies with 
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5,182 people found that electronic search criteria & GP review had a median diagnostic yield 
for identification of FH of 14.16% (range 1.27 to 29.4%), with a number needed to test of 10 
(range 4 to 35) using Simon Broome (n=1) or DLNC (n=5) criteria. From 3 studies with 676 
people, genetic testing had a median diagnostic yield for identification of genetically defined 
FH of 13% (range 0.014% to 37.90%), with a number needed to test of 7 (range 3 to 69). 
The most relevant study to UK clinical practice used an informatics tool to identify cases of 
possible FH (diagnostic yield 0.05%, number needed to test = 2,013), then had targeted 
case-finding; a nurse assessed people at risk of FH, but not yet screened (overall diagnostic 
yield 22.2%, number needed to test = 5). 
Primary care -uptake rate 
Low quality evidence from 1 study with 2,762 people had an uptake rate from primary care 
searches of index individuals with FH of 26%. 
2.5.1.4 Secondary care electronic databases 
Pathology databases 
Very low quality evidence from: 
 3 studies of 85,616 people found that case finding of FH through pathology databases had 
a median diagnostic yield for identification of clinically defined FH of 8.5% (range 1.2 to 
9.2%), with a number needed to test (DLCN) of 12 (range 11 to 398) and a number 
needed to test of 27 using Simon Broome criteria. 
 3 studies with 641 people found that case finding of FH through pathology databases had 
a median diagnostic yield for identification of genetically defined FH of 26.7% (range 12.9 
to 30.4%) and a number needed to test of 4 (range 3 to 8). 
 2 studies with 4,517 people had an uptake rate of 13.2% for people at increased CV risk 
attending clinical assessment, and 61.6% for those at high risk of FH attending specialist 
review. 
Lipid clinics/registries 
Very low quality evidence from: 
 4 studies with 1,343 people found that case finding of FH through lipid clinics or registries 
had a median diagnostic yield for identification of clinically defined FH of 51.0% (range 
33.5 to 87.8%), with a number needed to test of 2 for DLCN criteria, and a number 
needed to test of 2 for both Simon Broome and Medped criteria. 
 6 studies with 1,955 people found that case finding of FH through lipid clinics or registries 
had a median diagnostic yield for identification of genetically defined FH of 33.3% (range 
10.9 to 51.0%), with a number needed to test of 3 (range 2 to 9). 
No studies reported uptake rate of testing through lipid clinics or registries. 
Coronary units/ MINAP 
Moderate to low quality evidence from: 
 4 studies with 12,331 people found that case finding of FH through coronary care units or 
using the MINAP database had a median diagnostic yield for identification of clinically 
defined FH of 5.9% (range 1.2 to 14.3%), with a number needed to test of 37 for DLCN 
and 19 for Simon Broome criteria. 
 1 study with 231 people found that case finding of FH through coronary care units or using 
the MINAP database had a median diagnostic yield for identification of genetically defined 
FH of 1.23%, with a number needed to test of 77. 
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 1 study with 231 people found that uptake rate for DNA testing in coronary units is 50.1%.  
Screening programs 
Very low quality evidence from: 
 2 studies with 19,768 people found that case finding of FH through screening programs 
had a diagnostic yield for identification of clinically defined FH ranging from 0.001 to 
0.145%, and a number needed to test ranging from 991 to 1,262. 
 3 studies with 10,432 people found that case finding of FH through screening programs 
had a median diagnostic yield for identification of genetically defined FH of 17.0% (range 
0.4 to 57.0%), and a median number needed to test of 6 (range 2 to 273). 
 1 study with 189 people found that case finding of FH through screening programs had an 
uptake rate of 43.4%. 
2.5.2 Health economic evidence statements 
De novo economic modelling conducted for the update found that a strategy of case 
identification in primary care, clinical assessment using the SB criteria, and cascade testing 
the relatives of both current and new index cases was the most cost-effective strategy that 
maximised health benefits at an ICER below the cost-effectiveness threshold compared with 
seven other strategies, including genetic cascade testing alone. The analysis was assessed 
as directly applicable with potentially serious limitations.From the published literature, 1 
Australian and 2 British studies found that cascade testing was cost effective. One American 
study found that cascade testing was not cost effective. 
2.6 Evidence to recommendations 
 Committee discussions 
Relative value of 
different outcomes 
The committee identified the critical outcome from the clinical review as the 
diagnostic yield of people identified with FH through each case finding 
strategy. The outcome of uptake rate was identified by the committee as an 
important outcome, as this is a point in the care pathway where a lot of 
people are lost, and therefore it is crucial to maximise uptake rate. 
Quality of evidence The overall quality of the evidence contributing to the outcomes of interest 
was very low (ranging from moderate to very low) for cascade testing, low 
(ranging from moderate to very low) for primary care searching and very low 
(ranging from moderate to very low quality) for secondary care searching. 
Generally cascade testing and primary care searching had the greatest 
diagnostic yield and uptake rate for testing. 
There was a relatively large volume of evidence. However, the interventions 
and methods of assessing the diagnosis of FH were heterogeneous. 
Therefore the committee decided that data on primary care searching 
should not be combined as the interventions were too heterogeneous. The 
committee also agreed that the secondary care review should be split into 
sections for pathology databases, lipid registries or clinics, CCU or MINAP 
and screening as it was inappropriate to consider these different 
populations as one section due to the different populations. 
Cascade testing 
There was variation in whether direct or indirect cascade testing was used, 
and in some cases the study did not report which type of cascade testing 
was used. No studies reported on reverse cascade testing as a single 
strategy (though Wald 2016 implements reverse cascade testing as part of 
a screening strategy). Some included studies used methods of diagnosis 
that are not used in the UK (Medped) and older studies reporting on genetic 
testing of FH have used methods with lower sensitivity than current 
methods and are no longer applicable to current practice. A study that 
assessed child-parent screening (Wald et al 2016), in primary care was 
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 Committee discussions 
discussed. As this study was based in a primary care setting, and was not 
cascade screening, it was not included in this section, but in the secondary 
care screening section. 
Where evidence for uptake rate was available cascade testing had the 
highest uptake rate; with direct cascade testing having a greater uptake rate 
than indirect cascade testing; this is in agreement with the clinical 
experience of the topic experts. 
Primary care 
The overall quality of the evidence was low and included strategies of 
database searching only and database searching plus nurse assessment. 
The committee discussed that the most relevant study to UK practice was a 
study by Green (2016) which used database searching and nurse 
assessment to identify people with FH. 
Secondary care 
The quality of the evidence was very low for pathology databases, lipid 
clinics/ registries, moderate to low for CCU/ MINAP and very low quality for 
screening programs. The greatest diagnostic yield and uptake rate was 
from lipid clinics or registries, where there was a population with early MI; 
the lowest diagnostic yield was from screening programs. The committee 
noted that it was difficult to interpret the results from pathology databases, 
as this may have included data from primary care. The committee also 
discussed that the NNT depended on the cholesterol level used to identify 
“at risk” patients. 
Trade-off between 
benefits and harms 
The committee considered that the benefit of cascade testing was that 
affected relatives of an index patient with an identified FH mutation could be 
identified and treated relatively quickly to reduce the risk of a cardiovascular 
event. It was noted that direct cascade testing (for genetic and clinical 
diagnosis) had a greater uptake rate and therefore identified and treated 
more “at risk” people than indirect cascade testing. For primary care, the 
committee noted that database searching was an effective method of 
identifying a lot of people at risk from FH. For secondary care searching, the 
committee discussed the variation in the population and testing strategies of 
the different subsections (pathology databases, lipid registries, CCU/MINAP 
and screening strategies) and that this variation was reflected in the vastly 
different diagnostic yield and uptake rates of the different sections. Overall, 
any strategy (cascade testing, primary care or secondary care database 
searching) was more effective than not undertaking case finding. However, 
the committee agreed that cascade testing (current practice) and primary 
care searching were the most comprehensive and practical ways of 
identifying people who may have FH. The committee did not identify any 
clinical harms associated with case-finding for FH. 
The committee discussed the impact of the new evidence on the other 
recommendations in this section, and decided that they should stand (see 
recommendations 1.2.2, 1.2.3 and 1.2.4 in the short version of the guideline 
for these recommendations). 
Trade-off between 
net health benefits 
and resource use 
The committee considered that the weight of published economic evidence, 
including the economic analysis conducted for the original guideline, found 
that cascade testing was cost effective. Recent studies are more relevant to 
current decision-making because of developments in genetic testing and 
the ability to focus resources on cascade testing from index cases with a 
confirmed monogenic mutation. 
A new, unpublished economic analysis was considered by the committee 
(Kerr et al., 2017). This study compared monogenic cascade testing with no 
cascade testing and found that cascade testing was cost effective with an 
ICER of £5,806 per QALY.  
Having established that cascade testing was cost effective based on 
existing analyses, including the original guideline, the committee decided 
that a de novo analysis was required to determine whether case 
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 Committee discussions 
identification strategies in primary care or secondary care or both in addition 
to cascade testing were cost effective – evidence that was not available 
from the published literature. The committee were also interested in the 
most cost-effective cholesterol threshold for case finding, the relative 
diagnostic performance between the most popular clinical assessment tools 
(the Simon Broome criteria and the DLCN criteria), and the optimal 
threshold in each tool that should be used for referral to a lipid clinic. The 
prevalence of FH had been estimated within a variety of cholesterol 
thresholds in the literature but the only threshold for which there was strong 
evidence (cases were genetically confirmed, within a relevant population 
and data agreed with known epidemiology) was total cholesterol greater 
than 9.3 mmol/L. The committee discussed that while this threshold was 
quite high and would likely miss a large number of cases, it was the only 
one with strong enough evidence to underpin recommendations with a 
potentially high resource impact. 
The results of the analysis confirmed that cascade testing was cost-
effective, and showed that the addition of primary care case finding based 
on a total cholesterol threshold of >9.3mmol/L was cost-effective with an 
ICER of £1,538/QALY gained. The results were robust to nearly all of the 
sensitivity analyses but sensitive under some scenarios: higher prevalence 
of FH in people with early MI (potential new index cases in secondary care), 
a ‘rule in’ (definite FH only) profile for the sensitivity and specificity of the 
clinical assessment tools in primary care, a ‘rule in’ profile in both primary 
and secondary care, and multiplying the number of relatives approached for 
cascade testing four-fold. The committee determined that a ‘rule in’ profile 
for clinical assessment tools was likely to miss too many cases of FH due to 
having a very low level of sensitivity and was associated with lower net 
monetary benefit values so was not cost effective compared to the less 
specific but more sensitive criteria. Identifying and contacting 8 relatives per 
index case was thought to be unlikely to be achieved in clinical practice.  
The committee discussed that the sensitivities of both clinical assessment 
tools under the ‘rule out’ profile (possible or definite FH under the Simon 
Broome criteria; score >5 under the DLCN criteria) are quite similar and that 
the associated costs and QALYs were extremely similar. The committee 
therefore decided to recommend that either tool could be used to decide 
which patients are referred for genetic testing. While this would theoretically 
involve a change in current practice as the Simon Broome criteria had 
previously been recommended in CG71, topic experts advised there is a 
proportion of primary care clinicians who use the DLCN or do not currently 
use any clinical assessment tool. The committee discussed that any 
appropriately-trained clinician working in primary care should be able to 
recognise the signs and symptoms required to populate the DLCN criteria 
and noted that improvements to the DLCN are an active area of research so 
did not want to unduly discourage its use.  
The model concluded that secondary care case finding in people with an 
early MI was not cost effective with ICERs in the region of £60-
80,000/QALY gained. This was due to the low prevalence of FH in the 
target population, which would have to triple in order to change the 
conclusions, which the committee considered unlikely. 
The committee discussed several limitations of the current analysis, mainly 
relating to lack of data availability in certain key areas including the true 
QRISK and age/sex distribution of people likely to be found by the case 
finding strategies, the relative risks of cardiovascular events in people with 
and without FH and a total cholesterol above 9.3, the true relative risk of 
high intensity statin treatment in these people (which was thought to be 
greater than in the non-FH group) and the proportion of people with and 
without MI already treated with statins. Despite these limitations, it was 
noted that the conclusions of the model were robust to even extreme 
variation in parameters. 
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 Committee discussions 
The committee discussed the implications of case finding using a blanket 
total cholesterol threshold of 9.3 for patients of all ages and for patients of 
both sexes. Particular concern was expressed that patients below the age 
of 30 have, on average, considerably lower total cholesterol levels than 
older patients. Therefore, using a single threshold across all age groups 
would mean that a negligible number of younger patients with FH would be 
identified through case finding. Furthermore, total cholesterol levels differ by 
sex across different age groups; for individuals between the ages of 
approximately 25 to 55, total cholesterol is, on average, higher for males 
than for females, whereas the reverse is true for individuals outside of this 
range. Concern was therefore expressed that using a blanket threshold may 
advantage one sex over another. 
The de novo economic model developed for this update relied on data from 
a study which reported a genetically confirmed prevalence of FH above a 
threshold of 9.3 mmol/L (Futema 2015). These data were not nuanced by 
age or gender. However, the reported data show that the threshold of 9.3 
mmol/L corresponds to the 99.5th percentile of total cholesterol in the study 
cohort. Therefore, a solution was discussed in which total cholesterol 
thresholds corresponding to the 99.5th percentile across various age and 
sex groups could be calculated using alternative, large-sample data from 
the Health Survey for England (HSE) in order to produce appropriately 
granular thresholds. Due to the large sample size and wide geographic 
coverage, the HSE data was seen as a robust source of population level 
cholesterol values, particularly at the top end of the distribution. In order for 
the committee to make recommendations nuanced by age or sex groups, 
the assumption that the proportion of patients with FH in the 99.5th 
percentile of total cholesterol reported by the Futema study would not be 
radically lower in each patient subgroup derived from the Health Survey for 
England data would have to hold. The committee agreed that, since the 
economic model showed that case finding is highly cost-effective, any 
reasonable assumptions about these values would not qualitatively change 
the results. 
The committee discussed the appropriate number of age categories by 
which to nuance the case finding threshold. It was felt that splitting the 
population into a larger number of groups would provide more granularity 
and ensure that the recommendations addressed variation in cholesterol 
levels across age groups more accurately. However, the committee also 
agreed that case finding on a primary care database is a time-consuming 
activity, and introducing a large number of age groups would substantially 
increase the workload for GP surgery staff, making the recommendations 
less likely to be implemented. Furthermore, in the absence of an audit tool 
for FH case finding, practice staff would have to design and conduct their 
own searches, which could act as a further barrier to implementation.   
The committee agreed that specifying thresholds for two age groups 
(patients aged 16-29 and patients aged >30) struck an appropriate balance 
between these two competing factors. These groupings appropriately 
account for the lower total cholesterol levels in younger patients, while 
retaining a practical number of groups for case finding on a practice system. 
The committee also discussed the potential for nuancing the threshold by 
sex. It was noted that if the preferred age groups of 16-29 and >30 were 
further subdivided by sex, the resulting total cholesterol thresholds would be 
lower for males than for females across both groups. The committee agreed 
that such a divide would favour males, as the thresholds do not adequately 
reflect the period between the ages of 25-55 where, on average, males 
have a higher total cholesterol than women. It was felt that, to appropriately 
reflect the intersectionality between age and sex, at least 4 age brackets 
would be required, resulting in 8 subgroups overall. The committee 
considered that, on balance, a simpler recommendation with only 2 
thresholds based on age would likely result in better guidance uptake and 
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 Committee discussions 
adherence, and would therefore provide greater benefit to both sexes than 
a more nuanced recommendation which is impractical to implement. 
Moreover, the committee noted that the variation in total cholesterol 
according to patients’ age is substantially greater than according to gender, 
and therefore nuancing recommendations by the former axis is of primary 
importance. 
The committee discussed the thresholds for the selected age groups 
observed in the Health Survey for England data: 7.6 mmol/L for patients 
aged 16-29 and 9.0 mmol/L for patients aged >30. It was suggested that the 
threshold for the younger group of patients should be slightly lowered to 7.5 
mmol/L in order to be consistent with the threshold for suspecting FH 
elsewhere in the guideline. The committee agreed that, while this 
represented a slight departure from the empirical data, it would lend clarity 
to the guidance, and potentially assist with its uptake. Treating FH is much 
more cost-effective in younger age groups so it is highly unlikely that slightly 
lowering the threshold would result in cost-ineffective care. It was also 
confirmed that the value of 7.5 mmol/L lies within the 95% confidence 
interval for the 99.5th percentile of total cholesterol for this age group. It was 
therefore judged that the change is justified by the evidence. The resource 
impact of reducing the threshold was also discussed, and was estimated to 
be negligible, given the relatively small number of patients below the age of 
30 whose cholesterol levels are recorded.  
The committee noted that implementing more granular recommendations 
could be made more practical in the future with an appropriately designed 
audit tool. Therefore, it was concluded that a research recommendation 
should be made on this topic.  
The committee noted that data on the true prevalence of FH within different 
cholesterol thresholds are sparse and conflicting but that, given the highly 
cost-effective nature of primary care case finding in populations with total 
cholesterol above 9.3, it is likely that conducting case finding in lower 
thresholds would still represent a cost-effective use of NHS resources. The 
resource impact associated with the various strategies in the model was 
calculated to be high, however, and any further increases would have to be 
based on more robust evidence than was available during this update. 
Other 
considerations 
Monogenic FH vs polygenic hypercholesterolaemia: genetic testing will 
identify “true” monogenic FH. Polygenic hypercholesterolaemia presents 
with the clinical phenotype of FH, which can mimic monogenic FH, however 
people with polygenic hypercholesterolaemia often have higher triglycerides 
than people with monogenic FH. The committee discussed that the risk of 
CHD is lower in people with polygenic hypercholesterolaemia than in people 
with monogenic FH; no evidence was presented for this, but this was 
recorded from anecdotal discussion by the committee. Both people with 
monogenic FH and polygenic hypercholesterolaemia require statin 
treatment; however, people with polygenic hypercholesterolaemia respond 
better (need a lower dose of lipid-lowering drugs) because they do not have 
the LDLR, APOB or PCSK9 defect. 
The committee discussed that the current gold standard test for FH is 
genetic testing using next generation sequencing, which captures the three 
genes of interest: LDLR, APOB and PCSK9. The committee agreed that 
good quality evidence should have genetic confirmation of FH as a 
reference standard. The evidence review assessed clinical and genetic 
cascade testing of FH separately; although there were a small number of 
studies assessing cascade testing using clinical or genetic methods, the 
trend was towards a higher diagnostic yield in genetic cascade testing.  
The committee discussed the issue of dropouts/ non-uptake of testing which 
is an important issue, and is where a lot of people are “lost” from the care 
pathway. 
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 Committee discussions 
It was noted that direct cascade testing can either be via a letter sent by a 
healthcare professional, or by making contact by phone. It was the 
committee’s opinion that most direct cascade testing in the UK is believed 
to be via letter, whether direct or indirect (NB. This has equalities issues – 
ensuring materials are made available in alternative formats, different 
languages). The setting of cascade testing was also discussed: The 
committee agreed that cascade testing should be carried out in specialist 
centres as these settings provide genetic counselling which is necessary 
when offering people genetic testing (see 2011 genetic counselling 
guidelines). 
An issue with GP database searching is the use of Read codes and/or ICD 
codes: different GP practices and datasets have different codes, for 
example there is no Read code for tendon xanthoma (a diagnostic criterion 
for FH). It was also discussed that there may be detection bias arising from 
the fact that some people listed in primary care databases may have a 
recorded cholesterol measurement, and these may have different 
characteristics to those without a cholesterol measurement. There is also 
inadequate information stored in GPRD that would enable diagnosis to be 
made using DLCN criteria. The committee discussed that there is an issue 
with accurate coding of FH; for example, a person with FH, CHD and 
tendon xanthoma may have a code for FH and CHD, one as a diagnosis 
and one as a major event and may or may not have a code for tendon 
xanthoma. 
The committee noted that, for people 40 years or older. NHS health checks 
provide a systematic means of measuring and recording cholesterol, and a 
high uptake of these would enable more people with FH to be identified 
through primary care case finding. 
With regards to identification of FH in children of index cases of FH, the 
committee discussed that diagnosis would now only be made by genetic 
testing (gold standard), not by obtaining LDL-C concentrations. The original 
recommendation for identifying FH in children of an affected individual with 
FH was to use DNA testing if the mutation was known, or LDL-C 
concentration where a mutation was not identified. Given that adults with a 
definitive diagnosis of FH will now have an identified mutation, the 
committee considered that genetic testing of a child (who has a parent with 
FH) was sufficient to identify FH in the child of a person with FH, and that 
measuring LDL-C concentration to identify FH in children of affected adults 
was unnecessary. The committee decided that the recommendation 
regarding measuring of LDL-C concentration in children to diagnose FH 
should be stood down to reflect this change in technology and clinical 
practice. The results for cascade testing support this decision; as genetic 
identification of FH has a higher diagnostic yield (across direct, indirect and 
direct and indirect methods) compared to clinical diagnosis; therefore 
indicating that genetic identification of FH is more effective than clinical 
methods (e.g. DLCN) alone. 
The committee discussed and noted that there could be various equalities 
issues: 
 Consideration was given to patients where English is not their first 
language, and there may be the need for translation services. 
 If either direct or indirect cascade testing is used then written materials 
should be available in alternative formats/ languages. A translation 
service would need to be considered if contacting people by phone call. 
 Families where individuals are estranged, including single parent families 
and in cases of adoption. 
 There is regional variation in availability of and access to FH services and 
genetic testing. 
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 Committee discussions 
 Ethnicity: in general there is a lack of data on prevalence of FH in different 
ethnic groups: it has been suggested that FH is less common in people of 
African family origin. 
 Gender: males with FH have a risk of MI at an earlier age than females, 
this reflects the general population. However, in both males and females 
with FH, there is a greater risk of MI in untreated FH.  
 Young people: there may be a greater risk of MI in younger people with 
FH if they remain untreated, Effective early treatment reduces their risk to 
that of the general population. 
 Pregnancy/breastfeeding: the treatment for FH is high intensity statin, 
pregnant or breastfeeding women are not advised to take statins. 
The committee discussed the need for new research recommendations; 
there was consensus that more research was needed on the effectiveness 
of using different LDL-C concentration thresholds in primary care case 
finding, the effectiveness of secondary care case finding, and the 
comparative effectiveness of direct and indirect cascade testing. The 
research recommendations are outlined in more detail in section 2.8 
2.7 Recommendations 
1. Suspect familial hypercholesterolaemia (FH) as a possible diagnosis in adults 
with: 
 a total cholesterol level greater than 7.5 mmol/l and/or 
 a personal or family history of premature coronary heart disease (an 
event before 60 years in an index individual or first-degree relative). 
[2008, amended 2017] 
2. Systematically search primary care records for people: 
 younger than 30 years, with a total cholesterol concentration greater 
than 7.5 mmol/l and 
 30 years or older, with a total cholesterol concentration greater than 9.0 
mmol/l 
as these are the people who are at highest risk of FH. [2017] 
3. For people with a personal or family history of premature coronary heart disease 
(an event before 60 years in an index individual or first-degree relative), but whose 
total cholesterol is unknown, offer to measure their total cholesterol. [2017] 
4. Carry out cascade testing using DNA testing to identify affected first-and second-
and, when possible, third-degree biological relatives of people with a genetic 
diagnosis of FH. [2017] 
5. In children aged 0-10 years at risk of FH because of one affected parent, offer a 
DNA test at the earliest opportunity. If testing of a child at risk has not been 
undertaken by the age of 10 years, offer an additional opportunity for a DNA test.  
[2017] 
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2.8 Research recommendations 
2.8.1 Using different thresholds of low-density lipoprotein cholesterol concentration 
in primary care case-finding  
What is the clinical and cost-effectiveness of using different thresholds of low-density 
lipoprotein cholesterol (LDL-C) concentration in primary care case- finding? 
Why this is important 
The clinical community recognises that familial hypercholesterolaemia (FH) is 
underdiagnosed, with prevalence more likely to be approximately 1 in 250 rather than the 
widely cited 1 in 500. Searching electronic primary care databases is an effective way of 
identifying people with FH. One of the ways in which people are identified through electronic 
primary care database searching is to search using total cholesterol or low-density 
lipoprotein cholesterol (LDL-C) concentration. Currently, the entire evidence base for 
identifying cohorts of people with FH through primary care case finding uses a total 
cholesterol concentration cut-off of 9.3 mmol/l. This is a very high concentration and 
anecdotal evidence suggests that this identifies older people but may miss younger people 
with FH. This could lead to missed opportunities to identify and treat people with FH at an 
earlier age. Research is needed to identify whether using different total cholesterol and LDL-
C concentrations to identify people with FH through primary care database searching affects 
the diagnostic yield of FH. Additionally, there is a lack of data on the ethnicity, age and 
triglyceride concentration of people with FH identified through primary care database 
searching. These should be included as outcomes in future research.  
Table 9 Specification for research recommendation 
PICO Population: 
People registered with a general practice in England 
 
Intervention:  
Searching primary care electronic databases using the following cut-offs: 
 
Total cholesterol (TC) concentration: 
- >7.5 mmol/L 
 
LDL-C concentration: 
- >8.5 mmol/L 
- 6.5-8.4 mmol/L 
- 5-6.4 mmol/L 
- 4-4.9 mmol/L 
- >4.9 mmol/L 
 
Comparison: 
N/A 
 
Outcomes:  
Diagnostic yield of people with FH 
Age of those identified with FH 
Ethnicity of those identified with FH 
Triglyceride concentration of people identified with FH 
Current evidence base Currently, the most robust evidence base for identifying cohorts of 
people with FH through primary care case finding uses a total 
cholesterol concentration cut-off of 9.3 mmol/L only. More research is 
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needed to establish whether there is a greater diagnostic yield when 
using different LDLC or TC cut-offs. Additionally, there is a paucity of 
information on the ethnicity, age and triglyceride concentration of people 
diagnosed with FH, therefore this information should be captured in this 
question. 
Study design Prospective or retrospective cohort studies 
2.8.2 Evaluate the benefits of different search strategies in primary care case finding 
What is the clinical and cost-effectiveness of identifying people with FH through primary care 
case-finding using more factors than low-density lipoprotein cholesterol (LDL-C) 
concentration alone? 
Why this is important 
The currently available data only allow for recommendations around primary care case 
finding for people with FH to be based on LDL-C and age. More sophisticated algorithms 
incorporating a wider range of potential risks factors (analogous to ones available in other 
areas, such as the Framingham CVD risk assessment and FRAX osteoporosis score) may 
allow for more sensitive and specific electronic searches to be conducted, based on data 
routinely available in primary care systems. This research would also help to address issues 
around the feasibility and practicality of these searches in primary care. 
Table 10: Specification for research recommendation 
PICO Population:  
People registered with a general practice in England 
 
Intervention:  
Searching primary care electronic databases using multidimensional 
algorithms, which may include factors such as: 
 
LDL-C concentration 
Total cholesterol concentration 
Triglyceride concentration 
Age 
Sex 
Personal history of CVD 
Family history of CVD 
 
Comparison: 
N/A 
 
Outcomes:  
Diagnostic yield of people with FH 
Age of those identified with FH 
Ethnicity of those identified with FH 
Triglyceride concentration of people identified with FH 
Current evidence base Currently, the entire evidence base for case finding in secondary care is 
not robust enough; with the interventions being too disparate to pool and 
the diagnostic yield being very low. More research is required on the 
efficacy of case-finding using secondary care databases on particular 
populations to establish whether it is more clinically and cost-effective to 
identify FH this was in specific sub-populations (e.g. younger people, 
smokers v non-smokers). 
Study design Prospective or retrospective cohort studies 
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2.8.3 Evaluate the benefits of different search strategies in secondary care case 
finding 
What is the clinical and cost-effectiveness of identifying people with FH through secondary 
care case-finding? 
Why this is important 
There is a lack of good quality evidence on secondary care case-finding. More research is 
required to assess the mutation detection rate in people, especially with regards to those that 
have had MI at different ages, differences in mutation detection between males and females, 
and in smokers compared to non-smokers. The detection of FH in young people through 
secondary care searches is of particular importance, as current opinion is that case finding is 
more likely to identify older people; if more people with FH can be identified at an earlier age, 
they can benefit from earlier intervention and treatment. 
Table 11: Specification for research recommendation 
PICO Population:  
People attending secondary care setting, with data in secondary care 
databases. 
 
Intervention:  
Searching secondary care electronic databases to identify people with 
clinical FH. 
 
Comparison: 
N/A 
 
Outcomes:  
Diagnostic yield of people with FH 
Ethnicity of those identified with FH 
Triglyceride concentration of people identified with FH 
 
Outcomes should be subgrouped by age, gender, age of MI and 
smoking status. 
Current evidence base Currently, the entire evidence base for case finding in secondary care is 
not robust enough; with the interventions being too disparate to pool and 
the diagnostic yield being very low. More research is required on the 
efficacy of case-finding using secondary care databases on particular 
populations to establish whether it is more clinically and cost-effective to 
identify FH this was in specific sub-populations (e.g. younger people, 
smokers v non-smokers). 
Study design Prospective or retrospective cohort studies 
2.8.4 Evaluate the efficacy of direct and indirect cascade testing 
What is the clinical and cost-effectiveness of identifying relatives of people with FH through 
direct cascade testing directly compared to indirect cascade testing? 
Why this is important 
There is a lack of evidence directly comparing direct cascade testing to indirect cascade 
testing. More high quality research is required to directly compare the uptake rate amongst 
relatives of index individuals with FH using direct and indirect cascade testing to establish 
which is the more effective clinically and with regards to cost. 
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Table 12: Specification for research recommendation 
PICO Population: 
Relatives of people diagnosed with FH  
 
Intervention:  
Direct cascade testing: a healthcare professional makes direct contact 
with the relatives of the index case already diagnosed with (or identified 
as having) FH 
 
Comparison: 
Indirect cascade (the index case contacts their own relatives 
themselves) 
 
Outcomes:  
Uptake rate of relatives of people with FH contacted via cascade testing 
Diagnostic yield of FH detected through cascade testing process 
Current evidence base Currently, there are no studies that directly compare direct and indirect 
cacade testing for identifying relatives of index individuals with FH. 
Direct comparison of these methods of cascade testing is required to 
fully inform the clinical and cost-effectiveness of these methods of 
cascadet testing. 
Study design RCT, Prospective cohort. 
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3 Evidence review and recommendations: 
Diagnosis 
3.1 Introduction 
DNA diagnosis is the gold standard for diagnosing monogenic FH (presence of a mutation in 
one of the LDR, APOB or PCSK9 genes). Prior to widespread access to DNA testing, a 
diagnosis of FH could be based on either DNA testing or the Simon Broome criteria. 
Currently, scoring criteria are more commonly used to assist in identifying people at risk of 
FH. These scoring criteria attribute a score to personal and family medical history, physical 
examination, lipid concentrations and genetic mutations; an increasing score reflects an 
increased likelihood of a diagnosis of FH. In the UK, the two most commonly used scoring 
criteria are Simon Broome criteria and Dutch Lipid Clinic Network (DLCN) criteria.  
DNA testing has changed greatly since the publication of the original guideline in 2008; with 
Next Generation Sequencing (NGS) now more widely available. This has reduced the cost of 
DNA testing for FH causing mutations. Given these changes in DNA technology and the use 
of scoring criteria in the diagnostic pathway, the clinical question has been updated to reflect 
current clinical practice: whether Simon Broome or DLCN criteria are more effective at 
identifying people with genetic FH. 
3.2 Review question 
In adults with suspected FH, what is the clinical and cost effectiveness of different scoring 
criteria to diagnose FH? 
3.3 Clinical evidence review 
3.3.1 Methods 
This review was conducted according to the process outlined in the review protocol (see 
Appendix C.2) with the following exceptions:  
Where four or more studies were available for all included strata, a bivariate model was fitted 
using the mada package in R v3.3.1, which accounts for the correlations between 
sensitivities and specificities. Where sufficient data were not available, separate pooling was 
performed for sensitivity and specificity, using Microsoft Excel, treating the data as simple 
proportions. This approach is likely to somewhat underestimate test accuracy as it fails to 
account for the correlation and trade-off between sensitivity and specificity (see Deeks 2010). 
Random-effects models (der Simonian and Laird) were fitted for all syntheses, as 
recommended in the Cochrane Handbook for Systematic Reviews of Diagnostic Test 
Accuracy (Deeks et al. 2010). 
Poor sensitivity or specificity was considered as 50% (0.5) or less: moderate sensitivity or 
specificity was considered >50 and ≤75% and high sensitivity or specificity was considered 
>75%. 
Inconsistency 
This criterion applied only when meta-analysis had been performed. I2 was calculated to 
assess the heterogeneity of contributing studies. Inconsistency was rated as ‘serious’ if there 
was substantial unexplained heterogeneity (I2>40%) in either of the sensitivity or specificity 
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analyses, and very serious if there was very substantial heterogeneity (I2>75%) in either 
analysis. Visual inspection of the results was used as an additional tool to assess whether 
there was heterogeneity. 
Imprecision: 
The GRADE working group recommend downgrading if confidence intervals are wide, but 
what constitutes ‘wide’ depends on the specific review. The topic experts were consulted on 
maximum width of 95% CIs deemed acceptable when considering imprecision around the 
sensitivity and specificity. A range of >15% in either the sensitivity or specificity estimate was 
considered serious imprecision and a range of >15% in both sensitivity and specificity was 
considered very serious imprecision.  
A sensitivity analysis was undertaken for the outcomes of DLCN >5, Simon Broome possible 
and definite and Simon Broome definite; removing data from the Haralambos (2015) study 
due to reporting of imputed values for the Simon Broome diagnostic accuracy and because 
this study used a modified DLCN criteria. 
It was originally planned that PPV and NPV would be reported where the prevalence of FH 
was judged to be similar between studies. However, the level of between-study 
heterogeneity in prevalence was consistently judged to be too great, and therefore PPV and 
NPV values (specified as a non-critical outcome) were not reported. 
3.3.2 Results 
A systematic search was conducted (see appendix D) which identified 2,146 articles. The 
titles and abstracts were screened and 62 articles were identified as potentially relevant. Full-
text versions of these articles were ordered and reviewed against the criteria specified in the 
review protocol (appendix C.2). Of these, 53 were excluded as they did not meet the criteria 
and 9 studies met the criteria and were included.  
A review flowchart is provided in appendix E.2, and the excluded studies (with reasons for 
exclusion) are shown in appendix F.2. 
Six studies addressed the effectiveness of DLCN criteria to identify genetic FH (Bell 2014; 
Bell 2014b; Haralambos 2015 Hooper 2012; Kirke 2015; Maglio 2014). Four studies 
assessed both DLCN and Simon Broome criteria to identify FH compared to genetic methods 
(Clarke 2013; Futema 2013; Haralambos 2015; Jannes 2015). Bell 2014, Bell 2014b, Kirke 
2015 and Maglio 2014 provided information to calculate diagnostic yield only.  
Table 13: Summary of included studies 
Study 
reference 
(including 
study 
design) 
Study 
population 
and setting 
Index test Reference standard 
(or gold standard) 
Accuracy 
measures 
Bell (2014) 196 (100 
cases and 96 
historical 
controls) 
Secondary 
care – 
pathology 
database 
DLCN probable 
or definite 
Genetic test for LDLR, 
APOB and PCSK9 
mutations 
Diagnostic yield 
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Study 
reference 
(including 
study 
design) 
Study 
population 
and setting 
Index test Reference standard 
(or gold standard) 
Accuracy 
measures 
Bell (2014b)  N=153 (n=30 
with DLCN ≥4 
underwent 
genetic 
testing) 
Primary care 
DLCN ≥4 
(probable or 
definite) 
Genetic test for LDLR, 
APOB and PCSK9 
mutations 
Diagnostic yield of 
DLCN to detect 
genetic FH 
Clarke 
(2013).  
 
N=204 
Secondary 
care – lipid 
clinic 
SB (definite or 
possible) DLCN 
definite, 
probable, 
possible) 
Genetic test – does not 
state which mutations 
screened for 
Sensitivity and 
specificity of 
clinical score to 
detect genetic FH 
Diagnostic yield 
Futema 
(2013) 
289 probands 
+ another 
cohort of 220, 
aged 18 or 
over. 
Secondary 
care – lipid 
clinic 
DLCN (unlikely, 
possible, 
probable, 
definite) or SB 
(definite, 
possible, 
unclassified) 
scoring criteria 
Genetic test for mutations 
in APOB, PCSK9 or 
LDLR genes. 
Diagnostic yield 
Haralambos 
(2015) 
1,206 
 
Secondary 
care – lipid 
clinic 
SB (definite or 
possible) 
modified DLCN 
definite, 
probable, 
possible) 
Genetic test for mutations 
in APOB, PCSK9 or 
LDLR genes. 
Sensitivity and 
specificity of 
clinical score to 
detect genetic FH 
Diagnostic yield 
Hooper 
(2012) 
N=343 
(n=337 
genetic test  
where DLCN 
available) 
Primary care 
DLCN possible, 
probable or 
definite 
Genetic test for mutations 
in APOB, PCSK9 or 
LDLR genes. 
Diagnostic yield 
Jannes 
(2015) 
 
N=248 
Primary care 
DLCN (unlikely, 
possible, 
probable, 
definite), Simon 
Broome 
(definite, 
probable, no) 
Genetic test for mutations 
in APOB, PCSK9 or 
LDLR genes. 
Sensitivity and 
specificity of DLCN 
to detect genetic 
mutation. 
Diagnostic yield 
Kirke (2015) N=1,316 
(n=86 had 
clinical FH 
(DLCN>5) 
Primary and 
secondary 
care 
DLCN >5 
(subset that had 
genetic testing 
offered) 
Genetic test for mutations 
in APOB, PCSK9 or 
LDLR genes. 
Diagnostic yield of 
DLCN to detect 
genetic FH 
Maglio (2014) N=77 
Secondary 
care – lipid 
clinic 
DLCN >2 Genetic test for mutations 
in APOB, PCSK9 or 
LDLR genes. 
Diagnostic yield 
DLCN to detect 
genetic FH 
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Table 14:  Diagnostic test accuracy results 
Study 
Sensitivity 
(95% CI) 
Specificity 
(95%CI) PPV NPV 
Diagnostic yield 
(n +ve mutation/ 
n clinically 
positive) 
Simon Broome: Definite 
Clarke 2013 0.49 (0.40, 
0.59) 
0.00 (0.00, 
0.17) 
73.3 55.8 55/75 (73.3%) 
Futema 2013 0.48 (0.37, 
0.58) 
0.91 (0.86, 
0.95) 
73.3 77.4 44/60 (73.3%) 
Haralambos 
2015 
0.43 (0.38, 
0.49) 
0.89 (0.87, 
0.91) 
60.17 80.31 145/241 (60%) 
Jannes 2015 0.11 (0.05, 
0.20) 
1.00 (0.97, 
1.00) 
100 62.6 8/8 (100%) 
Simon Broome: possible + definite 
Clarke 2013 0.88 (0.80, 
0.93) 
0.16 (0.09, 
0.25) 
56.0 51.7 98/175 (56%) 
Futema 2013 0.89 (0.81, 
0.95) 
0.33 (0.26, 
0.41) 
40.6 85.7 82/202 (40.6%) 
Haralambos 
2015 
0.93 (0.89, 
0.95) 
0.18 (0.15, 
0.21) 
30.24 86.19 310/1025 (30.2%) 
Jannes 2015 0.84 (0.74, 
0.92) 
0.52 (0.42, 
0.61) 
53.6 83.1 64/119 (53.8%) 
DLCN: Definite (score > 8) 
Clarke 2013 0.56 (0.46, 
0.65) 
0.81 (0.70, 
0.90) 
82.2 53.8 60/73 (82.2%) 
Futema 
20013 
0.54 (0.43, 
0.65) 
0.69 (0.60, 
0.77) 
53.9 68.7 48/89 (53.9%) 
Hooper 2012 0.70 (0.62, 
0.78) 
0.82 (0.76, 
0.87) 
70.3 81.8 90/128 (70.3%) 
Jannes 2015 0.45 (0.34, 
0.56) 
0.88 (0.79, 
0.94) 
77.6 63.5 38/49 (77.6%) 
DLCN: probable + definite (score >5) 
Bell 2014 NR NR NR NR 9/29 (31%) 
Bell 2014b NR NR NR NR 4/30 (13.3%) 
Clarke 2013 0.76 (0.67, 
0.84) 
0.57 (0.44, 
0.68) 
73.2 60.0 82/112 (73.2%) 
Futema 2013 0.76 (0.66, 
0.85) 
0.46 (0.37, 
0.55) 
48.6 74.1 67/138 (48.6%) 
Haralambos 
2015 
0.98 (0.94, 
0.99) 
0.22 (0.18, 
0.26) 
32.76 96.04 171/522 (32.8%) 
Hooper 2012 0.91 (0.84, 
0.95) 
0.52 (0.45, 
0.59) 
53.7 90.1 116/216 (53.7%) 
Jannes 2015 0.77 (0.67, 
0.86) 
0.56 (0.45, 
0.66) 
61.9 72.9 65/105 (61.9%) 
Kirke 2015 NR NR NR NR 11/86 (12.8%)a 
DLCN: possible+ probable + definite (score >2) 
Clarke 2013 0.96 (0.91, 
0.99) 
0.25 (0.17, 
0.35) 
61.0 85.2 108/177 (61%) 
Futema 2013 0.97 (0.90, 
0.99) 
0.08 (0.04, 
0.14) 
41.5 76.9 86/207 (41.5%) 
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Study 
Sensitivity 
(95% CI) 
Specificity 
(95%CI) PPV NPV 
Diagnostic yield 
(n +ve mutation/ 
n clinically 
positive) 
Hooper 2012 1.00 (0.97, 
1.00) 
0.05 (0.02, 
0.09) 
39.1 100 128/327 (39.1%) 
Jannes 2015 0.96 (0.90 
0.99) 
0.20 (0.12, 
0.29) 
52.6 85.7 81/154 (52.6%) 
Maglio 2014 NR NR NR NR 50/77 (64.9%) 
(a) *data presented in paper, no original data available 
3.4 Health economic evidence (diagnosis) 
3.4.1 Methods 
The same methods were used as specified in section 2.4.1. 
3.4.2 Results of the economic literature review 
A total of 153 papers were identified in the literature search. All were excluded based on title 
and abstract. No economic studies were included for this review question. 
3.4.3 Economic modelling 
The evidence gathered for this review question was included in the economic modelling 
conducted for the case-finding review question. Please see section 2.4.3 and appendix O. 
3.5 Evidence statements 
3.5.1 Clinical evidence statements 
Sensitivity and specificity 
Evidence for the accuracy of 2 different diagnostic scoring systems (compared with the gold 
standard of genetic testing for mutations in LDLR, APOB and PCSK9 genes) was evaluated 
for different diagnostic thresholds. 
Simon Broome criteria 
Very low quality evidence from 4 studies with 1,872 people suggested the Simon Broome 
definite criteria had low sensitivity (0.36 [0.186, 0.581]) and high specificity (0.86 [0.158, 
0.995]). Sensitivity analysis (3 studies, 666 people, very low quality evidence) removing the 
Haralambos (2015) study also showed low sensitivity 0.335 [0.156, 0.578] and high 
specificity (0.804 [0.073, 0.950]). 
Very low quality evidence from 4 studies with 1,872 people suggested the Simon Broome 
possible and definite criteria had high sensitivity (0.89 [0.845, 0.924] and low specificity 
(0.287 [0.160, 0.459]). Sensitivity analysis (3 studies, 656 people, very low quality evidence) 
removing the Haralambos (2015) study also showed high sensitivity 0.87 [0.825, 0.905] and 
low specificity (0.325 [0.173, 0.526]). 
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DLCN criteria 
Low quality evidence from 4 studies with 1,088 people suggests that DLCN definite criteria 
(>8) had a moderate sensitivity of 0.567 [0.460, 0.669] and high specificity of (0.802 [0.713, 
0.869]).  
Low quality evidence from 4 studies with 1,531 people suggested that DLCN probable and 
definite criteria (>5) had high sensitivity (0.868 [0.711, 0.946]) but had low specificity (0.457 
[0.320, 0.601]). Sensitivity analysis (3 studies, 859 people, moderate quality evidence) 
removing the Haralambos (2015) study showed a high sensitivity of 0.807 [0.716, 0.874] and 
moderate specificity (0.517 [0.472, 0.561]). 
Low quality evidence from 4 studies with 936 people suggested that DLCN possible, 
probable and definite criteria (>2) had high sensitivity 0.967 [0.939, 0.983] respectively). The 
specificity was low (0.125 [0.057, 0.253]).  
3.5.2 Health economic evidence statements 
No economic evidence was identified in the literature for this review question. The DLCN 
criteria is slightly more expensive to administer than the Simon Broome criteria due to the 
additional clinical time required to obtain extra information. However, because the DLCN 
criteria has a higher specificity compared with the Simon Broome criteria, it is likely to result 
in a reduced use of lipid clinic resources, including genetic testing, through the increased 
confidence that people who are referred are more likely to have FH. 
3.6 Evidence to recommendations 
 Committee discussions 
Relative value of 
different outcomes 
The committee discussed that sensitivity and specificity were the most 
important outcomes, and that there needed to be a compromise between 
high sensitivity (true positive rate) and high specificity (true negative rate). 
Whilst FH can be treated relatively easily, the committee noted that the test 
needed to be adequately specific to avoid unnecessary referrals for genetic 
testing. The committee further discussed that the specificity required 
depended on whether a one or two stage process was to be used: a two 
stage process (using a scoring system to decide whether to refer to 
secondary care for further assessment) would tolerate a lower specificity 
(higher false positive rate) in the first stage of the process. 
Quality of evidence Very low quality evidence was available for the sensitivity and specificity of 
the Simon Broome definite criteria and Simon Broome definite + probable 
criteria to identify people with a genetic mutation. Low quality evidence was 
available for sensitivity and specificity for the Dutch Lipid Clinic Network 
(DLCN) criteria (possible, probable, definite, (score >2); DLCN probable 
and definite criteria, (score >5) and DLCN definite criteria (score >8) to 
identify people with a genetic mutation. 
A sensitivity analysis was undertaken for the Simon Broome possible + 
definite and definite criteria to see whether the removal of the Haralambos 
(2015) data had any effect. A sensitivity analysis was undertaken for the 
outcomes of DLCN >5, Simon Broome possible and definite and Simon 
Broome definite; removing data from the Haralambos (2015) study due to 
reporting of imputed values for the Simon Broome diagnostic accuracy and 
because this study used a modified DLCN criteria. 
There was no significant difference when Haralambos (2015) was removed 
from the meta-analysis for Simon Broome possible + definite and definite 
criteria. A sensitivity analysis was also undertaken on DLCN score >5 
(probable and definite) as Haralambos (2015) used a modified DLCN 
criteria, which reduces the score depending on triglyceride concentration. 
None of the sensitivity analyses made a significant difference to the results. 
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 Committee discussions 
No evidence was reported for PPV and NPV because the heterogeneity in 
prevalence rates between-studies was considered to be too large for pooled 
results to be robust.  
Results for the outcome of diagnostic yield were reported in section 2: case 
finding and are not reported here to avoid duplication. 
Trade-off between 
benefits and harms 
The committee noted that there is a trade-off between the sensitivity and 
specificity of diagnostic criteria: the benefit of diagnosis and treatment of FH 
vs unnecessary referrals of people who turn out not to have FH. 
The committee discussed that Simon Broome definite criteria had the 
lowest sensitivity and highest specificity for predicting a positive genetic 
diagnosis. Consideration was given to the high sensitivity and low specificity 
of Simon Broome possible + definite criteria: it was discussed that there 
was very serious inconsistency between studies. The committee went on to 
assess the evidence for DLCN criteria to predict a genetic FH mutation: The 
topic experts discussed that the DLCN criteria score of >2 (possible, 
probable and definite) had excellent sensitivity, but the low specificity could 
lead to many people who did not need referrals to secondary care receiving 
them. It was noted that a DLCN score of >5 (probable or definite) gave a 
high enough sensitivity, however specificity was poor (<50%). Conversely, a 
DLCN score of >8 (definite) had high specificity but moderate sensitivity, 
which could lead to a substantial number of people with FH being missed 
(increased false negatives). The committee concluded that using either a 
DLCN score of >5 or Simon Broome possible and definite criteria to refer on 
to genetic testing gave the best compromise between adequate sensitivity 
and specificity. The Committee agreed that the evidence was not sufficiently 
robust to be able to determine which of these two alternatives was most 
appropriate, and therefore agreed it was correct to recommend that either 
could be used. 
The committee considered the recommendations in the diagnosis section in 
terms of this evidence review and decided that recommendations 1.1.4, 
1.1.7 to 1.1.12, 1.1.14 and 1.1.16 should stand unchanged. 
Trade-off between 
net health benefits 
and resource use 
This review question was used to inform the economic modelling conducted 
for case finding. 
No economic studies were identified in the systematic review. The 
committee discussed that the DLCN criteria is slightly more expensive to 
administer than the Simon Broome criteria due to the additional clinical time 
required to obtain extra information. However, because the DLCN criteria 
has a higher specificity compared with the Simon Broome criteria, it is likely 
to result in a more appropriate use of lipid clinic resources, including genetic 
tests, through the increased confidence that people who are referred are 
more likely to have FH. 
Other 
considerations 
Given that both Simon Broome possible and definite and DLCN criteria >5 
are similar with regards to sensitivity and specificity of diagnosing FH, the 
committee asked the Topic Experts about the feasibility of using either 
Simon Broome or DLCN criteria in primary care. It was noted that the DLCN 
criteria could be viewed as being more complex than Simon Broome 
criteria. The committee discussed that it is currently easier to search 
primary care records using Simon Broome criteria, due to coding of records. 
However, in practice, electronic records would only be searched for total 
cholesterol and/ or LDL-C measurement and the rest of the assessment 
using either the Simon Broome or DLCN criteria would be undertaken by a 
healthcare professional. The committee went on to discuss that there may 
be the need for education amongst health professionals with regards to 
using DLCN criteria for diagnosing FH in primary care. This is because the 
DLCN criteria may be less familiar than Simon Broome criteria; however 
this was not considered an issue because clinicians would now have the 
option of using either Simon Broome or DLCN criteria to clinically diagnose 
FH. Furthermore, there is significant overlap in the criteria used by both 
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 Committee discussions 
Simon Broome and DLCN: both criteria assess LDL-C concentration, 
presence of DNA mutation, personal and family history and clinical features. 
It was considered that clinicians who currently assess patients for FH are 
already familiar with these aspects of FH, and that introducing the option to 
use DLCN to assess whether a person may have FH was merely a case of 
becoming more familiar with the DLCN scoring system rather than learning 
new clinical features or procedures. 
The committee considered the assessment of children at risk of FH 
because of one affected parent. It was stated that it is not appropriate to 
use DLCN or Simon Broome criteria to assess people in this patient group. 
Children at risk of FH because of an affected parent had previously been 
assessed using either LDL-C concentration of DNA testing; however the 
committee discussed this was no longer appropriate and children of people 
diagnosed with FH should have a DNA test only.  
The committee discussed the clinical need for further research in this 
clinical area and added a research recommendation comparing the use of 
the Simon Broome and DLCN criteria in identifying FH in a general 
population. 
3.7 Recommendations 
6. Use the Simon Broome or Dutch Lipid Clinic Network (DLCN) criteria to make a 
clinical diagnosis of FH in primary care settings. This should be done by a 
healthcare professional competent in using the criteria. [2017] 
7. Refer the person to an FH specialist service for DNA testing if they meet the 
Simon Broome criteria for possible or definite FH, or they have a DLCN score 
greater than 5. [2017] 
8. Inform all people who have an identified mutation diagnostic of FH that they have 
an unequivocal diagnosis of FH even if their LDL-C concentration does not meet 
the diagnostic criteria (see recommendation 6). [2008, amended 2017] 
3.8 Research recommendations 
3.8.1 Compare the Simon Broome criteria and the DLCN score in a prospective 
cohort of general population subjects. 
What is the clinical and cost-effectiveness of identifying people with FH by using the DLCN 
score compared to Simon Broome criteria in the general population? 
Why this is important 
There is a lack of good quality evidence on direct comparison of Simon Broome and DLCN 
score in diagnosing clinical FH when compared to the gold standard of next generation 
sequencing for the three common FH-causing genes. 
Table 15: Specification for research recommendation 
PICO Population: 
General population 
 
Index test:  
Simon Broome criteria 
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DLCN score 
 
Reference test: 
Next generation sequencing of APOB, PCSK9 and LDLR. 
 
Outcomes:  
Sensitivity of mutation detection 
Specificity of mutation detection 
 
Outcomes should be subgrouped by age, gender, age of MI and 
smoking status. 
Current evidence base Currently, there is no evidence for a direct comparison of Simon Broome 
and DLCN compared to a reference standard of NGS for all 3 FH 
causing mutations. 
Study design Cross sectional diagnostic accuracy study 
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4 Evidence review and recommendations: 
Management (Statin monotherapy) 
4.1 Introduction 
Current clinical management of FH routinely includes pharmacological therapy. Statin 
monotherapy is currently the initial treatment of choice for FH in adults and children. 
Treatments including bile acid sequestrants, fibrates and nicotinic acid are now 
infrequently used, as they have been superseded by newer pharmacological treatments 
such as ezetimibe, alirocumab and evolucumab; therefore a decision was made to only 
address the efficacy of statin vs placebo, as prescribing practice with regards to older 
therapies has not changed since the publication of the guideline in 2008. Guidance on 
ezetimibe, alirocumab and evolucumab has been published by the Technology 
Appraisals programme, and is not addressed here (although the guideline does now 
include a cross-reference to these appraisals). An update of this question was required 
due to a change in costs associated with statin treatment and to identify any further 
safety information on long term safety of statin therapy in children.  
4.2 Review question 
What is the clinical and cost effectiveness of statins compared to placebo in improving 
outcomes in individuals with FH?  
4.3 Clinical evidence review 
4.3.1 Methods 
The methods used to conduct this review are outlined in the review protocol (see Appendix 
C3). 
Imprecision 
As stated in the review protocol, the topic experts were asked to provide minimal important 
differences for the outcomes of this review as there were no published MIDs reported in the 
literature, No consensus of agreement was reached and therefore default MIDs of 0.75 and 
1.25 were used for dichotomous outcomes, and 0.5 x SD of the control group for continuous 
outcomes. 
4.3.2 Results 
A systematic search was conducted (see appendix D3) which identified 6,096 articles. The 
titles and abstracts were screened and 24 articles were identified as potentially relevant. Full-
text versions of these articles were ordered and reviewed against the criteria specified in the 
review protocol (appendix C3). Twenty two studies (including 9 that were included in the 
original guideline) were excluded from this review as they did not meet the criteria in the 
review protocol. One Cochrane review (Vuorio 2014) and one RCT (McCrindle 2002) met the 
inclusion criteria and were included. Four of the studies included in the Cochrane review 
were excluded from this analysis as their intervention was Lovastatin or Simvastatin, which is 
not licensed for use in children with heterozygous FH in the UK (Stein 1999; Clauss 2005; de 
Jongh 2002a; Couture 1988).The excluded studies and the reasons for exclusion are in 
Appendix F3. 
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All of the included studies had a population of children and young people; no studies of high 
intensity statins in adult populations were identified. A summary of the included studies is in 
Table 18 below and the full data extraction can be found in Appendix G3. 
Adults 
No studies of high intensity statins compared to placebo in adults with FH were identified. As 
set out in the protocol, if no RCTs were identified in a direct population then the committee 
considered it appropriate to extrapolate the effects of high-intensity statins from an indirect 
population without FH.  
CG181 Lipid Modification (published 2014) has a relevant review question on high-intensity 
statins in a non-FH population: 
 What is the clinical and cost-effectiveness of statin therapy for adults without established 
CVD (primary prevention) and with established CVD (secondary prevention)? 
Full details of the review can be found in NICE Clinical Guideline 181, section 11; appendix C 
(review protocol), appendix G (evidence tables) and appendix I (forest plots). 
How is CG181 relevant in terms of the PICO?  
The review from CG181 was based on an indirect non-FH population (adults 18 years or 
over; including those with or without established CVD, Type 1 diabetes, Type 2 diabetes and 
CKD). The interventions and comparators included in the CG181 review were low, medium 
and high-intensity statins and placebo. For the purposes of this review, only results for high-
intensity statins vs placebo were included; as indicated in the review protocol (Appendix C3). 
The high-intensity statins include Atorvastatin 20mg, 40mg or 80mg; Rosuvastatin 10mg, 
20mg or 40mg and Simvastatin 80mg, Outcomes reported in CG181 were the same as those 
specified in the FH protocol with the exception of unstable angina and dropouts not being 
reported in CG181. CG181 reported mean difference in LDL-C concentration at end of follow 
up; where possible, we used this data to impute the outcomes of % of people seeing a 50% 
or greater reduction and mean % change in LDL-C. 
The committee considered it appropriate to base their discussions of the evidence and 
recommendations on the evidence from CG181.  
How the evidence from CG181 was used  
The committee considered the evidence review from CG181 for this review question was 
relevant as statins have a comparable effect in people with or without FH. However the 
committee discussed and agreed that they could not just cross refer to the CG181 guidance, 
as a separate recommendation would be required when considering use of statins in people 
with FH. 
It was decided that the evidence should not be downgraded for indirectness of using a non-
FH population for several reasons. A non-FH population is the most appropriate; RCTs of 
statins v placebo are unethical in a population with FH. Statins are believed to have the same 
effect on people whether they have FH or not, therefore there is no difference in the action of 
statins on people with FH compared to people who do not have FH. 
CG181 Results  
Seven studies were included in the CG181 review for high intensity statins vs placebo. For 
the outcome of reduction in LDL-C concentration, the pooled results (final concentration 
mean difference) for high-intensity statin v placebo were 1.26 mmol/L (95%CI 1.23, 1.29). 
For the individual statins the results are shown in the table 11 below. There was no GRADE 
or quality assessment for the outcome of reduction in LDL-C concentration. 
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Table 16: Final LDL-C concentrations for individual high-intensity statins 
High intensity statin 
Final LDL-C concentration (mmol/L), mean 
difference (95% CI) 
Atorvastatin 20mg 1.70 (1.65, 1.75) 
Atorvatatin 80mg 1.30 (1.15, 1.06)a 
Rosuvastatin 10mg 0.43 (0.12, 0.97) 
Simvastatin 80mg 1.35 (1.14, 1.56) 
(a) Copied directly from CG181, assumed an incorrect figure 
The committee also considered the outcomes of all-cause mortality, CV mortality, non-fatal 
MI, stroke and adverse events (myalgia, liver adverse events, new-onset diabetes and 
rhabdomyolysis) reported in CG181. A summary of these results and their quality rating are 
reported in table 12 below. 
Table 17: Outcomes (results and summary of quality) reported in CG181 
Outcome 
Number of 
studies N of patients 
Relative 
effect 
(95%CI) 
Absolute 
effect Quality 
  Statins Placebo    
All cause 
mortality 
3 563/14037 
(4%) 
629/13627 
(4.6%) 
RR 0.9 (0.8, 
1) 
5 fewer per 
1000 (rom 9 
fewer to 0 
more) 
High 
CV 
mortality 
4 186/13283 
(1.4%) 
254/13292 
(1.9%) 
RR0.73 
(0.61, 0.88) 
5 fewer per 
1000 (from 
2 fewer to 7 
fewer) 
moderate 
Non-fatal 
MI 
4 96/11618 
(0.83%) 
207/11207 
(1.8%) 
0.46 (0.37, 
0.59) 
10 fewer 
per 1000 
(from 8 
fewer to 12 
fewer) 
High 
Stroke 4 339/13283 
(2.6%) 
425/13292 
(3.2%) 
0.8 (0.7, 
0.91) 
6 fewer per 
1000 (from 
3 fewer to 
10 fewer) 
Moderate 
Adverse events 
Myalgia 3 218/3865 
(5.6%) 
175/3447 
(5.1%) 
0.95 (0.78, 
1.16) 
3 fewer per 
1000 (from 
11 fewer to 
8 more) 
High 
Liver 
adverse 
events 
4 85/12766 
(0.67%) 
32/12348 
(0.26%) 
2.57 (1.71, 
3.85) 
4 more per 
1000 (from 
2 more to 7 
more) 
Moderate 
New onset 
diabetes 
1 270/8901 
(3%) 
216/8901 
(2.4%) 
1.25 (1.05, 
1.49) 
6 more per 
1000 ( from 
1 more to12 
more) 
Moderate 
Rhabdomyo
lysis 
4 4/13183 
(0.03%) 
5/12773 
(0.04%) 
0.64 (0.2, 
2.09) 
0 fewer per 
1000 (from 
0 fewer to 0 
more) 
Low 
(a) This information has been taken directly from CG181; it has not been adapted or changed in any way for the 
purposes of this guideline. 
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Table 18: Summary of included studies: children 
Study ID  Study population Intervention & 
comparator 
Outcomes reported 
Vuorio 2014 
(Cochrane 
review) 
8 RCTs, (4 included 
in review) with n= 
650* children <18 
years with FH 
(diagnosed by 
genetic testing or 
clinical criteria) 
Pravastatin 5-20mg 
(Knipscheer 1996), 
pravastatin 20-40mg 
(Wiegman 2004),  
Atorvastatin 10-20mg 
(McCrindle 2003), 
rosuvastatin 5-20mg 
(Avis 2010). All 
compared to placebo. 
Change in LDL-C concentration 
Myocardial infarction 
Adverse events: 
Liver dysfunction 
Myopathy 
Rhabdomyolysis 
Other adverse events 
Adherence  
 
Where an outcome listed in the 
review protocol is not listed in 
Cochrane, the original study will 
be used to extract the data. 
McCrindle 
2002 
(RCT) 
N=36 children with 
FH (diagnosed by a 
positive family 
history of 
hypercholesterolem
ia or premature 
atherosclerotic 
cardiovascular 
disease in 1st-
degree relatives, 
a minimum fasting 
LDL-C before 
enrolment 
> 4.15 mM/L) and 
familial combined 
hyperlipidaemia 
Pravastatin 10mg + 
colestipol v colestipol 
only 
Change in LDL-C concentration 
Adverse events 
Compliance 
*the original Vuorio publication had n=1,074, however we did not include 4 studies in this review as the 
intervention was not in the protocol, therefore n=650 of relevant studies. 
A review flowchart is provided in appendix E3, and the excluded studies (with reasons for 
exclusion) are shown in appendix F3. 
4.4 Health economic evidence (statin monotherapy) 
4.4.1 Methods 
The same methods were used as specified in section 2.4.1. 
4.4.2 Results of the economic literature review 
A total of 665 papers were identified by the literature search. Three full papers were obtained 
and reviewed. All full text papers were excluded. No economic studies from the published 
literature were included in this review question. 
4.5 Evidence statements 
4.5.1 Clinical evidence statements 
Adults 
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No studies were identified on the use of high-intensity statins in adults with FH. Evidence 
statements on the effect of high-intensity statins in people without FH can be found in 
CG181, section 11.7.1, and are reproduced below as they stood at the time of the publication 
of this update: 
High quality evidence showed that high-intensity statins are more effective when compared 
to placebo at reducing all-cause mortality at up to 5 years, but the effect size is too small to 
be clinically important [6 studies, n=27,664]. 
Moderate quality evidence showed that high-intensity statins are more effective when 
compared to placebo at reducing CV mortality at up to 6 years, but the effect size is too small 
to be clinically important at up to 5 years, but the effect size is too small to be clinically 
important [4 studies, n=26,576]. 
High quality evidence showed that high-intensity statins are more clinically more effective 
when compared to placebo at reducing non-fatal MI at up to 5 years [4 studies, n=22,825]. 
Moderate quality evidence suggested that there may be no clinical difference between high-
intensity statins when compared to placebo at reducing stroke at up to 5 years, but the 
direction of the estimate of effect favoured high-intensity statins [4 studies, n=26,575]. 
High quality evidence showed that there is no clinical difference between high-intensity 
statins and placebo in causing myalgia at up to 5 years [3 studies, n=7312]. 
Moderate quality evidence suggested that there may be no clinical difference between 
placebo and high-intensity statins in causing new-onset diabetes at 2 years, but the direction 
of the estimate of effect favoured placebo [1 study, n=17,802]. 
Low quality evidence suggested that high-intensity statin when compared to placebo caused 
fewer rhabdomyolysis events at up to 5 years, but the direction of the estimate of effect could 
favour either intervention [4 studies, n=25,965]. 
Children 
Evidence from 3 studies (n=469) indicated that statins were more effective than placebo in 
reducing serum LDL cholesterol concentration (%) by the end of follow up (up to 1 year). The 
quality of the evidence was very low. 
Evidence indicated that there was no difference between statins and placebo for the 
following outcomes: 
 Number of people experiencing adverse events at 1 month or 6 months (three studies 
(n=435). Certainty in the evidence ranged from low to very low.  
 Number of people with change in aspartate aminotransferase (3 x ULN) at end of 
follow up. (3 studies (n=470). Certainty in the evidence was low. 
 Number of people with change in alanine aminotransferase (3 x ULN) at end of follow 
up (2 studies (n=398). Certainty in the evidence was low. 
 Number of people with Myopathy (change in serum creatinine phosphokinase 
concentration 10 x ULN). (2 studies (n=227), Certainty in the evidence was low. 
 Compliance (%) to rosuvastatin 5mg, 10mg, 20mg or placebo. (1 study, (n=177), 
certainty in the evidence was low. 
The following outcomes: mortality, cardiovascular mortality, non-fatal MI, non-fatal stroke or 
unstable angina were not reported in any of the included studies. 
4.5.2 Health economic evidence statements 
No economic studies were identified in the literature for this review question.  
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4.6 Evidence to recommendations 
 Committee discussions 
Relative value of 
different outcomes 
Reduction in risk of cardiovascular events, indicated by cardiovascular 
outcomes (cardiovascular mortality, non-fatal MI, stroke) and reduction in 
LDL concentration were the most important outcomes.  
Quality of evidence Adults 
For the review of statins vs placebo in the adult population, there was no 
evidence from a population of adults with FH (it is unethical to carry out 
placebo controlled trials of statins in people with FH). Therefore the 
committee decided it was most appropriate to extrapolate the effects of high 
intensity statins in a non-FH population. The review for the comparison of 
high intensity statin v placebo in a non-FH population was presented from 
CG181 Lipid Modification guideline. The evidence and quality assessment 
from CG181 was presented as it was in the original guideline (no updates or 
modifications). It was decided that the evidence should not be downgraded 
for indirectness of using a non-FH population for several reasons: 
 A non-FH population is the most appropriate 
 RCTs of statins v placebo is unethical in a population with FH. 
 Statins have the same effect on people whether they have FH or not, 
therefore there is no difference in the action of statins on people with FH 
compared to people who do not have FH. 
High quality evidence was available for the outcomes of all-cause mortality, 
non-fatal MI and myalgia. There was moderate quality evidence for the 
outcomes of cardiovascular mortality, stroke, liver adverse events and new 
onset diabetes. Low quality evidence was available for the outcome of 
rhabdomyolysis. 
Results showed that high-intensity statins have a clinically significant effect 
in reducing non-fatal MI. There was a trend towards a beneficial effect (but 
this was not significant) for high-intensity statins in reducing cardiovascular 
mortality and all -cause mortality. There were more liver related adverse 
events with high-intensity statins up to 5 years follow up compared with 
placebo. There was no difference between high-intensity statins and 
placebo for outcomes of stroke, myalgia, new onset diabetes or 
rhabdomyolysis. 
The committee were aware that there are studies on homozygous FH, 
reporting a reduction of LDL-C with statins and LDL-C apheresis, and 
shorter term outcome on CHD morbidity. However, people with 
homozygous FH were excluded from this review. 
Children 
Five studies were included in the review for statin vs placebo in children. No 
studies reported the outcomes of mortality, cardiovascular mortality, non-
fatal MI, non-fatal stroke or unstable angina. The outcome of percentage 
reduction in LDLC showed that statins were clinically effective compared to 
placebo, there was very low quality evidence contributing to this outcome. 
The outcomes of adverse events, elevated liver enzymes, myopathy and 
compliance indicated that there was no difference between statins and 
placebo for these outcomes; all of which had low quality evidence. 
Trade-off between 
benefits and harms 
A reduction in LDLC concentration, and resulting reduction in the risk of 
cardiovascular events must be balanced against the possible adverse 
events associated with statin use (including elevated liver enzymes and 
myopathy).  
The committee noted that there is a lack of evidence on adverse events in 
long term statin use (i.e. started in childhood and continued for lifetime).  
Adults 
The committee considered the evidence presented to them on high-intensity 
statins vs placebo from CG181. The committee unanimously agreed that 
that high-intensity statins significantly reduced final LDL-C concentration 
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 Committee discussions 
compared to placebo for pooled high-intensity statins: the committee also 
agreed that final LDL-C concentration was significantly reduced for 
individual statins Atorvastatin 20mg and 80mg and Simvastatin 80mg 
compared to placebo, but not for Rosuvastatin 10mg compared to placebo. 
The committee noted that whilst the final LDL-C concentration for high-
intensity statins was reported in CG181, there was no quality assessment of 
this evidence and no evidence statements: it was reported in CG181 that 
this information was included to ensure the information was available for the 
GDG if they needed to make recommendations about individual drugs and 
targets. 
The committee noted that the only outcomes not reported in CG181 that 
were specified in the protocol for this review were unstable angina and 
number of dropouts. Whilst this information would have further informed the 
committee’s decision making, they considered that CG181 provided 
information on the beneficial effect of high-intensity statins on critical 
outcomes of all-cause mortality, CV mortality, non-fatal MI and stroke, and 
that they had sufficient information to make recommendations on use of 
high-intensity statins in people with FH. The committee then went on to 
discuss the negative effects of high-intensity statins and agreed that there 
was an increase in liver-related adverse events with high-intensity statins up 
to 5 years follow-up. The committee concluded that, taking into account the 
indirect population, high-intensity statins showed benefit which the 
committee stated they would expect to see in a population with FH. The 
recommendation on statin therapy in adults was updated from the 2008 
guideline; however, it was considered appropriate to maintain the wording 
about using a statin with the lowest acquisition cost, as no evidence to 
indicate using a particular statin was considered during this update. 
The committee considered the effect of the evidence review on the 
recommendations associated with statin treatment in adults and decided 
that recommendations 1.3.1.1, 1.3.1.3 and 1.3.1.10 to 1.3.1.16 should stand 
unchanged. 
Children 
In children, the use of statins must be balanced against possible 
developmental adverse events caused by statins; the committee and topic 
experts discussed that rosuvastatin or pravastatin were most appropriate 
due to their hydrophilic nature, which makes them less likely to cross the 
blood-brain barrier. The committee discussed the age at which statin 
treatment would start; topic experts responded that the age varies, but 
treatment by the age of 10 was considered appropriate to balance reduction 
in cardiovascular risk and adverse events. The topic experts discussed that 
there were no hard outcome measures to assess the efficacy of statins in 
children (cIMT is hard to monitor and not validated over time), but the 
general principle was to prescribe the lowest dose that gives a beneficial 
effect with few adverse effects. The committee considered the effect of the 
evidence review on the recommendations associated with statin treatment 
in children and decided that recommendations 1.3.1.17 to 1.3.1.19, and 
1.3.1.23 to 1.3.1.27 should stand unchanged. 
Trade-off between 
net health benefits 
and resource use 
There were no included economic studies for this review question. 
The findings from the clinical review were used to inform the economic 
modelling conducted for case finding. 
The committee discussed that rosuvastatin is more expensive than others 
that are just as effective although it is about to come off patent next year. 
The committee noted that better diagnosis through case identification and 
cascade testing will include some children and increase demand for 
specialist paediatric lipid services. The committee considered that there is 
no evidence that one statin is safer than another in children. 
Other 
considerations 
The committee previously discussed that pregnant or breastfeeding women 
should not take statins; therefore they should receive appropriate 
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 Committee discussions 
counselling and advice about cessation of statins prior to pregnancy and 
whilst breastfeeding.  
The committee discussed that the previous guideline CG71 had a target of 
at least 50% reduction in LDL-C concentration with statin treatment. The 
committee discussed this in the context of the updated evidence 
presentation and current European guidelines for reduction in LDL-C 
concentration with statin treatment in people with FH. It was highlighted that 
an issue is that a person with FH may have a much higher baseline LDL-C 
concentration than a person without FH; therefore a 50% reduction may not 
reduce their LDL-C sufficiently. The committee discussed how a target LDL-
C may be more appropriate; however there is uncertainty as to what an 
appropriate target is. Therefore the committee concluded that there was a 
lack of evidence to change the 50% reduction target and that it was useful 
to have as a guide as to what reduction in LDL-C concentration was 
appropriate for treatment with statins. 
The committee discussed that although simvastatin 80mg is a high-intensity 
statin, it is unlikely to be used in practice due to a warning issued by the 
MHRA. 
With regards to use of statins in children, the committee summarised that 
that there was a beneficial effect in children and made a recommendation 
thus “Offer statins to children with FH by the age of 10 years”. The 
committee discussed that the original recommendation 1.3.1.22 stated 
“When the decision to initiate lipid-modifying drug therapy has been made in 
children and young people, statins should be the initial treatment. 
Healthcare professionals with expertise in FH in children and young people 
should choose a statin that is licensed for use in the appropriate age group.” 
The committee agreed that this recommendation was in an outdated style 
and was too long. The committee were concerned that the new 
recommendation to prescribe statins did not mention anything about 
expertise required in prescribers or licensing of the drugs. Therefore the 
committee agreed that it was appropriate to also make a recommendation 
on using an appropriately licensed statin for a child with FH, and amend the 
old recommendation 1.3.1.22 to state that the healthcare professional 
should have expertise in treating children and young people in a child-
focussed setting.  
The committee discussed and decided that there was a clinical need to 
make research recommendations on the effect of treatment with long term 
statins in children, see section 4.8.1. 
The committee noted the guideline already contained a recommendation 
that “coronary heart disease risk estimation tools, such as those based on 
the Framingham algorithm, should not be used because people with FH are 
already at a high risk of premature coronary heart disease.” The committee 
agreed this recommendation still remained highly relevant, but that it should 
be amended to also contain reference to QRISK2 as a tool rthat should not 
be used in people with FH, as this is now the one commonly used in the 
UK, and is recommended in other NICE guidelines to use in people who do 
not have FH. 
4.7 Recommendations 
9. Offer a high-intensity statin with the lowest acquistion cost as the initial treatment 
for all adults with FH and aim for at least a 50% reduction in LDL-C concentration 
from the baseline measurement. [2017]  
10. Offer statins to children with FH by the age of 10 years or at the earliest 
opportunity thereafter. [2017] 
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11. For children and young people with FH, consider a statin that is licensed for use in 
the appropriate age group. [2017] 
12. Statin therapy for children and young people should be initiated by a healthcare 
professional with expertise in treating children and young people with FH, and in a 
child-focused setting. [2008, amended 2017] 
13. Coronary heart disease risk estimation tools, such as QRISK2 and those based on 
the Framingham algorithm, should not be used because people with FH are 
already at a high risk of premature coronary heart disease. [2008, amended 2017] 
4.8 Research recommendations 
4.8.1 Long-term monitoring of sub-clinical atherosclerosis in children with FH who 
are treated with statin therapy  
What are the long-term effects of statin therapy on sub-clinical atherosclerosis in children 
with FH who are treated with statin therapy? 
Why this is important 
Although statins are increasing in use, there is still a lack of data on the long-term effects of 
statins in children. It is particularly important to determine any long-term adverse effects of 
statin treatment in a population with FH, as people generally take statins for the rest of their 
lives once treatment starts. 
Table 19: Specification for research recommendation 
PICO Population:  
People with FH taking statins 
 
Intervention:  
Statin treatment from the age of 10 years, or 
Statin treatment for >5 years 
 
Comparator: 
Statin treatment started after 10 years of age, or 
Statin treatment for ≤5 years 
 
Outcomes:  
Measurements of sub-clinical atherosclerosis 
cIMT (this was chosen as a commonly used measure in clinical trials of 
statins, so would allow for comparisons with other data) 
Current evidence base There is no long term data on the effect of statins prescribed in children 
for a prolonged time. More information is needed on the adverse effects 
of long term statin therapy. 
Study design Prospective or retrospective cohort studies 
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6 Glossary and abbreviations 
Please refer to the NICE glossary. 
Additional terms used in this document are listed below. 
6.1 Glossary 
Cascade testing: Cascade testing is a mechanism for identifying people at risk of a genetic 
condition by a process of family tracing. For FH the test employed is measurement of (LDL) 
cholesterol in the blood, and/or a DNA test if a disease-causing mutation has been identified 
in the proband (see below). Cascade testing can be direct or indirect:  
Cascade testing, Direct: Direct cascade testing is where a healthcare professional makes 
direct contact with the relatives of the Index case already diagnosed with (or identified as 
having ) FH 
Cascade testing, Indirect; indirect cascade testing is where the Index case contacts their 
own relatives themselves. 
Cascade testing, Reverse: See cascade testing; the difference here is that index case is 
identified in a paediatric population (e.g. through school population screening or newborn 
screening), and then the testing cascades up and the parents and older relatives receive 
cascade testing once an index individual is identified. 
Case finding: A strategy of surveying a population to find those who have the specified 
disease or condition which is under investigation. 
Coronary heart disease (CHD): An event is defined as angina, acute coronary syndrome, 
myocardial infarction, need for coronary artery bypass grafting, need for percutaneous 
coronary intervention or definite coronary artery disease on coronary angiography. 
Dominant pattern of inheritance (autosomal dominant pattern of inheritance): An 
affected individual has one copy of a mutant gene and one normal gene on a pair of 
autosomal (i.e. non-sex) chromosomes. Individuals with autosomal dominant diseases have 
a 50-50 chance of passing the mutant gene, and therefore the disorder, onto each of their 
children. 
Dutch Lipid Network score: A set of criteria used to diagnose FH. The criteria include: 
family history or clinical history of premature coronary artery disease or peripheral arterial 
disease, LDL concentration, DNA mutation and physical signs. Each aspect is given a score 
which leads to the identification of definite, probable, possible or unlikely FH. 
First degree relatives: A person’s biological parents, brothers and sisters and children.  
Heterozygous FH: High LDL cholesterol concentration in the blood caused by an inherited 
mutation from one parent only. Individuals with FH are at increased risk of premature 
cardiovascular disease. 
High potency statin: Statins can be grouped into low, medium and high intensity according 
to how much they reduce LDL concentration (expressed as a percentage). A high intensity 
statin is one which lowers the LDL concentration by more than 40%; and includes 
atorvastatin at 20, 40 or 80mg; or rosuvastatin at 10, 20 or 40 mg. 
Homozygous FH: Very high LDL cholesterol level in the blood caused by an inherited 
mutation from both parents. Where a person inherits exactly the same affected gene from 
both parents this is called homozygous FH. When the mutations in the LDL receptor gene (or 
equivalent) are different, this state is called “compound heterozygous”. In general the overall 
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effect in both states is similar, in that LDL cholesterol concentrations are very high. Both 
groups of patients have the same clinical pattern and very high risk of cardiovascular disease 
early in life. 
ICER: Incremental cost-effectiveness ratio. This is difference in costs divided by the 
difference in health benefits. 
Index case/ index individual/ proband: The original or "first" patient (proband) in a family 
who is identified as having FH, and is the starting point for follow up of their family members 
to identify which other family members have also inherited the causative gene mutation  
Monogenic familial hypercholesterolaemia: A mutation in one of the three genes known to 
cause familial hypercholesterolaemia (LDLR, APOB, or PCSK9) 
Mutation: An identified change in the DNA sequence of a gene which is predicted to change 
the normal function of the gene and so may cause disease.  
Polygenic hypercholesterolaemia: inheritance of a greater than average number of common 
LDL-C-raising alleles, each causing a slight effect, leading to an increase in LDL-C above the 
diagnostic cutoff. 
Premature CHD: For the purpose of this guideline this refers to a coronary event that has 
occurred below age 60 in an index individual or first-degree relative 
QALY: Quality-adjusted life year. This is measure of health benefit that combines both 
changes in survival and the quality of that survival. 
Read code: Read codes are the standard clinical terminology system used in General 
Practice in the United Kingdom.  
Reverse cascade testing: See cascade testing; the difference here is that index case is 
identified in a paediatric population (e.g. through school population screening or newborn 
screening), and then the testing cascades up and the parents and older relatives receive 
cascade testing once an index individual is identified. 
Simon Broome register: A computerized research register of individuals with FH, based in 
Oxford. Research from this voluntary register has led to several publications describing the 
natural history of FH in the UK. The “Simon Broome Criteria” for diagnosis were based on 
study of this group of individuals with FH. 
Simon Broome criteria: A set of criteria used to diagnose definite or possible FH. The 
criteria includes clinical history and family history, age-related LDL concentration, clinical 
signs or identification of a DNA mutation to identify definite FH. 
Tendon xanthoma: A clinically detectable nodularity and/or thickening of the tendons 
caused by infiltration with lipid-laden histiocytes (macrophages in connective tissue). A 
distinctive feature of FH which most frequently affects the Achilles tendons but can also 
involve tendons on the back of the hands, elbows, and knees. 
6.2 Abbreviations 
CAD: Coronary artery disease 
CHD: Coronary heart disease 
FH: Familial hypercholesterolaemia 
HDL: High density lipoprotein 
LDL: Low density lipoprotein 
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TC: Total cholesterol 
TG: Triglycerides
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Appendix C: Review protocol 
C.1 Case finding  
Review Protocol 
Components Details 
Review question 
What is the clinical-and cost-effectiveness of using the following strategies for 
identifying people with FH through: 
 Primary care electronic databases to identify people with 
a. history of early myocardial infarction (MI) (<60 years) and 
hypercholesterolemia  
b. family history of ischemic heart disease and hypercholesterolemia 
or;  
 Secondary care electronic databases  
o within cardiac care facilities or cardiac investigation units to 
identify people with history of early MI (<60 years) and 
hypercholesterolemia or  
o within pathology departments to identify people through 
pathology databases with history of early MI (<60 years) and 
hypercholesterolemia  
 Direct and Indirect cascade testing (including reverse cascade testing)? 
 
The wording of the review question has been changed from the original review 
question. The original clinical question was “What is the effectiveness (defined as 
case identification and cost-effectiveness secondarily) of the following strategies for 
identifying people with FH:  
 GP note searching using electronic data bases identifying patients with (i) 
history of early MI (<60 years) and Tcholesterol (TC) >7.5mmol/L (ii) family 
history of ischemic heart disease and hypercholesterolemia or;  
 Secondary care registers (i) within coronary care units through identifying 
patients with history of early MI (<60 years) and Tcholesterol (TC) 
>7.5mmol/L or (ii) identification of patients through pathology registers 
with age <60 years and TC>9 mmol/L and LDL>5.5mmol/L or;  
 Cascade screening 
The specific changes and reasons for the changes are: 
1. To bring the wording into line with current NICE style guidelines, “patients” 
changed to “people” and “clinical and cost effectiveness” term introduced. 
2. To reflect the change in how patient data is stored and searched; the 
words “GP note searching” was changed to “Primary care electronic 
database”, “records” and “registers” were updated to “databases”. The 
care settings were updated to capture the areas where people with 
potential FH may receive care; “cardiac care facilities or cardiac 
investigation units” was added to ensure that all relevant care settings are 
included in the terms. 
The specifications of total cholesterol concentrations were replaced by the 
broader term ‘hypercholesterolemia’ so that the performance of strategies 
for identifying FH using different levels of TC or LDL-cholesterol could be 
assessed, rather than restricting the review to assessing the performance 
of strategies that use only the TC or LDL-cholesterol concentrations that 
are used in the Simon Broome or the Dutch Lipid Network criteria for 
diagnosis of FH . 
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Background/ 
objectives 
The case identification question was included in CG71 and is being updated to 
consider new evidence (4 studies) identified during the surveillance process relating 
to the clinical and cost effectiveness of case identification of FH.  
Types of study to be 
included 
Include: 
Searches for this review will not be restricted by study design. The rationale for this 
is that filters for observational studies can be unreliable and may not identify all 
relevant studies indexed in the database. 
Exclude: 
For the outcomes of sensitivity and specificity, we will include only those study 
types that can provide data amenable to use in a 2 x 2 table (case reports and 
qualitative studies will be excluded). 
For all other outcomes, any study design with n=>10 will be included. case reports 
and qualitative studies will be excluded from the review question 
Language English only 
Status All published articles, will be considered for inclusion as this is a new search and 
therefore will be run with no date limit  
Population 
 People of any age registered with a GP 
 People < 60 years of age admitted to a cardiac care facility or cardiac 
investigation unit 
 People < 60 years of age listed in pathology databases 
 People of any age identified through direct or indirect cascade testing 
(including reverse cascade testing) 
 People < 60 years of age listed in databases with a discharge code of 
myocardial infarction (MI) or acute coronary syndrome (ACS) 
 People < 60 years of age listed in the Myocardial Ischaemia National 
Research Project (MINAP) database 
Intervention Case identification methods 
For adults  
 Identification of people through primary care electronic database 
searches using the following criteria: 
a. history of early myocardial infarction (MI) (<60 years) and 
hypercholesterolemia or 
b. family history of ischemic heart disease and 
hypercholesterolemia 
 Identification of people through cardiac care facility or cardiac 
investigation databases using the following criteria: 
a. history of early MI (<60 years) and hypercholesterolemia 
 Identification of people through pathology databases  
 Identification of people < 60 years of age listed in the Myocardial 
Ischaemia National Research Project (MINAP) database 
For both adults and children  
 Direct and indirect cascade testing 
 Reverse cascade testing  
 
Comparator 
 All interventions listed above will be compared to no formal case finding 
(including incidental case finding)  
 Indirect and direct cascade testing in children and adults will also be compared 
to each other (indirect testing will be compared to direct testing in adults; 
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indirect testing will be compared to direct testing in children; cascade testing in 
adults will not be compared to cascade testing in children) 
Outcomes For all testing strategies: 
 Sensitivity for detection of people with FH  
 Specificity for detection of people with FH 
 Number of individuals identified in proportion to those assessed (diagnostic 
yield) 
 Uptake rate of testing 
For the comparisons of indirect and direct cascade testing and reverse cascade 
testing only: 
 Proportion of people referred for treatment 
Any other 
information or 
criteria for 
inclusion/exclusion 
The committee will be sent the list of included and excluded studies prior to the 
committee meeting. The committee will be requested to cross check whether any 
studies have been excluded inappropriately, and whether there are any relevant 
studies they know of which haven’t been picked up by the searches. 
Analysis of 
subgroups or subsets 
No population subgroups were identified where identification of FH may require 
further considerations in addition to those for the general population. 
For cascade testing we will subgroup by children and adults 
Data extraction and 
quality assessment 
Sifting 
 Full double sifting will not be conducted due to the anticipated large number of 
studies returned when a new search is completed without date limits. The 
support analyst will sift 10% of the database to assess agreement of included 
studies. If there is disagreement for this 10% sample, a further 10% will be 
double sifted by the support analyst to quality assure study inclusion. ( In cases 
of further uncertainty, the lead technical analyst will discuss with the technical 
adviser  
Data extraction: 
 Information from included studies will be extracted into standardised evidence 
tables. Extracted data will be checked by the support analyst. 
Critical appraisal: 
The following checklist will be used to assess the quality of each included study  
1. Joanna Briggs checklist for case series studies 
(http://joannabriggs.org/assets/docs/sumari/ReviewersManual-
2014.pdf)checkilst will be used.  
2. For other study types (Diagnostic test accuracy studies, RCTs, observational 
studies), the corresponding NICE checklists will be used. 
Quality assessment: 
 GRADE methodology will be used to assess the quality of evidence for each 
outcome as follows; 
o Risk of bias will be assessed using the critical appraisal checklist. The 
quality of the outcomes will not be downgraded if the population of 
the study does not have FH diagnosed by DNA analysis. Diagnosis of FH 
should be by either Simon Broome criteria or the Dutch Lipid Network 
criteria. 
o Inconsistency will be assessed using the I2 value where we can pool 
data. 
o Indirectness will be assessed using population, intervention, 
comparison and outcomes for comparative studies. For all other study 
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types indirectness will be assessed using population, intervention and 
outcomes. 
o Imprecision will be assessed by analysing the surrogate outcome of 
number needed to test: as this question addresses the issue of 
screening in a population, we need to know the number needed to 
test in order to identify 1 extra case and thus compare the 
effectiveness of the different strategies. For the outcome of diagnostic 
yield, we will assess imprecision using the range around the point 
estimate, an MID of 1 will be used. For the outcomes of sensitivity and 
specificity, it is envisaged that the default thresholds of 95% will be 
used to assess imprecision, this will be discussed with the committee. 
Imprecision will not be assessed for uptake rate because we do not 
anticipate there being an MID based on the quality standard for FH 
(QS41). For the outcome of people referred to treatment, the topic 
experts will be asked to provide MIDs. 
Reliability of quality assessment:  
 The following quality assurance mechanisms will be in place: 
o Internal QA by support analyst and CGUT technical adviser on the 
quality assessment that is being conducted. 
o The committee will be sent the evidence synthesis prior to the 
committee meeting; they will be asked to comment on the quality 
assessment, which will serve as a further QA function. 
Strategy for data 
synthesis 
Due to the nature of the review and the outcomes reported, it is anticipated that 
meta-analysis will not be undertaken. The results will be reported in a modified 
GRADE table. 
COMET and published literature will be checked for appropriate minimal important 
differences (MID) for each outcome and if none are available topic experts will be 
asked to provide MID’s.  
Analyses and results will be presented in modified GRADE profiles and summary 
evidence statement formats. 
Searches 
 Sources to be searched 
o Clinical searches -Medline, Medline in Process, Embase, Cochrane 
CDSR, CENTRAL, DARE (legacy records), HTA and PubMed. 
o Economic searches -Medline, Medline in Process, Embase, PubMed, 
NHS EED (legacy records) and HTA, with economic evaluations and 
quality of life filters applied. 
 
 Supplementary search techniques  
o None identified 
 
 Limits 
o Studies reported in English 
o Study design – no study filter will be applied 
o Animal studies will be excluded from the search results 
o Conference abstracts will be excluded from the search results in 
Embase 
o No date limit will be applied 
Key papers Papers identified through surveillance process: 
Economics: 
Ademi Z, Watts GF, Juniper A et al. (10-9-2013) A systematic review of economic 
evaluations of the detection and treatment of familial hypercholesterolemia. 
[Review]. International Journal of Cardiology 167:2391-2396. 
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Pears R, Griffin M, and Watson M. (2014) The reduced cost of providing a 
nationally recognised service for Familial hypercholesterolaemia. Open Heart 
1:e000015. 
Ademi Z, Watts GF, Juniper A et al. (10-9-2013) A systematic review of economic 
evaluations of the detection and treatment of familial hypercholesterolemia. 
[Review]. International Journal of Cardiology 167:2391-2396. 
Benn M, Watts GF, Tybjaerg-Hansen A et al. (2012) Familial hypercholesterolemia 
in the danish general population: prevalence, coronary artery disease, and 
cholesterol-lowering medication. Journal of Clinical Endocrinology & Metabolism 
97:3956-3964. (Erratum in J Clin Endocrinol Metab. 2014 Dec;99(12):4758-9.) 
Cascade screening: 
Talmud PJ, Shah S, Whittal R et al. (2013) Use of low-density lipoprotein 
cholesterol gene score to distinguish patients with polygenic and monogenic 
familial hypercholesterolaemia: a case-control study. Lancet 381:1293-1301. 
Wald DS, Kasturiratne A, Godoy A et al. (2011) Child-parent screening for familial 
hypercholesterolemia. Journal of Pediatrics 159:865-867. 
Screening: 
Besseling J, Kindt I, Hof M et al. (2014) Severe heterozygous familial 
hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 
14,000 mutation carriers. Atherosclerosis 233:219-223. 
Primary care: 
Weng SF, Kai J, Andrew Neil H et al. (2015) Improving identification of familial 
hypercholesterolaemia in primary care: derivation and validation of the familial 
hypercholesterolaemia case ascertainment tool (FAMCAT). Atherosclerosis 
238:336-343. 
Studies in progress: 
 Two large studies on the utility of carrying out FH case finding in general 
practice will be published shortly [no further details provided]. 
 A study funded by the MRC on Child-parent Cascade Testing is likely to report in 
2016 [no details provided]. 
 A Health Technology Assessment has been proposed to examine total 
cholesterol cut-offs for FH using The Health Survey for England Time Series 
Dataset and the QRESEARCH large consolidated database [no further details 
provided]. 
 BHF funded work being carried out to look at the improvement in cost 
effectiveness of cascade testing only in those with a monogenic cause and how 
reduction in costs of off patent statins influences QALYS and ICER. To report 
2016. 
C.2 Diagnosis  
Review Protocol 
Components Details 
Review question In adults with suspected FH, what is the clinical and cost effectiveness of 
different scoring criteria to diagnose FH? 
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The wording of the review question has been changed from the original review 
question. The original clinical question was: 
 In adults and children, what is the effectiveness of the 
following tests to diagnose familial hypercholesterolaemia 
(FH): 
o Biochemical assays? 
o Clinical signs and symptoms? 
o DNA testing? 
o Combinations and/or sequences of above? 
What is the effectiveness of DNA testing in all people (adults 
and children) who are suspected to have FH? 
What is the effectiveness of DNA testing for FH mutations among relatives of 
people with identified mutations for FH? 
Background/ objectives This question was identified as requiring updating during the 6 year surveillance 
process. Changes in DNA testing technology, and costs associated with diagnosis 
and management of FH were the main drivers of the update. 
Population Adults with suspected FH 
Index tests In adults: 
 Scoring criteria, to include: 
o Definite FH according to the Simon Broome criteria 
o Possible or definite FH according to the Simon Broome criteria 
o Definite FH according to the DLCN criteria (>8) 
o Probable or definite FH according to the DLCN criteria (>=6) 
o Possible, probable or definite FH according to the DLCN criteria 
(>=3) 
Reference test Adults: 
 DNA testing (For any mutation in all 3 FH-causing genes [LDLR, APOB 
and PCSK9]). 
Outcomes Adults: 
Sensitivity 
Specificity 
Positive predictive value (PPV) 
Negative predictive value (NPV) 
Diagnostic yield (number of people who have SB or DLCN scoring who progress 
to a positive diagnosis with genetic testing) 
Type of review question Adults:  
Diagnostic test accuracy (DTA) 
Types of study to be 
included 
Adults: 
DTA review: Cross-sectional studies 
Language English language 
Status Published papers, after 2008. 
Papers included in the original guideline will be considered for inclusion. 
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Any other information 
or criteria for 
inclusion/exclusion 
The committee will be sent the list of included and excluded studies prior to the 
committee meeting. The committee will be requested to check whether any 
studies have been excluded inappropriately, and whether there are any relevant 
studies they know of which haven’t been picked up by the searches or have been 
incorrectly sifted out. 
Analysis of subgroups or 
subsets 
Adults with: 
1. Definite FH according to the Simon Broome criteria 
2. Possible or definite FH according to the Simon Broome criteria 
3. Definite FH according to the DLCN criteria (>8) 
4. Probable or definite FH according to the DLCN criteria (>=6) 
5. Possible, probable or definite FH according to the DLCN criteria (>=3) 
Data extraction and 
quality assessment 
Sifting 
Relevant studies will be identified through sifting the abstracts and excluding 
studies clearly not relevant to the PICO. In the case of relevant or potentially 
relevant studies, the full paper will be ordered and reviewed, whereupon studies 
considered not to be relevant to the topic will be excluded.  
i) Selection based on titles and abstracts 
A full double-sift of titles and abstracts will not be conducted due to the nature 
of the review question (typical diagnostic test accuracy review); a support 
analyst will sift a 10% sample of titles and abstracts, and % agreement will be 
assessed. Where the percentage is less than 100%:  
- Any papers identified by the support analyst that were not identified by 
the lead analyst, the full text will be ordered and assessed for inclusion 
- If agreement is less than 95%, a further 10% sample will be sifted by the 
support analyst to ensure rigorous identification and selection of 
studies.  
ii) Selection based on full papers 
A full double-selecting of full papers for inclusion/exclusion will not be 
conducted due to the nature of the review question (as mentioned above). 
However in cases of uncertainty the following mechanisms will be in place: 
 
- technical analyst will discuss with a support technical analyst 
- comparison with included studies of other systematic reviews  
- recourse to members of the committee 
Data extraction 
Information from included studies will be extracted into standardised evidence 
tables.  
Critical appraisal 
The risk of bias of each included study will be assessed using standardised 
checklists available in the NICE manual for diagnostic studies identified: 
o QUADAS 2 
Quality assessment  
GRADE methodology will be used to assess the quality of evidence on an 
outcome basis: 
o Risk of bias will be assessed using critical appraisal checklists 
(QUADAS2) 
o Inconsistency will be assessed using I2: 
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 0-40%: no serious  
 41-70%: serious 
 71-100%: very serious 
o Indirectness will be assessed after considering the population, 
index and reference test and outcomes of included studies, relative 
to the target population; 
o Imprecision: For the outcomes of sensitivity and specificity, 
imprecision will be assessed using the default thresholds of 95%;  
*please note, a post-hoc change to the review protocol was made with respect 
to assessing inconsistency and imprecision. We did not originally specificy the 
software that would be used to undertake meta-analysis; it was decided that the 
meta-analysis would be undertaken in R to provide a summary statistic and 
therefore the results reported were sensitivity and false positive rate (not 
specificity). Inconsistency and imprecision were therefore based on sensitivity 
and false positive rate. 
Reliability of quality assessment: 
A full double-scoring quality assessment will not be conducted due to the nature 
of the review question (typical diagnostic accuracy review) and the studies that 
are likely to be included. Other quality assurance mechanisms will be in place as 
the following:  
 Internal QA (10%) by CGUT technical adviser on the risk of bias and quality 
assessment that is being conducted. Any disagreement will be resolved 
through discussion.  
The committee will be sent the evidence synthesis prior to the committee 
meeting and the committee will be requested to comment on the quality 
assessment, which will serve as another QA function. 
Strategy for data 
synthesis 
If possible, where there are 2 or more studies, a meta-analysis of available study 
data will be carried out to provide a more complete picture of the evidence body 
as a whole. A random effects model will be used as it is indicated that there is 
variation in test accuracy between included studies, which is too big to be 
explained by chance. A random effects model provides an average accuracy of 
each test and describes the variability of the test. If only a single study is 
available for each parameter then the relevant outcomes from this study will be 
reported in an appropriate form. 
Where four or more studies were available for a particular analysis, a bivariate 
model was fitted using the mada package in R v3.3.1, which accounts for the 
correlations between sensitivities and specificities. Where sufficient data were 
not available, separate pooling was performed for sensitivity and specificity, 
using Microsoft Excel. This approach is likely to somewhat underestimate test 
accuracy (see Deeks 2001). 
Random-effects models (der Simonian and Laird) were fitted for all syntheses, as 
recommended in the Cochrane Handbook for Systematic Reviews of Diagnostic 
Test Accuracy (Deeks et al. 2010). 
A narrative evidence summary outlining key issues such as volume, applicability 
and quality of evidence and presenting the key findings from the evidence as it 
relates to the topic of interest will be produced 
Searches 
 Sources to be searched:  
o Clinical searches -Medline, Medline in Process, PubMed, Embase, 
Cochrane CDSR, CENTRAL, DARE (legacy records) and HTA. 
o Economic searches -Medline, Medline in Process, PubMed, 
Embase, NHS EED (legacy records) and HTA, with economic 
evaluations and quality of life filters applied. 
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 Supplementary search techniques  
o If relevant systematic reviews are identified, the reference list will 
be analysed for any further studies relevant to the question. 
 Limits 
o Studies reported in English 
o Animal studies will be excluded from the search results 
o Conference abstracts will be excluded from the search results 
o The search will be run from 2008 to the present 
 
Key papers No key papers identified by topic experts. 
    1.  Oosterveer DM, Versmissen J, Yazdanpanah M et al. (2009) Differences in 
characteristics and risk of cardiovascular disease in familial 
hypercholesterolemia patients with and without tendon xanthomas: a 
systematic review and meta-analysis. Atherosclerosis 207:311-317. 
 2. Sharma P, Boyers D, Boachie C et al. (2012) Elucigene FH20 and LIPOchip 
for the diagnosis of familial hypercholesterolaemia: a systematic review 
and economic evaluation. [Review]. Health Technology Assessment 
(Winchester, England) 16:1-266. 
 3. Norsworthy PJ, Vandrovcova J, Thomas ER et al. (2014) Targeted genetic 
testing for familial hypercholesterolaemia using next generation 
sequencing: a population-based study. BMC Medical Genetics 15. 
 4. Hinchcliffe M, Le H, Fimmel A et al. (2014) Diagnostic validation of a 
familial hypercholesterolaemia cohort provides a model for using targeted 
next generation DNA sequencing in the clinical setting. Pathology 43:60-
68. 
 5. Vandrovcova J, Thomas ER, Atanur SS et al. (2013) The use of next-
generation sequencing in clinical diagnosis of familial 
hypercholesterolemia. Genetics in Medicine 15:948-957. 
 6. Futema M, Plagnol V, Whittall RA et al. (2012) Use of targeted exome 
sequencing as a diagnostic tool for Familial Hypercholesterolaemia. 
Journal of Medical Genetics 49:644-649. 
 7. Pears R, Griffin M, and Watson M. (2014) The reduced cost of providing a 
nationally recognised service for Familial hypercholesterolaemia. Open 
Heart 1:e000015. 
C.3 Management (statin monotherapy) 
Review Protocol 
Components Details 
Review question What is the clinical and cost effectiveness in improving outcome in individuals 
with FH of the following monotherapy:  
 Statins versus placebo? 
The wording of the review question has been changed from the original review 
question. The original clinical question was: 
 What is the effectiveness in improving outcomes in 
individuals with FH of the following monotherapies: 
o Statins versus placebo 
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o Resins (bile acid sequestrants) versus placebo 
o Niacin versus placebo 
o Fibrates versus placebo 
o Fish oils (omega 3 fatty oils) versus placebo 
o Ezetimibe versus placebo)? 
Background/ objectives This area was identified as requiring updating during the 6 year surveillance 
process. New evidence was highlighted that was relevant to statin treatment in 
adults and children with FH; this area is being updated here. 
With regards to statin treatment in adults with FH, the surveillance process 
identified that new studies on statins in adults may have an impact on the 
effectiveness data for the Health Economics model.  
Population Adults and children with heterozygous FH 
Intervention In adults, high intensity statins: 
 Atorvastatin 20mg,40mg or 80mg 
 Rosuvastatin 10, 20 or 40mg 
 Simvastatin 80mg 
In children, the following at any dose: 
 Atorvastatin 
 Rosuvastatin 
 Pravastatin 
Comparator Placebo 
Outcomes All-cause mortality 
Cardiovascular events: 
 Cardiovascular mortality 
 Non-fatal MI 
 Nonfatal stroke 
 Unstable angina  
LDL-C concentration: 
 % of people seeing a 50% or greater reduction 
 mean % change on LDL-C 
Number of people with adverse effects 
Adherence: 
 Number of drop outs due to lack of efficacy 
 Number of drop outs due to lack of tolerance 
 Number of people switching to alternative treatment  
Type of review question Intervention 
Types of study to be 
included 
For the population of adults and children with FH, only RCTs will be included. 
If no evidence is identified on the direct population of people with FH, then we 
will refer to indirect evidence with a population of people with 
hypercholesterolaemia. A recent systematic review on the effect of statin v 
placebo in people with hypercholesterolaemia was undertaken for CG181 Lipid 
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Modification guideline (2014), and the committee agreed that this data can be 
used to extrapolate to the FH population. 
Abstracts, posters, reviews, letter/editorials, foreign language publications and 
unpublished studies will be excluded. 
Language English language only. 
Status Published studies (full text only) from 2008 onwards. 
Studies included in the relevant comparison in the original guideline will also be 
considered. 
Any other information 
or criteria for 
inclusion/exclusion 
The committee will be sent the list of included and excluded studies prior to the 
committee meeting. The committee will be requested to check whether any 
studies have been excluded inappropriately, and whether there are any relevant 
studies they know of which haven’t been picked up by the searches or have been 
incorrectly sifted out. 
Evidence on Ezetimibe is not included in this review as a TA (TA385) was recently 
published (February 2016) and incorporated into CG71. Evidence on Alirocumab 
(TA393) and Evolocumab (TA394) is also not included in this review as 
Technology Appraisals were published in June 2016. 
Analysis of subgroups or 
subsets 
Adults with FH 
Children with FH 
Data extraction and 
quality assessment 
Sifting 
Relevant studies will be identified through sifting the abstracts and excluding 
studies clearly not relevant to the PICO. In the case of relevant or potentially 
relevant studies, the full paper will be ordered and reviewed, whereupon studies 
considered not to be relevant to the topic will be excluded.  
i) Selection based on titles and abstracts 
A full double-sift of titles and abstracts will not be conducted due to the nature 
of the review question (typical intervention question); a support analyst will sift 
a 10% sample of titles and abstracts, and % agreement will be assessed. Where 
the percentage is less than 100%:;  
- Any papers identified by the support analyst that were not identified by 
the lead analyst, the full text will be ordered and assessed for inclusion 
- If agreement is less than 95%, a further 10% sample will be sifted by the 
support analyst to ensure rigorous identification and selection of 
studies.  
ii) Selection based on full papers 
A full double-selecting of full papers for inclusion/exclusion will not be 
conducted due to the nature of the review question (as mentioned above). 
However in cases of uncertainty the following mechanisms will be in place: 
- technical analyst will discuss with a support technical analyst 
- comparison with included studies of other systematic reviews  
- recourse to members of the committee 
Data extraction 
Information from included studies will be extracted into standardised evidence 
tables.  
Critical appraisal 
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The risk of bias of each included study will be assessed using standardised 
checklists available in the NICE manual for intervention/observational studies 
identified: 
o NICE RCT checklist 
Quality assessment  
GRADE methodology will be used to assess the quality of evidence on an 
outcome basis: 
o Risk of bias will be assessed using critical appraisal checklists 
o Inconsistency will be assessed using I2: 
 0-40%: no serious  
 41-70%: serious 
 71-100: very serious  
o  Indirectness will be assessed after considering the population, 
intervention and outcomes of included studies, relative to the 
target population; 
o Imprecision will be assessed using whether the confidence intervals 
around point estimates cross the MIDs for each outcome. COMET 
and published literature will be checked for appropriate minimal 
important differences (MID) for each outcome and if none are 
available Topic Experts will be asked to provide MID’s.  
 Where evidence from CG181 is referred to we will undertake GRADE 
assessment of the evidence as it applies to the FH population. 
Reliability of quality assessment: 
A full double-scoring quality assessment will not be conducted due to the nature 
of the review question (typical intervention review) and the studies that are 
likely to be included. Other quality assurance mechanisms will be in place as the 
following:  
 Internal QA (10%) by CGUT technical adviser on the risk of bias and quality 
assessment that is being conducted. Any disagreement will be resolved 
through discussion.  
The committee will be sent the evidence synthesis prior to the committee 
meeting and the committee will be requested to comment on the quality 
assessment, which will serve as another QA function. 
Strategy for data 
synthesis 
 If possible a meta-analysis of available study data will be carried out to 
provide a more complete picture of the evidence body as a whole. A fixed 
effects model will be used as it is expected that the studies will be 
homogenous in terms of population and we can assume a similar effect size 
across studies. A random effects model will be used if this assumption is not 
correct. 
A narrative evidence summary outlining key issues such as volume, applicability 
and quality of evidence and presenting the key findings from the evidence as it 
relates to the topic of interest will be produced 
Where evidence from CG181 is referred to, the original meta-analysis will be 
used in committee decision making, where appropriate to an FH population. In 
the scenario where the studies in the original review have specific subgroup data 
that applies to people with FH, this data will be extracted and used for the basis 
of decision making. 
Searches 
 Sources to be searched:  
o Clinical searches -Medline, Medline in Process, PubMed, Embase, 
Cochrane CDSR, CENTRAL, DARE (legacy records) and HTA. 
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o Economic searches -Medline, Medline in Process, PubMed, 
Embase, NHS EED (legacy records) and HTA, with economic 
evaluations and quality of life filters applied. 
 Supplementary search techniques  
o If relevant systematic reviews are identified, the reference list will 
be analysed for any further studies relevant to the question. 
 Limits 
o Studies reported in English 
o Study design SR and RCT filters will be applied, observational 
studies filter wil be applied for the long-term adverse events 
question,  
o Animal studies will be excluded from the search results 
o Conference abstracts will be excluded from the search results 
o The search will be run from 2008 to the present 
Key papers    1.   Ara R, Tumur I, Pandor A et al. (2008) Ezetimibe for the treatment of 
hypercholesterolaemia: A systematic review and economic evaluation. 
Health Technology Assessment 12:1-92. 
 2. Pandor A, Ara RM, Tumur I et al. (2009) Ezetimibe monotherapy for 
cholesterol lowering in 2,722 people: systematic review and meta-analysis 
of randomized controlled trials. Journal of Internal Medicine 265:568-580. 
 3. Bass A, Hinderliter AL, and Lee CR. (2009) The impact of ezetimibe on 
endothelial function and other markers of cardiovascular risk. Annals of 
Pharmacotherapy 43:2021-2030. 
 4. Kawashiri MA NA. (2008) Comparison of effects of pitavastatin and 
atorvastatin on plasma coenzyme Q10 in heterozygous familial 
hypercholesterolemia: results from a crossover study. Clinical 
pharmacology and therapeutics 83:731-739. 
 5. Nozue T, Michishita I, Ito Y et al. (2008) Effects of statin on small dense 
low-density lipoprotein cholesterol and remnant-like particle cholesterol 
in heterozygous familial hypercholesterolemia. Journal of Atherosclerosis 
& Thrombosis 15:146-153. 
 6. Marais AD RFSERDB. (2008) A dose-titration and comparative study of 
rosuvastatin and atorvastatin in patients with homozygous familial 
hypercholesterolaemia. Atherosclerosis 197:400-406. 
 7. Masoura C, Pitsavos C, Aznaouridis K et al. (2011) Arterial endothelial 
function and wall thickness in familial hypercholesterolemia and familial 
combined hyperlipidemia and the effect of statins. A systematic review 
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Appendix D: Search strategy 
D.1 Case-finding 
Databases that were searched, together with the number of articles retrieved from each 
database are shown in table Table 20: Clinical search summary. The Medline and 
Medline in Process search strategy is shown in Table 21. The same strategy was translated 
for the other databases listed. 
Table 20: Clinical search summary 
Database Date searched Number retrieved 
Cochrane Central Register of Controlled Trials (CENTRAL)  05/05/16 1203 
Cochrane Database of Systematic Reviews (CDSR) 05/05/16 40 
Database of Abstracts of Reviews of Effect (DARE) (legacy 
records) 
05/05/16 6 
Embase (Ovid) 05/05/16 8341 
Health Technology Assessment (HTA Database) 05/05/16 5 
MEDLINE (Ovid) 05/05/16 5612 
MEDLINE In-Process (Ovid) 05/05/16 615 
PubMedc 05/05/16 783 
Table 21: Clinical search terms (Medline and Medline in Process) 
Line number/Search term/Number retrieved 
1 Hyperlipidemia, familial combined/ (728) 
2 Hyperlipoproteinemia Type II/ (5582) 
3 ((famil* or essential* or monogenic* or hereditar* or inherit* or heterozygous* or homozygous*) 
adj4 (hypercholest* or hyperlip* or cholest* or lipid* or FH)).tw. (12687) 
4 (FH or HoFH or HeFH).tw. (5440) 
5 Cholesterol, LDL/ or Receptors, LDL/ (30339) 
6 (LDL* adj (cholester* or receptor* or lipoprotein*)).tw. (24729) 
7 (low* adj1 densit* adj1 lipoprotein* adj1 (receptor* or cholesterol*)).tw. (22208) 
8 (LDLR or LDL-R or LDL R or LDLC or LDL-C or LDL C).tw. (13734) 
9 Apolipoprotein B-100/ (1735) 
10 (Famili* adj2 apolipoprotein*).tw. (220) 
11 ((Apolipoprotein* or Apo or Apo-) adj1 (B or B-100 or B100 or B 100) adj1 (deficien* or syndrom* 
or defectiv*)).tw. (240) 
12 Hyperlipoproteinemia Type I/ or Apolipoprotein C-II/ (1088) 
13 ((Apolipoprotein* or Apo or Apo-) adj1 (C or C-II or CII or C II or "C-2" or "C2" or "C 2") adj1 
(deficien* or syndrom* or defectiv*)).tw. (21) 
14 ((ApoC2 or ApoCII or ApoB) adj1 (deficien* or syndrom* or defectiv*)).tw. (65) 
15 or/1-14 (72796) 
16 Medical Records Systems, Computerized/ (18525) 
17 Medical Records/ (63140) 
18 Hospital Records/ (3195) 
19 Databases, factual/ (51573) 
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Line number/Search term/Number retrieved 
20 Registries/ (62395) 
21 Medical Audit/ (15588) 
22 ((gp or general practi* or doctor* or nurse* or physician* or primary care or secondary care or 
clinic* or patient* or medical* or hospital* or computer* or electronic* or clinical practice*) adj2 (note* 
or record* or database* or regist* or audit* or data or datalink)).tw. (324817) 
23 (GPRD or CPRD).tw. (448) 
24 Medical History Taking/ or anamnes*.tw. (25456) 
25 ((patient* or case* or medic*) adj2 (histor* or identif* or find* or screen*)).tw. (210882) 
26 ((famil* or parent* or grand* or relative* or relation*) adj2 (histor* or case* or tracing or trace* or 
screen* or identif*)).tw. (82595) 
27 (Simon adj1 Broom*).tw. (34) 
28 (Dutch Lipid adj2 (clinic* or network* or criteria* or diagnos* or score*)).tw. (25) 
29 DLCNCS.tw. (2) 
30 Make Early Diagnosis to Prevent Early Death.tw. (9) 
31 MEDPED.tw. (21) 
32 ((cardiac* or coronar* or stroke or myocardial infarction or MI or heart attack) adj2 (care* or facili* 
or team* or unit* or investigat*) adj2 (note* or record* or database* or regist* or audit* or data)).tw. 
(222) 
33 Myocardial Ischaemia National Audit Project.tw. (32) 
34 MINAP.tw. (42) 
35 National Institute for Cardiovascular Outcomes Research.tw. (14) 
36 NICOR.tw. (10) 
37 QRESEARCH.tw. (69) 
38 National Audit of Percutaneous Coronary Intervention.tw. (1) 
39 PCI.tw. (14238) 
40 National Adult Cardiac Surgery.tw. (17) 
41 NACSA.tw. (1) 
42 Health Survey for England.tw. (339) 
43 ((Patholog* or biochemistr* or lab or laborator*) adj2 (note* or record* or database* or regist* or 
audit* or data)).tw. (25804) 
44 Genetic testing/ (29356) 
45 ((cascade* or genetic*) adj2 (test* or train* or screen*)).tw. (24752) 
46 ((selectiv* or proband* or proposit* or risk factor* or program*) adj2 (screen* or test*)).tw. 
(31704) 
47 or/16-46 (858551) 
48 15 and 47 (6236) 
49 Animals/ not Humans/ (4191697) 
50 48 not 49 (6205) 
51 Limit 50 to english language (5612 
D.2 Diagnosis 
Databases that were searched, together with the number of articles retrieved from each 
database are shown in Table 22: Clinical search summary. The Medline and Medline in 
Process search strategy is shown in Table 23. The same strategy was translated for the 
other databases listed. 
Table 22: Clinical search summary 
Databases Date searched No. retrieved 
Cochrane Central Register of Controlled Trials 
(CENTRAL)  
05/10/16 78 
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Cochrane Database of Systematic Reviews (CDSR) 05/10/16 4 
Database of Abstracts of Reviews of Effect (DARE) 
(legacy records) 
05/10/16 1 
Embase (Ovid) 05/10/16 2246 
Health Technology Assessment (HTA Database) 05/10/16 2 
MEDLINE (Ovid) 05/10/16 938 
MEDLINE In-Process (Ovid) 05/10/16 198 
PubMedd 05/10/16 311 
Table 23: Clinical search terms (Medline and Medline in Process) 
Line number/Search term/Number retrieved 
1 Hyperlipidemia, familial combined/ (732) 
2 Hyperlipoproteinemia Type II/ (5749) 
3 ((famil* or essential* or monogenic* or hereditar* or inherit* or heterozygous* or homozygous*) 
adj4 (hypercholest* or hyperlip* or cholest* or lipid* or FH)).tw. (13192) 
4 (FH or HoFH or HeFH).tw. (5742) 
5 Cholesterol, LDL/ or Receptors, LDL/ (31538) 
6 (LDL* adj (cholester* or receptor* or lipoprotein*)).tw. (25495) 
7 (low* adj1 densit* adj1 lipoprotein* adj1 (receptor* or cholesterol*)).tw. (23397) 
8 (LDLR or LDL-R or LDL R or LDLC or LDL-C or LDL C).tw. (14573) 
9 Apolipoprotein B-100/ (1816) 
10 (Famili* adj2 apolipoprotein*).tw. (220) 
11 ((Apolipoprotein* or Apo or Apo-) adj1 (B or B-100 or B100 or B 100) adj1 (deficien* or syndrom* 
or defectiv*)).tw. (240) 
12 Hyperlipoproteinemia Type I/ or Apolipoprotein C-II/ (1109) 
13 ((Apolipoprotein* or Apo or Apo-) adj1 (C or C-II or CII or C II or "C-2" or "C2" or "C 2") adj1 
(deficien* or syndrom* or defectiv*)).tw. (21) 
14 ((ApoC2 or ApoCII or ApoB) adj1 (deficien* or syndrom* or defectiv*)).tw. (66) 
15 or/1-14 (75847) 
16 (Simon adj1 Broom*).tw. (36) 
17 (Dutch Lipid adj2 (clinic* or network* or criteria* or diagnos* or score*)).tw. (33) 
18 Dutch score*.tw. (4) 
19 (DLCNCS or DLCN).tw. (10) 
20 ((famil* or parent* or grand* or relative* or relation*) adj2 (histor* or case* or tracing or trace* or 
screen* or identif*) adj2 (famil* or essential* or monogenic* or hereditar* or inherit* or heterozygous* 
or homozygous*) adj4 (hypercholest* or hyperlip* or cholest* or lipid* or FH)).tw. (1503) 
21 ((famil* or parent* or grand* or relative* or relation*) adj2 (histor* or case* or tracing or trace* or 
screen* or identif*) adj2 (coronar* or Ischaemic* or ischemic*) adj2 heart* adj2 (diseas* or 
disorder*)).tw. (324) 
22 Genetic testing/ (30939) 
23 ((cascade* or genetic* or dna) adj2 (test* or train* or screen*)).tw. (35227) 
24 (tendon xanthomata or xanthelasmas).tw. (124) 
25 ((corneal* or senil*) adj1 arcus).tw. (211) 
26 or/16-25 (59196) 
27 15 and 26 (2154) 
28 animals/ not humans/ (4292287) 
29 27 not 28 (2142) 
30 limit 29 to ed=20070101-20161006 (1001) 
31 limit 30 to english language (938) 
 
                                               
d Limit search to publisher[sb] and last 3 days only. Tips on searching PubMed here 
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D.3 Management (statin monotherapy) 
Databases that were searched, together with the number of articles retrieved from each 
database are shown in Table 24. The Medline and Medline in Process search strategy is 
shown in Table 23. The same strategy was translated for the other databases listed. 
Table 24: Clinical search summary 
Databases Date searched No. retrieved 
Cochrane Central Register of Controlled Trials 
(CENTRAL)  
29/09/16 2134 
Cochrane Database of Systematic Reviews (CDSR) 29/09/16 15 
Database of Abstracts of Reviews of Effect (DARE) 
(legacy records) 
29/09/16 34 
Embase (Ovid) 29/09/16 4972 
Health Technology Assessment (HTA Database) 29/09/16 0 
MEDLINE (Ovid) 29/09/16 3082 
MEDLINE In-Process (Ovid) 29/09/16 321 
PubMede 29/09/16 172 
Table 25: Clinical search terms (Medline and Medline in Process) 
Line number/Search term/Number retrieved 
1 Hyperlipidemia, familial combined/ (732) 
2 Hyperlipoproteinemia Type II/ (5744) 
3 ((famil* or essential* or monogenic* or hereditar* or inherit* or heterozygous* or homozygous*) 
adj4 (hypercholest* or hyperlip* or cholest* or lipid* or FH)).tw. (13163) 
4 (FH or HoFH or HeFH).tw. (5729) 
5 Cholesterol, LDL/ or Receptors, LDL/ (31478) 
6 (LDL* adj (cholester* or receptor* or lipoprotein*)).tw. (25456) 
7 (low* adj1 densit* adj1 lipoprotein* adj1 (receptor* or cholesterol*)).tw. (23332) 
8 (LDLR or LDL-R or LDL R or LDLC or LDL-C or LDL C).tw. (14522) 
9 Apolipoprotein B-100/ (1813) 
10 (Famili* adj2 apolipoprotein*).tw. (220) 
11 ((Apolipoprotein* or Apo or Apo-) adj1 (B or B-100 or B100 or B 100) adj1 (deficien* or syndrom* 
or defectiv*)).tw. (240) 
12 Hyperlipoproteinemia Type I/ or Apolipoprotein C-II/ (1105) 
13 ((Apolipoprotein* or Apo or Apo-) adj1 (C or C-II or CII or C II or "C-2" or "C2" or "C 2") adj1 
(deficien* or syndrom* or defectiv*)).tw. (21) 
14 ((ApoC2 or ApoCII or ApoB) adj1 (deficien* or syndrom* or defectiv*)).tw. (66) 
15 or/1-14 (75700) 
16 Atorvastatin Calcium/ (5539) 
17 (Atorvastatin or Lipitor).tw. (6063) 
18 Rosuvastatin Calcium/ (1958) 
19 (Rosuvastatin or Crestor).tw. (2220) 
20 Simvastatin/ or Ezetimibe, Simvastatin Drug Combination/ (6747) 
21 (Simvador or Zocor or Inegy).tw. (112) 
22 Pravastatin/ (3231) 
23 (Statin* or Pravastatin).tw. (31316) 
24 or/16-23 (38724) 
25 15 and 24 (9237) 
                                               
e Limit search to publisher[sb] and last 3 days only. Tips on searching PubMed here 
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Line number/Search term/Number retrieved 
26 Randomized Controlled Trial.pt. (431498) 
27 Controlled Clinical Trial.pt. (91725) 
28 Clinical Trial.pt. (505774) 
29 exp Clinical Trials as Topic/ (302612) 
30 Placebos/ (33707) 
31 Random Allocation/ (89038) 
32 Double-Blind Method/ (139483) 
33 Single-Blind Method/ (22859) 
34 Cross-Over Studies/ (39679) 
35 ((random$ or control$ or clinical$) adj3 (trial$ or stud$)).tw. (860218) 
36 (random$ adj3 allocat$).tw. (24024) 
37 placebo$.tw. (170178) 
38 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).tw. (136594) 
39 (crossover$ or (cross adj over$)).tw. (63097) 
40 or/26-39 (1554896) 
41 Meta-Analysis.pt. (73666) 
42 Meta-Analysis as Topic/ (15408) 
43 Review.pt. (2109968) 
44 exp Review Literature as Topic/ (9095) 
45 (metaanaly$ or metanaly$ or (meta adj3 analy$)).tw. (85278) 
46 (review$ or overview$).ti. (316819) 
47 (systematic$ adj5 (review$ or overview$)).tw. (80380) 
48 ((quantitative$ or qualitative$) adj5 (review$ or overview$)).tw. (5641) 
49 ((studies or trial$) adj2 (review$ or overview$)).tw. (30076) 
50 (integrat$ adj3 (research or review$ or literature)).tw. (6724) 
51 (pool$ adj2 (analy$ or data)).tw. (18370) 
52 (handsearch$ or (hand adj3 search$)).tw. (6907) 
53 (manual$ adj3 search$).tw. (3860) 
54 or/41-53 (2295137) 
55 40 or 54 (3569304) 
56 25 and 55 (6052) 
57 Animals/ not Humans/ (4288026) 
58 56 not 57 (5981) 
59 limit 58 to ed=20070101-20160930 (3329) 
60 limit 59 to english language (3082) 
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Appendix E: Review flowchart 
E.1 Case-finding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*including 5 of the 6 studies from the original guideline 
E.2 Diagnosis 
 
 
 
 
 
 
 
 
 
 
 
Search retrieved 
11,012 articles  
10,893 excluded based 
on title/abstract 
122 full-text articles 
examined +  
78 excluded based on 
full-text article 
43 included studies 
(from 44 publications)* 
Search retrieved 2,146 
articles  
2084 excluded based 
on title/abstract 
62 full-text articles 
examined 
53 excluded based on 
full-text article + 21 
studies included in 
original CG71 review 
9 included studies 
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E.3 Management (statin monotherapy) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Vuorio (2014) has 8 included studies; 4 excluded as used statins that are not licensed for 
use in children in the UK.
Search retrieved 6,096 
articles  
6,072 excluded based 
on title/abstract 
24 full-text articles 
examined 
14 excluded based on 
full-text article + 9 from 
CG71 
2 included studies (1 
Cochrane review (n=4 
studies*) + 1 RCTs 
from previous 
guideline) 
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Appendix F: Excluded studies 
F.1 Case finding  
Reference Reason for exclusion 
Abaitua FR, Martinez JI, Lopez RE et al (1996). Family history as 
a predictor for childhood hyperlipidemia. Cardiovascular Risk 
Factors, 6, 277-83. 
Incidence of hyperlipidaemia 
and hypercholesterolaemia, 
not FH 
Alves A, Medeiros A, Francisco V et al (2009). Familial 
hypercholesterolaemia: A perspective of 10 years of study in 
Portugal. Atherosclerosis Supplements 
Conference abstract 
Anonymous . (1991). Risk of fatal coronary heart disease in 
familial hypercholesterolaemia. Scientific Steering Committee on 
behalf of the Simon Broome Register Group. BMJ, 303, 893-6. 
Incidence of mortality in people 
with FH 
Dennison BA, Jenkins PL and Pearson TA. (1994). Challenges to 
implementing the current pediatric cholesterol screening 
guidelines into practice. Pediatrics, 94, 296-302. 
Study to identify children who 
should have cholesterol 
screened; assessing parental 
hypercholesterolaemia and 
family history of CHD 
Bachman RP, Schoen EJ, Stembridge A et al (1993). Compliance 
with childhood cholesterol screening among members of a 
prepaid health plan. American Journal of Diseases of Children, 
147, 382-5. 
Assess compliance of parents/ 
children attending for 
cholesterol tests due to family 
history of 
hypercholesterolaemia 
Bangert S K, Eldridge P H, and Peters T J. (1992). Neonatal 
screening for familial hypercholesterolaemia by 
immunoturbidimetric assay of apolipoprotein B in dried blood 
spots. Clinica Chimica Acta, 213, 95-101. 
Study on method development 
for measurement of 
apolipoprotein B in dried blood 
spots 
Bates T, Magana N, Chan H et al (2011). Predicting the yield of 
cascade screening for familial hypercholesterolaemia. Heart Lung 
and Circulation 
Conference abstract 
Bell MM, and Joseph S. (1990). Screening 1140 fifth graders for 
hypercholesterolemia: family history inadequate to predict results. 
Journal of the American Board of Family Practice, 3, 259-63. 
Sensitivity and specificity of 
family history of high 
cholesterol or premature CVD 
to predict elevated cholesterol 
in child. 
Bell D, Hooper A, Bender R et al (2012). Opportunistic screening 
for familial hypercholesterolaemia via a community laboratory. 
Heart Lung and Circulation, Conference 
Conference abstract 
Besseling J, Kindt I, Hof M et al (2014) Severe heterozygous 
familial hypercholesterolemia and risk for cardiovascular disease: 
a study of a cohort of 14,000 mutation carriers. Atherosclerosis. 
2014 Mar;233(1):219-23 
Risk of people with FH having 
a CV event 
Besseling J, Huijgen R, Martin SS et al (2016). Clinical phenotype 
in relation to the distance-to-index-patient in familial 
hypercholesterolemia. Atherosclerosis, 246, 1-6. 
Distance to index effect on 
LDL-C and CVD. 
Besseling J, Reitsma JB, Gaudet D et al (2016). Selection of 
individuals for genetic testing for familial hypercholesterolaemia: 
development and external validation of a prediction model for the 
presence of a mutation causing familial hypercholesterolaemia. 
European Heart Journal ehw135 
Development of model to 
predict presence of FH 
causing mutation in people 
referred by GPs 
Bistritzer T, Batash D, Barr J et al (1996). Routine childhood 
screening for hyperlipidemia in Israel. Israel Journal of Medical 
Sciences, 32, 725-9. 
No outcomes of interest 
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Reference Reason for exclusion 
Bogar MD, Basford JR, and Thomas RJ (2005). Rate and 
adequacy of cholesterol screening in patients admitted to a large 
rehabilitation unit after stroke. Archives of Physical Medicine & 
Rehabilitation, 86, 69-72. 
Cholesterol screening in 
patients who have had a 
stroke; number on lipid 
lowering treatment prior to 
stroke 
Boregowda K, Rice S, Grey B et al (2013). Screening for familial 
hypercholesterolaemia. In: Atherosclerosis. 27th Annual 
Conference of HEART UK 2013 Bristol University 
Conference abstract 
Boulton TJ (1979). The validity of screening for 
hypercholesterolaemia at different ages from 2 to 17 years. 
Australian and New Zealand Journal of Medicine, 9, 542-6. 
Cases of 
hypercholesterolaemia and 
family history of CHD. 
Calonge N, and Guirguis-Blake J. (2007). Screening for familial 
hypercholesterolaemia. BMJ, 335, 573-4. 
Editorial 
Catalan-Ramos A, Verdu JM, Grau M et al (2014). Population 
prevalence and control of cardiovascular risk factors: what 
electronic medical records tell us. Atencion Primaria, 46, 15-24. 
Prevalence of cardiovascular 
risk factors in population. Not 
FH. 
Datta BN, McDowell I F, and Rees A. (2010). Integrating provision 
of specialist lipid services with cascade testing for familial 
hypercholesterolaemia. Current Opinion in Lipidology, 21, 366-71. 
Narrative review 
Finnie RM. (2010). Cascade screening for familial 
hypercholesterolaemia in Scotland. British Journal of Diabetes 
and Vascular Disease, 10, 123-5. 
Narrative review 
Finnie RM, Bell C, Bloomfield P et al (2012). The first hundred 
families diagnosed with familial hypercholesterolaemia in two lipid 
clinics in Lothian. British Journal of Diabetes and Vascular 
Disease, 12, 243-7. 
Reports number of different 
mutations found in people 
diagnosed with FH 
Fouchier SW, Kastelein JJ, and Defesche JC (2005). Update of 
the molecular basis of familial hypercholesterolemia in The 
Netherlands. Human Mutation, 26, 550-6. 
Description of molecular 
diagnoses of FH in Dutch 
registry; methods and 
mutations identified. 
Galema-Boers JM, Versmissen J, Roeters van Lennep, HW et al 
(2015). Cascade screening of familial hypercholesterolemia must 
go on. Atherosclerosis, 242, 415-7. 
All children had FH; assessing 
CVD in family history, % of 
patients with CVD incidence in 
parents and grandparents 
Gidding SS, Whiteside P, Weaver S et al (1989). The child as 
proband. High prevalence of unrecognized and untreated 
hyperlipidemia in parents of hyperlipidemic children. Clinical 
Pediatrics, 28, 462-5. 
Hyperlipidaemia in children 
and number of parents with 
hyperlipidaemia, not FH.  
Griffin TC, Christoffel KK, Binns HJ et al (1989). Family history 
evaluation as a predictive screen for childhood 
hypercholesterolemia. Pediatric Practice Research Group. 
Pediatrics, 84, 365-73. 
Sensitivity and PPV of family 
history in predicting LDL-C 
Hadfield G S, and Humphries SE. (2007). Familial 
hypercholesterolaemia: Cascade testing is tried and tested and 
cost effective. BMJ, 335, 683. 
Earlier report of Hadfield 
(2009) data; more up to date 
and relevant data in Hadfield 
(2009) 
Herman K, Van Heyningen C, and Wile D. (2009). Cascade 
screening for familial hypercholesterolaemia and its effectiveness 
in the prevention of vascular disease. British Journal of Diabetes 
and Vascular Disease, 9, 171-74. 
Non-systematic review 
Humphries SE, and Hadfield G. (2008). Identifying patients with 
familial hypercholesterolaemia in primary care. Heart, 94, 695-6. 
Editorial 
Imtiaz F. (2009). Estimation of heritability of familial 
hypercholesterolemia among 335 family members of five 
Does not report diagnostic 
yield of FH in relatives. 
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Reference Reason for exclusion 
hypercholesterolemic probands of Pakistani population. Journal of 
Ayub Medical College, and Abbottabad: JAMC, 21, 58-61. 
Kashani M, Eliasson A, Vernalis M et al (2015). A systematic 
approach incorporating family history improves identification of 
cardiovascular disease risk. Journal of Cardiovascular Nursing, 
30, 292-7. 
Family history of CVD, not 
familial hypercholesterolaemia. 
Kastelein JJ. (2000). Screening for familial hypercholesterolaemia. 
Effective, safe treatments and dna testing make screening 
attractive. BMJ, 321, 1483-4. 
Correspondence 
Kirke A, Watts G F, and Emery J. (2012). Detecting familial 
hypercholesterolaemia in general practice. Australian Family 
Physician, 41, 965-8. 
Narrative review with focus on 
management of FH in primary 
care 
Kusters DM, de Beaufort C , Widhalm K et al (2012). Paediatric 
screening for hypercholesterolaemia in Europe. Archives of 
Disease in Childhood, 97, 272-6. 
Narrative review on paediatric 
screening strategies 
Marang-van de Mheen PJ, ten Asbroek AH, Bonneux L et 
al(2002). Cost-effectiveness of a family and DNA based screening 
programme on familial hypercholesterolaemia in The Netherlands. 
European Heart Journal, 23, 1922-30. 
Cost effectiveness 
Marks D, Wonderling D, Thorogood M et al. (2000) Screening for 
hypercholesterolaemia versus case finding for familial 
hypercholesterolaemia: a systematic review and cost 
effectiveness analysis. Health Technology Assessment; 4 (29) :1-
123. 
Review >5 yrs old. 
Marks D, Wonderling D, Thorogood M et al 2002). Cost 
effectiveness analysis of different approaches of screening for 
familial hypercholesterolaemia. BMJ, 324, 1303. 
Health economics paper 
Marks D, Thorogood M, Neil HA et al (2003). Comparing costs 
and benefits over a 10 year period of strategies for familial 
hypercholesterolaemia screening. Journal of Public Health 
Medicine, 25, 47-52. 
Health economics paper 
Neely RD. (2014). The importance of early diagnosis: How to 
identify patients with FH for diagnosis and referral. Primary Care 
Cardiovascular Journal, 7, 31-5. 
Narrative review 
Neil H A, Hammond T, Huxley R et al (2000). Extent of 
underdiagnosis of familial hypercholesterolaemia in routine 
practice: prospective registry study. BMJ, 321, 148. 
Short report on underdiagnosis 
of FH with insufficient detail to 
critically appraise. 
Nherera L, Marks D, Minhas R et al (1175). Probabilistic cost-
effectiveness analysis of cascade screening for familial 
hypercholesterolaemia using alternative diagnostic and 
identification strategies. Heart, 97, 1175-81. 
Economic analysis 
O'Loughlin J, Lauzon B, Paradis G et al (1723). Usefulness of the 
American Academy of Pediatrics recommendations for identifying 
youths with hypercholesterolemia. Pediatrics, 113, 1723-7. 
Prevalence of 
hypercholesterolaemia, not 
focussed on FH 
Pears R, Griffin M, Watson M et al (2014). The reduced cost of 
providing a nationally recognised service for familial 
hypercholesterolaemia. Open Heart, 1, e000015. 
Economic analysis 
Pears R, Griffin M, Futema M et al (2015). Improving the cost-
effectiveness equation of cascade testing for familial 
hypercholesterolaemia. Current Opinion in Lipidology, 26, 162-8. 
Opinion 
Ramaswami U, Cooper J, and Humphries SE. (2016). The UK 
Paediatric Familial Hypercholesterolaemia Register: preliminary 
data. Archives of Diseases in Children 
Description of demographics of 
children with FH. No detail on 
how identified. 
Sazonov V, Beetsch J, Phatak H et al (2010). Association 
between dyslipidemia and vascular events in patients treated with 
Association between high 
levels of HDL and 
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Reference Reason for exclusion 
statins: report from the UK General Practice Research Database. 
Atherosclerosis, 208, 210-6. 
cardiovascular or 
cerebrovascular events in 
people with high concentration 
of LDL. 
Skovby F, Micic S, Jepsen B et al. (1991). Screening for familial 
hypercholesterolaemia by measurement of apolipoproteins in 
capillary blood. Archives of Disease in Childhood, 66, 844-7. 
 
Does not report yield of FH in 
relatives; unreliable/ unclear 
method of diagnosis of FH. 
Staunton A, Vallance D T, Child A et al (1994). Unrecognized 
dyslipoproteinemia in United Kingdom families recruited to a 
genetic register because of unexplained coronary heart disease. 
Journal of Laboratory & Clinical Medicine, 123, 842-8. 
No outcomes of interest: 
selected probands and 
relatives, incidence of FH not 
reported; study reports 
demographics and lipid profiles 
of population. 
Starr B, Hadfield SG, Hutten BA et al (2008). Development 
of sensitive and specific age-and gender-specific low-
density lipoprotein cholesterol cutoffs for diagnosis of first-
degree relatives with familial hypercholesterolaemia in 
cascade testing. Clinical Chemistry & Laboratory Medicine, 
46, 791-803. 
 
Study focussed on formulation 
of age specific LDL cut-offs 
using Netherland FH data; 
validation of study-developed 
criteria through application to 
Danish and Norwegian 
datasets to assess sensitivity 
and specificity of new criteria. 
Steyn K, Fourie J M, and Shepherd J. (1569). Detection and 
measurement of hypercholesterolaemia in South Africans 
attending general practitioners in private practice -The cholesterol 
monitor. South African Medical Journal, 88, 1569-74. 
Survey of primary care 
practitioners, prevalence of 
reported FH only, no screening 
strategy. 
Talmud P, Tybjaerg-Hansen A, Bhatnagar D et al (1991). Rapid 
screening for specific mutations in patients with a clinical 
diagnosis of familial hypercholesterolaemia. Atherosclerosis, 89, 
137-41. 
Development of specific DNA 
test for a FH mutation. Not a 
“whole population” screen, but 
looking for a specific 
phenotype and how mutation 
specific therapy may be 
developed for this mutation. 
Talmud PJ, Shah S, Whittall R et al (2013). Use of low-density 
lipoprotein cholesterol gene score to distinguish patients with 
polygenic and monogenic familial hypercholesterolaemia: A case-
control study. The Lancet, 381,1293-301. 
Using LDL gene score to 
distinguish between 
monogenic and polygenic FH 
ten Asbroek AH, de Mheen PJ, Defesche JC et al (2001). Results 
from a family and DNA based active identification programme for 
familial hypercholesterolaemia. Journal of Epidemiology & 
Community Health, 55, 500-2. 
Analyses prevalence of FH 
and prevalence of mutations in 
those with FH 
Tonstad S, Vollebaek LE and Ose L. (1995). Screening for familial 
hypercholesterolaemia in relatives. Lancet, 346, 1438. 
Correspondence  
Troxler RG, Park MK, Miller MA et al (1991). Predictive value of 
family history in detecting hypercholesterolemia in predominantly 
Hispanic adolescents. Texas Medicine, 87, 75-9. 
Family history of premature 
CVD, predictive value of 
premature CVD in a parent on 
the total cholesterol level in 
child 
Tyerman P F, and Tyerman G V. (2002). Another way of 
screening for familial hypercholesterolaemia. BMJ, 325, 340 
Correspondence 
Umans-Eckenhausen MA, Defesche JC, van Dam MJ et al 
(2003). Long-term compliance with lipid-lowering medication after 
genetic screening for familial hypercholesterolemia. Archives of 
Internal Medicine, 163, 65-8. 
Follow up questionnaire to 
assess proportion of people 
diagnosed with FH receiving 
treatment 
 102 
 
Reference Reason for exclusion 
van Aalst-Cohen ES, Jansen AC, Tanck MW et al (2006). 
Diagnosing familial hypercholesterolaemia: the relevance of 
genetic testing. European Heart Journal, 27, 2240-6. 
Assesses clinical and 
biochemical differences in 
those with or without LDLR 
mutation. 
van Maarle MC, Stouthard ME, and Bonsel GJ. (2003). Quality of 
life in a family based genetic cascade screening programme for 
familial hypercholesterolaemia: a longitudinal study among 
participants. Journal of Medical Genetics, 40, e3. 
Quality of life outcomes for 
people undergoing FH 
screening 
Wald D S, Bestwick JP, and Wald NJ. (2007). Child-parent 
screening for familial hypercholesterolaemia: screening strategy 
based on a meta-analysis. BMJ, 335, 599 
Only reports mean TC or LDL; 
not an outcome of interest 
Weng S F, Kai J, Andrew Neil, H , Humphries S E, and Qureshi N. 
(2015). Improving identification of familial hypercholesterolaemia 
in primary care: derivation and validation of the familial 
hypercholesterolaemia case ascertainment tool (FAMCAT). 
Atherosclerosis, 238, pp.336-43. 
Validation of FH assessment 
tool; does not report outcomes 
of interest. 
Wilcken DE, Blades BL and Dudman NP. (1988). A neonatal 
screening approach to the detection of familial 
hypercholesterolaemia and family-based coronary prevention. 
Journal of Inherited Metabolic Disease, 11 Suppl 1, 87-90. 
Number of people with FH 
diagnosed not reported 
Wilson C. (2013). Targeting cascade screening in familial 
hypercholesterolaemia. Nature Reviews Cardiology, 10, 
Correspondence 
Wonderling D, Umans-Eckenhausen MA et al (2004) Cost-
effectiveness analysis of the genetic screening program for 
familial hypercholesterolemia in The Netherlands. Seminars in 
Vascular Medicine; 4 (1) :97-104. 
Economic analysis 
F.2 Diagnosis 
Reference Reason for exclusion 
Agnieszka Wegrzyn, A , Fijalkowski M, Taszner M, Chmara M, 
Wasag B, Limon J, Rynkiewicz A, and Gruchala M. (2014). Familial 
hypercholesterolemia in Polish population-clinical and molecular 
diagnosis. European Journal of Preventive Cardiology, 21(1 SUPPL. 
1), pp.S88. 
Abstract 
Ahmad Z S, Andersen R L, Andersen L H, O'Brien E C, Kindt I, 
Shrader P, Vasandani C, Newman C B, deGoma E M, Baum S J, 
Hemphill L C, Hudgins L C, Ahmed C D, Kullo I J, Gidding S S, Duffy 
D, Neal W, Wilemon K, Roe M T, Rader D J, Ballantyne C M, Linton 
M F, Duell P B, Shapiro M D, Moriarty P M, and Knowles J W. (2016). 
US physician practices for diagnosing familial hypercholesterolemia: 
data from the CASCADE-FH registry. Journal of Clinical Lipidology, 
10(5), pp.1223-9. 
Comparison of clinical 
scoring systems only: 
Simon Broome vs DLCN vs 
medped 
Benlian P, Turquet A, Carrat F, Amsellem S, Sanchez L, Briffaut D, 
and Girardet J P. (2009). Diagnosis scoring for clinical identification 
of children with heterozygous familial hypercholesterolemia. Journal 
of Pediatric Gastroenterology & Nutrition, 48(4), pp.456-63. 
Does not use Simon 
Broome or Dutch Lipid 
Clinic scoring system 
Besseling J, Reitsma J B, Gaudet D, Brisson D, Kastelein J J, 
Hovingh G K, and Hutten B A. (2016). Selection of individuals for 
genetic testing for familial hypercholesterolaemia: development and 
external validation of a prediction model for the presence of a 
mutation causing familial hypercholesterolaemia. Eur Heart J, , pp.. 
Development of a model to 
predict presence of FH 
mutation. No DLCN or SB 
criteria used. 
Bourbon M, Medeiros A M, Alves A C, Francisco V, Gaspar I M, Rato 
Q, Gaspar A, and Guerra A. (2010). Clinical diagnosis versus genetic 
diagnosis in familial hypercholesterolaemia. European Journal of 
Cardiovascular Prevention and Rehabilitation, 17, pp.S5. 
Abstract 
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Reference Reason for exclusion 
Breen J, Jones J, and Barbir M. (2011). Genetic screening for familial 
hypercholesterolaemia in a cardiothoracic tertiary referral centre. 
Atherosclerosis, 218(2), pp.e5. 
Abstract 
Civeira F, Ros E, Jarauta E, Plana N, Zambon D, Puzo J, Martinez 
de Esteban, J P, Ferrando J, Zabala S, Almagro F, Gimeno J A, 
Masana L, and Pocovi M. (2008). Comparison of genetic versus 
clinical diagnosis in familial hypercholesterolemia. American Journal 
of Cardiology, 102(9), pp.1187-93, 1193.e1. 
Only tests for mutations in 
LDLR and APOB genes, 
not PCSK9. 
Cohen S S, Shirey-Rice J, Hardin J, et al. (2016). Identification of 
patients with familial hypercholesterolemia (FH) using the Dutch lipid 
network (DLN) criteria in electronic health records (EHR). Circulation, 
133. 
 
Abstract 
Fabregate R, Fabregate M, Martinez C, et al. (2014). Result of 
genetic testing for diagnosis of LDLR and apob related heterozigous 
Familial Hypercholesterolemia (FH) in patients with clinical criteria. 
Journal of the American Society of Hypertension, 8(4 SUPPL. 1), 
e107. 
Abstract 
Finnie R M, Walker S, Simpson W G, and Miedzybrodzka Z. (2011). 
The first ninety families diagnosed with mutation positive familial 
hypercholesterolaemia in two lipid clinics in a Scottish Health Board 
area. Atherosclerosis, 218(2), pp.e3. 
Abstract 
Finnie R M, Bell C, Bloomfield P, Ho C K. M, Jenks S, Shand N, and 
Walker S W. (2012). The first hundred families diagnosed with 
familial hypercholesterolaemia in two lipid clinics in lothian. British 
Journal of Diabetes and Vascular Disease, 12(5), pp.243-247. 
Analysis of distribution of 
mutations within genetically 
identified FH only. No 
clinical diagnosis 
undertaken. 
Freiberger T, Plotena M, Zapletalova P, Goldmann R, Tichy L, and 
Fajkusova L. (2009). Familial hypercholesterolemia family screening 
in the Czech Republic. Atherosclerosis Supplements, 10(2), pp.no 
pagination. 
Abstract 
Freiberger T, Fajkusova L, Tichy L, Soska V, Ravcukova B, Ceska R, 
and Vrablik M. (2014). Fifteen years of active search for patients with 
familial hypercholesterolemia in the czech republic. Atherosclerosis, 
235(2), pp.e197. 
Abstract 
Futema M, Whittall R, Wood G, Curtis M, McEwan J, and Humphries 
S E. (2011). Identification of patients with familial 
hypercholesterolaemia (FH) through the application of genetic testing 
in young mi patients from the MINAP register. Atherosclerosis, 
218(2), pp.e5. 
Abstract 
Graesdal A, Ostli L, and Arnesen K E. (2009). Familial 
hypercholesterolemia in norway -Substantial variation in frequency of 
genetic testing and degree of follow up in different geographical 
regions. Atherosclerosis Supplements, 10(2), pp.no pagination. 
Abstract 
Grenkowitz T, Kassner U, Marz W, Binner P, Steinhagen-Thiessen E, 
and Demuth I. (2015). Mutation spectrum in German patients with 
familial hypercholesterolemia. Medizinische Genetik, 27(1), pp.127-
128. 
Foreign language paper 
Grenkowitz T, Kassner U, Salewsky B, Marz W, Binner P, 
Steinhagen-Thiessen E, and Demuth I. (2016). Mutation spectrum in 
german patients with familial hypercholesterolemia-an update. 
Medizinische Genetik, 28(1), pp.152. 
Foreign language paper 
Haralambos K, Whatley S D, Datta B N, et al. (2013). Familial 
hypercholesterolaemia (FH) in Wales is genetically heterogeneous. 
Atherosclerosis, 231(2), pp.e2. 
Abstract 
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Reference Reason for exclusion 
Haralambos K, Whatley S D, Edwards R, et al. (2014). Genetic 
variants of uncertain significance (VUS) in familial 
hypercholesterolaemia (FH): Can family based association studies 
help determine pathogenicity?. Atherosclerosis, 236(2), pp.e304. 
Abstract 
Ho C K, Stirling D, Hannant W, and Walker S W. (2012). Genetic 
mutations in patients with possible familial hypercholesterolaemia in 
South East Scotland. Scottish Medical Journal, 57(3), pp.148-51. 
Comparison of clinical 
criteria to genetic testing: 
LDLR and APOB only. 
Honeychurch J, Dean P, O'Shea S, et al. (2014). The impact of 
routine next generation sequencing testing for familial 
hypercholesterolaemia-8 months service experience. Clinical 
Chemistry and Laboratory Medicine, 52(11), eA340. 
Abstract 
Honeychurch J, Yarram-Smith L, O'Shea S, et al.(2014). Genetic 
testing of familial hypercholesterolaemia at BGL-a five year audit. 
Clinical Chemistry and Laboratory Medicine, 52(11), pp.eA340. 
Abstract 
Hooper A J, Nguyen L T, Burnett J R, et al (2009). Molecular 
screening approach for identification of mutations causing familial 
hypercholesterolaemia in Western Australia. Twin Research and 
Human Genetics, 12(2), 218. 
Abstract 
Huijgen R, Hutten B A, Kindt I, et al.. (2012). Discriminative ability of 
LDL-cholesterol to identify patients with familial 
hypercholesterolemia: a cross-sectional study in 26,406 individuals 
tested for genetic FH. Circulation. Cardiovascular Genetics, 5(3), 
354-9. 
All people had genetic 
testing for FH; no clinical 
diagnosis undertaken. 
Comparison of mutation 
and severity of LDL-C 
concentration. 
Ibarretxe D, Feliu A, Ferre R, Merino J, Guijarro E, Andres P, Ramon 
R, Amigo E, Masana L, and Plana N. (2015). Heterozygous familial 
hypercholesterolemia detection in children: The decopin project. 
Atherosclerosis, 241(1), pp.e113. 
Abstract 
Langsted A, Kamstrup P R, Benn M, Tybjaerg-Hansen A, and 
Nordestgaard B G. (2016). High lipoprotein(a) as a possible cause of 
clinical familial hypercholesterolaemia: a prospective cohort study. 
The Lancet Diabetes & Endocrinology, 4(7), pp.577-87. 
 
Association of mutation or 
clinical diagnosis with 
raised LDL-C levels; 
genetic analysis unclear, 
appears only to analyse 
mutations in LDLR and 
APOB. 
Lee S, Shin D, Han S, Park S, Kang S, Jang Y, and Lee J. (2015). 
Clinical diagnosis of familial hypercholesterolemia in Korea: 
Comparison of mutation-prediction by simon broome-,Dutch, and 
MED/PED criteria. Atherosclerosis, 241(1), pp.e110-e111. 
Abstract 
Leren T P, Finborud T H, Manshaus T E, Ose L, and Berge K E. 
(2008). Diagnosis of familial hypercholesterolemia in general practice 
using clinical diagnostic criteria or genetic testing as part of cascade 
genetic screening. Community Genetics, 11(1), pp.26-35. 
Only tests for mutations in 
LDLR and APOB. Unclear 
what clinical diagnosis 
used. 
Lipworth L, Shirey-Rice J, Wei W Q., et al. (2015). Identification and 
characterization of heterozygous familial hypercholesterolemia 
patients using the Vanderbilt University medical center synthetic 
derivative database. European Heart Journal, 36,.927. 
Poster 
Lu C, Poulter E, Bates T.,et al. (2012). Assessment of the prevalence 
of familial hypercholesterolaemia in patients with premature coronary 
artery disease using three clinical tools. Heart Lung and Circulation, 
21, S29-S30. 
Abstract 
Mabuchi H, Nohara A, Noguchi T, Kobayashi J, Kawashiri M A, Tada 
H, Yamagishi M, Inazu A, and Koizumi J. (2010). Usefulness of DNA 
analysisr the diagnosis of familial hypercholesterolemia (FH) and 
extraordinarily high frequency of FH in Japan. Atherosclerosis 
Supplements, 11(2), pp.115. 
Abstract 
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Reference Reason for exclusion 
Maglio C, Mancina R M, Motta B M, Pirazzi C, Wiklund O, and 
Romeo S. (2014). Targeted next generation sequencing for genetic 
diagnosis of familial hypercholesterolemia. Atherosclerosis, 235(2), 
pp.e100. 
Abstract 
Mata N, Alonso R, Badiman L, et al. (2011). Clinical characteristics 
and evaluation of LDL-cholesterol treatment of the Spanish Familial 
Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). 
Lipids in Health and Disease, 10, pp.no pagination. 
No detail on clinical 
diagnosis. 
Medeiros AM, Alves AC, Francisco V et al (2010). Update of the 
Portuguese Familial Hypercholesterolaemia Study. Atherosclerosis, 
212, 553-8. 
 
Medeiros A M, Alves A C, and Bourbon M. (2013). Mutational 
analysis of the portuguese cohort with clinical diagnosis of familial 
hypercholesterolemia. Cardiology (Switzerland), 126, pp.19. 
Abstract 
Medeiros A, Alves A, Aguiar P, and Bourbon M. (2014). APOB/apoA1 
ratio improves clinical criteria sensitivity for the identification of FH 
children. Atherosclerosis, 235(2), pp.e64. 
Abstract 
Mickiewicz A, Chmara M, Futema M, Fijalkowski M, Chlebus K, 
Galaska R, Bandurski T, Pajkowski M, Zuk M, Wasag B, Limon J, 
Rynkiewicz A, and Gruchala M. (2016). Efficacy of clinical diagnostic 
criteria for familial hypercholesterolemia genetic testing in Poland. 
Atherosclerosis, 249, 52-8. 
Does not test for all three 
mutations (LDLR, APOB 
and PCSK9); APOB and 
LDLR only. 
O'Brien E C, DeGoma E, Moriarty P, et al.(2015). Initial results from 
the CASCADE-FH registry: CASCADE screening for awareness and 
detection of familial hypercholesterolemia. Journal of the American 
College of Cardiology, 65(10 SUPPL. 1), A1372. 
Poster 
Palacios L, Stef M, Taylor A et al. (2010). Rapid and accurate genetic 
diagnosis by LIPOchip in UK FH patients. Atherosclerosis 
Supplements, 11(2), 31. 
Abstract 
Poke S, Watts G, Maxwell S, Brameld K, and O'Leary P. (2009). 
Familial hypercholesterolaemia (FH) pilot cascade screening project. 
Twin Research and Human Genetics, 12(2), 229. 
Abstract 
Qureshi N, Weng S, and Tranter J. (2016). Erratum: Feasibility of 
improving identification of familial hypercholesterolaemia in general 
practice: Intervention development study (BMJ Open (2016) 6 
(e011734)). BMJ Open, 6(6). 
Erratum to Qureshi 2016  
Qureshi N, Weng S, Tranter J, El-Kadiki A, and Kai J. (2016). 
Feasibility of improving identification of familial 
hypercholesterolaemia in general practice: intervention development 
study.[Erratum appears in BMJ Open. 2016;6(6):e011734corr1; 
PMID: 27338885]. BMJ Open, 6(5).e011734. 
Unclear whether undertook 
genetic testing to confirm 
clinical diagnosis. No 
details of mutations tested 
for. 
Raal F, Stein E A, Cariou B, et al. (2014). The diagnosis of 
heterozygous familial hypercholesterolemia: Genotype versus 
phenotype. Circulation, 130. 
Abstract 
Ruotolo A, D'Agostino M N, D'Angelo A, Di Taranto , M D, 
Guardamagna O, Malamisura B, De Matteo , A , Licenziati M R, 
Lenta S, Marotta G, and Fortunato G. (2014). Molecular diagnosis of 
familial hypercholesterolemia in pediatric cohort. Biochimica Clinica, 
38(5), 512. 
Not available from any 
sources. 
Townsend D, Edmunds L, Gingell R, et al. (2013). Identification of 
familial hypercholesterolaemia within primary care-a collaborative 
approach with community GP networks. Atherosclerosis, 231(2),.e9-
e10. 
Abstract 
Townsend D, Gingell R, Edwards R, et al. (2013). Initiation of a nurse 
led FH clinic for the identification of individuals with familial 
Abstract 
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Reference Reason for exclusion 
hypercholesterolaemia (FH) in a rural setting. Atherosclerosis, 
231(2), pp.e5-e6. 
van Aalst-Cohen , E S, Jansen A C, Tanck M W, Defesche J C, Trip 
M D, Lansberg P J, Stalenhoef A F, and Kastelein J J. (2006). 
Diagnosing familial hypercholesterolaemia: the relevance of genetic 
testing. European Heart Journal, 27(18), pp.2240-6. 
Only tested for LDLR 
mutation in people with FH 
according to DLCN score. 
Wald D S, Kasturiratne A, Godoy A, et al (2011). Child-parent 
screening for familial hypercholesterolemia. Journal of Pediatrics, 
159(5), 865-7. 
Meta-analysis of LDL-C 
concentration, incorrect 
intervention. 
Wald D S, Bangash F A, and Bestwick J P. (2015). Prevalence of 
DNA-confirmed familial hypercholesterolaemia in young patients with 
myocardial infarction. European Journal of Internal Medicine, 26(2), 
pp.127-30. 
No clinical diagnosis, 
genetic testing only. 
Widhalm K, Dirisamer A, Lindemayr A, and Kostner G. (2007). 
Diagnosis of families with familial hypercholesterolaemia and/or 
APOB-100 defect by means of DNA analysis of LDL-receptor gene 
mutations. Journal of Inherited Metabolic Disease, 30(2), pp.239-47. 
Used medped criteria – not 
in protocol; only assessed 
LDR receptor mutation. 
Yarram L, Greenslade M, Bayly Get al. (2013). Genetic testing of 
familial hypercholesterolaemia at BGL-a four year audit. 
Atherosclerosis, 231(2), e2. 
Abstract 
Yarram-Smith L, Dean P, O'Shea S, et al. (2014). The impact of 
routine next generation sequencing testing for familial 
hypercholesterolaemia-5 months service experience. Atherosclerosis, 
236(2),e304. 
Abstract 
F.3 Management (statin monotherapy) 
Reference Reason for exclusion 
AstraZeneca . (2008). A phase IIIb, efficacy, and safety study of 
rosuvastatin in children and adolescents 10 to 17 years of age with 
heterozygous familial hypercholesterolemia (HeFH): a 12-week, 
double-blind, randomized, multicenter, placebo-controlled study with 
a 40-week, open-label, follow-up period. Protocol D3561C00087 or 
4522IL/0087,  
Protocol only 
Avis H J, Hutten B A, Gagne C, Langslet G, McCrindle B W, 
Kastelein J J, and Stein E A. (2009). Efficacy and safety of 
rosuvastatin therapy for children with familial hypercholesterolemia: 
Results from the PLUTO study. Journal of the American College of 
Cardiology, 53(10), pp.A208. 
 
Duplicate of Avis 2010 
study (included) 
Berthold H K, and Nitschmann S. (2008). [Therapy of familial 
hypercholesterolemia with or without ezetimibe]. Der Internist, 49(10), 
pp.1274-6. 
Paper not in English 
Braamskamp M J, Kusters D M, Avis H J, Wijburg F A, Kastelein J J, 
Wiegman A, and Hutten B A. (2013). Patients with familial 
hypercholesterolemia who initiated statin treatment in childhood are 
at lower risk for chd then their affected parents. Circulation, 128(22 
suppl. 1), pp.. 
Abstract 
Braamskamp M J, Tsimikas S, Wiegman A, Kastelein J J, and Hutten 
B A. (2013). Statin therapy and secretory phospholipase A2 in 
children with heterozygous familial hypercholesterolemia. 
Atherosclerosis, 229(2), pp.404-7. 
No outcomes reported that 
match protocol. 
Braamskamp M J, Kusters D M, Wiegman A, Avis H J, Wijburg F A, 
Kastelein J J, van Trotsenburg , A S, and Hutten B A. (2015). 
Gonadal steroids, gonadotropins and DHEAS in young adults with 
Open label extension of 
RCT; no outcomes of 
interest reported. 
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Reference Reason for exclusion 
familial hypercholesterolemia who had initiated statin therapy in 
childhood. Atherosclerosis, 241(2), pp.427-32. 
Hernandez C, Francisco G, Ciudin A, Chacon P, Montoro B, 
Llaverias G, Blanco-Vaca F, and Simo R. (2011). Effect of 
atorvastatin on lipoprotein (a) and interleukin-10: A randomized 
placebo-controlled trial. [French]. Diabetes & metabolism, 37(2), 
pp.124-30. 
Article not in English 
language 
Kusters D M, Hutten B A, McCrindle B W, Cassiman D, Francis G A, 
Gagne C, Gaudet D, Morrison K M, Langslet G, Kastelein J J, and 
Wiegman A. (2013). Design and baseline data of a pediatric study 
with rosuvastatin in familial hypercholesterolemia. Journal of Clinical 
Lipidology, 7(5), pp.408-13. 
Not an RCT 
Lozano P, Henrikson N B, Dunn J, Morrison C C, Nguyen M, Blasi P 
R, Anderson M L, and Whitlock E P. (2016). Lipid Screening in 
Childhood and Adolescence for Detection of Familial 
Hypercholesterolemia: Evidence Report and Systematic Review for 
the US Preventive Services Task Force. JAMA, 316(6), pp.645-55. 
Systematic review on 
effectiveness of screening 
for FH 
Perry C M. (2010). Colesevelam: in pediatric patients with 
heterozygous familial hypercholesterolemia. Paediatric Drugs, 12(2), 
pp.133-40. 
Narrative report on 
Colesevelam 
Pfizer Inc. (2011). A 1-year study in children and adolescents with 
familial or severe hypercholesterolemia comparing atorvastatin to 
placebo (6-month double-blind treatment), followed by atorvastatin 
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pp.664-8. 
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RCT. All participants 
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colvesevalem 
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Incorrect study design: 
Case control study (siblings 
with FH vs unaffected 
siblings) 
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Reference Reason for exclusion 
analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE 
studies. Circulation. Cardiovascular imaging, 3(4), pp.398-404. 
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Appendix G: Evidence tables 
G.1 Case finding 
G.1.1 Cascade testing 
Bell 2015 
Bibliographic reference Bell 2015 
Study type Prospective 
Aim Investigate effectiveness of cascade testing family members of the first 100 index cases with genetically confirmed 
FH in centralised service in western Australia.  
Patient characteristics Relatives of index patients; 62% from primary care. 
Index cases:male n= 41/100; age (yrs) 47.0 (SD 15.8) [n=6 aged 1-16 yrs) 
Mutation positive relatives: male 91/188 (48.4%); age 37.6 (SD 19.6) yrs; 18.6% had tendon xanthoma 
Mutation negative relatives: male 87/178 (48.9%); age 35.6 (SD 19.2) yrs; none had tendon xanthoma  
Number of patients 366 relatives of 100 index patients with genetically proven FH (with at least one family member had been 
genetically screened). Index cases diagnosed using DLNC. 
6 index cases aged 10-16 yrs. 
Index test Genetic cascade testing (direct) 
Trained nurse contacted family members; firstly by letter then a 2nd letter or phone call if no response to 1st letter. 
Reference standard (or 
Gold standard) 
Lipid tests 
Genetic cascade testing (direct): APOB, LDLR, PCSK9 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location Australia 
Results Index cases were diagnosed using Dutch Lipid Network Criteria. 
 
Family cascade testing initiated appropriate consent; trained nurse contacted family members. 
8 declined testing. 
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FH causing mutation found in 188 people (51.4%) 
178 mutation negative 
Source of funding Not reported 
Comments Index patients diagnosed with DLNC, not clear whether they also had genetic testing. 
Demographics of mutation positive and negative relatives presented separately. 
Bhatnager 2000 
Bibliographic reference Bhatnager 2000 
Study type Case finding among relatives of patients with FH 
Aim To assess the feasibility of detecting cases of heterozygous familial hypercholesterolaemia by using a nurse-led 
genetic register. 
Patient characteristics Relatives of probands aged 18 years and over, attending lipid clinics for the 1st time between 1987 and 1998, 
identified by using the Simon Broome criteria for diagnosis of FH. 
Number of patients 259 probands (137 men, 122 women), 285 first degree relatives. 
Index test Probands identified using Simon Broome criteria. 
First degree relatives sent a standardised letter explaining reason why suspected that they may have FH. Either 
chose to see nurse at hospital, or attend GP practice. Results of relatives serum cholesterol test sent to GP 
explaining why test had been done and importance of results. Location of nearest lipid clinic provided when the 
test gave a positive result. 
Concentrations of serum cholesterol, HDL-C, triglycerides, LDL-C and lipoprotein were measured in all people. 
Reference standard (or 
Gold standard) 
N/A 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location Two lipid clinics in central and south Manchester 
Results Of 262 probands identified, 259 agreed to participate. 216 had at least 1 living first degree relative, estimated to be 
285 in total; 205 of these were tested. 
 
Results for cholesterol concentration available for 200 relatives. 
121 (46 men, 75 women) proved positive. 
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79 had serum cholesterol less than 7.5 mmol/L 
Source of funding NHS research and development grant and NHS research and development levy. 
Comments No DNA detection methods for FH used. 
Male probands less likely to produce a cooperative relative than female proband (p<0.0005) 
Hadfield 2009 
Bibliographic reference Hadfield 2009 
Study type Retrospective 
Aim To identify the effect of the implementation of systematic recording and tracing first-degree family members of 
people with FH. 
Patient characteristics Index cases 931 FH patients  
643 index cases responded  
2292 first degree relatives identified, 798 already tested so not contacted, 1494 contacted. 
Number of patients 931 index cases contacted, 643 responded, 545 index cases provided details for family tracing. 
2292 living first degree relatives (FDRs). 
Index test Retrospective audit of medical notes of known FH patients (diagnosed using SB criteria). 
Nurse led cascade testing and family tracing. 
Reference standard (or 
Gold standard) 
N/A: audit  
Time between testing & 
treatment 
N/A: no treatment  
Length of follow-up No follow up. Relatives who were diagnosed with FH were offered lifestyle advice and therapeutic options for the 
management of their hyperlipidaemia, as per normal practice  
Location London. Clinic sites Manchester, Nottingham, Birmingham, Surrey, Bournemouth 
Results Diagnostic yield: 
219/1494 had likely FH (168/990 living within catchment area, 51/504 living outside the catchment area) 
(103 uncertain diagnosis, 445 unlikely FH) 
Uptake rate of testing: 
643/931 index cases responded, 545 index cases provide information for family tracing (43 report all family 
members have been tested). 
591/1494 FDRs come forward for testing (591/990 within catchment area, 78/504 outside of catchment area) 
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 Age in 
Y 
           
0-14 15-24 25-34 35-44 45-54 55 and 
over  
Males  Femal
es  
Males  Femal
es  
Males  Femal
es  
Males  Femal
es  
Males  Femal
es  
Males  Femal
es  
Upper limit 
of grey zone  
5.3 5.6 5.3 6.0 6.3 6.2 6.6 6.4 7.2 7.0 7.3 7.6 
 3.4 3.7 3.4 3.8 4.5 4.2 4.7 4.3 5.2 4.8 5.2 5.2 
Lower limit 
of grey zone  
5.0 5.3 4.8 5.4 5.4 5.5 5.9 5.8 6.3 6.2 6.2 6.6 
 3.1 3.4 3.0 3.3 3.8 3.6 4.0 3.7 4.4 4.0 4.3 4.4 
 
Source of funding Department of Health, UK IDEAS genetics knowledge park, BHF grant. 
Comments Excluded FDRs that were known to have already been tested. 
Scored well on CASP QA tool.  
Jannes 2015 
Bibliographic reference Jannes 2015 
Study type Prospective 
Aim To describe the clinical and genetic data obtained from cascade screening in a large Brazilian cohort. 
Patient characteristics Study participants were referred from: 
1. Lipid clinics with a clinical suspicion of FH,  
2. Subjects not from the lipid clinic but who had performed a cholesterol test for other reasons and presented or 
referred previous LDL-C concentrations of >5.4mmol/L for adults and >4.3mmol/L for children 
3. Subjects referred directly to cascade screening due to elevated cholesterol levels. 
Number of patients 248 index patients, 394 relatives 
Index test Genetic testing 
Reference standard (or 
Gold standard) 
Genetic testing: LDLR, APOB and PCSK9 mutation. 
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Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location Brazil 
Results Trained nurse applied a questionnaire and performed physical examination. Presence of early coronary disease 
history in patients and family. 
Of 248 possible cases, 175 SB criteria and 190 DLNC answered questionnaires that contemplated FH diagnosis. 
All relatives with identified FH mutation referred to InCors Lipid Clinic outpatient unit. 
 
Index cases: 
125/248 (50.4%) mutation positive (123 mutation negative) 
 
Relatives: 
234/394 (59.4%) mutation positive (160 mutation negative) 
 
Sensitivity and specificity of DLNC and SB to detect FH mutation 
DLNC Mutation 
+ve, % (n) 
Mutation –
ve, % (n) 
Sensitivity 
% (CI) 
Specificity 
% (CI) 
PPV  
% (CI) 
NPV  
% (CI) 
0-2 points 3.6 (3) 19.8 (18)     
3-5 – 
possible 
19 (16) 36.3 (33) 96.4 (89.1-
99) 
19.7 (12.4-
29.7) 
52.5 (44.4-
60.6) 
85.7 (62.6-
96.2) 
6-8 
probable 
32.1 (27) 31.9 (29) 77.3 (66.7-
85.5) 
56.0 (45.2-
66.3) 
61.9 (51.8-
71.0) 
72.8 (60.7-
82.4) 
>8 
definitive 
45.2 (38) 12.1 (11) 45.2 (34.4-
56.4) 
87.9 (78.9-
93.5) 
77.5 (63.0-
87.7) 
63.4 (54.3-
71.7) 
total 100 (84) 100 (91)     
 
SB Mutation 
+ve, % 
(n) 
Mutation 
–ve, % 
(n) 
Sensitivity 
% (CI) 
Specificity 
% (CI) 
PPV  
% (CI) 
NPV  
% (CI) 
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Definitive 10.5 (8) 0 10.5 (4.9-
20.2) 
10.5 
(95.9-
100) 
100 
(59.7-
100) 
62.6 
(55.1-
69.5) 
Probable 73.7 (56) 48.2 (55) 84.2 
(73.6-
91.2 ) 
51.7 
(42.2-
61.1) 
53.7 
(44.4-
62.8) 
83.0 
(71.9-
90.5) 
No 15.8 (12) 51.8 (59)     
Total 100 (76) 100 (114)     
 
Source of funding Sociedade Hospital Samaritano and Ministerio da Saude. 
Comments Sensitivity and specificity data for DLNC and SB to detect mutation not carried out on whole cohort. Only n=175 for 
DLNC and n=190 for SB data. Unclear why not all included participants included in analysis. 
Lee 1998 
Bibliographic reference Lee 1998 
Study type Prospective cohort 
Aim To track the LDL receptor gene in individual families with phenotypic FH and to identify and characterise any 
mutations of the LDLR gene that may be common in the west of Scotland FH population. 
Patient characteristics Patients with familial defective ApoB excluded by testing for ApoB-3500 
Number of patients 80 probands, 200 relatives of probands and 50 normal controls 
Index test Clinical criteria for FH were: 
Fasting TC >9mmol/L, LDLC >7mmol/L plus one of the following: 
-strong family history of CHD 
-presence of either tendon xanthoma or xanthelasma 
-personal history of heart disease 
Reference standard (or 
Gold standard) 
Genetic test: LDLR gene only. 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location Scotland 
Results 3 probands had C163Y mutation 
8 relatives had mutation and raised serum cholesterol 
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Source of funding Not reported 
Comments Only tracking a specific mutation in LDLR gene only 
No baseline demographics reported. 
Study differs in numbers of mutations reported in different figures compared to text: Table 1 reports 7 probands 
with mutation and 11 relatives with mutatio 
Leren 2008 
Bibliographic reference Leren 2008 
Study type Prospective cohort 
Aim Experience of the use of genetic cascade testing in Norway to diagnose FH patients 
Patient characteristics 1st degree relatives of patients with molecularly defined FH consented to genetic cascade screening; 53% male 
1415/1805 were 18 yrs or older 
Number of patients 2472 relatives of 440 index patients 
Index test Genetic testing: LDLR and APOB 
Reference standard (or 
Gold standard) 
N/A 
Time between testing & 
treatment 
N/A 
Length of follow-up Additional questionnaire at 6 months follow up 
Location Norway 
Results Uptake:1805 (73%) blood samples received 
 
Diagnostic yield: 808/1805 (44.8%) mutation carriers,  
997 had no mutation. 
357/808 on lipid lowering therapy at time of testing 
 
Questionnaire 
1062 adult relatives returned questionnaire (75.1%) 
970 had TC measured 
551 had elevated TC 
209/551 (37.9%) had clinical diagnosis of FH 
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184/209 had clinical and molecular diagnosis of FH 
 
Assuming that no person with low or normal serum cholesterol had been given a diagnosis of clinical FH, 46.2% 
(193/418) with molecularly defined FH would have been diagnosed by clinical criteria in general practice. 
Data indicated that a clinical diagnosis of FH in general practice has a sensitivity of 46.2% and specificity of 88.0% 
 
At 6 months; questionnaire sent to mutation carriers 10 years and older. 
768 mutation carriers had been contacted and 361 (47%) have returned questionnaire along with a blood sample. 
61.6% of mutation carriers on lipid lowering drugs at time of genetic testing 
79% on lipid lowering therapy at 6 month follow up  
Source of funding Not reported 
Comments PCSK9 mutation not tested for. 
Unclear what clinical criteria used when FH clinically diagnosed. 
Marks 2006 
Bibliographic reference Marks 2006 
Study type Case finding (secondary care) 
Aim To determine the proportion of cases of heterozygous FH would be identified by cascade screening conducted by 
a specialist hospital clinic. 
Patient characteristics 227 eligible adult index cases, with 1075 first degree relatives. 225 eligible adult relatives.117 eligible children (<18 
years) 
Number of patients Hospital clinic serving a population of 605,900 in Oxfordshire, UK 
354 patients currently or previously attending the Oxford lipid clinic and meeting the diagnostic criteria of the 
Simon Broome Familial Hyperlipidaemia Register for definite or possible familial hypercholesterolaemia were 
identified by January 2002, after excluding 22 cases managed exclusively in primary care. 
48 of the 354 were children aged under 18 years.  
Index test Using either pre-treatment measurements or the highest measurement on treatment, definite familial 
hypercholesterolaemia was defined as: 
(1) a total cholesterol concentration >7.5 mmol/L in adults (>6.7 mmol/L in children under 16 years) or an LDL 
cholesterol concentration >4.9 mmol/L in adults (>4.0 mmol/L in children), plus  
(2) tendon xanthomata in the patient or a first-or second-degree relative. A possible diagnosis of familial 
hypercholesterolaemia required the first definition above plus one of the following: 
(1) family history of myocardial infarction before age 50 years in second-degree relative or before age 60 years 
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in first-degree relative, or  
(2) family history of raised total cholesterol concentration above 7.5 mmol/L in first-or second-degree relative. 
 
Total cholesterol concentration was measured on a non-fasting finger-prick capillary blood sample using a 
Cholestech LDX analyser (CholestechCorporation, Hayward, CA, USA) with a coefficient of variation of 4.9%.17 
Those with diagnostic or borderline results were advised to have a confirmatory fasting venous specimen taken. 
Reference standard (or 
Gold standard) 
Results classified by US MedPed (Make Early Diagnosis Prevent Early Death) Program criteria using age-specific 
total cholesterol cut-points (age o20 years 5.7 mmol/L; 20–29 years 6.2 mmol/L; 30–39 years 7.0 mmol/L; and 40þ 
years 7.5 mmol/L) 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location Oxfordshire, England  
Results 227 adult index cases had 1075 first degree relatives – 442 adults (41%) and 117 children (11%) aged less than 
18 yrs lived in Oxfordshire. 
171 previously screened unaffected adults and 46 (too ill or elderly and infirm) were excluded  
225 eligible adult relatives 28 responders (12%) planned to consult their general practitioner and 52 (23%) 
attended the clinic for testing.  
Parents of 113 children (97%) asked for their children to be tested and, with the exception of three families, all the 
parents asked for the tests to be done at home. 
The positive diagnostic rate was 29% (15/52) in adults and 32% (36/113) in children. 
Based on the population of Oxfordshire at the 2001 census, cascade screening increased the prevalence by 
14.4% from 0.58/1000 (95% CI 0.52–0.65) to 0.67/1000 (95% CI 0.60–0.73), which represents a detection rate of 
33.5% based on the estimated gene frequency of 2/1000. 
Source of funding Hyperlipidaemia education and research trust (Heart UK) and Pfizer  
SEH is funded by the British Heart Foundation and in part by a grant from the Department of Health to the London 
Genetics Knowledge Park. 
Comments Please see additional figure for this paper at the end of this evidence table document  
Good paper – many of the boxes ticked yes in the CASP tool. Just not sure about the confounding factors. 
Cascade testing relies on index patients providing all and the correct information. Some relatives may have been 
missed using this method.  
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Bibliographic reference Muir 2010 
Study type Case series 
Aim To identify the dianostic and treatment rates for FH in New Zealand. 
Patient characteristics 588 people, out of a possible 10,500 affected people, who presented with a pre-treatment cholesterol _8.0 
mmol/L, lipid stigmata or a strong family history of cardiovascular disease (CVD), 
Number of patients 588 people referred for mutation screening; 76 index cases identified; 353 relatives screened. 
Index test DNA testing of LDLR gene 
Reference standard (or 
Gold standard) 
N/A 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location New Zealand 
Results Between 2004 and 2008, 588 people were identified from pathology laboratory database were DNA tested for FH 
if they had TC >8 mmol/L (pre-treatment); lipid stigmata or a strong family history of CVD. 
 
76 index cases identified from path lab database.  
 
Cascade testing: 
Patients with an identified mutation referred to clinical nurse specialist at CDHB lipid clinic for cascade testing. 95 
patients with a severe phenotype who met criteria for mutation analysis but did not have an identified mutation, 
were also referred. 
 
All index patients provided contact details for their relatives who were sent letters explaining FH, consent forms 
and laboratory request forms. 
Source of funding None reported. 
Comments Not clear how many people were invited to cascade screening, unable to calculate uptake rate. 
Norsworthy 2014 
Bibliographic reference Norsworthy 2014 
Study type Generation Scotland: Scottish Family Health study (pathology database) 
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Aim Targeted use of next generation sequencing as a potential route to diagnosis of FH in primary care population 
subset selected for hypercholesterolaemia. Cascade testing using molecular diagnostics. 
Patient characteristics Biological samples were obtained from the ‘Generation Scotland: Scottish family Health study (GS:SFHS). 
Samples collected were from patients who were likely to have FH, based on previously reported population total 
cholesterol data in FH. Age and BMI thresholds were also used to reduce the inclusion of age and obesity related 
cases of hyperlipidaemia.  
Number of patients 617 (selected on basis of total cholesterol data).  
Index test Genetic testing for FH. 
Patients were selected from the cohort using searches for TC, age and BMI cut-offs, termed the “High cholesterol 
group” (TC >8.5 mmol/L, TC 8-8.4mmol/L age <50 yrs, TC 8-8.4 mmol/L / age >50/ bmi <25, TC 7-7.9 mmol/L/ 
age <40) 
A cholesterol therapy group was selected (moderately high cholesterol despite lipid lowering therapy), and a 
control group. 
Reference standard (or 
Gold standard) 
N/A 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location Scotland 
Results Diagnostic yield 
FH causing mutations identified through testing in : 
4/193 (2.1%) of subjects in high cholesterol group 
5/232 (2.2%) in cholesterol therapy group 
0/192 in normocholesterolaemic group 
Cascade testing: 
DNA available for cascade testing in relatives of 6/9 (66%) index cases identified. 
12 available first degree relatives (FDRs) 
5 molecular diagnoses of FH were made. 
Source of funding Generation Scotland has received core funding from the Chief Scientist Office of the Scottish Government Health 
Directorates CZD/16/6 and the Scottish Funding Council HR03006. We also acknowledge funding from the 
MRC Clinical Sciences Centre and the British Heart Foundation to TJA, from a Wellcome Trust Clinical Training 
Fellowship to ERAT, and from the NIHR-funded Imperial Biomedical Research Centre to TJA. 
Comments Data for LDL-C ot reported in this study 
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Bibliographic reference Stempel 2016 
Study type Retrospective review and prospective 
Aim To describe indications for initial cholesterol screening and examine outcomes of cascade screening efforts in 
family members of children with FH 
Patient characteristics 42 paediatric patients from 34 unrelated families. 9 had existing diagnosis of FH. 55% male, mean age 10.4 years 
(range 6.1 – 20.2 years) 
Number of patients N=42, n=30 identified as families proband. 
Index test <18 years with LDLC ≥160mg/dL (22.2 mmol/L) on 2 lipid profiles, when a family history of high LDLC or 
premature CVD was identified in a parent of grandparent. Or, 
With LDLC ≥190mg/dL (26.4 mmol/L) on 2 lipid profiles when a family history unknown or incomplete. 
 
>18 years old with personal or family history of premature CVD with LDL-C ≥190mg/dL(26.4 mmol/L) 
Reference standard (or 
Gold standard) 
N/A 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location USA 
Results Provider obtained family history and discussed cacade screening with parents. Parents obtained cholesterol 
results for themselves and family members to share with providers. If family member deceased and cause of 
death was premature cardiovascular disease, given a presumptive diagnosis of FH,  
 
Cascade screening led to 63 new diagnoses in relatives of children 
58/63 were adults 
5/63 were siblings of probands 
Source of funding Not reported 
Comments None 
Taylor 1993 
Bibliographic reference Taylor 1993 
Study type Prospective cohort 
Aim To evaluate a more effective method of identifying children with FH by screening a population high a risk. 
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Patient characteristics 200 children who were 1st or second degree relatives of people with premature onset coronary artery disease (120 
families). 
Number of patients 200 children identified from 120 families.  
Index test People with premature CAD (previous MI or angina) <50 yrs men, <55 yrs women considered as index cases, 
families approached by a health visitor via a GP. 
Reference standard (or 
Gold standard) 
Not detailed  
Time between testing & 
treatment 
No treatment given  
Length of follow-up 6 months if diagnosed with FH  
Location Sheffield, UK 
Results 12/200 new cases of FH 
(Diagnostic criteria: history of early CAD in 1st or 2nd degree relative, fasting TC of >5.9 mmol/L, HDL cholesterol 
<1.5 mmol/L, LDL-C >3.5 mmol/L, normal fasting triglyceride values (<2.3 mmol/L). the risk of developing 
ischaemic heart disease in children with confirmed hypercholesterolaemia calculated from ratio of total: HDL 
cholesterol.) 
 
Case 
No 
Age 
(years) 
Total 
cholesterol  
Triglyceride 
(mmol/l) 
HDL cholesterol 
(mmol/l) 
LDL cholesterol 
(mmol/l) 
1 12.4 5 8** 0.5 1.3 4.27 
2 7.4 7.7 0.9 0.84 6.45 
3 4.7 8.2 1.2 0.81 6.84 
4 12.0 6.4 1.0 1.26 4.14 
5 10.2 5.7** 0.8 1.37 3.96 
6 1.4* 11.1 1.8 0.53 9.75 
7 11.7 6.4 0.9 1.16 4.23 
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8 5.9 9.5 0.6 0.84 8.39 
9 3.3 7.1 0.7 0.95 5.83 
10 15.8 8.9 1.1 1.26 7.14 
11 9.3 6.6 0.9 1.33 4.86 
12 1.0* 9.8 1.5 1.02 8.10 
*Children under 2 years not sampled unless siblings of known patient. 
**Previous total cholesterol >5 9 mmol/l. 
 
Source of funding Not reported  
Comments CASP – can’t tell whether authors have identified all confounding factors or whether they have taken account of 
the confounding factors in the design and/or analysis. It also wasn’t clear whether the follow up of the subjects was 
complete or complete enough. Paper didn’t contain any CI’s to show how precise the results were. More research 
needed to show how the results will impact on practice. 
Thorsson 2003 
Bibliographic reference Thorsson 2003 
Study type Prospective 
Aim Novel approach to systematic family screening compared to conventional proband screening for patients in 
Iceland. 
Patient characteristics Affected males: n=37), non-affected n=125; affected females n=26, non-affected n= 136. 
 Males Females 
 Affected male 
(n=37) 
Nonaffected male 
(n=125) 
Affected female 
(n=26) 
Nonaffected female 
(n=136) 
TC 9.5 (1.9) 5.6 (1.0) 9.4 (2.3) 5.9 (1.3) 
HDL 1.0 (0.3) 1.2 (0.5) 1.2 (0.2) 1.5 (0.4) 
TG 1.4 (0.9) 1.4 (0.8) 1.1 (0.6) 1.3 (0.6) 
 
Number of patients 364 key individuals. 78 offspring of positive key individuals. 
Index test Clinical criteria used to identify probands: 
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TC >8.5mmol/L in the proband and a first degree relative, tendon xanthoma in proband or first degree relative, 
myocardial infarction in proband or first degree relative before the age of 55 years. 
Reference standard (or 
Gold standard) 
Genetic testing: 
Only probands with the common mutation identified in Iceland (14T+2C) were included. Family tracing partly from 
computerised database derived from censuses (first carried out 1703), church records and birth and marriage 
certificates). Once a common ancestor was identified a list of all descendants was produced. 
The oldest individual was identified in a key individual and was contacted for cholesterol measurements and 
genetic testing. If positive for genetic testing, offspring were recruited for testing. 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location Iceland 
Results 2201 living individuals in 4 family clusters 
364 key individuals identified 
306 responded  
35/306 (11%) key individuals who responded were positive for common mutation. 
Of 35 key individuals who were positive, 7 had not been previously diagnosed. 
 
Genealogical tracing identified 78 living offspring of positive key individuals. 
68 were recruited 
40 (59%) of these were positive 
21 had already been diagnosed with FH, 19 had not been diagnosed previously and were not receiving lipid 
lowering therapy. 
14 individuals of 75 FH patients identified in the families were from previously unknown family lineages. 
Source of funding Icelandic research council 
Comments Lack of baseline characteristics 
Unclear what the conventional proband screening method was 
Study has limited applicability to UK population because of the screening methods used. 
Umans-Eckenhausen 2001 
Bibliographic reference Umans-Eckenhausen 2001 
Study type Case finding among relatives of patients with FH 
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Aim Case finding programme to for individuals with FH, based on family investigation and DNA testing  
Patient characteristics Relatives of patients diagnosed with FH who are carriers of the mutation that causes FH.  
Age 
<40 n = 2678 
40-59 n = 1819 
Number of patients 1994-1998, 5442 people were enrolled into the identification programme.  
Carriers of the genetic mutation n = 2039 
Non carriers of the genetic mutation n = 3403 
Index test Family members of patients diagnosed with FH (index-cases) receive an information brochure describing the 
nature of FH by mail; they are then telephoned by a Genetic Field Worker (GFW) where the purpose of the 
screening programme is explained. GFW conducts a house visit with as many as possible family members 
present. Consent, health questionnaire conducted, names and addresses of family members to be contacted to be 
contacted later, and blood taken. Blood analysed for the presence of the mutation causing FH and total 
cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides tested.  
Reference standard (or 
Gold standard) 
Not defined 
Time between testing & 
treatment 
Not defined  
Length of follow-up Index patients were usually seen for an additional 1 or 2 follow up visits – time not specified.  
Location Identification: The Amsterdam lipid research clinic at the medical centre of the University of Amsterdam and the 
Slotevaart University teaching hospital.  
Screening: patients homes and at 1 of 75 lipid clinics in Amsterdam 
 
Results  5442 index patients agreed to participate in the study.  
Characteristics  Carriers  Noncarriers  P 
n 2039 9 (37.5%) 3403 (62.5%)  
Age distribution (years) 
<40 1189 (58.3%) 1489 (43.7%) <.001 
40-59 559 (27.4%) 1260 (37.0%) <.001 
Additional data in adults  
Positive history of 
cardiovascular disease  
186 (10.7%) 189 (6.0%) <.001 
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Previously known TC 
>290 mg/dL 
875 (50.5%) 289 (9.4%) * 
Treatment with statins  667 (38.5%) 160 (5.2%) * 
Lipoproteins 
Total cholesterol  SD 
(mg/dL) 
287  64 212  52 * 
LDL-cholesterol  SD 
(mg/dL) 
217  61 137  43 * 
HDL cholesterol  SD 
(mg/dL) 
42  13 46  14 * 
Triglycerides  SD 
(mg/dL) 
130  95 147  97 * 
 
Source of funding The research was supported with grants from the Dutch Ministry of Public Health, Welfare and Sport; the Health 
and Care Insurance Council; the Netherlands heart Foundation  
Comments Total age data (n = 4497) doesn’t add up to sample size  
Good paper – following review of the paper with the CASP tool. Shows benefits of cascade testing. Once a patient 
diagnosed with FH was identified, they were expected to gather as many family members as possible for testing, 
therefore used both direct and indirect cascade testing. Probably would need more specific details on the average 
number of family members patients with FH identified though.  
Umans-Eckenhausen 2002 
Bibliographic reference Umans-Eckenhausen 2002 
Study type Cohort 
Aim To assess the effect of different LDL receptor gene mutations on plasma lipoproteins and risk of CVD, after adjusting for 
familial risk factors  
Patient characteristics Relatives of index cases 
Number of patients 1695 relatives of 66 index cases 
Index test LDL receptor gene mutation. Selection was based solely on the mendelian inheritance pattern of the LDL receptor mutations 
and not on referral type. 
Reference standard (or 
Gold standard) 
N/A 
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Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location Amsterdam, Netherlands 
Results N=608 carriers of LDL gene mutation. N=399 were not receiving medication. 
N=1087 non-carriers, 1048 not receiving medication 
 
  Null Alleles  Other Alleles  Unaffected relatives  
N (total) 124 484 1087 
Mean age, ySEM 34.81.6 36.80.9 40.7_0.6 
Age range, y 16-80 16-84 16–96 
Sex, male/female 61/63 233/251 511/576 
Risk Factors, no. (%SEM) 
Hypertension   9 (72%)  17 (41%)  62 (6_0%)  
Diabetes, type 2 0 (00%) 2 (00%) 26 (2_1%) 
Former smokers  29 (234%) 77 (162%)* 197 (18_1%) 
Current smokers  32 (264%) 93 (192%)** 284 (26_1%) 
N (untreated) 26 (f)  28 (m) 178 (f)  167 (m) 559 (f)  495 (M) 
Total Cholesterol, mg/dL 328 (67) 291 (48) 289 (63) 277 (52) 199 (45) 213 (58) 
LDL Cholesterol, mg/dL  258 (59) 229 (44) 217 (59) 211 (49) 134 (40) 137 (40) 
HDL cholesterol, mg/dL 39 (8) 37 (10) 45 (14) 37 (12) 49 (14) 41 (13) 
Triglycerides, mg/dL 153 (78) 128 (73) 126 (79) 135 (86) 103 (89) 168 (115) 
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Lipoprotein values are mean values (_SD). 
*In comparison with the other two groups, P_0.2; in comparison with the null alleles group, P_0.07. 
**Significantly lower than in the other two groups (P_0.03). 
 
Source of funding This work was supported by grants from the Dutch Ministry of Public Health, Welfare, and Sport, the Health Care Insurance 
Council, and the Netherlands Heart Foundation. 
Comments To avoid ascertainment bias, index cases were excluded from all analyses, since a proportion could have been referred 
based on the onset of CVD and this would lead to overestimation of the risk from FH. On the other hand, index cases were 
selected on being alive, which could also introduce a selection bias leading to underestimation of the risk from the disorder. 
Individuals receiving any form of cholesterol-lowering medication were excluded from analyses of the lipid and lipoprotein 
parameters. 
CASP tool – good paper, scored well with tool.  
Van Maarle 2002 
Bibliographic reference Van Maarle 2002 
Study type Prospective cohort 
Aim To assess preventative care and the short term clinical outcome in people testing positive for FH as a proxy for 
expected long term level of coronary artery disease 
Patient characteristics N=677. Aged 18 and over 
Gave consent to genetic testing and the study  
A positive FH test result  
Number of patients 677 people screened as part of the programme -215 tested positive for FH 
 
Index test Genetic screening 
Reference standard (or 
Gold standard) 
Key recommendations of the Dutch guidelines on hypercholesterolaemia and quality of clinical outcome by 
achieved cholesterol level, body mass index, and smoking status 
Time between testing & 
treatment:  
Not detailed  
Length of follow-up 18 months (questionnaires completed at screening, 7 months and 18 months) 
Location Netherlands  
Results N=215 tested positive for FH. 
N=166 responded to questionnaire 
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Lost to follow up – differed in only 1 characteristic – use of statin (57% vs 39% [<0.05) 
Newly identified cases n=41 
Confirmed cases (known to have FH at screening) n= 125 
 
Proportion of people referred for treatment (drug/statin/ diet) 
 Newly identified (n=41) Confirmed cases (n=125) 
 At screening Follow up At screening Follow up 
Use of drugs 0 14 (34%) 99 (79%) 113 (90%) 
Statins 0 14 95 (76%) 102 (82%) 
Diet 5 (12%) 19 (46%) 87 (70%) 94 (75% 
 
Source of funding Health Research and Development Council of the Netherlands (grant number 282751). 
Comments QA by use of the CASP tool: 
Focussed aim and recruited in an appropriate way, but not sure how any biases or confounding factors were 
managed as this isn’t detailed in the paper. Don’t think the follow up time was long enough for the aims. Think the 
results can be applied to the local population to a level as FH is a genetic condition.  
Vergotine 2001 
Bibliographic reference Vergotine 2001 
Study type Prospective  
Aim DNA diagnosis of FH evaluated against biochemical diagnosis used to identify subjects with FH 
Patient characteristics Hypercholesterolaemics referred for a molecular diagnosis of FH. Evaluation of biochemical vs DNA diagnosis 
performed in families with Afrikaner foundation mutations D206E, V408M, D154N. 
Index patients were selected on the basis of elevated TC levels, genotype/ phenotype correlation studies were 
only performed on family members recruited through tracing of defective genes in the pedigree. 
Follow up mutation screening performed/ extended in families where FH related mutation had been identified in 
the index case. Index cases without known mutations subject to extensive mutation screening followed by 
mutation screening in relevant at-risk relatives. In these index patients, pretreatment TC levels had to be at least 
equal to 90th percentile for age and gender, with normal triglyceride levels. The FH study participants had to either 
have clinical features of FH or a family history of CHD. 
Number of patients 379 index cases and 790 at risk relatives 
Index test Genetic testing 
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Reference standard (or 
Gold standard) 
MEDPED 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location South Africa 
Results 
 
65 mutations identified in 379 index cases 
338/790 inherited disease related LDLR gene mutation 
 
Reported data on 443 at-risk family members (screened for 1 of 3 Afrikaner founder mutations) 
 
NPV: 89.3.% 
PPV: 81.9% 
FH diagnosis according to TC values (using 80th percentile values) 
 Sensitivity: 89.3% 
Specificity: 81.9% 
Mutation No. relatives >95th percentile (%) >80th percentile (%) 
D206E 93 61 (66) 82 (88) 
V408M 27 20 (74) 23 (85) 
D154N 30 25 (83) 29 (97) 
No mutation 293 12 (4) 53 (18) 
Total 443 118 187 
 
Source of funding University of Stellenbosch, Tygerberg hospital, South African Medical Research Council, grant from Merck. 
Comments CASP appraisal: 
Unclear whether mutations identified are applicable to wider population. 
G.1.2 Primary care 
Bell 2014b 
Bibliographic reference Bell 2014b 
Study type Retrospective review & prospective case finding 
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Aim Whether individuals with FH can be identified in primary care (agreement between primary care and specialist) 
Patient characteristics People at risk identified by laboratory reports of high LDL-C concentration, or by using informatics tool to search 
the primary care database. 
 
Number of patients 153,n=80 male, median age 54 (9) yrs, TC 7.5 mmol/L, n=93 on statin therapy. 
Index test DLCNS assessment by primary care (one of 3 nurses and 1 of 2 GPs) & genetic testing  
Nurse interviewed and examined all individuals at risk and collect data required to calculate DLNCS. 
GP would review data and calculate DLNCS. 
Clinical FH defined as probable or definite FH using DLCNC categories. 
Reference standard (or 
Gold standard) 
Assessment by specialist: 
Lipid specialist calculated DLCNS on de-identified data. Lipid specialist blinded to GP’s DLNCS. 
If patient on lipid-lowering treatment, 30% added to LDL-c whilst on lipid lowering therapy. 
Lipid specialist subsequently reviewed 30 individuals with DLNCS >4 as assessed by lipid specialist with primary 
care data, in telehealth clinic and determined their likelihood of FH using information obtained during this 
consultation. Lipid specialist blinded to all previous DLNCS and FH genetic testing until they had calculated the 
DLNCS for the telehealth consultation. 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location Australia 
Results Diagnostic yield 
Specialist: 45 individuals with clinical FH (probable or definite) 
GP assessed 39/45 of these correctly. 
GPs had specificity of 60% and sensitivity of 80% compared with specialist diagnosis in telehealth review. 
Likelihood of FH 
as assessed by 
GPs 
Likelihood of FH as assessed by the specialist 
 Unlikely (0-2) Possible (3-5) Probable (6-8) Definite (>8) Total 
Unlikely (0-2) 32 2 0 0 34 
Possible (3-5) 1 66 13 0 80 
Probable (6-8) 1 5 27 1 34 
Definite (>8) 0 1 1 3 5 
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Total 34 74 41 4 153 
 
Genetic testing performed in 30 individuals assessed by specialist; 4 had disease causing mutations. 
Source of funding Sub study of research that received funding from Val Lishman Foundation and Royalties for Regions 
Comments CASP appraisal: Low quality (serious concerns about validity of results and unsure whether results could be 
applied locally). 
There was a lack of detail about the informatics tool and the search terms used within it. Lack of details as to what 
concentration of DL-C was considered elevated. No detail about the population of the GP database.  
Gray 2008 
Bibliographic reference Gray 2008 
Study type Case identification through search of primary care database (electronic and manual search) 
Aim To assess the utility of combined computer and notes-based searches in identifying index cases of FH in primary 
care, and to uncover the degree of case overlap with secondary care. 
Patient characteristics  108 (0.89%) patients had ischemic heart disease (IHD), including 35 with early onset IHD 
 106 (0.87%) had a lipid diagnosis 
 290 (2.4%) were receiving a statin 
 1596 (13.2%) patients had a cholesterol test recorded on the computer  
 Young age profile mentioned in discussion but mean age not reported??  
Number of patients 12,100 patients in a south London medical practice. 
Index test Dutch criteria used 
Computer searches for: IHD, lipids, statin, cholesterol >7.00 mmol/L (n=402 identified) 
Computer record and notes searched – data entered onto spreadsheet and Dutch core calculated for each patient. 
Specialist review by lipidologist and GP, n=169 excluded. 
Reference standard (or 
Gold standard) 
N/A 
Time between testing & 
treatment 
n/a 
Length of follow-up n/a 
Location South London GP practice. 
Results Dutch score >8 (definite)= 12 
Dutch score 5-8 (probable)= 8 
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3-5 (possible) = 216 (47 requiring future face-face interview) 
<3 (unlikely)= 166 
 
Early-onset IHD  
TP = 9 
FP = 26 
FN = 11 
TN = 12054 
Sensitivity = 45.0 (25.8, 65.8) 
Specificity = 99.8 (99.7, 99.2) 
 
Cholesterol > 7.5 
TP = 17 
FP = 108 
FN = 1 
TN = 11974 
Sensitivity = 94.4 (74.2, 99.0) 
Specificity = 99.1 (98.9, 99.3) 
 
Cholesterol > 7.0 
TP = 20 
FP = 181 
FN = 0 
TN = 11899 
Sensitivity = 100 (83.9, 100.0) 
Specificity = 98.5 (98.3, 98.7) 
Source of funding Not reported 
Comments  In 30 cases, a higher cholesterol reading was recorded in the paper notes than on the computer records 
suggesting that computer records have not captured all the available information  
CASP appraisal: (Low quality due to concerns about validity of results). 
No DNA testing was undertaken to confirm FH, therefore DLCN diagnosis not verified. Computer searches 
constructed using read codes for IHD, lipid disorders, prescription for statins and cholesterol >7.0mol/L. 
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Study type Prospective: primary care database audit, followed by nurse-led cascade testing. 
Aim To improve detection of FH by identifying people with raised cholesterol concentrations. 
Patient characteristics Patients who visited their GP who were identified as being at potential risk of FH via the audit tool.  
Number of patients Approximately 290,000 from 56 general practices in Medway CCG. 
Index test Two-stage study: 
1. Audit undertaken using search terms for TC >7.5 mmol/L in adults or >4.0 mmol/L in children <16 years or LDL-
C >4.9mmol/L in adults or >4.0mmol/L in children, for further assessment. Over the next two years, electronic 
prompts appeared when the patient attended the practice to enhance GP decision making on FH diagnosis. 
 
2. Nurse reviewed audit list of “at risk and unscreened” to identify any missing parameters. Once parameters 
collated, DLCN score calculated. 
Reference standard (or 
Gold standard) 
Simon Broome criteria 
Time between testing & 
treatment 
Not detailed 
Length of follow-up 2 years (2011-2014) for audit, 9 months nurse led clinics 
Location Medway CCG, UK 
Results Baseline (diagnosed using SB criteria): 
FH: 331/262,030 
Probable FH: N/A 
Possible FH: 12/ 262,030 
2 year audit (diagnosed using SB criteria): 
FH: 354/ 199,346 
Probable FH: n/a 
Possible FH: 88/ 199,346 
Nurse advisor programme (diagnosed using DLNC or SB criteria): 
FH: 546/281,655 
Probable FH: 83/ 281,655 
Possible FH: 147/ 281,655 
Source of funding The NHS Medway FH Audit tool was supported from Medway CCG annual budget. 
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Comments Also reports at risk and unscreened – T/c >7.5mmol/L and/ or LDL-C>4.9 mmol/L and had not been assessed 
using SB criteria. 1164/199,346 at 2 year audit, 398/281,655 for nurse advisor programme. 
 
Paper not clear to follow. Unsure of the patient pathways following identification from the audit tool. GP practices 
were already using tool before the study, so were familiar with it. This could lead to some bias. Would have been 
better for GPs who were naïve to the tool to be tested. Not sure how this could be applied to a wider population – 
as it has funding implications.  
CASP appraisal: (Moderate due to concerns about validity of results) 
No DNA testing was undertaken to to confirm FH. People identified throught the audit+ tool only received a 
diagnosis of possible FH according to SB criteria, o further verification of the diagnosis was described. As a whole, 
the paper and figures reported within it were unclear and difficult to follow. 
Kirke 2015 
Bibliographic reference Kirke 2015 
Study type Prospective 
Aim To compare three methods of case detection for identifying FH 
Patient characteristics Workplace screening: workforce of a large mineral processing operation. Workers offered short, 5 question 
questionnaire on CAD risk, administered as part of their annual health assessment. Participation voluntary. 
Respondants identifying 2 or more positive responses for CAD were contacted by a research nurse and offered a 
primary care assessment. 
 
GP database: screening of electronic records of 2 private general practices using data extraction software 
(Canning Tool). Criteria were: age 18-70 yrs, history of cardiac event <60 yrs, any CAD, diagnosis of lipid disorder, 
TC >7.5mmol/L, LDL >4.0mmol/L or prescription for statins. Unclear what contact patients had when informed if 
high risk. 
 
Pathology laboratory: involved 3 pathology laboratory providers, performed data extraction of records of all 
patients aged 18-60 yrs with TC >7.5mmol/L or LDLC >4.5mmol/L over previous 5 years from south west Australia 
postcodes. Pathology laboratories contacted patients by mail and they were recruited when they contacted the 
research office for a primary care assessment. 
 
All participants at risk of CAD or elevated cholesterol invited to participate in 30 minute face-face assessment by a 
trained nurse to screen for FH: assessment included medical and family history and calculation of dutch lipid 
network score (DLCNCS). Pretreatement score calculated if taking cholesterol lowering treatment by adding 30% 
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to cholesterol value. People with DLCN score >5 high risk and were invited to further follow up at specialist lipid 
clinic via referral from their GP; patients with >5 offered DNA testing that required informed consent. 
 
DNA testing included APOB, LDLR and PCSK9. 
 
Children and adolescents not included in risk assessment. 
Number of patients 94379 patients recruited from workplace (primary care), GP practice (primary care) or pathology laboratory 
database (secondary care) 
Primary care: 42179 
Secondary care: 52200 
Index test Dutch lipid criteria 
Reference standard (or 
Gold standard) 
DNA diagnosis: LDLR, APOB and PCSK9 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location Australia 
Results 94,379 patients/ questionnaires/ records screened for increased CV risk; 
Path lab: 52200 patient results 
Workplace assessment: 1079 risk questionnaires 
GP database: 41100 patient records 
 
7279 participants with increased CV risk invited for clinical assessment of FH risk (n= 5963 declined invitation, 
n=1230 low risk of FH) 
Path lab: 4517 
Workplace assessment: 268 
GP database: 2494 
 
86 participants high risk FH offered referral to specialist (Dutch lipid score >5): (27 declined referral or failed to 
respond) 
Path lab: 51 
Workplace assessment: 3 
GP database: 32 
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59 reviewed by lipid specialist and DNA tested: 
Path lab: 30 
Workplace assessment: 3 
GP database: 26 
 
11 DNA positive, n=48 DNA negative 
Path lab: 8 
Workplace assessment: 0 
GP database: 3 
 
Uptake of specialist review (people at high risk): 
Pathology lab: 597/4517= 13% 
Workplace: 30/268= 22% 
GP: 659/2494= 26% 
 
Uptake of DNA testing= 69% 
Path lab:30/51= 58.8% 
Workplace: 3/3= 100% 
GP: 26/31= 83.9% 
Source of funding Val Lishman Health Research Foundation, Royalties for regions and lottery west funding 
Comments DNA analysis – complete screen, no measurement bias. 
Selection bias for workplace assessment group as people volunteered to take part in assessment of risk. Uptake 
rates differed between groups, may lead to bias in reporting. 
Unclear how GP group contacted if they were at high risk of FH (1st stage of screening), no details provided in 
paper. 
CASP appraisal: (Low qulaitydue to concerns about validity of results) 
Recruitement of workplace portion of participants was voluntary, therefore susceptible to selection bias. 
Norsworthy 2014 
Bibliographic reference Norsworthy 2014 
Study type Generation Scotland: Scottish Family Health study (pathology database) 
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Aim Targeted use of next generation sequencing as a potential route to diagnosis of FH in primary care population 
subset selected for hypercholesterolaemia. Cascade testing using molecular diagnostics. 
Patient characteristics Biological samples were obtained from the ‘Generation Scotland: Scottish family Health study (GS:SFHS). 
Samples collected were from patients who were likely to have FH, based on previously reported population total 
cholesterol data in FH. Age and BMI thresholds were also used to reduce the inclusion of age and obesity related 
cases of hyperlipidaemia.  
Number of patients 617 (selected on basis of total cholesterol data).  
Index test Patients were selected from the cohort using searches for TC, age and BMI cut-offs, tered the “High cholesterol 
group” (TC >8.5 mmol/L, TC 8-8.4mmol/L age <50 yrs, TC 8-8.4 mmol/L / age >50/ bmi <25, TC 7-7.9 mmol/L/ 
age <40) 
A cholesterol therapy group was selected (moderately high cholesterol despite lipid lowering therapy), and a 
control group. 
Reference standard (or 
Gold standard) 
Genetic testing for FH. 
 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location Scotland 
Results Diagnostic yield 
FH causing mutations identified through screening in : 
4/193 (2.1%) of subjects in high cholesterol group 
5/232 (2.2%) in cholesterol therapy group 
0/192 in normocholesterolaemic group 
Cascade testing: 
DNA available for cascade testing in relatives of 6/9 (66%) index cases identified. 
12 available first degree relatives (FDRs) 
5 molecular diagnoses of FH were made. 
Source of funding Generation Scotland has received core funding from the Chief Scientist Office of the Scottish Government Health 
Directorates CZD/16/6 and the Scottish Funding Council HR03006. We also acknowledge funding from the 
MRC Clinical Sciences Centre and the British Heart Foundation to TJA, from a Wellcome Trust Clinical Training 
Fellowship to ERAT, and from the NIHR-funded Imperial Biomedical Research Centre to TJA. 
Comments Data for LDL-C not reported in this study 
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CASP appraisal: (Very low quality due to concerns about validity of results, and whether the results will help 
locally) 
This was a database study, not primary research. The population of the study was older (35-65 years) at 
recruitement. LDL-C concentration not routinely collected,therefore recruitment on basis of TC and age only, which 
does not reflect how a person with FH would be identified in the real world as it ay identify a broader population 
than those truly at risk of FH. 
Qureshi 2016 
Bibliographic reference Qureshi 2016 
Study type Prospective (feasibility study) 
Aim To assess the feasibility of improving identification of FH in primary care, and of collecting outcome measures to 
inform a future trial. 
Patient characteristics 6 GP practices in central England. People with TC >7.5mmol/L and aged >18 years 
Number of patients N=831 
Index test Simon Broome 
Reference standard (or 
Gold standard) 
N/A 
Time between testing & 
treatment 
N/A 
Length of follow-up 17 months duration 
Location UK 
Results 831 eligible patients with TC >7.5 mmol/L. 
N=127 consented and recruited to study (via mail-out and opportunistic study packs) 
N=125 eligible for assessment 
N=32 with possible FH (Simon Broome) 
N=14 patients seen by GP, n=9 referred by GP 
N=7 seen by specialist 
Referral outcomes: 
N=2 definite FH 
N=5 confirmed possible FH 
Source of funding NIHR school of primary care research 
Comments CASP appraisal: (Low quality due to concerns about validity of results). 
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This was a small study, the primary focus of which was not identifying uptake rate; rather it was the influence of an 
educational intervention for healthcare professionals on the identification of people with FH. There was no genetic 
confirmation of diagnosis ad there was a very low uptake rate of the intervention. 
Troeung 2016 
Bibliographic reference Troeung 2016 
Study type Retrospective review of medical records  
Aim To evaluate the performance of a new electronic screening tool (TARB-Ex) in detecting general practice patients 
at potential risk of familial hypercholesterolaemia (FH). 
Patient characteristics Patients from large General practice 
 53.3% female 
 Mean age 43.5±24.6 years 
 1126 (30.4%) had at least one recorded LDL-C measurement  
 39 patients on statin treatment at the time of highest LDL-C measurement and required cholesterol 
correction  
 35 patients had a recorded history of premature cardiovascular disease and 2 had premature ischemic 
heart disease  
Number of patients 3708 for screening 
N=360 with high lipid concentration identified. 
Index test Dutch Lipid Network Criteria >5 using TARB-Ex (electronic medical records search). Searched for active patients 
with 3 or more visits within the last 3 years, TC ≥7.0 mmol/L or LDL-C ≥4.0 mmol/L, family history using drop down 
and free text (a dictionary of terms was created to account for variation). 
Reference standard (or 
Gold standard) 
GP review using DLNC 
Time between testing & 
treatment 
N/A 
Length of follow-up Clinical follow up: patients considered at high risk of FH were recalled for clinical assessment with the GP and lipid 
specialist team – length of follow-up unclear  
Location Australia 
Results Electronic screening: 
Possible FH: (DLNCS 3-5): 76 
Probable: (DLNCS 6-8): 3 
Definite (DLNCS >9): 0 
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Total at risk (DCLNS ≥ 5): n = 32 (1 patient had existing diagnosis of FH) 
 
Manual review: 
GP manually reviewed n=360 with high lipid concentration 
Identified n=22 at risk of FH (DLNCS >5) 
 
GP review of TARB-X and manual records:  
Identified 10 people at high risk of FH. 
22 excluded due to overcorrection of LDL-C concentration. 
3/10 unable to attend 
6/7 diagnosed with phenotypic FH on clinical examination 
1 referred for genetic testing for FH. 
 
Agreement between 2 methods: 
Sensitivity: 95.5% 
Specificity: 96.7% 
PPV: 65.6% 
NPV: 99.7% 
Source of funding Supported through the Australian Government’s Collaborative Research Networks (CRN) programme 
Comments  Statin strength data were not extractable in the electronic medical records and so the lowest adjustment factor 
for each medication was applied as a conservative strategy  
CASP appraisal: (Moderate quality due to concerns about validity of results). 
There was no genetic confirmation of the diagnosis of FH and details about family history missing for 65.2% of 
patients 
G.1.3 Secondary care 
Bates 2008 
Bibliographic reference Bates 2008 
Study type Retrospective 
Aim To investigate the prevalence of FH in patients of a younger age group presenting to cardiology service. 
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Patient characteristics Cardiac patients presenting to cardiology department with cardiac type chest pain, or diagnostic coronary 
angiography, men <55 yrs, women <60 yrs;  
Mean age 49 (SD 7.2); 65% men; 69% Caucasian; 26% diabetic; 55% hypertensive; 69% current or ex-smokers; 
43% taking statins on admission; TC 5.3 mmol/L; LDL-C 3.2 mmol/L (sd 1.1 mmol/L);  
Number of patients 509/917 available were selected randomly for audit 
334 patients met inclusion criteria 
Index test Dutch Lipid Network Criteria used to assess diagnosis of FH. Classed as indeterminate if insufficient information 
available to assess FH status. 
Reference standard (or 
Gold standard) 
N/A 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location Australia 
Results (% reported only, n calculated by analyst) 
Definite/ probable:1.2%, n=4 
Possible: 30.5%, n= 102 
Unlikely: 27.8%, n=93 
Indeterminate: 40.4%, n= 135 
Source of funding Pfizer 
Comments CASP appraisal: 
No issues. 
Bell 2012 
Bibliographic reference Bell 2012 
Study type Case series 
Aim To determine the ability of a laboratory to screen for individuals with potential FH 
Patient characteristics Serum LDL concentrations reviewed over a 1 year period (2010-2011) in western Australia. 
All serum cholesterol requests were included, no exclusion criteria. 
Number of patients  99,467 serum LDL cholesterol results from 84,823 people. 
 GPs requested 91.8%, cardiologist requested 3.2%. Other 5% requested by other specialists. 
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 51.2% of LDL cholesterol measurements performed in women (mean age 56 ±15 years); 48.8% in men (mean 
age 56+15 years) 
 Median and mean serum LDL-cholesterol concentrations were 3.0 and 3.1mmol/l respectively  
Index test Comparison of MED-PED, dutch lipid network criteria and Simon Broome criteria. 
 
Reference standard (or 
Gold standard) 
N/A 
Time between testing & 
treatment 
Not reported  
Length of follow-up 1 year period  
Location Australia 
Results Medped: 
criteria People meeting criteria/ number of people in age 
category 
Age <20 yrs, LDL >5.1 mmol/L 6/748 
Age 20-29 yrs, LDL cholesterol >5.6 mmol/L 19/2980 
Age 30-39 yrs, LDL cholesterol >6.5 mmol/L 33/7169 
Age >40 yrs, LDL >6.7 mmol/L 118/73926 
 
Simon Broome (serum LDL-C cutoff of >4.9 mmol/L in people aged >16 yrs. 
3124/84823 (prevalence 1:27) 
 
Dutch lipid network criteria: 
Categories (LDL-C concentration, mmol/L) Number of people (n=84823) (prevalence) 
4.0-4.9 11030 (1:8) 
5.0-6.4 2911 (1:29) 
6.5-8.4 198 (1:428) 
>8.5 15 (1:5655) 
 
Potential FH based on non-age adjusted LDL-cholesterol cut offs: 
LDL-C (mmol/L) Number of people (prevalence) 
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>8.5 15 (1:5655) 
>8.0 23 (1:3688) 
>7.5 48 (1:1767) 
>7.0 90 (1:942) 
>6.5 213 (1:398) 
>6.0 472 (1:180) 
>5.5 1227 (1:69) 
>5.0 3124 (1:27) 
>4.5 6879 (1:12) 
>4.0 14154 (1:6) 
 
Source of funding None 
Comments  No specialist review to confirm whether individuals had confirmed FH 
Bell 2014 
Bibliographic reference Bell 2014 
Study type Case-control 
Aim To determine whether a phone call from a chemical pathologist to requesting GP of individuals at high risk of FH 
increases specialist referral and detection of FH. 
Patient characteristics People with raised cholesterol (>6.5mmol/L)l identified from community laboratory. 
Characteristics Controls Cases Significance 
N 96 100  
Female (n) 68 57 0.05 
Age (yr), meand (SD) 53.7 (10.7) 49.3 (12.4) 0.009 
LDL-C (mmol/L) 7.1 (0.8) 7.1 (0.7) 1.0 
Referred to specialist, n 4 (4) 27 (27) <0.0001 
Clinical (Probable or 
definite) FH, n (% of 
clinically assessed) 
4 (4) 18 (18) 0.003 
Probable FH, n (% of 
clinically assessed) 
2 (50%) 6 (24%)  
 144 
 
Bibliographic reference Bell 2014 
Definite FH, n (% of 
clinically assessed) 
2 (50%) 12 (48%) 0.01 
Mutation identified, n (% 
of genetically tested) 
2 (50%) 7 (30%)  
 
Number of patients 196 (100 cases, 96 controls) 
Index test Cases received laboratory report comments and the GP received a telephone call from the chemical pathologist to 
highlight patient’s risk of FH and suggest specialist referral. 
Reference standard (or 
Gold standard) 
Control GPs were not phoned. 
Time between testing & 
treatment 
N/A 
Length of follow-up 12 months 
Location Australia 
Results Cases: 
27 referred to specialist clinic (1 known to be mutation positive, 2 failed to attend appt) 
25 underwent specialist review 
18 diagnosed with FH (6 probable, 12 definite) 
Genetic testing performed in 23 people. 
7 had identifiable FH causing mutations. 
 
Controls: 
4 referred to specialist clinic, all 4 diagnosed with FH. 
2 probable, 2 definite. 
Genetic testing performed on all 4; 2 clinically definite FH had identifiable FH causing mutations, 2 probable 
individuals did not. 
 
Cascade screening (cases only): 
Genotypic cascade screening in 12 family members from 4 mutation positive FH individuals in intervention group; 
7 confirmed to carry mutation, 5 did not. 
Source of funding None 
Comments CASP appraisal: 
Cases and controls significantly different in age. No other concerns 
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Study type Prospective cohort  
Aim To develop an immunoassay for detection of hypercholesterolaemia – specifically aimed at neonates with 
hyperlipidaemias 
Patient characteristics Newborn infants in the King’s Healthcare catchment on the 6th or 7th postnatal day 
Number of patients 9673 neonates screened for FH 
Index test Blood samples taken by heel prick on the 6th or 7th postnatal day after all routine screening had been completed.  
Immunoturbidimetric assay of apo A-1 and B 
Reference standard (or 
Gold standard) 
Immunoneph apoA-1 and apoB reference standards  
Time between testing & 
treatment 
No treatment offered  
Length of follow-up No follow up within the study. All families were referred to the vascular risk clinic for diagnosis and follow up.  
Location England  
Results 189 infants recalled (APOB levels in top percentile of each batch, or apo A1-B ratio of <1) 
82 individuals attended recall clinic 
16 families (24 individuals) had abnormal lipid profiles 
7 had lipid profiles consistent with FH (14 individuals) 
 
Family   Total 
cholesterol 
(mmol/l) 
TAG 
(mmol/l) 
HDL 
(mmol/l ) 
LDL 
(mmol/l) 
HDL/TC 
ratio 
Reference range Infants 
Adult females 
Adult males 
3.0-5.0 
3.4-5.9 
3.5-6.4 
0.4-1.3 
0.4-1.7 
0.6-2.9 
0.9-1.9 
0.9-2.0 
0.7-1.7 
1.7-4.6 
1.8-4.2 
2.0-4.6 
- 
- 
- 
1 Infant  
Mother  
1.8  
7.7 
1.4  
2.7 
- 
- 
- 
5.3 
- 
0.8 
2 Infant  
Mother  
Father 
[2.1]a  
5.5 
7.7 
- 
1.2 
2.2 
- 
1.4 
1.2 
- 
3.6 
5.5 
- 
0.34 
0.18 
3 Infant  3.7 1.2  1.1  2.1  0.42  
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Mother 8.3 0.8 1.5 6.4 0.22 
4 Infant  
Mother  
Father 
4.2 
7.0 
5.5 
1.2 
1.9 
0.6 
1.0 
1.5 
1.4 
2.7 
4.6 
3.8 
0.31 
0.27 
0.34 
5 Infant  
Mother  
Father 
5.7 
4.8 
6.5 
2.7 
2.8 
2.2 
1.2 
0.6 
0.9 
3.3 
2.9 
4.5 
0.26 
0.14 
0.16 
6 Infant  
Mother  
Father 
5.1 
4.1 
3.6 
1.7 
0.5 
0.8 
0.9 
1.3 
0.8 
3.6 
2.6 
2.4 
0.21 
0.46 
0.29 
7 Infant  
Mother  
Father 
3.8 
4.7 
7.4 
1.1 
0.7 
1.6 
0.9 
1.7 
1.4 
2.4 
2.7 
5.3 
0.31 
0.57 
0.23 
8 Infant  
Mother  
father 
6.4 
5.7 
8.1 
2.4 
0.8 
1.1 
1.4 
1.9 
0.8 
3.9 
3.4 
6.8 
0.28 
0.50 
0.11 
9 Infant  
Mother  
Father 
4.2 
5.1 
8.1 
3.8 
0.8 
2.5 
1.0 
1.6 
1.5 
1.5 
3.1 
5.5 
0.31 
0.46 
0.23 
10 Infant  
Mother  
Father 
5.1 
4.0 
5.8 
2.4 
0.7 
1.4 
1.2 
1.2 
1.2 
2.8 
2.5 
4.0 
0.31 
0.43 
0.26 
11 Infant  
Mother  
Father 
4.1 
4.8 
6.3 
1.4 
0.5 
0.9 
1.3 
1.2 
1.8 
2.2 
3.4 
4.1 
0.46 
0.33 
0.40 
12 Infant  
Mother  
Father 
5.5 
5.3 
4.9 
1.2 
0.9 
1.3 
- 
1.3 
1.0 
- 
3.6 
3.3 
- 
0.33 
0.26 
13 Infant  
Mother  
Father 
[1.53]a 
3.6 
6.6 
- 
1.5 
2.3 
- 
1.0 
0.7 
- 
1.9 
4.9 
- 
0.38 
0.12 
 147 
 
Bibliographic reference Besso 1999 
14 Infant  
Mother  
Father 
[1.59]a 
9.7 
4.2 
- 
3.2 
1.6 
- 
1.3 
1.0 
- 
6.9 
2.5 
- 
0.15 
0.31 
15 Infant  
Mother  
6.7 
Known FH  
1.0 
- 
1.1 
- 
5.1 
- 
0.2 
- 
16 Infant  
Mother  
Father 
7.0 
5.6 
5.2 
0.9 
0.6 
1.7 
1.0 
- 
- 
5.6 
- 
- 
0.17 
- 
- 
a If total cholesterol level is unknown in infants, blood spot apoB is given in square brackets (reference 
range 0.2±0.5 g/l). Other reference ranges are from [14] and represent the 5th to 95th percentiles for age 
and gender. 
 
Source of funding South Thames Regional Health Authority 
Comments CASP – nothing to note, good paper.  
Chung 1999 
Bibliographic reference Chung 1999 
Study type Cohort  
Aim To identify cases of FH in Taiwan  
Patient characteristics Patients with hyperlipidaemia attending metabolic clinic. 
Number of patients 11 
Index test Simon Broome criteria which identifies a definitive or possible diagnosis of FH. A medical, cardiocascular and 
family history were taken, along with plasma lipid profiles. The thickness of xanthomas in patients were measured 
by soft tissue ultrasonography.  
Reference standard (or 
Gold standard) 
Simon Broome criteria 
Time between testing & 
treatment 
All patients received treatment, but this was initiated prior to the commencement of the study.  
Length of follow-up No follow up  
Location Taiwan 
Results  5 had definitive FH 
6 possible FH 
 148 
 
Bibliographic reference Chung 1999 
 
Diagnosis  Age  Gender  BP 
(mmHg) 
PH of 
CHD or 
CVA 
FH of 
CHD or 
CVA 
Pre-treatment  Post-
treatment 
   TC LDL  TG TC LDL 
(mg/dl) (mg/dl) 
Definitive Familial 
hypercholesterolemia  
60 F 117/54 CVA CVA 116 254 103 288 188 
62 F 173/74 - - 326 248 173 321 258 
46 F 104/66 - - 418 346 105 311 236 
76 M 141/54 - - 368 278 81 295 206 
48 M 130/60 CHD CHD 637 549 292 524 465 
Possible Familial 
hypercholesterolemia 
36 F 110/72 CVA  CHD 339 245 101 277 188 
42 F 115/48 - CVA 360 302 57 229 173 
56 M 174/85 - - 406 332 134 250 189 
49 F 110/78 - - 406 317 96 389 315 
36 F 90/60 - - 382 323 53 433 341 
51 F - - - 335 242 63 278 181 
 
Source of funding Not detailed  
Comments Secondary causes of hypercholesterolaemia, including abnormal liver function, endocrine disorders renal disease, 
as well as other known forms of hyperlipidaemia were excluded.  
Small sample and so some results not generalizable. All patients recruited into the trial were being treated at a 
metabolic clinic already so sample biased. All were already receiving treatment for their hyperlipidaemia which 
may mean the results were not accurate of their true biochemical measurements.  
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Bibliographic reference Clarke 2013 
Study type Retrospective review of new FH presentations from a university teaching hospital lipid clinic.    
Aim To determine utility of secondary stratification measures to improve ascertainment of index cases of FH 
Patient characteristics  112 with identified FH mutations, 92 with no monogenic FH mutation 
 Genetic diagnosis obtained in 75% of TX-patients and 44% TX+ patients 
 Age: 55 ± 14 years 
 47% male 
 LDL-C was 6.20 (2.24) mmol/l  
 21% with established CHD 
Number of patients 204 FH patients in lipid clinic registry, using Simon Broome criteria  
Index test Dutch criteria, lipoprotein A, history of CHD, family history CHD or TC, cholesterol concentrations. 
Reference standard (or 
Gold standard) 
Simon Broome criteria (for purposes of case-finding review: genetic testing was undertaken but was not the 
reference standard for case-finding). 
Time between testing & 
treatment 
Not reported  
Length of follow-up N/A 
Location UK 
Results Criteria TP TN FP FN Sensitivity Specificity 
Simon Broome 
(+) 
112 0 92 0 100 (96.7, 100) 0 (0, 4.0) 
SB possible 65 0 92 47 58.0 (48.8, 66.8) 0 (0, 4.0) 
Dutch score >5 78 59 33 34 69.6 (60.6, 77.4) 64.1 (53.9, 73.2) 
Lp(a) >0.5g/L 37 49 41 73 33.6 (25.5, 42.9) 54.4 (44.2, 64.3) 
Personal history 
CHD <60 yrs 
26 81 11 86 23.2 (16.4, 31.8) 88.0 (79.8, 93.2) 
Relative with 
CHD at <60 yrs 
53 57 35 59 47.3 (38.3, 56.5) 62.0 (51.7, 71.2) 
Relative with TC 
>7.5 mmol/L 
17 74 18 95 15.2 (9.7, 23.0) 80.4 (71.2, 87.3) 
LDL-C >8 
mmol/L 
26 89 3 86 23.2 (16.4, 31.8) 96.7 (90.8, 98.9) 
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LDL-C >6.5 
mmol/L 
61 76 16 51 54.4 (45.2, 63.4) 82.6 (73.6, 89.0) 
LDL-C >5 
mmol/L 
92 31 61 20 82.1 (74.0, 88.1) 33.7 (24.9, 43.8) 
LDL-C 
>4mmol/L 
100 20 72 12 89.3 (82.2, 93.8) 21.7 (31.2, 31.2) 
SB criteria + 
premature CHD 
    88 23 
 
Source of funding None 
Comments  Retrospective  
 Cohort elected using Simon Broome criteria, genetic testing for LDLR, APOB and PCSK9 mutations was 
undertaken but it was not used asthe reference standard for case-finding of FH in this population.  
 Enough information was provided in the paper to assess the proportion of people diagnosed with FH with 
DLCN or SB who had genetic mutations in one of the three identified genes; therefore this paper could be 
included in the diagnostic review. 
De Backer 2015 
Bibliographic reference De Backer 2015 
Study type Cross sectional survey in 24 European countries; standardised interview, bioclinical examination and venous 
blood sampling  
Aim To estimate the prevalence of clinical heterozygous FH (HeFH) in a large group of patients with CHD who 
participated in the EUROASPIRE IV survey. Also, to compare the potential HeFH patients with the other patients 
with respect to different clinical characteristics and their management.  
Patient characteristics  Patients aged ≥18 and <80 years who had been hospitalised for a coronary event between 6 months and 
3 years before the interview.  
 Mean age at interview, mean (SD):  
- Potential FH group: 58.2 (10.0) 
- Others: 64.8 (9.3)  
 
 5335 men; 1709 women  
 Among all patients with potential FH, 55% were on high intensity statin  
Number of patients N=7044  
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Index test Adapted version of the Dutch Lipid Clinic Network Criteria – a score was given based on various criteria with the 
following definitions: 
- Unlikely FH – total score 0-2 
- Possible FH-total score 3-5 
- Probable FH – total score 6-8 
- Definite FH – total score >8 
Reference standard (or 
Gold standard) 
N/A 
Time between testing & 
treatment 
Not reported  
Length of follow-up N/A 
Location Various – 24 European countries  
Results Category N FH classification 
  Unlikely Possible Probable Definite potential 
All 7044 4234 2223 510 77 587 
Age <60 yrs 2212 719 1152 304 37 341 
 
Source of funding Survey was supported through unrestricted research grants to the European Society of Cardiology from Amgen, 
AstraZeneca, Bristol-Myers Squibb and AstraZeneca, F.Hoffman-La Roche, GlaxoSmithKline and Merck Sharp 
and Dohme.  
Comments None 
Futema 2013 
Bibliographic reference Futema 2013 
Study type Cross sectional 
Aim To determine frequency and spectrum of mutations causing FH in patients attending a single UK specialist 
hospital lipid clinic in Oxford and to identify characteristics contributing to a high mutation detection rate. 
Patient characteristics All patients Caucasian, aged over 18 years, diagnosed with either definite or possible FH using Simon Broome 
criteria, or as having unclassified hypercholesterolaemia (UH) (defined as total cholesterol and/ or LDL-C above 
the SB criteria cut off (>7.5mmol/L or >4.9mmol/L respectively, but with no family history of early CHD or no family 
history that could be elicited). 
52% (n=150) possible FH; 23% (n=65) definite FH; 26% (n=74) UH. No difference between age and male: female 
ratio between the 3 groups.  
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Mean pre-treatment cholesterol significantly different between groups: Definite had highest TC (9.79mmol/L) and 
LDL-C (6.93mmol/L) Possible and UH groups had similar pre-treatment TC and LDL-C levels. Highest pre-
treatment Triglyceride levels observed in UH patients (2 mmol/L), significantly different between groups, but similar 
to possible FH group. 
Number of patients 289 (272 probands) 
Separate cohort of 409 FH patients classified using SB criteria, comparing to DLNC. 
Index test Genetic testing: APOB, LDLR, PCSK9 mutations 
Simon Broome criteria 
Dutch Lipid Network Criteria (DLNC) 
Reference standard (or 
Gold standard) 
Genetic testing 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location UK 
Results Baseline characteristics of people classified with FH according to Simon Broome criteria 
Mutation  Definite FH (SB) Possible FH (SB) Unclassified FH 
+ve 44 38 10 
-ve 16 104 60 
 
Mutation found in 101 individuals (44/65 with definite FH; 38/150 with possible FH; 10/74 with UH) 
 
DLCN Number of patients Mutation +ve (%) Mutation –ve  DFH (SB) 
(%) 
No FH (SB 
crit) 
<3 13 3 (23) 10 2 (15) 11 
3-5 69 19 (28) 50 9 (13) 60 
6-8  49 19 (39) 30 8 (16) 41 
>8 89 48 (54) 41 45 (51) 44 
Total 220 89 131 64 156 
 
Source of funding NIHR paid for genetic testing 
Comments CASP critical appraisal: 
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No concerns, appropriate genetic testing, 
Haralambos 2015 
Bibliographic reference Haralambos 2015 
Study type Prospective cohort 
Aim To assess an FH scoring system based on modified DLCN criteria to guide genetic testing of index patients 
presenting with hypercholesterolaemia 
Patient characteristics 1206 consecutive index patients who had been referred to lipid clinics inWales over the course of 24 
months (between November 2010 and November 2012). The study group did not include relatives of index 
patients detected by cascade testing 
Number of patients 1,206 
Index test Modified Dutch Lipid Clinic Network criteria (deducted points for high triglyceride concentrations) 
 
Reference standard (or 
Gold standard) 
Genetic testing of LDLR, APOB and PCSK9 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location Lipid clinics, Wales 
Methods and results Patients with a score of 6 or greater were offered genetic testing. If a patient scored ess than 5 they would not 
routinely e offered genetic testing, but only if their clinicians considered that there were particular circumstances 
that may make FH more likely.(e,g, family history of CHD).  
1206 patients scored 
N=547 score of ≥6. Of which, n=522 genotyped and 30 not genotyped. Variants (class 2-5) found in n=218 (41%) 
N=659 score of <6. Of which n=101 genotyped and 558 not genotyped. Variants found in n=13 (13%). 4 people 
had class 5 variants. 
 
LDLC correction factor applied on statins was applied 164/623 patients. 
N=173 class 5 variants identified. 
N=58 class 2-4 variants 
N=6 had a class 2 variant 
Diagnostic yield for genetic mutations at different score cut-offs: 
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Score cut off Diagnostic yield 
≥6 32% 
≥7 40% 
≥9 53% 
≥11 66% 
≥13 78% 
≥15 85% 
 
Cohort also scored for Simon Broome. 
20% classified as SB definite. Mutation pick up rate of SBD was 60% 
65% classified as possible Simon Broome. Mutation pick up rate for SBP 21% 
Mutation pick up for those not meeting SB criteria was 14% 
 
2x2 tables (n calculated by analyst, using% supplied in paper) 
 N TP FP FN TN 
Simon 
Broome 
definite 
1206 145 96 190 775 
Simon 
Broome 
possible 
and 
definite 
1206 310 715 25 156 
Modified 
DLCN 
possible 
and 
definite 
623 171 351 4 97 
 
Source of funding Supported by Cardiff university and the Wales FH service 
Comments Only n=623 of people who had DLCN scoring genotyped. For SB cirteria, not reported how many had genetic test, 
therefore assumed all did. 
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Study type Retrospective 
Aim To describe the FH genetic testing service and diagnostic results over first 4 years of operation. 
Patient characteristics Patient diagnosed using Simon Broome criteria, adults and children 
Number of patients 227 probands, 141 family members referred from lipid clinics and GPs 
People were referred if they had FH according to Simon Broome criteria.(definite or probable). 
Any child suspected of having FH but did not meet every criteria was still analysed for LDLR and APOB mutations. 
Index test Genetic testing 
Reference standard (or 
Gold standard) 
 Genetic testing: from frozen whole blood or buccal samples; SSCP analysis. LDLR major rearrangements 
screened by analysing exons 3 5, 8, 14, 17 by universal primer. PCR. R3500Q and R3531C mutations screened 
by direct PCR. R3500W mutation only tested in patients of Asian background. 
Time between testing & 
treatment 
n/a 
Length of follow-up n/a 
Location UK 
Results Mutations designated as pathogenic identified in 76 probands; 67 in LDLR and 9 in APOB 
Adult detection rate: 28% (n=170) 
Paediatric : 53% (n=57) Significant difference p<0.01 
Adults definite FH: (n=122), detection rate 32% 
Adults possible FH (n=48), detection rate 14% 
Significant p<0.01 
 
Patients screened for APOB R3500Q mutation 
 
LDLR were screened by SSCP analysis 
Source of funding Not reported 
Comments States population included probands and relatives, only give number of mutations identified in probands, not 
relatives. 
Only analysed LDLR and APOB mutations, not PCSK9? 
Unclear why only one mutation assessed in Asian population only, no information about this provided elsewhere in 
literature 
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Bibliographic reference Hu 2013 
Study type Retrospective 
Aim To assess whether Chinese population had lower LDL concentration and prevalence of xanthomata in people with 
FH compared to Caucasian population. 
Patient characteristics <18 yrs: n= 43 Mean age 12.2 (SD 4.0),; xanthomata n=4/36 (11.1%); 
>18 yrs: n=209; mean age 41.9 (SD 13.4); xanthomata n=97/195 (49.7%); CHD n=18//200 (9.0%) 
 
From 1990-2000 132 families with a member who had TC >7.5mmol/L without secondary causes were screened. 
Number of patients 446 (87 probands, 165 affected relatives)  
Index test Medped 
Reference standard (or 
Gold standard) 
Genetic testing: detection of mutations in the promotor and 18 coding exons of the LDLR using a double stranded 
DNA cycle sequencing kit. 
Time between testing & 
treatment 
n/a 
Length of follow-up n/a 
Location Hong Kong 
Results 252 clinically diagnosed as He FH (87 probands and 165 relatives)/446 total people screened. 
Source of funding Not reported 
Comments Only searched for genetic mutations in LDLR gene. 
Kirke 2015 
Bibliographic reference Kirke 2015 
Study type Prospective 
Aim To compare three methods of case detection for identifying FH 
Patient characteristics  
Number of patients 94379 patients recruited from workplace (primary care), GP practice (primary care) or pathology laboratory 
database (secondary care) 
Index test Dutch lipid criteria 
Reference standard (or 
Gold standard) 
DNA diagnosis (LDLR, ApOB, PCSK9) 
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Time between testing & 
treatment 
n/a 
Length of follow-up n/a 
Location Australia 
Results 94,379 patients/questionnaires/records screened for increased CV risk; 
Path lab: 52,200 patient results 
Workplace assessment: 1,079 risk questionnaires 
GP database: 41,100 patient records 
 
7,279 participants with increased CV risk invited for clinical assessment of FH risk (n=5,963 declined invitation, 
n=1,230 low risk of FH) 
Path lab: 4,517 
Workplace assessment: 268 
GP database: 2,494 
 
86 participants high risk FH offered referral to specialist (Dutch lipid score >5): (27 declined referral or failed to 
respond) 
Path lab: 51 
Workplace assessment: 3 
GP database: 32 
 
59 reviewed by lipid specialist and DNA tested: 
Path lab: 30 
Workplace assessment: 3 
GP database: 26 
 
11 DNA positive,( n=48 DNA negative) 
Path lab: 8 
Workplace assessment: 0 
GP database: 3 
Source of funding Val Lishman Health Research Foundation, Royalties for regions and lottery west funding 
Comments None 
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Bibliographic reference Klancar 2015 
Study type Prospective 
Aim Genetic identification of FH from a cohort of children with elevated serum total cholesterol 
Patient characteristics Slovenian children born between 1989 and 2009, TC >6mmol/L or >5mmo/L and family history positive for 
premature cardiovascular complications. 
Age 7.3 (SD 3.1) years; cardiovascular complication rate –positive family history according to Simon Broome 
criteria in 33.1% 
Number of patients 272 
Index test Serum total cholesterol (TC) level of more than 6 mmol/l (231.7 mg/dl) without family history of cardiovascular 
(CV) complications, or: 
Serum TC level of more than 5 mmol/l (193.1 mg/dl) with family history of CV complications 
Reference standard (or 
Gold standard) 
Genetic testing: next generation sequencing of APOB, LDLR, PCSK9, APOE. 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location Slovenia 
Results FH= 155/272 (57%) 
Source of funding Not reported 
Comments Part of national screening program for hypercholesterolaemia in children. 
Laurie 2004 
Bibliographic reference Laurie 2004 
Study type Letter to the editor  
Aim To discuss experience in implementing and maintaining a diagnostic screening program for low-density lipoprotein 
receptor and ApoB-100 gene mutations from both a clinical and laboratory perspective.  
Patient characteristics People with TC >8.0mmol/L selected for genetic screening 
Number of patients N=65 
Index test Genetic screening 
Reference standard (or 
Gold standard) 
n/a 
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Time between testing & 
treatment 
Not reported 
Length of follow-up Not reported 
Location New Zealand  
 
Results 17% had LDLR mutation (n=33, calculated by analyst) 
ApoB-100 mutations in 1.6% (n=22, calculated by analyst) of patients screened since 1993 (n=1354) 
Source of funding Not reported 
Comments n/a 
Medeiros 2010 
Bibliographic reference Medeiros 2010 / Bourbon 2007/ (data from Medeiros as more recent publication encompassing Bourbon 
2007 data) 
Study type Case series 
Aim To identify the genetic cause of hypercholesterolaemia in individuals with a clinical diagnosis of Familial 
Hypercholesterolaemia 
Patient characteristics 318 adults, 164 children 
Number of patients 1340 blood samples from 482 index patients and 858 relatives, samples sent from secondary care. 
Index test Genetic testing (LDLR, APOB, PCSK9) 
Reference standard (or 
Gold standard) 
Modified Simon Broome 
Time between testing & 
treatment 
n/a 
Length of follow-up n/a 
Location Portugal 
Results From 482 index patients received, only 359 have their molecular study completed, results presented here. 
LDLR gene: 
165 families, 80 mutations identified 
Screening of 443 individuals in 165 families – additional identification of 226 genetically diagnosed FH patients. 
APOB gene: 
Found in 3 unrelated index patients 
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PCSK9 gene:3 patients 
52% patients it was not possible to identify a mutation in any of 3 genes analysed. 
Mutation found in 14% (8/59) of patients that did not fulfil the SB criteria 
Mutation identified in 45% children and 51% of adults studied (I.e. met SB and genetic criteria) 
 
Source of funding The following grants are acknowledge: “Clinical and molecu-lar characterization of Portuguese FH patients” 
Portuguese Society of Cardiology (2006–2009), “PIC/IC/83333/2007” Science and Tech-nology Foundation (2009-
2011) and SFRH/BD/27990/2006 (AC Alves, PhD grant) Science and Technology Foundation 
Comments CASP: 
Numbers analysed: referred are unclear. Unclear whether includes probands and relatives. 
Muir 2010 
Bibliographic reference Muir 2010 
Study type Retrospective 
Aim To identify the diagnostic and treatment rates for FH in New Zealand 
Patient characteristics People with a pre treatment cholesterol of >8 mmol/L, lipid stigmata or a strong family history of CVD were tested 
for mutations of LDLR gene; average of 147 per annnum. 
Number of patients 588 people referred for mutation screening; 76 index cases identified; 353 relatives screened. 
Index test pre-treatment cholesterol _8.0 mmol/L, lipid stigmata or a strong family history of CVD 
Reference standard (or 
Gold standard) 
Genetic testing of LDLR gene. 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location New Zealand 
Results Between 2004-2008, 588 people were identified from pathology laboratory database were DNA tested for FH if 
they had TC >8 mmol/L (pre-treatment); lipid stigmata or a strong family history of CVD. 
 
76 index cases identified from path lab database (76/588) 
 
Cascade testing: 
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Bibliographic reference Muir 2010 
Patients with an identified mutation referred to clinical nurse specialist at CDHB lipid clinic for cascade testing. 95 
patients with a severe phenotype who met criteria for mutation analysis but did not have an identified mutation, 
were also referred. 
 
All index patients provided contact details for their relatives who were sent letters explaining FH, consent forms 
and laboratory request forms. 
 
353 relatives screened. 
159/353 (43.34%) positive familial LDLR mutation 
Source of funding None reported. 
Comments Not clear how many people were invited to cascade screening, unable to calculate uptake rate. 
Only one genetic mutation analysed? LDLR only? 
No follow up of patients with severe disease phenotype but no mutation, or children of index patients who had 
reached teenage years 
Nanchen 2015 
Bibliographic reference Nanchen 2015 
Study type Retrospective multi-centre cohort study, secondary care database (Coronary) 
Aim To assess prevalence and management of clinical FH among patients with acute coronary syndrome (ACS) 
Patient characteristics  Patients with acute coronary syndrome  
 1425 patients using lipid lowering drugs before hospitalisation  
 Dutch Lipid Clinic Network Simon Broome Register 
 
 
Probable/definit
e FH (>5 points) 
Possible FH (3-5 
points) 
No FH Possible FH No FH 
Age in 
years, 
mean (SD) 
49.5 (9.3) 52.4 (10) 64.8 (11.5) 51.6 (9.8) 63.8 (12.2) 
Female, 
n(%) 
18 (23.1) 172 (20.2) 818 (21.3) 62 (23.9) 946 (20.9)  
Premature 
CHD, n(%) 
70 (89.7) 684 (80.3) 697 (18.1) 203 (78.4) 1248 (27.6) 
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LDL-
cholesterol 
in mmol/l, 
mean (SD) 
6.6 (1.6) 4.3 (1.1) 3.2 (0.9) 5.8 (1.1) 3.3 (1.0) 
Statins, 
n(%)  
31 (39.7) 199 (23.4) 1155 (30.0) 84 (32.4) 1301 (28.8)  
 
Number of patients 4778 patients with ACS from multicentre cohort in Switzerland 
Index test People diagnosed with ACS. 
Reference standard (or 
Gold standard) 
Dutch Lipid Clinic Network (DLCN) Criteria – possible diagnosis with score 3-5, probable/definite diagnosis when 
score 6 or higher.  
Simon Broome criteria – requires both an elevated LDL-cholesterol ?4.9mmol/l (or total cholesterol >7.5mmol/l) 
along with a family/personal history of premature atherosclerosis 
Time between testing & 
treatment 
Not reported  
Length of follow-up Not reported  
Location Switzerland 
Results Diagnostic yield 
DLNC: 
Probable/ definite:78/4778 
Possible: 852/4778 
SB criteria: 
Possible:259/4778 
Combined DLCN + SB:  
Probable/ definite: 77 (977 patients identified with either DLNC or SB in total) 
Source of funding Supported by the Swiss National Science Foundation  
Comments  Signs of lipid accumulation and genetic tests were not available, therefore a diagnosis of definite FH according 
to SB criteria could not be evaluated. 
 The study assessed the proportion of people with ACS assessed as having FH according to SB or DLCN 
criteria. The study did not report the agreement between SB and DLCN criteria in diagnosing FH. It was stated 
that this is available in supplementary onine material, however this could not be located. 
 Also compared prevalence of FH in people with ACS vs premature ACS: In premature ACS (N=1451)47.1% 
possible FH with DLNC, 4.8% probable/ definite; 14% possible FH with Simon Broome, 4.8% probable/ 
definite and 49.3% possible FH using combined definition 
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Pang 2015 
Bibliographic reference Pang 2015 
Study type Prospective 
Aim To investigate point prevalence of FH in a coronary care unit among patients with early onset CAD. 
Patient characteristics Patients admitted with CAD at age <60 yrs (ACS, coronary revascularisation or angina) 
Number of patients 175 patients recruited over a 2 12 week periods each in 2011 and 2013 of patients admitted to the CCU of the 
Royal Perth Hospital.  
Index test Modified Dutch Lipid Network Criteria and the prevalence of individuals with a family history of premature CAD, 
LDL cholesterol and the prevalence of meeting both the family history and LDL cholesterol assessment criteria.  
Reference standard (or 
Gold standard) 
Modified Dutch Lipid Network Criteria 
Time between testing & 
treatment 
No treatment given  
Length of follow-up 2 periods of 12 weeks in 2011 & 2013 
Location Australia 
Results 25 with FH 
150 no FH 
 
Prevalence of FH according to different criteria  With FH (n=25) Without FH (n=150) 
Age at admission to CCU, y  SD 50.55  1.42 50.21  0.58 
LDL cholesterol at admission, mmol/L  SD 3.82  0.24 3.30  0.09 
Untreated LDL cholesterol, mmol/L  SD 6.49  0.26 3.73  0.08 
Male, % (95% CI)  72.0 (53.1-90.9) 82.0 (75.8-88.2) 
Diabetes, % (95% CI) 32.0 (12.3-51.7) 18.7 (12.4-25.0) 
Hypertension, % (95% CI) 48.0 (27.0-69.0) 46.0 (37.9-54.1) 
Obesity, % (95% CI) 16.0 (5.6-31.4) 11.3 (6.2-16.5) 
Current or ex-smoking, % (95% CI) 40.0 (19.4-60.6) 54.7 (46.6-62.7) 
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Use of statins, % (95% CI) 68.0 (48.3-87.7) 21.3 (14.7-28.0) 
 
Source of funding The Australian Better Health Initiative and the Department of Health  
Comments Individuals on statins had their plasma LDL cholesterol conservatively adjusted by a correction factor that depends 
on the dose and potency of specific statins to estimate the pre-treatment levels.  
 
Good paper. Sample may have been biased as all patients recruited from an inpatient CCU.  
Taylor 2010 
Bibliographic reference Taylor 2010 
Study type Prospective/ reported in Letter 
Aim To describe a rapid, stepwise screening strategy to screen for mutations in patients with FH in the UK. 
Patient characteristics Adult and paediatric patients; 19 definite FH, 91 possible FH 
Number of patients 110 people from lipid clinics 
Index test Simon Broome criteria 
Reference standard (or 
Gold standard) 
 Genetic test 
Time between testing & 
treatment 
n/a 
Length of follow-up n/a 
Location UK 
Results Mutation detected in 43/110, 63.2% in definite FH, 34% in possible FH 
 
% reported in paper, n calculated by analyst 
Mutation Possible FH n=91 Definite FH, n=19 
ARMS 20%, n=18 32%, n=6 
LDLR 12%, n=11 21%, n=4 
LDLR MLPA rearrangement 2%, n=2 10%, n=2 
No mutation 66%, n=60 37%, n=7 
 
Source of funding DoH, department of trade and industry, London IDEAS genetic knowledge park. 
Comments CASP: 
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Results valid, lack of detail on study population; unclear how many adults and children. 
Wald 2015 
Bibliographic reference Wald 2015 
Study type Cohort 
Aim To report prevalence of DNA confirmed FH in young patients with acute MI, relative contribution of smoking and 
diabetes and to compare those rates with those 
Patient characteristics Patients with MI, admitted to hospital 
Number of patients 3076 people with acute MI admitted to hospital; 240 underwent DNA analysis 
Index test FH48 panel, bidirectional sanger sequencing, entire LDLR gene coding region 
Reference standard (or 
Gold standard) 
n/a 
Time between testing & 
treatment 
n/a 
Length of follow-up n/a 
Location UK 
Results 3/231 FH cases diagnosed 
Between June 2011 and April 2013; 3076 patients with acute MI admitted to hospital and 474 were aged 50 or 
less. 240 underwent DNA analysis; 
66 declined testing 
43 did not speak English 
35 were too unwell 
90 were not offered testing because they were weekend admissions. 
DNA analysis failed in 9 patients 
Source of funding Barts and the London Charity service enhancement grant 
Comments Appropriate DNA sequencing 
Widhalm 2007 
Bibliographic reference Widhalm 2007 
Study type Prospective cohort 
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Bibliographic reference Widhalm 2007 
Aim To compare conventional MED-PED criteria with DNA analysis for diagnosis of familial hypocholesteraemia in 
children, adolescents and their relatives.  
Patient characteristics  Patients with premature atherosclerosis and/or hypercholesterolemia – children and adolescents less than 
18 years and their families were referred to the lipid clinic by either general practitioners or hospital 
specialists because a member of the family was suffering from early CVD (<50 years) or had died due to 
MCI or stroke at an early age (<50 years). Others were noticed incidentally as presenting elevated serum 
lipid levels during checking of routine blood parameters. Some families came on their own initiative asking 
for further information on FH.  
 116 children – 57 girls; 59 boys; mean age: 11.6 (4.1); mean LDL-C in mg/dl: 198 (67) 
 147 adults – 4 women; 83 men;  
 Mean age for women 41.5 (13.7); mean LDL-C in mg/dl: 210 (67) 
 Mean age for men 42.8 (10.8); mean LDL-C in mg/dl: 233 (83) 
 Definite (where the family had a t least one member with confirmed FH) and possible FH (whose family 
had no member with proven FH) included  
Number of patients N=263 from 148 families 
Index test MED-PED criteria (make early diagnosis; prevent early death): the criteria are recommended for patients to 
confirm diagnosis in so-called index patients (IPs) and for relatives of index patients (rIPs).  
Reference standard (or 
Gold standard) 
DNA analysis: whole blood taken for LDLR gene analysis by DNA isolation, PCR and denaturing gradient gel 
electrophoresis  
Time between testing & 
treatment 
Not reported  
Length of follow-up Not reported  
Location Austria  
Results Genetic diagnosis: 
N=116  
N=57 children 
N= 62 adults 
 
Diagnosis according to MED-PED (% of genetic diagnosis presented only, n calculated by analyst): 
 Adults (n=147) Children (n=116) 
Criteria for index case 16 19 
Criteria for relative of index case 20 33 
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Do not meet criteria 22 11 
 
Source of funding Not reported  
Comments  Unclear numbers presented for MEDPED diagnosis – only % presented. 
 All patients with confirmed FH received a special diet low in saturated fats and rich in monounsaturated fats 
using rapeseed oil.  
Wald 2016 
Bibliographic reference Wald 2016 
Study type Prospective cohort 
Aim To assess the efficacy and feasibility of child parent screening for FH in primary care practice. 
Patient characteristics Male,n (%) 5213 (52%); median age (IQR) 12.7 months (12.4, 13.3); family history of premature MI, n (%) 1094 
(11%) 
Number of patients 10,095 children aged 1-2 years. 
Index test Genetic testing for LDLR, APOB, PCSK9 
Reference standard (or 
Gold standard) 
N/A 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location 92 GP practices, UK 
Results Blood sample taken from heel stick sample of capillary blood. Total cholesterol, HDL and triglyceride levels were 
measured, LDL initially calculated by the Friedwald equation, and later independently calculated at the study 
centre. 
LDL converted to multiples of the median (MoM) for all children screened. Median value from a pilot study used 
initially and was updated after every 2000 measurements. 
Children who had a cholesterol level at least 1.53 MoM and also had a FH mutation or cholesterol level of at least 
1.53MoM on the repeat test were considered to have positive screening results for FH. The parent was classified 
as having FH if they had the same mutation as the child, or if they had a high cholesterol level. 
 
Cholesterol level was at least 1.53MoM in 92 children; 20 people had an FH mutation. 
Cholesterol level was less than 1.53MoM. 17 had an FH mutation.  
(37 mutations in 10095 children) 
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Parents of 32 children tested for FH (5 unavailable or did not consent) 
28 parents identified when using cut-off of 1.53 MoM used 
40 parents identified when cut-off of 1.35 MoM used. 
Source of funding Supported by the medical research council 
Comments 23 incorrect results (<0.3%) found to be a result of transcription errors, were identified and excluded from the 
analyses. (original sample size 10,118). The use of MoM helps to overcome analytic differences among 
instruments and avoids imprecision in the estimation of extreme percentile cut-offs in new populations. 
 
Study used different cut-offs for MoM measurements to assess how many detected. Also used 1.35MoM (95th %) 
+ mutation or two cholesterol values of at least 1.50MoM (99th %) which identified 40 children who had positive 
screening results for FH (32 with mutation and 8 without mutation) and 40 parents with positive screening results 
for FH. 
Unclear whether parents had genetic testing – no results available in paper. 
Did not use recognised scoring criteria (e.g. SB or DLCN) 
G.2 Diagnosis 
Please see appendix G1 for evidence tables for Bell (2014), Bell (2014a), Clarke (2013), Futema (2013), Hralambos (2015), Jannes (2015) and 
Kirke (2015). 
Hooper 2012 
Bibliographic reference Hooper A J, Nguyen L T, Burnett J R, Bates T R, Bell D A, Redgrave T G, Watts G F, van Bockxmeer , and F 
M. (2012). Genetic analysis of familial hypercholesterolaemia in Western Australia. Atherosclerosis, 224(2), 
pp.430-4 
Study type Prospective cohort 
Aim To determine the spectrum of mutations associated with FH and their detection rate in the FH western Australia 
program 
Patient characteristics Consecutive patients considered to have phenotypic FH referred for DNA testing at Lipid Disorders Clinic at Royal 
Perth Hospital. 
Number of patients N=343 (337 had DLCN score available) 
Index test DLCN score (phenotypic details only) 
>8: definite 
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Bibliographic reference Hooper A J, Nguyen L T, Burnett J R, Bates T R, Bell D A, Redgrave T G, Watts G F, van Bockxmeer , and F 
M. (2012). Genetic analysis of familial hypercholesterolaemia in Western Australia. Atherosclerosis, 224(2), 
pp.430-4 
6-8: probable 
3-5:possible 
>3: unlikely  
Reference standard (or 
Gold standard) 
 Genetic testing for mutations in LDLR, APOB and PCSK9. 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location Western Australia 
Diagnostic accuracy 
measures (2 x 2 table) 
129 people had mutations identified in 343 people referred for genetic testing 
Distribution of DLCN scores 
DLCN score N (337) (n calculated by analyst) N with mutation (n calculated by 
analyst) 
>8: definite 128 (38%) 90 (70%) 
6-8: probable 88 (26%) 26 (29%) 
3-5:possible 111 (33%) 12 (11%) 
>3: unlikely 10 (3%)  
 
Source of funding Grants from the Health Department of Western Australia and University of Western Australia 
Comments None 
Maglio 2014 
Bibliographic reference Maglio C, Mancina R M, Motta B M, Stef M, Pirazzi C, Palacios L, Askaryar N, Boren J, Wiklund O, and 
Romeo S. (2014). Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation 
sequencing. Journal of Internal Medicine, 276(4), pp.396-403. 
Study type Prospective cohort 
Aim To combine clinical criteria and NGS to establish a diagnosis of FH 
Patient characteristics Adults with DLCN score ≥3 (possible, probable or definite FH). 
Male 38 (49%); mean age 51 (14) years; mean pre-treatment LDL-C 6.9 (1.7) mmol/L; Dutch score ≥6 (definite or 
probable FH 57 (74%) 
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Romeo S. (2014). Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation 
sequencing. Journal of Internal Medicine, 276(4), pp.396-403. 
Number of patients 77 
Index test DLCN score ≥3 
Reference standard (or 
Gold standard) 
NGS for LDLR, APOB and PCSK9. 
Time between testing & 
treatment 
N/A 
Length of follow-up N/A 
Location Sweden 
Diagnostic accuracy 
measures (2 x 2 table) 
50/77 people had mutation detected. 
Source of funding Swedish Research Council, Swedish Diabetes foundation, Swedish heart-lung foundation, regional agreement on 
medical training and clinical research, Wilhelm and Martina Lundgren Science fund and Nilsson-Ehle funds. 
Comments No detail on number of mutations found in DLCN subgroups e.g. possible, probable or definite separately. 
Cannot calculate sensitivity and specificity as all participants had DLCN and no distinction as to definite, probable 
or possible. 
G.3 Management (statin monotherapy) 
McCrindle 2002 
Bibliographic reference McCrindle BW1, Helden E, Cullen-Dean G, et al. (2002) A randomized crossover trial of combination pharmacologic 
therapy in children with familial hyperlipidemia. Pediatr Res.. 51(6):715-21. 
Study type Randomised, open label, crossover 
Aim To determine whether a low-dose combination of a bile-acid – binding resin (coletipol) with pravastatin would result 
in improved acceptability, compliance and effectiveness in lipid-lowering compared with conventional therapy of 
colestipol only at a higher dose. 
Patient characteristics Aged 8 -18 yrs, positive family history of hypercholesterolaemia or premature artherosclerotic cardiovascular 
disease in first-degree relatives. No significant differences between groups. 
All patients instructed to stop takeing any lipid lowering medications at least 8 weeks before start of study. 
 Colestipol only (n=16) Colestipol + pravastatin (n=20) 
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therapy in children with familial hyperlipidemia. Pediatr Res.. 51(6):715-21. 
Male: female 11:5 14:6 
Age, Median (range) 14 (10,18) 14 (9,18) 
Family history of father with 
hyperlipidaemia 
12/15 (80%) 12/18 (67%) 
Family history of father with CV 
event 
6/15 (40%) 6/18 (33%) 
Family history of mother with 
hyperlipidaemia 
7/15 (47%) 7/18(39%) 
Mean fasting LDL-C (mM/L) 5.91 (1.20) 6.37 (1.50) 
Mean TC (mM/L) 7.61 (1.26) 8.32 (1.52) 
 
Number of Patients N=36 
Intervention Colestipol (5g) + pravastatin (10mg) 
 
All patients adhered to American Heart Association type 2 diet throughout the study. 
Comparison Colestipol (10g per day) 
All patients adhered to American Heart Association type 2 diet throughout the study. 
Length of follow up 2 x 18 week medication periods with an intervening 8 week washout period. 
Location Canada 
Outcomes measures and 
effect size 
LDL-C (mM/L), mean (SD) Colestipol only Colestipol + pravastatin 
Absolute change -0.65 (0.80) -1.07 (1.06) 
Relative change (%) -9.9 (13.4%) -16.8 (15.8)* 
*p<0.05 
 
Adverse events: reported as % of people causing constipation/ bloating or gas/ stomach ache/ headache/ muscle 
ache. Higher % in colestipol only group for all AEs. NR whether significant. 
 
Compliance from counts of returned unused medication (mean, SD) [expressed as % of medication presumed taken 
vs dose prescribed] 
 Colestipol only (10g/d) Colestipol (5g/d) Pravastatin (10mg/d) 
First 8 week 63 (29) 66 (27) 65 (26) 
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therapy in children with familial hyperlipidemia. Pediatr Res.. 51(6):715-21. 
Second 10 week 57 (44) 58 (33) 60 (39) 
total 60 (31) 62 (27) 62 (28) 
 
Source of funding NR 
Comments Randomisation stratified by 2 centres, random blocks of 4, 6 and 8 using a random number generator. Sample size 
required calculated as 40. 
Vuorio 2014 
Bibliographic reference Vuorio A, Kuoppala J, Kovanen PT et al. (2014) Statins for children with familial hypercholesterolemia. Cochrane 
Database of Systematic Reviews CD006401. 
Study type Cochrane systematic review: 4 of 8 studies included in analysis. Randomised and non-randomised but controlled 
inical studies with systematic allocation. 
Aim To assess the effectiveness and safety associated with the use of statins in children heterozygous for FH. 
Patient characteristics Children and adolescents up to 18 yrs at start of study, 
Number of Patients 4 studies ( Knipscheer 1996; Wiegman 2004; McCrindle 2003; Avis 2010) 
Intervention Active treatment with a statin (lovastatin, simvastatin, pravastatin, fluvastatin, rosuvastatin, atorvastatin) 
 
The Cochrane review included all statin types, this review specified only fluvastatin, rosuvastatin, atorvastatin, 
therefore 4 studies reporting on other statins not included, listed in comments below.  
Comparison Control treatment with another statin, or with placebo or with other lipid-lowering agents, or with diet alone or with no 
treatment. 
Length of follow up Median 24 weeks (range 6 weeks – two years) 
Location Various 
Outcomes measures and 
effect size 
Change in serum LDL-Cholesterol level (%) 
Study Statins, mean change (SD) Placebo, mean change (SD) 
Knipscheer (1996) -22 (10) -3 (13) 
Wiegman (2004) -23.8 (16.7) 0 (15.2) 
 
Liver dysfunction 
a. Change in aspartate aminotransferase levels, 3 x ULN (n) 
 Statins Placebo 
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Database of Systematic Reviews CD006401. 
Knipscheer (1996) 0/54 0/18 
Wiegman (2004) 0/104 2/107 
 
b. Change in alanine aminotransferase levels, 3 x ULN (n) 
 
Statins Placebo 
Wiegman (2004) 
0/104 0/107 
Change in serum creatine kinase levels (myopathy), 10 x ULN (n) 
 Statins Placebo RR (95%CI) 
Avis (2010); Knipscheer 
(1996) 
4/167 0/60 3.23 (0.18, 38.84 
 
Rhabdomyolysis-NR 
Myocardial infarction-not reported in any study. 
Compliance: Wiegman (2004) reported that children adhered to the protocol (84% of tablets among children studied 
were taken for full 2 years of study) 
Adverse events. 
 Statins Placebo RR (95%CI) 
At 1 month 83/184 34/64 0.86 (0.65, 1.13) 
 
Source of funding Not reported 
Comments Stein 1999; Clauss 2005; Couture 1988; de Jongh 2002a excluded as simvastatin and lovastatin were interventions. 
Only data from included studies reported here. 
Other primary outcomes in Cochrane were change in thickness of carotid intima, change in measures of growth and 
maturation. Other secondary outcomes were change in endothelial function, change in serum total, HDL and 
triglyceride levels, quality of life 
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Appendix H: Forest plots 
H.1 Case finding 
No forest plots 
H.2 Diagnosis 
Figure 1: Sensitivity and specificity of possible and definite Simon Broome criteria to detect genetic FH 
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Figure 2: Sensitivity and specificity of definite Simon Broome criteria to detect genetic FH 
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Figure 3: Sensitivity and specificity of possible, probable and definite DLCN criteria (score >2) to detect genetic FH 
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Figure 4: Sensitivity and specificity of probable and definite DLCN criteria (score >5) to detect genetic FH 
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Figure 5: Sensitivity and specificity of definite DLCN criteria (score >8) to detect genetic FH 
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H.3 Management (statin monotherapy) 
Figure 6: Change in LDL-C concentration (%) 
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Figure 7: Adverse events  
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Figure 8: Change in aspartate aminotransferase (x3 ULN) 
 
 
Figure 9: Change in alanine aminotransferase (x3 ULN) 
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Figure 10: Myopathy: change in CK (x10 ULN) 
 
 
Figure 11: Compliance (%) 
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Appendix I: GRADE profiles 
I.1 Case-finding 
I.1.1 Cascade testing 
Table 26: Cascade testing: Diagnostic yield for genetic and clinical diagnoses and uptake rate. 
Quality assessment No of patients Effect estimate Quality 
No of 
studies 
Design Risk of 
bias 
Indirectness Inconsistency Imprecision Other 
considerations  
N with FH N tested Median (range) 
Outcome: Diagnostic yield from clinical diagnosis of FH in direct cascade testing: Adults (SB, DLCN criteria) 
2 1 case 
series, 
1 
prospe
ctive 
cohort 
Very 
serious6 
No serious Not applicable4 Cannot be 
assessed5 
none 133 405 6.0 – 59.0%* Very low 
Outcome: Diagnostic yield from clinical diagnosis of FH in indirect cascade testing: Adults (medped, other clinical diagnostic criteria) 
2 Case 
series 
Very 
serious1 
No serious Not applicable4 Cannot be 
assessed5 
none 289 776 30.5 -37.9%* Very low 
Outcome: Diagnostic yield from clinical diagnosis of FH in indirect and direct cascade testing: Adults (SB criteria) 
2 Prospc
tive 
cohort 
Serious3 No serious Not applicable4 Cannot be 
assessed5 
none 440 1,879 14.7 -57.5%* Low 
Outcome: Diagnostic yield from genetic cascade testing (direct) 
5 4 case 
series, 
1 
prospe
ctive 
cohort 
Very 
serious8 
Serious2 Not applicable4 Cannot be 
assessed5 
none 2,636 7,144 37.5% (11.4 -51.4%) Very low 
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Quality assessment No of patients Effect estimate Quality 
No of 
studies 
Design Risk of 
bias 
Indirectness Inconsistency Imprecision Other 
considerations  
N with FH N tested Median (range) 
Outcome: Diagnostic yield from genetic cascade testing (indirect) 
1 Case 
series 
Very 
serious1 
No serious Not applicable4 Cannot be 
assessed5 
none 808 1,805 44.8% Very low 
Outcome: Diagnostic yield from genetic cascade testing (direct and indirect) 
1 Prospe
ctive 
cohort 
No 
serious 
No serious Not applicable4 Cannot be 
assessed5  
none 359 642 55.9% Moderat
e 
Outcome: Diagnostic yield from genetic cascade testing (unknown methods) 
2 1 case 
series, 
1 
prospe
ctive 
cohort 
Very 
serious7 
Very serious7 Not applicable4 Cannot be 
assessed5 
none 958 2,910 32.8 -33.9%* Very low 
Outcome: Uptake rate of testing-direct cascade testing: index individuals 
3 1 case 
series, 
2 
prospe
ctive 
cohort
sl 
Very 
serious2 
No serious Not applicable4 Cannot be 
assessed5 
none 1,208 1,557 84.1% (69.1 -98.9%) Very low 
Outcome: Uptake rate of testing--direct cascade testing: relatives of index individuals  
2 1 case 
series, 
1 
prospe
ctive 
cohort 
Very 
serious6 
No serious Not applicable4 Cannot be 
assessed5 
none 563 582 84.1 -98.9%* Very low 
Outcome: Uptake rate of testing-indirect cascade testing: relatives of index individuals 
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Quality assessment No of patients Effect estimate Quality 
No of 
studies 
Design Risk of 
bias 
Indirectness Inconsistency Imprecision Other 
considerations  
N with FH N tested Median (range) 
1 Case 
series 
Very 
serious1 
No serious Not applicable4 Cannot be 
assessed5 
none 1,805 2,474 73.0% Very low 
Outcome: Uptake rate of testing-both indirect and direct cascade testing: relatives of index individuals 
1 Prospe
ctive 
cohortl 
Serious3 No serious Not applicable4 Cannot be 
assessed5 
none 1,494 2,292 65.2% Low 
*where only 2 studies report an outcome only the range is reported, as median cannot be calculated from two studies or less. 
1. Leren (2008) assumes that all those with low serum cholesterol did not have clinical FH, did not take account of those on lipid lowering therapy at time of testing. Judged 
that concerns did not affect results as study results not at extremes of range. PCSK9 mutation not tested for. Leren (2008) and Marks (2006) both case series studies and 
therefore quality starts at low. 
2. Thorsson (2003) indirect population; study undertaken in Iceland using family tracing methods that would not be applicable to UK population. Bhatnager (2000) was a 
case series study and therefore low quality. 
3. Hadfield (2009) no data on first degree relatives FDRs known to have FH not included. 
4. Data from the studies was not pooled, therefore judged as no serious inconsistency, not downgraded. 
5. Imprecision could not be formally assessed because median and range were reported. Downgraded 1 level due to the resulting uncertainty around the precision of the 
estimate. 
6. Taylor (1993) included a population of children only; does not use standardised diagnostic criteria (e.g. DLNC), relies on clinical criteria only. Taylor (1993), unable to tell 
whether authors identified all confounding factors; unclear whether follow up complete. Bhatnager (2000) is a case series study and therefore starts at low quality. 
7. Vergoline (2001) undertaken in South African population, looking for Afrikaner foundation mutations, unclear whether applicable to UK population. Lee (1998) did not 
undertake full genetic testing, only LDLR gene mutations. Vergoline (2001) was a case series study, therefore low quality. 
8.  Four studies contributing to the outcome were case series and one was a prospective cohort, therefore low quality. 
I.1.2 Primary care 
No GRADE profiles were produced for this question, as a narrative quality assessment is reported in the evidence review (section 2.3.2). 
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I.1.3 Secondary care 
Table 27: Secondary care: Diagnostic yield and uptake rate:  
Quality assessment No of patients Effect estimate Quality 
No of 
studies 
Design Risk of 
bias 
Indirectness Inconsistency Imprecision Other 
considerations  
N with FH N tested for 
FH 
Median (range) 
Outcome: Diagnostic yield – clinical diagnosis FH: pathology databases (Bell 2012, Bell 2014 and Kirke 2015) 
3  1 
case 
series, 
2 
prospe
ctive 
cohort
s 
Very 
serious1, 
11 
No serious Not applicable9 Cannot be 
assessed 10 
none 1045 85,616 8.5% (1.2-9.2%) Very low 
Outcome: Diagnostic yield – clinical diagnosis FH: lipid clinics or registries (Chung 1999, Haralambos 2015, Widhalm 2007 and Hu 2013) 
4 2 case 
series, 
2 
prospe
ctive 
cohort
s 
Very 
serious2 
No serious Not applicable9 Cannot be 
assessed 10 
none 892 1343 51.0% (33.5 – 87.8%) Very low 
Outcome: Diagnostic yield – clinical diagnosis FH: coronary care units/ MINAP (Bates 2008, De Backer 2015, Nanchen 2015, Pang 2015) 
4 Prospe
ctive 
cohort 
No 
serious3 
No serious Not applicable9 Cannot be 
assessed 10 
none 694 12,331 5.9% (1.2 – 14.3%) Moderat
e 
Outcome: Diagnostic yield – clinical diagnosis FH: screening (Beeso 1999, Wald 2016) 
2 Prospe
ctive 
cohort 
Very 
serious4 
Serious4 Not applicable9 Cannot be 
assessed 10 
none 22 19,768 0.001-0.145%* Very low 
Outcome: Diagnostic yield – genetic diagnosis FH: pathology databases (Kirke 2015, Muir 2010, Bell 2014) 
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Quality assessment No of patients Effect estimate Quality 
No of 
studies 
Design Risk of 
bias 
Indirectness Inconsistency Imprecision Other 
considerations  
N with FH N tested for 
FH 
Median (range) 
3 2 case 
series, 
1 
prospe
ctive 
cohort 
Serious1
, 5, 11 
No serious Not applicable9 Cannot be 
assessed 10 
none 91 641 26.7% (12.9 -30.4%) Very low 
Outcome: Diagnostic yield – genetic diagnosis FH: lipid clinics or registries (Futema 2013, Heath 2001, Medeiros 2010, Taylor 2010, Widhalm 2007) 
6 3 case 
series, 
2 
prospe
ctive 
cohort
s 
Very 
serious6 
No serious Not applicable9 Cannot be 
assessed 10 
none 700 1,955 33.3% (10.9 -51.0%) Very low 
Outcome: Diagnostic yield – genetic diagnosis FH: coronary care units/ MINAP (Wald, 2015) 
1 Prospe
ctive 
cohort 
Serious7 Serious Not applicable9 Cannot be 
assessed 10 
none 3 231 1.2% Low 
Outcome: Diagnostic yield – genetic diagnosis FH: screening (Laurie 2004, Klancar 2015; Wald 2016) 
3 2 case 
series, 
1 
prospe
ctive 
cohort 
Very 
serious8 
Serious8 Not applicable9 Cannot be 
assessed 10 
none 203 10,432 17.0% (0.4, 57.0%) Very low 
Outcome: Uptake rate of FH testing: pathology databases (Bell 2014, Kirke 2015) 
Increase
d CV 
risk 
attendin
g clinical 
1 case 
series, 
1 
prospe
Very 
serious1, 
11 
No serious Not applicable9 Cannot be 
assessed 10 
none Increased 
CV risk 
attending 
clinical 
assessme
Increased 
CV risk 
attending 
clinical 
Increased CV risk 
attending clinical 
assessment for FH: 
13.2% 
 
Very low 
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Quality assessment No of patients Effect estimate Quality 
No of 
studies 
Design Risk of 
bias 
Indirectness Inconsistency Imprecision Other 
considerations  
N with FH N tested for 
FH 
Median (range) 
assess
ment for 
FH: 1 
 
Attendin
g 
specialis
t review: 
2 
ctive 
cohort 
nt for FH: 
597 
 
Attending 
specialist 
review: 53 
assessment 
for FH: 4517 
 
Attending 
specialist 
review: 86 
  
 
 
Attending specialist 
review: 61.6% 
Outcome: Uptake rate of FH testing: coronary care units/ MINAP (Wald 2015) 
1 Prospe
ctive 
cohort 
No 
serious 
Serious7 Not applicable9 Cannot be 
assessed 10 
none 240 474 50.1% Low 
Outcome: Uptake rate of FH testing: screening (Beeso 1999) 
1 Prospe
ctive 
cohort 
Serious4 Serious4 Not applicable9 Cannot be 
assessed 10 
none 82 189 43.4% Very low 
*where only 2 studies report an outcome only the range is reported, median cannot be calculated for 2 or fewer studies 
1. Bell (2012) used Medped, Simon Broome, DLNC and >6.5 mmol/L as criteria to diagnose FH, mean value used for quality assessment; Simon Broome criteria significantly 
higher diagnostic rate (3.68%) compared to other 3 methods (mean 0.306%). Bell (2014)was a case control study where efficacy of telephone call by chemical pathologist 
in diagnosing FH 
2. Chung (1999) is small study (n=11) with an indirect ethnic population (Chinese), case series; Hu (2013) is also in an indirect ethnic population and a case series design; 
Widhalm (2007) had population with early CVD, or family history of early CVD or high serum cholesterol; study does not report how many index patients or relatives 
diagnosed, different medped criteria used for these groups, molecular method of diagnosis unclear. 
3. Bates (2008) does not use molecular methods to confirm diagnosis, but quality not down-graded as relatively small study contributing to overall effect. 
4. Beeso (1999) population of neonates only; used apolipoprotein A1: B ratio to assess presence of FH. 
5. Muir (2010) identified people on basis of raised TC (>8mmol/L) not raised LDL-C, case series design. 
6. Widhalm (2007) had population with early CVD, or family history of early CVD or high serum cholesterol; study does not report how many index patients or relatives 
diagnosed, different medped criteria used for these groups, molecular method of diagnosis unclear. Taylor (2010) had population already diagnosed with definite FH 
according to Simon Broome criteria. Futema (2013) had population diagnosed with FH according to Simon Broome criteria, case series design. Medeiros (2010) reporting 
of numbers included and diagnosed unclear. Heath (2001) population was people with FH using SB criteria, did not report n of children included; Heath (2001) using old, 
insensitive method therefore not reliable outcome, case series design. Haralambos (2015) used adapted Dutch Lipid criteria (welsh criteria) to assess FH. 
7. Wald (2015) is a relatively small study. 
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8. Laurie (2004) had population with TC >8 mmol/L, lack of detail about study. Laurie (2004) and Klancar (2015) small studies with identification methods not applicable to 
UK, both case series design. 
9. Data from the studies was not pooled, therefore judged as no serious inconsistency, not downgraded. 
10. Imprecision could not be formally assessed because median and range were reported. Downgraded 1 level due to the resulting uncertainty around the precision of the 
estimate. 
11.  Kirke (2015) identified patients from a pathology laboratory – very low uptake rate for further testing amongst people at high risk of FH. 
I.2 Diagnosis 
Table 28: Diagnostic accuracy of Simon Broome and DLCN criteria to identify genetic FH 
Number of studies 
Number of 
participants R
is
k
 o
f 
b
ia
s
  
In
d
ir
e
c
tn
e
s
s
  
In
c
o
n
s
is
te
n
c
y
 
Im
p
re
c
is
io
n
 
 
 
 
 
 
TP 
 
 
 
 
 
FP 
 
 
 
 
 
FN 
 
 
 
 
 
TN 
Sensitivity (%) 
(95% CI) 
Specificity (%) 
(95% CI) 
GRADE 
quality 
Index test 1: Simon Broome possible + definite 
4 1,872 VS2 S VS4 NS 494 817 61 290 0.890 (0.845, 
0.924) 
0.287 (0.160, 
0.459) 
Very low 
Index test 2: Simon Broome possible + definite – sensitivity analysis (without Haralambos 2015 data) 
3 656 NS NS VS4 VS1 384 102 36 134 0.870 (0.825, 
0.905) 
0.325 (0.173, 
0.526) 
Very low 
Index test 3: Simon Broome definite 
4 1,872 VS2 S VS4 VS3 252 132 363 1125 0.360 (0.186, 
0.581) 
0.86 (0.158, 
0.995) 
Very low 
Index test 4: Simon Broome definite – sensitivity analysis (without Haralambos 2015 data) 
3 666 NS NS VS4 VS3 107 36 173 350 0.335 (0.156, 
0.578) 
0.804 (0.073, 
0.995) 
Very low 
Index test 5: DLCN possible, probable and definite (score>2) 
4 936 NS NS VS4 NS 403 462 10 61 0.967 (0.939, 
0.983) 
0.125 (0.057, 
0.253) 
Low 
Index test 6: DLCN probable and definite (score>5) 
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Number of studies 
Number of 
participants R
is
k
 o
f 
b
ia
s
  
In
d
ir
e
c
tn
e
s
s
  
In
c
o
n
s
is
te
n
c
y
 
Im
p
re
c
is
io
n
 
 
 
 
 
 
TP 
 
 
 
 
 
FP 
 
 
 
 
 
FN 
 
 
 
 
 
TN 
Sensitivity (%) 
(95% CI) 
Specificity (%) 
(95% CI) 
GRADE 
quality 
4 1,531 NS NS VS4 NS 501 592 82 356 0.868 (0.711, 
0.946) 
0.457 (0.320, 
0.601) 
Low 
Index test 7: DLCN probable and definite (score>5) -sensitivity analysis (without Haralambos data) 
3 859 NS NS S5 NS 330 241 78 259 0.807 (0.716, 
0.874) 
0.517 (0.472, 
0.561) 
Moderate 
Index test 8: DLCN definite (score>8) 
4 1,088 NS NS VS4 NS 236 103 173 397 0.567 (0.460, 
0.669) 
0.802 (0.713, 
0.869) 
Low 
1.95%CI extend more than 15% in one direction for sensitivity and/or sensitivity, downgraded 1 level.  
2.Haralambos 2015 did not report n for those assessed by Simon Broome and undergoing genetic testing. Therefore n calculated on whole cohort. 
3.95%CI extend more than 15% in each direction for both sensitivity and specificity, therefore downgraded 2 levels 
4.I2 >75% for sensitivity and/or specificity, therefore very serious inconsistency (downgraded 2 levels)..  
5.I2 >40% for sensitivity and/or specificity, therefore serious inconsistency (downgraded 1 level). 
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I.3 Management (statin monotherapy) 
For high-intensity statin therapy in adults, please refer to CG181, section 11.3.1, table 41 
Table 29: Management (Statin monotherapy) in children and young people: dichotomous outcomes  
Quality assessment No of patients Effect estimate Quality 
No of 
studies 
Design Risk of 
bias 
Indirectness Inconsistency Imprecision Other 
considerations  
Treatment Comparator Relative 
(96% CI) 
Absolute 
Outcome: Adverse events: 1 month 
2 RCT No 
serious 
No serious very serious2  Serious1 none 83/184 (45.1%) 34/64 
(53.1%) 
0.86 
[0.65, 
1.13] 
74 fewer 
per 1000 
(from 186 
fewer to 
69 more) 
Very 
low 
Outcome: Adverse events: 6 months 
1 RCT No 
serious 
No serious No serious Serious1 none 88/140 29/47 1.02 
[0.79, 
1.32] 
12 more 
per 1000 
(from 130 
fewer to 
197 more) 
Low 
Outcome: change in aspartate aminotransferase concentration (x3 ULN) 
3 RCT No 
serious 
No serious No serious Very serious3 none 2/298 (0.67%) 2/172 
(1.16%) 
0.55 
[0.08, 
3.61] 
5 fewer 
per 1000 
(from 11 
fewer to 
30 more) 
Low 
Outcome: change in alanine aminotransferase concentration (x3 ULN) 
2 RCT No 
serious 
No serious No serious Very serious3 none 1/244 (0.41%) 0/154 (0%) 1.02 
[0.04, 
24.65] 
n/a Low 
Outcome: change in CK concentration (x>10 ULN) 
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Quality assessment No of patients Effect estimate Quality 
No of 
studies 
Design Risk of 
bias 
Indirectness Inconsistency Imprecision Other 
considerations  
Treatment Comparator Relative 
(96% CI) 
Absolute 
2 RCT No 
serious 
No serious No serious Very serious3 none 4/167 (2.4%) 0/60 (0%) 3.23 
[0.18, 
58.84] 
n/a Low 
1. Confidence intervals: extend >25% in one direction, serious imprecision 
2. Inconsistency very serious as I2=85% 
3. Confidence intervals extend >25% in both directions, therefore very serious imprecision. 
Table 30: Management (statin monotherapy) in children and young people: continuous outcomes  
Quality assessment No of patients Effect estimate Quality 
No of 
studies 
Design Risk of 
bias 
Indirectness Inconsistency Imprecision Other 
considerations  
Treatment 
(T) 
Comparator 
(C) 
Mean difference (95% 
CI) 
Outcome: Change in serum LDL cholesterol level (%) at end of follow up  
3 RCT Serious1 No serious Very serious3 Very 
serious4 
none 297 172 -30.53 [-33.30, -
27.77] 
Very low 
Outcome: Compliance (%): Rosuvastatin 5mg 
1 RCT No 
serious 
No serious No serious No serious none 42 46 0.30 [-6.23, 6.83] High 
Outcome: Compliance (%) Rosuvastatin 10mg 
1 RCT No 
serious 
No serious No serious Serious2 none 44 46 3.40 [-2.72, 9.52] Moderate 
Outcome: Compliance (%): Rosuvastatin 20mg 
1 RCT No 
serious 
No serious No serious Serious2 none 45 46 2.50 [-3.80, 880] Moderate 
1.Allocation concealment not reported in Knipscheer 1996, McCrindle 2003 or Wiegman 2004 
2. Confidence intervals more than 0.5 x SD in one direction and cross line of no difference, therefore serious imprecision.. 
3. I2 94%, very serious inconsistency 
4. Confidence intervals more than 0.5 x SD in both directions and cross line of no difference, therefore very serious imprecision..
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Appendix J: Economic search strategy 
J.1 Case finding 
Databases that were searched, together with the number of articles retrieved from each 
database are shown in Table 31. The search strategy is shown in Table 32. The same 
strategy was translated for the other databases listed. 
Table 31: Economic search summary 
Economics 
Date 
searched Version/files 
No. 
retrieved 
MEDLINE (Ovid) 10/05/16 1946 to April Week 4 2016 446 
MEDLINE in Process (Ovid) 10/05/16 May 09, 2016 50 
Embase (Ovid) 10/05/16 1980 to 2016 Week 19 836 
EconLit (Ovid) 
 
10/05/16 1886 to March 2016 1 
NHS Economic Evaluation Database 
(NHS EED) (legacy database) 
10/05/16 Issue 2 of 4, April 2015 15 
Health Technology Assessment (HTA 
Database) 
10/05/16 Issue 2 of 4, April 2016 5 
PubMed 10/05/16 N/A 23 
Table 32: Economic search strategy 
Database: Medline & Medline in Process 
Search Strategy: 
-------------------------------------------------------------------------------- 
1 Hyperlipidemia, familial combined/ (728) 
 
2 Hyperlipoproteinemia Type II/ (5602) 
 
3 ((famil* or essential* or monogenic* or hereditar* or inherit* or heterozygous* or homozygous*) 
adj4 (hypercholest* or hyperlip* or cholest* or lipid* or FH)).tw. (12750) 
 
4 (FH or HoFH or HeFH).tw. (5475) 
 
5 Cholesterol, LDL/ or Receptors, LDL/ (30499) 
 
6 (LDL* adj (cholester* or receptor* or lipoprotein*)).tw. (24823) 
 
7 (low* adj1 densit* adj1 lipoprotein* adj1 (receptor* or cholesterol*)).tw. (22357) 
 
8 (LDLR or LDL-R or LDL R or LDLC or LDL-C or LDL C).tw. (13872) 
 
9 Apolipoprotein B-100/ (1746) 
 
10 (Famili* adj2 apolipoprotein*).tw. (220) 
 
11 ((Apolipoprotein* or Apo or Apo-) adj1 (B or B-100 or B100 or B 100) adj1 (deficien* or syndrom* 
or defectiv*)).tw. (240) 
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Database: Medline & Medline in Process 
 
12 Hyperlipoproteinemia Type I/ or Apolipoprotein C-II/ (1093) 
 
13 ((Apolipoprotein* or Apo or Apo-) adj1 (C or C-II or CII or C II or "C-2" or "C2" or "C 2") adj1 
(deficien* or syndrom* or defectiv*)).tw. (21) 
 
14 ((ApoC2 or ApoCII or ApoB) adj1 (deficien* or syndrom* or defectiv*)).tw. (66) 
 
15 or/1-14 (73212) 
 
16 Medical Records Systems, Computerized/ (18612) 
 
17 Medical Records/ (63220) 
 
18 Hospital Records/ (3197) 
 
19 Databases, factual/ (52126) 
 
20 Registries/ (62942) 
 
21 Medical Audit/ (15642) 
 
22 ((gp or general practi* or doctor* or nurse* or physician* or primary care or secondary care or 
clinic* or patient* or medical* or hospital* or computer* or electronic* or clinical practice*) adj2 (note* 
or record* or database* or regist* or audit* or data or datalink)).tw. (327937) 
 
23 (GPRD or CPRD).tw. (453) 
 
24 Medical History Taking/ or anamnes*.tw. (25534) 
 
25 ((patient* or case* or medic*) adj2 (histor* or identif* or find* or screen*)).tw. (212440) 
 
26 ((famil* or parent* or grand* or relative* or relation*) adj2 (histor* or case* or tracing or trace* or 
screen* or identif*)).tw. (83090) 
 
27 (Simon adj1 Broom*).tw. (34) 
 
28 (Dutch Lipid adj2 (clinic* or network* or criteria* or diagnos* or score*)).tw. (26) 
 
29 DLCNCS.tw. (2) 
 
30 Make Early Diagnosis to Prevent Early Death.tw. (9) 
 
31 MEDPED.tw. (21) 
 
32 ((cardiac* or coronar* or stroke or myocardial infarction or MI or heart attack) adj2 (care* or facili* 
or team* or unit* or investigat*) adj2 (note* or record* or database* or regist* or audit* or data)).tw. 
(223) 
 
33 Myocardial Ischaemia National Audit Project.tw. (33) 
 
34 MINAP.tw. (42) 
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Database: Medline & Medline in Process 
 
35 National Institute for Cardiovascular Outcomes Research.tw. (14) 
 
36 NICOR.tw. (10) 
 
37 QRESEARCH.tw. (69) 
 
38 National Audit of Percutaneous Coronary Intervention.tw. (1) 
 
39 PCI.tw. (14392) 
 
40 National Adult Cardiac Surgery.tw. (17) 
 
41 NACSA.tw. (1) 
 
42 Health Survey for England.tw. (340) 
 
43 ((Patholog* or biochemistr* or lab or laborator*) adj2 (note* or record* or database* or regist* or 
audit* or data)).tw. (25961) 
 
44 Genetic testing/ (29519) 
 
45 ((cascade* or genetic*) adj2 (test* or train* or screen*)).tw. (24970) 
 
46 ((selectiv* or proband* or proposit* or risk factor* or program*) adj2 (screen* or test*)).tw. 
(31888) 
 
47 or/16-46 (864942) 
 
48 15 and 47 (6236) 
 
49 Economics/ (26697) 
 
50 exp "Costs and Cost Analysis"/ (197191) 
 
51 Economics, Dental/ (1878) 
 
52 exp Economics, Hospital/ (21373) 
 
53 exp Economics, Medical/ (13855) 
 
54 Economics, Nursing/ (3934) 
 
55 Economics, Pharmaceutical/ (2615) 
 
56 Budgets/ (10427) 
 
57 exp Models, Economic/ (11634) 
 
58 Markov Chains/ (11182) 
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Database: Medline & Medline in Process 
59 Monte Carlo Method/ (22517) 
 
60 Decision Trees/ (9454) 
 
61 econom$.tw. (175446) 
 
62 cba.tw. (9050) 
 
63 cea.tw. (17578) 
 
64 cua.tw. (831) 
 
65 markov$.tw. (13288) 
 
66 (monte adj carlo).tw. (23357) 
 
67 (decision adj3 (tree$ or analys$)).tw. (9409) 
 
68 (cost or costs or costing$ or costly or costed).tw. (342963) 
 
69 (price$ or pricing$).tw. (25523) 
 
70 budget$.tw. (18907) 
 
71 expenditure$.tw. (38325) 
 
72 (value adj3 (money or monetary)).tw. (1513) 
 
73 (pharmacoeconomic$ or (pharmaco adj economic$)).tw. (2979) 
 
74 or/49-73 (720580) 
 
75 "Quality of Life"/ (136462) 
 
76 quality of life.tw. (158933) 
 
77 "Value of Life"/ (5492) 
 
78 Quality-Adjusted Life Years/ (8388) 
 
79 quality adjusted life.tw. (7127) 
 
80 (qaly$ or qald$ or qale$ or qtime$).tw. (5845) 
 
81 disability adjusted life.tw. (1533) 
 
82 daly$.tw. (1464) 
 
83 Health Status Indicators/ (21241) 
 
 197 
 
Database: Medline & Medline in Process 
84 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or 
shortform thirty six or short form thirtysix or short form thirty six).tw. (17078) 
 
85 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw. 
(1069) 
 
86 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or 
short form twelve).tw. (3177) 
 
87 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or 
short form sixteen).tw. (22) 
 
88 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or 
short form twenty).tw. (344) 
 
89 (euroqol or euro qol or eq5d or eq 5d).tw. (4796) 
 
90 (qol or hql or hqol or hrqol).tw. (28921) 
 
91 (hye or hyes).tw. (54) 
 
92 health$ year$ equivalent$.tw. (38) 
 
93 utilit$.tw. (125903) 
 
94 (hui or hui1 or hui2 or hui3).tw. (957) 
 
95 disutili$.tw. (250) 
 
96 rosser.tw. (72) 
 
97 quality of wellbeing.tw. (6) 
 
98 quality of well-being.tw. (340) 
 
99 qwb.tw. (182) 
 
100 willingness to pay.tw. (2665) 
 
101 standard gamble$.tw. (683) 
 
102 time trade off.tw. (803) 
 
103 time tradeoff.tw. (215) 
 
104 tto.tw. (658) 
 
105 or/75-104 (359506) 
 
106 74 or 105 (1030817) 
 
107 48 and 106 (482) 
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Database: Medline & Medline in Process 
 
108 Animals/ not Humans/ (4203766) 
 
109 107 not 108 (482) 
 
110 limit 109 to english language (446) 
 
J.2 Diagnosis 
Economics 
Date 
searched Version/files 
No. 
retrieved 
MEDLINE (Ovid) 07/10/16 1946 to September Week 4 
2016 
110 
MEDLINE in Process (Ovid) 07/10/16 October 03, 2016 14 
Embase (Ovid) 07/10/16  153 
EconLit (Ovid) 
 
07/10/16 1886 to September 2016 1 
NHS Economic Evaluation Database 
(NHS EED) (legacy database) 
07/10/16 Issue 2 of 4, April 2015 4 
Health Technology Assessment (HTA 
Database) 
07/10/16 Issue 3 of 4, July 2016 2 
PubMed 07/10/16 n/a 6 
 
Database: Medline & Medline in Process 
Search Strategy: 
-------------------------------------------------------------------------------- 
1 Hyperlipidemia, familial combined/ (732) 
2 Hyperlipoproteinemia Type II/ (5749) 
3 ((famil* or essential* or monogenic* or hereditar* or inherit* or heterozygous* or homozygous*) 
adj4 (hypercholest* or hyperlip* or cholest* or lipid* or FH)).tw. (13192) 
4 (FH or HoFH or HeFH).tw. (5742) 
5 Cholesterol, LDL/ or Receptors, LDL/ (31538) 
6 (LDL* adj (cholester* or receptor* or lipoprotein*)).tw. (25495) 
7 (low* adj1 densit* adj1 lipoprotein* adj1 (receptor* or cholesterol*)).tw. (23397) 
8 (LDLR or LDL-R or LDL R or LDLC or LDL-C or LDL C).tw. (14573) 
9 Apolipoprotein B-100/ (1816) 
10 (Famili* adj2 apolipoprotein*).tw. (220) 
11 ((Apolipoprotein* or Apo or Apo-) adj1 (B or B-100 or B100 or B 100) adj1 (deficien* or syndrom* 
or defectiv*)).tw. (240) 
12 Hyperlipoproteinemia Type I/ or Apolipoprotein C-II/ (1109) 
13 ((Apolipoprotein* or Apo or Apo-) adj1 (C or C-II or CII or C II or "C-2" or "C2" or "C 2") adj1 
(deficien* or syndrom* or defectiv*)).tw. (21) 
14 ((ApoC2 or ApoCII or ApoB) adj1 (deficien* or syndrom* or defectiv*)).tw. (66) 
15 or/1-14 (75847) 
16 (Simon adj1 Broom*).tw. (36) 
17 (Dutch Lipid adj2 (clinic* or network* or criteria* or diagnos* or score*)).tw. (33) 
18 Dutch score*.tw. (4) 
19 (DLCNCS or DLCN).tw. (10) 
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Database: Medline & Medline in Process 
20 ((famil* or parent* or grand* or relative* or relation*) adj2 (histor* or case* or tracing or trace* or 
screen* or identif*) adj2 (famil* or essential* or monogenic* or hereditar* or inherit* or heterozygous* 
or homozygous*) adj4 (hypercholest* or hyperlip* or cholest* or lipid* or FH)).tw. (1503) 
21 ((famil* or parent* or grand* or relative* or relation*) adj2 (histor* or case* or tracing or trace* or 
screen* or identif*) adj2 (coronar* or Ischaemic* or ischemic*) adj2 heart* adj2 (diseas* or 
disorder*)).tw. (324) 
22 Genetic testing/ (30939) 
23 ((cascade* or genetic* or dna) adj2 (test* or train* or screen*)).tw. (35227) 
24 (tendon xanthomata or xanthelasmas).tw. (124) 
25 ((corneal* or senil*) adj1 arcus).tw. (211) 
26 or/16-25 (59196) 
27 15 and 26 (2154) 
28 Economics/ (26800) 
29 exp "Costs and Cost Analysis"/ (203136) 
30 Economics, Dental/ (1892) 
31 exp Economics, Hospital/ (21897) 
32 exp Economics, Medical/ (13976) 
33 Economics, Nursing/ (3944) 
34 Economics, Pharmaceutical/ (2654) 
35 Budgets/ (10603) 
36 exp Models, Economic/ (12134) 
37 Markov Chains/ (11636) 
38 Monte Carlo Method/ (23292) 
39 Decision Trees/ (9741) 
40 econom$.tw. (183183) 
41 cba.tw. (9226) 
42 cea.tw. (18056) 
43 cua.tw. (850) 
44 markov$.tw. (13949) 
45 (monte adj carlo).tw. (24231) 
46 (decision adj3 (tree$ or analys$)).tw. (9835) 
47 (cost or costs or costing$ or costly or costed).tw. (359163) 
48 (price$ or pricing$).tw. (26536) 
49 budget$.tw. (19515) 
50 expenditure$.tw. (39995) 
51 (value adj3 (money or monetary)).tw. (1582) 
52 (pharmacoeconomic$ or (pharmaco adj economic$)).tw. (3055) 
53 or/28-52 (748730) 
54 "Quality of Life"/ (144021) 
55 quality of life.tw. (168881) 
56 "Value of Life"/ (5527) 
57 Quality-Adjusted Life Years/ (8879) 
58 quality adjusted life.tw. (7630) 
59 (qaly$ or qald$ or qale$ or qtime$).tw. (6223) 
60 disability adjusted life.tw. (1665) 
61 daly$.tw. (1575) 
62 Health Status Indicators/ (21912) 
63 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or 
shortform thirty six or short form thirtysix or short form thirty six).tw. (18085) 
64 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw. 
(1100) 
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Database: Medline & Medline in Process 
65 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or 
short form twelve).tw. (3449) 
66 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or 
short form sixteen).tw. (22) 
67 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or 
short form twenty).tw. (350) 
68 (euroqol or euro qol or eq5d or eq 5d).tw. (5281) 
69 (qol or hql or hqol or hrqol).tw. (30826) 
70 (hye or hyes).tw. (54) 
71 health$ year$ equivalent$.tw. (38) 
72 utilit$.tw. (132639) 
73 (hui or hui1 or hui2 or hui3).tw. (1018) 
74 disutili$.tw. (268) 
75 rosser.tw. (72) 
76 quality of wellbeing.tw. (8) 
77 quality of well-being.tw. (354) 
78 qwb.tw. (187) 
79 willingness to pay.tw. (2859) 
80 standard gamble$.tw. (705) 
81 time trade off.tw. (849) 
82 time tradeoff.tw. (217) 
83 tto.tw. (694) 
84 or/54-83 (379066) 
85 53 or 84 (1075611) 
86 27 and 85 (179) 
87 Animals/ not Humans/ (4292287) 
88 86 not 87 (179) 
89 limit 88 to ed=20070101-20161007 (117) 
90 limit 89 to english language (110) 
J.3 Management (statin monotherapy) 
Economics 
Date 
searched Version/files 
No. 
retrieved 
MEDLINE (Ovid) 07/10/16 1946 to September Week 4 
2016 
302 
MEDLINE in Process (Ovid) 07/10/16 October 03, 2016 25 
Embase (Ovid) 07/10/16  642 
EconLit (Ovid) 
 
07/10/16 1886 to September 2016 1 
NHS Economic Evaluation Database 
(NHS EED) (legacy database) 
07/10/16 Issue 2 of 4, April 2015 17 
Health Technology Assessment (HTA 
Database) 
07/10/16 Issue 3 of 4, July 2016 0 
PubMed 07/10/16 n/a 1 
 
Database: Medline & Medline in Process 
Search Strategy: 
-------------------------------------------------------------------------------- 
1 Hyperlipidemia, familial combined/ (732) 
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Database: Medline & Medline in Process 
2 Hyperlipoproteinemia Type II/ (5749) 
3 ((famil* or essential* or monogenic* or hereditar* or inherit* or heterozygous* or homozygous*) 
adj4 (hypercholest* or hyperlip* or cholest* or lipid* or FH)).tw. (13192) 
4 (FH or HoFH or HeFH).tw. (5742) 
5 Cholesterol, LDL/ or Receptors, LDL/ (31538) 
6 (LDL* adj (cholester* or receptor* or lipoprotein*)).tw. (25495) 
7 (low* adj1 densit* adj1 lipoprotein* adj1 (receptor* or cholesterol*)).tw. (23397) 
8 (LDLR or LDL-R or LDL R or LDLC or LDL-C or LDL C).tw. (14573) 
9 Apolipoprotein B-100/ (1816) 
10 (Famili* adj2 apolipoprotein*).tw. (220) 
11 ((Apolipoprotein* or Apo or Apo-) adj1 (B or B-100 or B100 or B 100) adj1 (deficien* or syndrom* 
or defectiv*)).tw. (240) 
12 Hyperlipoproteinemia Type I/ or Apolipoprotein C-II/ (1109) 
13 ((Apolipoprotein* or Apo or Apo-) adj1 (C or C-II or CII or C II or "C-2" or "C2" or "C 2") adj1 
(deficien* or syndrom* or defectiv*)).tw. (21) 
14 ((ApoC2 or ApoCII or ApoB) adj1 (deficien* or syndrom* or defectiv*)).tw. (66) 
15 or/1-14 (75847) 
16 Atorvastatin Calcium/ (5553) 
17 (Atorvastatin or Lipitor).tw. (6083) 
18 Rosuvastatin Calcium/ (1964) 
19 (Rosuvastatin or Crestor).tw. (2229) 
20 Simvastatin/ or Ezetimibe, Simvastatin Drug Combination/ (6756) 
21 (Simvador or Zocor or Inegy).tw. (112) 
22 Pravastatin/ (3235) 
23 (Statin* or Pravastatin).tw. (31429) 
24 or/16-23 (38853) 
25 15 and 24 (9271) 
26 Economics/ (26800) 
27 exp "Costs and Cost Analysis"/ (203136) 
28 Economics, Dental/ (1892) 
29 exp Economics, Hospital/ (21897) 
30 exp Economics, Medical/ (13976) 
31 Economics, Nursing/ (3944) 
32 Economics, Pharmaceutical/ (2654) 
33 Budgets/ (10603) 
34 exp Models, Economic/ (12134) 
35 Markov Chains/ (11636) 
36 Monte Carlo Method/ (23292) 
37 Decision Trees/ (9741) 
38 econom$.tw. (183183) 
39 cba.tw. (9226) 
40 cea.tw. (18056) 
41 cua.tw. (850) 
42 markov$.tw. (13949) 
43 (monte adj carlo).tw. (24231) 
44 (decision adj3 (tree$ or analys$)).tw. (9835) 
45 (cost or costs or costing$ or costly or costed).tw. (359163) 
46 (price$ or pricing$).tw. (26536) 
47 budget$.tw. (19515) 
48 expenditure$.tw. (39995) 
49 (value adj3 (money or monetary)).tw. (1582) 
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Database: Medline & Medline in Process 
50 (pharmacoeconomic$ or (pharmaco adj economic$)).tw. (3055) 
51 or/26-50 (748730) 
52 "Quality of Life"/ (144021) 
53 quality of life.tw. (168881) 
54 "Value of Life"/ (5527) 
55 Quality-Adjusted Life Years/ (8879) 
56 quality adjusted life.tw. (7630) 
57 (qaly$ or qald$ or qale$ or qtime$).tw. (6223) 
58 disability adjusted life.tw. (1665) 
59 daly$.tw. (1575) 
60 Health Status Indicators/ (21912) 
61 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or 
shortform thirty six or short form thirtysix or short form thirty six).tw. (18085) 
62 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw. 
(1100) 
63 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or 
short form twelve).tw. (3449) 
64 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or 
short form sixteen).tw. (22) 
65 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or 
short form twenty).tw. (350) 
66 (euroqol or euro qol or eq5d or eq 5d).tw. (5281) 
67 (qol or hql or hqol or hrqol).tw. (30826) 
68 (hye or hyes).tw. (54) 
69 health$ year$ equivalent$.tw. (38) 
70 utilit$.tw. (132639) 
71 (hui or hui1 or hui2 or hui3).tw. (1018) 
72 disutili$.tw. (268) 
73 rosser.tw. (72) 
74 quality of wellbeing.tw. (8) 
75 quality of well-being.tw. (354) 
76 qwb.tw. (187) 
77 willingness to pay.tw. (2859) 
78 standard gamble$.tw. (705) 
79 time trade off.tw. (849) 
80 time tradeoff.tw. (217) 
81 tto.tw. (694) 
82 or/52-81 (379066) 
83 51 or 82 (1075611) 
84 25 and 83 (596) 
85 Animals/ not Humans/ (4292287) 
86 84 not 85 (586) 
87 limit 86 to ed=20070101-20161007 (327) 
88 limit 87 to english language (302) 
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Appendix K: Economic review flowchart 
K.1 Case finding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Search retrieved 1,012 
articles  
990 excluded based on 
title/abstract 
22 full-text articles 
examined 
18 excluded based on 
full-text article 
3 included studies 
(from 4 articles) 
+ 
Unpublished study 
= 
4 included studies 
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K.2 Diagnosis 
 
 
 
 
 
 
 
 
 
 
K.3 Management (statin monotherapy) 
 
 
 
 
 
 
Search retrieved 153 
articles  
153 excluded based on 
title/abstract 
Search retrieved 665 
articles  
662 excluded based on 
title/abstract 
3 full-text articles 
examined 
3 excluded based on 
full-text article 
0 included studies  
0 included studies  
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Appendix L: Economic excluded studies 
The table below contains the full articles that were reviewed and excluded and the reasons 
for their exclusion. 
L.1 Case finding 
Table 33: Excluded economic studies (case finding) 
Reference Reason for exclusion 
Ademi Z, Watts G F, Juniper A, and Liew D. (2013). A systematic 
review of economic evaluations of the detection and treatment of 
familial hypercholesterolemia. International Journal of Cardiology, 
167, pp.2391-6. 
Systematic review, checked 
against included and 
excluded studies 
Antonanzas F, Rodriguez-Ibeas R, Hutter M F, Lorente R, Juarez C, 
and Pinillos M. (2012). Genetic testing in the European Union: does 
economic evaluation matter?. European Journal of Health 
Economics, 13, pp.651-61. 
Systematic review, checked 
against included and 
excluded studies 
Hadfield S G, and Humphries S E. ( ). Cascade testing is tried and 
tested and cost effective [1]. British Medical Journal, 335, pp.. 
Narrative review 
Fox K F. (1892). Familial hypercholesterolaemia -Screening is 
effective, but is it cost effective?. European Heart Journal, 23, 
pp.1892-1893. 
Narrative review 
Hadfield G S, and Humphries S E. (2007). Familial 
hypercholesterolaemia: Cascade testing is tried and tested and cost 
effective. BMJ, 335, pp.683. 
Narrative review 
Parrella A, Mundy L, and Hiller J E. (2007). Genetic screening for 
Familial Hypercholesterolaemia (Structured abstract). Health 
Technology Assessment Database, , pp.. 
Narrative review 
Pears R, Griffin M, Futema M, and Humphries S E. (2015). Improving 
the cost-effectiveness equation of cascade testing for familial 
hypercholesterolaemia. Current Opinion in Lipidology, 26, pp.162-8. 
Narrative review 
Hadfield S G, Horara S, Starr B J, Yazdgerdi S, Marks D, Bhatnagar 
D, Cramb R, Egan S, Everdell R, Ferns G, Jones A, Marenah C B, 
Marples J, Prinsloo P, Sneyd A, Stewart M F, Sandle L, Wang T, 
Watson M S, Humphries S E, Steering Group for the Department of 
Health Familial Hypercholest, and Project . (2009). Family tracing to 
identify patients with familial hypercholesterolaemia: the second audit 
of the Department of Health Familial Hypercholesterolaemia Cascade 
Testing Project. Annals of Clinical Biochemistry, 46, pp.24-32. 
Cost analysis only, 
selectively excluded 
because other included 
studies included health 
benefits 
Pears R, Griffin M, Watson M, Wheeler R, Hilder D, Meeson B, 
Bacon S, and Byrne CD. (2014). The reduced cost of providing a 
nationally recognised service for familial hypercholesterolaemia. 
BMJ, 1, pp.e000015. 
Cost analysis only, 
selectively excluded 
because other included 
studies included health 
benefits 
Atienza G. (2006). Familial hypercholesterolemia: evaluation of 
genetic screening by DNA microarrays (Structured abstract). Health 
Technology Assessment Database, , pp.. 
Could not obtain 
Anonymous . ( ). Family tracing most cost-effective way of detecting 
high cholesterol. Pharmaceutical Journal, 268, pp.. 
Could not obtain 
Oliva J, Lopez-Bastida J, Moreno S G, Mata P, and Alonso R. (2009). 
Cost-effectiveness analysis of a genetic screening program in the 
close relatives of Spanish patients with familial hypercholesterolemia 
(Structured abstract). Revista Espanola de Cardiologia, 62, pp.57-65. 
Could not obtain 
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Reference Reason for exclusion 
Marang-van de Mheen, P J, Asbroek A H, Bonneux L, Bonsel G J, 
and Klazinga N S. (2002). Cost-effectiveness of a family and DNA 
based screening programme on familial hypercholesterolaemia in 
The Netherlands (Structured abstract). European Heart Journal, 23, 
pp.1922-1930. 
Classified as not applicable 
by the quality assessment 
checklist for economic 
studies 
Marks D, Wonderling D, Thorogood M, Lambert H, Humphries S E, 
and Neil H A. (2000). Screening for hypercholesterolaemia versus 
case finding for familial hypercholesterolaemia: a systematic review 
and cost-effectiveness analysis. Health Technology Assessment 
(Winchester, and England), 4, pp.1-123. 
This study is over 15 years 
old and the methods used 
to diagnose FH, treat FH 
and conduct economic 
anslysis have changed 
Marks D, Wonderling D, Thorogood M, Lambert H, Humphries S E, 
and Neil H A. (2002). Cost effectiveness analysis of different 
approaches of screening for familial hypercholesterolaemia. BMJ, 
324, pp.1303. 
(journal article version of 
Marks et al 2000) This 
study is over 15 years old 
and the methods used to 
diagnose FH, treat FH and 
conduct economic anslysis 
have changed 
Marks D, Thorogood M, Neil H A, Wonderling D, and Humphries S E. 
(2003). Comparing costs and benefits over a 10 year period of 
strategies for familial hypercholesterolaemia screening. Journal of 
Public Health Medicine, 25, pp.47-52. 
Population screening 
Sharma P, Boyers D, Boachie C, Stewart F, Miedzybrodzka Z, 
Simpson W, Kilonzo M, McNamee P, and Mowatt G. (2012). 
Elucigene FH20 and LIPOchip for the diagnosis of familial 
hypercholesterolaemia: a systematic review and economic 
evaluation. Health Technology Assessment (Winchester, and 
England), 16, pp.1-266. 
These technologies are no 
longer commercially 
available following this HTA 
conducted for NICE 
diagnostics guidance 2 
Wonderling D, Umans-Eckenhausen M A, Marks D, Defesche J C, 
Kastelein J J, and Thorogood M. (2004). Cost-effectiveness analysis 
of the genetic screening program for familial hypercholesterolemia in 
The Netherlands. Seminars in Vascular Medicine, 4, pp.97-104. 
Classified as not applicable 
by the quality assessment 
checklist for economic 
studies 
L.2 Diagnosis 
Not applicable 
L.3 Management (statin monotherapy) 
Table 34: Excluded economic studies (management (statin monotherapy)) 
Reference Reason for exclusion 
Watts GF, Juniper A, van Bockxmeer F, Ademi Z, Liew D, O’Leary P. 
(2012). Familial hypercholesterolaemia: a review with emphasis on 
evidence for treatment, new models of care and health economic 
evaluations. International Journal of Evidence-Based Healthcare, 10: 
211-221 
Narrative review only 
Nherera L, Calvert NW, DeMott K, Humphries S, Neil HAW, Minhas 
R, Thorogood M. (2010). Cost-effectiveness analysis of the use of a 
high-intensity statin compared to a low-intensity statin in the 
management of patients with familial hypercholesterolaemia 
Inappropriate comparator, 
review protocol specifies 
placebo only 
Ademi Z, Watts GF, Juniper A, Liew D. (2013). A systematic review 
of economic evaluations of the detection and treatment of familial 
hypercholesterolaemia. International Journal of Cardiology, 167: 
2391-2396 
Systematic review, included 
studies checked against 
present included/excluded 
studies. 
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Appendix M: Full economic evidence tables 
These are the full evidence tables for all included economic studies. 
Table 35: Full economic evidence tables 
Bibliographic 
reference 
Kerr et al M, Pears R, Miedzybrodzka Z, Haralambos K, Cather M, Watson M, Humphries S. (2017). Cost effectiveness of cascade 
testing for familial hypercholesterolaemia, based on data from FH services in the UK.  
Overview  
Interventions Genetic cascade testing from index cases with a monogenic mutation 
Comparators No cascade testing 
Population People with monogenic FH 
Type of Analysis Cost-utility analysis 
Structure Decision tree and Markov model 
Cycle length 1 year 
Time horizon Lifetime 
Perspective NHS and PSS 
Country UK 
Currency unit £ 
Cost year 2015 
Discounting 3.5% 
Other comments This is an unpublished analysis provided by one of the topic experts. Methods and results considered by the 
committee may differ from those used in the final published version. 
 
Results  
Strategy Cost Effect Incremental cost Incremental effect ICER 
No cascade testing Incremental 
results only 
reported 
 - - - 
Genetic cascade testing   £2,781 0.48 £5,981/QALY 
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Bibliographic 
reference 
Kerr et al M, Pears R, Miedzybrodzka Z, Haralambos K, Cather M, Watson M, Humphries S. (2017). Cost effectiveness of cascade 
testing for familial hypercholesterolaemia, based on data from FH services in the UK.  
Data sources  
Base-line data  Risk of cardiovascular events from QRISK2 as per lipid modification guideline adjusted for FH-specific 
uplift from Simon Broome register 
Effectiveness data  Cholesterol Treatment Trialists Collaborators study 
Cost data  UK genetic testing service for genetic testing 
 Resource use from Welsh, Scottish and Wessex services 
 Reference costs from Personal and Social Services Research Unit 
Utility data  As per lipid modification guideline CG181 
 
Uncertainty  
One-way sensitivity 
analysis 
 Increased LDL-C reduction from 37% to 50%: ICER range £3,527 to £8,398 according to age band 
 Increased number of relatives approached to 6: ICER range from £2,227 to £3,785 according to age band 
 Reduce compliance to 70%: ICER range from £5,877 to £13,551 according to age band 
 Reduce cost of rosuvastatin and ezetimibe: ICER range £3,174 to £9,089 
Probabilistic 
sensitivity analysis 
Not conducted 
 
Applicability Partially Applicable 
 
 Case identification strategies not included 
Limitations Minor limitations 
 
 No probabilistic sensitivity analysis 
 Unclear how administration and staff costs supporting genetic testing were calculated 
 Unclear how gender is accounted for in the model (the lipid modification Markov model calculates cost effective separately for males 
and females) 
 
Conflicts Funded by Heart UK 
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Bibliographic 
reference 
Ademi Z, Watts G F, Pang J, Sijbrands E J, van Bockxmeer , F M, O'Leary P, Geelhoed E, and Liew D. (2014). Cascade screening 
based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. 
Journal of Clinical Lipidology, 8, pp.390-400. 
Overview  
Interventions Nurse-led cascade screening for FH using primarily genetic testing supplemented with the measurement of 
LDL-C, followed by treatment with statins 
Comparators No cascade screening 
Population Relatives of index cases (first and second degree relatives), start age 42 years of age 
Type of Analysis Cost-utility analysis 
Structure Decision tree and Markov model 
Cycle length 1 year 
Time horizon 10 years 
Perspective Australian public health care system 
Country Australia 
Currency unit Australian dollars 
Cost year 2013 
Discounting 5% costs and benefits, 3% in sensitivity analysis 
Other comments 3 health states for Markov model 
 Alive without CHD 
 Alive with CHD 
 Alive Dead 
Assumed relatives tested and found to be negative for FH received no further follow up or change in 
management of health so that downstream health and cost outcomes were identical between screening and 
no screening groups 
Assumed annual risk of death from non-CHD causes for general population was the same as that for FH 
patients without CHD 
Assumed all people identified as having FH would be started on atorvastatin at a weighted-average dose of 
60mg daily 
Compliance with statin treatment assumed to be 100% 
Software used: Excel with @Risk for probabilistic analysis 
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Bibliographic 
reference 
Ademi Z, Watts G F, Pang J, Sijbrands E J, van Bockxmeer , F M, O'Leary P, Geelhoed E, and Liew D. (2014). Cascade screening 
based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. 
Journal of Clinical Lipidology, 8, pp.390-400. 
Results  
Strategy Cost Effect Incremental cost Incremental effect ICER 
No cascade screening AUD$7,048 7.52 QALYs - - - 
Cascade screening AUD$8,084 7.81 QALYs AUD$1,036 0.29 AUD$3,565/QALY 
($2,004 to $5,228) 
or 
£1,749.25 (2016) 
 
Data sources  
Base-line data  Demographic information and clinical characteristics of 81 index cases and 175 adult relatives from the 
author’s own centre 
 Prevalence of FH assumed to be 54.3% based on DNA testing alone 
 11.9% per person per year probability of fatal and non-fatal CHD from Dutch cohort, 34.2% of this fatal, 
from published Western Australia study 
 Death from non-CHD causes from 2007 Australian life tables 
 Proportion of people newly identified with FH already taking cholesterol-lowering therapy 46.3% based on 
author’s own service (same for no cascade screen comparator) 
Effectiveness data  DNA testing 100% sensitivity and 100% specificity based on published studies on the author’s testing 
service 
 Relative risk of treatment with atorvastatin taken from Dutch cohort (0.24, 95% CI 0.18 to 0.30) 
Cost data  Cost of testing AUD$1,005 per relative based on author’s own centre 
 Cost of confirmation DNA test for index case, AUD$506 based on author’s own centre 
 Cost of all post-screening test for those identified with FH AUD$128 and annual clinic visits AUD$216 
from Australian Medical Benefit Schedule 
 Cost of atorvastatin based on Australian Pharmaceutical Benefits Scheme and assumed 50% on 40mg 
and 50% on 80mg resulting in an average cost of AUD$759 annually 
 Cost of incident CHD (1 event only) based on Australian Refined Diagnosis Related Groups 
o Nonfatal MI AUD$8,606 
o Fatal MI AUD$6,590 
 Ongoing cost of CHD AUD$4,879 based on published study and indexed 
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Bibliographic 
reference 
Ademi Z, Watts G F, Pang J, Sijbrands E J, van Bockxmeer , F M, O'Leary P, Geelhoed E, and Liew D. (2014). Cascade screening 
based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. 
Journal of Clinical Lipidology, 8, pp.390-400. 
Utility data  From published studies: 1 for alive without CHD; 0.9 (95% CI 0.81 to 1) for alive with CHD 
 
Uncertainty  
One-way sensitivity 
analysis 
ICERs most sensitive to annual risk of CHD and relative benefit of statins 
 RR prevention nonfatal myocardial infarction 0.85: AUD$12,626/QALY 
 RR prevention cardiovascular death: 0.87: AUD$16,880/QALY 
All one-way sensitivity analysis remains below AUD$17,000/QALY 
Additional analysis based on age-and gender-adjusted LDL-C threshold for diagnosis of close relatives with 
FH for cascade screening was observed as a cost-effective strategy compared with no screening with an 
ICER of AUD$3,287/QALY. The yield of FH relatives detected from index cases was comparable to genetic 
testing (1.09 to 1.17) with incrementally less costs because the cost of the DNA test can be removed. 
Probabilistic 
sensitivity analysis 
99% probability cascade screening was below AUD$50,000 per QALY threshold 
 
Applicability Partially Applicable 
 
 Based on the Australian health care system – although the general model of care is probably similar to cascade testing services offered 
in the UK, costs may not be representative of those incurred by the NHS. 
 The analysis focussed on the cost effectiveness of cascade screening only. The current update is also interested in the identification of 
index cases by searching databases. 
 Side effects of statin treatment not included. There may be additional events other than coronary heart disease that can be prevented by 
diagnosing FH and offering lipid modification. 
 5% discount rate used in base case, although 3% was used in a sensitivity analysis (3.5% is NICE’s reference case) 
 QALYs are used to represent health outcomes but it is unknown whether they were based on the EQ-5D 
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Bibliographic 
reference 
Ademi Z, Watts G F, Pang J, Sijbrands E J, van Bockxmeer , F M, O'Leary P, Geelhoed E, and Liew D. (2014). Cascade screening 
based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. 
Journal of Clinical Lipidology, 8, pp.390-400. 
Limitations Potentially serious limitations 
 
 Only 3 health states were used in the Markov model to represent patients with or without coronary heart disease. This may be an 
oversimplification of the events that could be avoided by diagnosing FH and providing lipid-modifying treatment. 
 Triangular distributions used for relative risk of fatal and nonfatal CHD events. Lognormal is preferred for this type of parameter. The 
choice to use a triangular distribution may have made the intervention more cost effective than it otherwise would have been to the 
extent that a lognormal distribution would have allowed less effective relative risks greater than the upper range of the triangular 
distribution, 0.3. 
 Uniform distribution used for costs. Gamma or lognormal distributions are preferred for this type of parameter. It is difficult to predict 
whether this would have favoured the intervention or comparator. 
 Age-dependent population norms for utilities not used 
 The additional analysis of LDL-C thresholds was not included as a discrete intervention in incremental analysis with the main results. 
Assuming this is a mutually exclusive option and is slightly less effective with less costs than the DNA testing strategy, the cost 
effectiveness of the DNA testing strategy should be calculated by comparing it against the LDL-C threshold category, not no cascade 
screening. Insufficient information was provided for the update analyst to conduct incremental analysis. 
 The time horizon is 10 years rather than lifetime specified in the reference case. 
 Diagnostic yield of testing programme based on author’s own centre experience of 81 index cases without cross-checking with 
published literature. 
 Scant details are provided on the resource use calculations adopted to calculate the cost of cascade screening. 
 
Conflicts Author’s FH programme funded by Australia Better Health Initiative and the Department of Health of Western Australia 
 
ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life year; CHD: coronary heart disease; FH: familial hypercholesterolaemia 
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Bibliographic 
reference 
Chen C X, and Hay J W. (2015). Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous 
familial hypercholesterolemia in the United States. International Journal of Cardiology, 181, pp.417-24. 
Overview  
Interventions  Genetic cascade screening of at-risk relatives 
 Enhanced lipid cascade screening and statin adherence programme 
Comparators Lipid cascade screening  
Population Caucasian male adults with a family history of FH and high-risk baseline cholesterol levels of 46 mg/dL 
HDL-C, 224 mg/dL LDL-C and 305 total cholesterol 
Type of Analysis Cost-utility analysis 
Structure Decision tree and Markov model 
Cycle length 1 year 
Time horizon Lifetime 
Perspective US societal 
Country United States 
Currency unit US$ 
Cost year 2013 
Discounting 3% 
Other comments Software: Excel 
Assume that people with a negative genetic test still receive statin therapy if they have high LDL-C. 
3 health states in Markov: 
 Pre-CVD 
 CVD event/stroke 
 Death 
Treatment based on 10mg atorvastatin 
Adherence decreases with time across all arms except for the intervention arm enhanced lipid cascade 
screening and statin adherence. 
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Chen C X, and Hay J W. (2015). Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous 
familial hypercholesterolemia in the United States. International Journal of Cardiology, 181, pp.417-24. 
Results  
Strategy Cost Effect Incremental cost Incremental effect ICER 
Lipid cascade screening $10,396 18.28 - - - 
Genetic cascade screening $15,594 18.29 $5,198 0.01 Extendedly 
dominated 
Lipid cascade screening and 
adherence programme 
$16,385 18.77 $5,989 0.49 US$12,223/QALY 
(£8,845 (2016)) 
 
If the lipid cascade screening and adherence programme is excluded from this analysis because it is deemed to be irrelevant to the 
update, genetic cascade screening had an ICER of US$519,813 per QALY, not cost effective compared with lipid cascade screening. 
 
Data sources  
Base-line data Baseline progression from Simon Broome Register 
Transition probabilities of CVD and CVD death from Framingham heart study 
Hazard ratio of death after CVD event or stroke: 5 
Baseline adherence (year 1-9 of therapy): 56% 
Baseline adherence (year 10 onwards): 52% 
Effectiveness data From peer-reviewed literature 
Sensitivity of DNA testing 78.5% 
Increase in adherence with adherence programme: 38% 
Decrease in total cholesterol due to statin therapy: 28% 
Decrease in LDL cholesterol due to statin therapy: 38% 
Cost data From peer-reviewed literature 
First year screen costs: 
 Lipid screening US$334 
 Lipid screen and adherence programme: US$334 
 Genetic screening US$5528 
Cholesterol testing for FH cases every 2 years 
 Lipid screening US$233 
 Lipid screen and adherence programme: US$233 
 Genetic screening US$233 
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Chen C X, and Hay J W. (2015). Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous 
familial hypercholesterolemia in the United States. International Journal of Cardiology, 181, pp.417-24. 
Annual statin treatment costs 
 Lipid screening US$106 
 Lipid screen and adherence programme: US$352 
 Genetic screening US$106 
Utility data From peer-reviewed literature 
Disutility in the pre-CVD state to reflect the act of taking a daily statin prescription with mild side effects 
0.004 
US population norms from the literature to adjust age-based utility 
CVD event/stroke state: 0.68 
 
Uncertainty  
One-way sensitivity 
analysis 
Only FH gene sequencing and DNA testing costs had a large effect on the ICER results between genetic 
cascade screening and lipid cascade screening, although the ICER remained above $150,000 per QALY. 
All other parameters only produced changes in this ICER less than 1%. 
Threshold analysis found that genetic cascade screening became cost effective at a threshold of $150,000 
per QALY when the first year screening cost was less than $1,830 per person. 
Probabilistic 
sensitivity analysis 
99% probability that lipid screening plus adherence programme is cost effective compared with lipid 
cascade screening 
55% probability that genetic cascade screening is cost effective compared with lipid cascade screening at a 
threshold of $150,000/QALY 
 
 
Applicability Partially Applicable 
 
 The modelled cohort is based on males only 
 It is likely the costs of the US health care system do not represent those incurred by the NHS. The first year screening cost of US$5,528 
far exceeds what would be incurred by the NHS. A sensitivity analysis found that genetic cascade screening was cost effective 
compared with lipid cascade screening for a first year screening cost of $1,830 and it is likely that the cost in the UK is less than this. 
 The 10mg dose of atorvastatin is less than the high potency treatment recommended by UK guidelines. 
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Chen C X, and Hay J W. (2015). Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous 
familial hypercholesterolemia in the United States. International Journal of Cardiology, 181, pp.417-24. 
Limitations Potentially serious limitations 
 
 The Markov model based on 3 health states may oversimplify the health states relevant to the risks that lipid-modification hopes to 
address 
 Inappropriate distributions used. Normal distributions used for transition probabilities and utilities. Triangle distributions used for hazard 
ratio of death after CVD event and disutility from statin medication in the pre-CVD state. 
 
Conflicts The authors report no relationship that could be construed as a conflict of interest. 
 
ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life year; CVD: cardiovascular disease; FH: familial hypercholesterolaemia 
 
Bibliographic 
reference 
National Collaborating Centre for Primary Care. (2008). Familial Hypercholesterolaemia, appendix E, health economic modelling. 
, NICE Clinical Guideline 71, pp.. 
Nherera L, Marks D, Minhas R, Thorogood M, and Humphries S E. (2011). Probabilistic cost-effectiveness analysis of cascade 
screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart, 97, pp.1175-1181. 
Overview  
Interventions 1. Cholesterol method – relatives diagnosed based on elevated LDL-C levels 
2. DNA method – only people with an identified FH-causing mutation were included for cascade testing, with 
the relatives tested for the family mutation, and secondary cascading for those with the family mutation 
3. DNA+DFH method – As per 2. DNA method, and in addition, in the relatives of definite familial 
hypercholesterolaemia index cases where no mutation can be found, cascade testing was undertaken 
using measures of LDL-C levels to identify affected relatives for treatments and for secondary cascading 
4. DNA+DFH+PFH method – As per 2. DNA method, and in addition, cascade testing is undertaken in both 
definite familial hypercholesterolaemia and probable familial hypercholesterolaemia index cases using 
LCL-C measures. 
Population Relatives of people with FH 
Type of Analysis Cost-utility analysis 
Structure Decision tree and Markov model 
Cycle length 1 year 
Time horizon Lifetime 
Perspective NHS 
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National Collaborating Centre for Primary Care. (2008). Familial Hypercholesterolaemia, appendix E, health economic modelling. 
, NICE Clinical Guideline 71, pp.. 
Nherera L, Marks D, Minhas R, Thorogood M, and Humphries S E. (2011). Probabilistic cost-effectiveness analysis of cascade 
screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart, 97, pp.1175-1181. 
Country United Kingdom 
Currency unit £ 
Cost year 2007 
Discounting 3.5% 
Other comments All index cases with a positive diagnosis of FH were offered high intensity statin treatment. 
In all strategies, all relatives identified with elevated LDL-C were offered lipid-lowering therapies (high 
intensity statins for mutation carriers and low intensity statins if they do not carry the family mutation).  
Assumed uptake of cascade testing 65% for first degree relatives and 60% for second degree relatives 
Assumed every index case had 5 first degree relatives, each of these five has two first degree relatives, and 
each of these has two first degree relatives. 
8 states for Markov:  
 Well 
 Unstable angina 
 Myocardial infarction 
 PAD stroke 
 Heart failure 
 Revascularisation 
 Cardiovascular death 
 Death from other causes 
 
Results Deterministic results reported by NCCPC 2008 
Strategy Cost Effect Incremental cost Incremental effect ICER (£/QALY) 
Cholesterol £38,921 32.87 - - - 
DNA £44,816 30.63 - - Dominated 
DNA+DFH £46,479 31.91 - - Dominated 
DNA+DFH+PFH £51,924 37.73 £13,003 4.86 £2,676 
 
Probabilistic results reported by Nherera et al. 2011 
Strategy Cost Effect Incremental cost Incremental effect ICER (£/QALY) 
Cholesterol £44,576 10.89 - - - 
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Nherera L, Marks D, Minhas R, Thorogood M, and Humphries S E. (2011). Probabilistic cost-effectiveness analysis of cascade 
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DNA £50,918 24.12 £6,341 13.23 £479 
DNA+DFH £52,670 24.28 - - Extendedly 
dominated 
DNA+DFH+PFH £54,799 25.18 £3,881 1.06 £3,666 
 
Data sources  
Base-line data Relative risk of CVD due to FH from Simon Broome database 
For relatives who have elevated LDL-C but no FH their risk was assumed to be 20% more than the general 
population. 
Based on UK FH audit 30% definite FH and 60% probable FH 
Effectiveness data Cholesterol method 
 assumed that 90% of the definite FH and 35% of the probable FH had true FH; and 10% definite FH and 
65% probable FH were false positive. For relatives, this was combined with published data on 
identification rates, true positive 32%, False positive 8%, true negative 42%, false negative 18% 
DNA method 
 Mutation detection rate in definite FH 80%, 50% in relatives 
 True positives 90% of definite FH; false negatives 7% of probable FH 
DNA+DFH method 
Additional testing using LDL-C diagnostic cutoffs in all 60/1000 no-mutation definite FH people of whom 
50% were true positive and 50% false positive. 
DNA+DFH+PFH method 
Additional LDL-C testing on 420/1000 non-mutation PFH index cases of whom 7% are true positive and 
93% false positive 
Cost data Treatment cost from Prescription Pricing Division 
Staff cost from PSSRU unit costs 
Time taken from FH audit report 
Cost of CVD events from TA94 
Utility data From literature 
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Nherera L, Marks D, Minhas R, Thorogood M, and Humphries S E. (2011). Probabilistic cost-effectiveness analysis of cascade 
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Uncertainty  
One-way sensitivity 
analysis 
Increase starting age to 65 (from 50) for index cases and 45 (from 30) for relatives: ICER reduced to 
£2,000/QALY 
Treatment effect using upper and lower 95% confidence interval of IDEAL and TNT trials: ICER stays below 
£3,000/QALY 
Treatment cost increased by £100 per year: ICER increases to £2,811/QALY 
Doubling and halving time and cost of staff time for cascade testing: ICERs stay around £3,000/QALY for 
DNA+DFH+PFH vs. cholesterol method 
Change in relatives per index case does not change ICER much 
Increased uptake rate to 85% for index cases (from 65%) and 80% for relatives (from 60%) and ICER fell. 
However, a decrease in uptake rate was not tested 
Reducing price of statin treatment reduced ICER to £2,509/QALY 
 
Probabilistic 
sensitivity analysis 
Conducted in Nherera et al. 2011, found that DNA+DFH+PFH has a 100% probability of being cost effective 
compared with the cholesterol method. 
 
Applicability Partially applicable 
 
Limitations Potentially serious limitations 
 
 The diagnostic definitions change according to strategy. For example, a true positive can have elevated LDL-C levels or be a carrier of 
the family mutation. That is, a person with a family mutation would be a true positive in a DNA strategy but not in the cholesterol strategy 
if they do not have raised cholesterol. Therefore, the results are not necessarily comparable between strategies. 
  
Conflicts As per declarations of interest in full guideline 
 
ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life year; DNA: Deoxyribonucleic acid; FH: familial hypercholesterolaemia; DFH: definite familial 
hypercholesterolaemia as defined by the Simon Broome criteria; PFH: possible familial hypercholesterolaemia as defined by the Simon Broome criteria 
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Appendix N: Quality assessment 
checklists for economic studies 
These are the quality assessment checklists for included economic studies. 
Table 36: Quality assessment checklists for economic studies 
 
Section 1: Applicability (relevance to specific 
review questions and the NICE reference case 
as described in section 7.5) 
This checklist should be used first to filter out 
irrelevant studies. 
Yes/par
tly/no/u
nclear/
NA 
Comments 
1.1 Is the study population appropriate for the 
review question? 
Yes  
1.2 Are the interventions appropriate for the 
review question? 
Partly No case identification strategies 
1.3 Is the system in which the study was 
conducted sufficiently similar to the current UK 
context? 
Yes  
1.4 Are the perspectives clearly stated and are 
they appropriate for the review question? 
Yes  
1.5 Are all direct effects on individuals included, 
and are all other effects included where they are 
material? 
Yes  
1.6 Are all future costs and outcomes 
discounted appropriately? 
Yes  
1.7 Is QALY used as an outcome, and was it 
derived using NICE’s preferred methods? If not, 
describe rationale and outcomes used in line 
with analytical perspectives taken (item 1.4 
above). 
Yes  
1.8 Are costs and outcomes from other sectors 
fully and appropriately measured and valued? 
n/a  
1.9 Overall judgement: Partially applicable 
There is no need to use section 2 of the checklist if the study is considered ‘not applicable’. 
Other comments: 
 
 
Section 2: Study limitations (the level of 
methodological quality) 
This checklist should be used once it has been 
decided that the study is sufficiently applicable 
to the context of the guideline 
Yes/par
tly/no/u
nclear/
NA 
Comments 
2.1 Does the model structure adequately reflect 
the nature of the topic under evaluation? 
Yes  
2.2 Is the time horizon sufficiently long to reflect 
all important differences in costs and outcomes? 
Yes  
2.3 Are all important and relevant outcomes 
included? 
Yes  
2.4 Are the estimates of baseline outcomes from 
the best available source? 
Partly The relative risk of non-fatal 
cardiovascular events for the FH 
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population are based on the 
increased risk of mortality reported 
by the Simon Broome register. 
2.5 Are the estimates of relative intervention 
effects from the best available source? 
Yes  
2.6 Are all important and relevant costs 
included? 
Yes  
2.7 Are the estimates of resource use from the 
best available source? 
Yes Unclear how administration and staff 
costs around genetic testing were 
calculated. 
2.8 Are the unit costs of resources from the best 
available source? 
Yes  
2.9 Is an appropriate incremental analysis 
presented or can it be calculated from the data? 
Yes  
2.10 Are all important parameters whose values 
are uncertain subjected to appropriate sensitivity 
analysis? 
Yes  
2.11 Is there any potential conflict of interest? Yes Funded by patient advocacy group 
2.12 Overall assessment: Minor limitations 
 
Other comments: 
 
No probabilistic sensitivity analysis 
Unclear how gender was accounted for considering the lipid modification model calculates results 
separately for males and females. 
 
 
Ademi Z, Watts G F, Pang J, Sijbrands E J, van Bockxmeer , F M, O'Leary P, Geelhoed E, and 
Liew D. (2014). Cascade screening based on genetic testing is cost-effective: evidence for 
the implementation of models of care for familial hypercholesterolemia. Journal of Clinical 
Lipidology, 8, pp.390-400. 
Section 1: Applicability (relevance to specific 
review questions and the NICE reference case 
as described in section 7.5) 
This checklist should be used first to filter out 
irrelevant studies. 
Yes/par
tly/no/u
nclear/
NA 
Comments 
1.1 Is the study population appropriate for the 
review question? 
Yes  
1.2 Are the interventions appropriate for the 
review question? 
Partly Apart from cascade testing, the 
update is also interested in index 
case identification through database 
searching 
1.3 Is the system in which the study was 
conducted sufficiently similar to the current UK 
context? 
Partly The study is based on the Australian 
health care system. The model of 
care sounded generally similar to 
what occurs in the UK but some of 
the costs may not represent those 
incurred by the NHS. 
1.4 Are the perspectives clearly stated and are 
they appropriate for the review question? 
Yes  
1.5 Are all direct effects on individuals included, 
and are all other effects included where they are 
material? 
Partly The side effects of statins are not 
included. There may additional 
events other than coronary heart 
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Liew D. (2014). Cascade screening based on genetic testing is cost-effective: evidence for 
the implementation of models of care for familial hypercholesterolemia. Journal of Clinical 
Lipidology, 8, pp.390-400. 
disease that are prevented by 
identifying FH. 
1.6 Are all future costs and outcomes 
discounted appropriately? 
Partly Costs and health benefits were 
discounted at 5% in the base case 
and 3% in sensitivity analysis 
1.7 Is QALY used as an outcome, and was it 
derived using NICE’s preferred methods? If not, 
describe rationale and outcomes used in line 
with analytical perspectives taken (item 1.4 
above). 
Partly QALYs are used to represent health 
outcomes but it is unknown whether 
they were based on the EQ-5D 
1.8 Are costs and outcomes from other sectors 
fully and appropriately measured and valued? 
n/a No other sectors are relevant 
1.9 Overall judgement: Partially applicable 
There is no need to use section 2 of the checklist if the study is considered ‘not applicable’. 
Other comments: 
 
 
Section 2: Study limitations (the level of 
methodological quality) 
This checklist should be used once it has been 
decided that the study is sufficiently applicable 
to the context of the guideline 
Yes/par
tly/no/u
nclear/
NA 
Comments 
2.1 Does the model structure adequately reflect 
the nature of the topic under evaluation? 
Partly Only 3 health states were used in 
the Markov model to represent 
patients with or without coronary 
heart disease. This may be an 
oversimplification of the events that 
could be avoided by diagnosing FH 
and providing lipid-modifying 
treatment. 
2.2 Is the time horizon sufficiently long to reflect 
all important differences in costs and outcomes? 
Partly Although 10 years is may be a 
sufficient timeframe to capture all the 
important cost and health 
consequences, a lifetime time 
horizon would be consistent with the 
NICE reference case and allow the 
benefits to extension in life to be fully 
captured. 
2.3 Are all important and relevant outcomes 
included? 
Partly Although the prevention of coronary 
heart disease is an important goal of 
case identification and lipid 
modification, other adverse events 
may also be prevented such as 
stroke. 
2.4 Are the estimates of baseline outcomes from 
the best available source? 
Yes The Dutch FH cohort is large and 
probably a good representation of 
the natural progression of the 
disease in a European population. 
2.5 Are the estimates of relative intervention 
effects from the best available source? 
 Effectiveness of cascade screening 
was based on the author’s own 
experiences in their centre. A review 
of the published literature would 
have been useful to at least 
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the implementation of models of care for familial hypercholesterolemia. Journal of Clinical 
Lipidology, 8, pp.390-400. 
establish if these estimates are 
consistent with findings in other 
centres. 
2.6 Are all important and relevant costs 
included? 
Unclear Scant details are provided on the 
resource use calculations adopted to 
calculate the cost of cascade 
screening. 
2.7 Are the estimates of resource use from the 
best available source? 
Unclear Not provided 
2.8 Are the unit costs of resources from the best 
available source? 
Unclear Not provided 
2.9 Is an appropriate incremental analysis 
presented or can it be calculated from the data? 
No An alternative strategy based on 
LDL-C thresholds rather than DNA 
testing was carried out as a 
sensitivity analysis rather than a 
discrete intervention. If this is a 
mutually exclusive valid option to 
DNA testing, this should have been 
included in incremental analysis with 
the cost effectiveness of the DNA 
cascade testing strategy compared 
against the LDL-C strategy rather 
than no cascade testing. This may 
have a material impact on the 
conclusions of the study. Insufficient 
detail was provided for this to be 
carried out by the update analyst. 
2.10 Are all important parameters whose values 
are uncertain subjected to appropriate sensitivity 
analysis? 
Partly Probabilistic sensitivity analysis was 
carried out but inappropriate 
distributions were used to represent 
uncertainty around important 
parameters. 
2.11 Is there any potential conflict of interest? Yes The authors have an interest in 
demonstrating the services they 
provide are cost effective. 
2.12 Overall assessment: Potentially serious limitations 
 
Other comments: 
 
 Triangular distributions used for relative risk of fatal and nonfatal CHD events. Lognormal is 
preferred for this type of parameter. The choice to use a triangular distribution may have made 
the intervention more cost effective than it otherwise would have been to the extent that a 
lognormal distribution would have allowed less effective relative risks greater than the upper 
range of the triangular distribution, 0.3. 
 Uniform distribution used for costs. Gamma or lognormal distributions are preferred for this type 
of parameter. It is difficult to predict whether this would have favoured the intervention or 
comparator. 
 Age-dependent population norms for utilities not used 
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Chen C X, and Hay J W. (2015). Cost-effectiveness analysis of alternative screening and 
treatment strategies for heterozygous familial hypercholesterolemia in the United States. 
International Journal of Cardiology, 181, pp.417-24. 
Section 1: Applicability (relevance to specific 
review questions and the NICE reference case 
as described in section 7.5) 
This checklist should be used first to filter out 
irrelevant studies. 
Yes/partl
y/no/uncl
ear/NA 
Comments 
1.1 Is the study population appropriate for the 
review question? 
Partly Common population mutations in 
the US may vary from those 
identified in the European 
population, but evidence from 
European populations has been 
used in the analysis 
Males only 
1.2 Are the interventions appropriate for the 
review question? 
Partly Genetic cascade screening is 
compared with lipid cascade 
screening but no screening and 
index case identification were not 
included in the analysis. 
The lipid cascade screening with 
adherence programme intervention 
is not really relevant to the 
decision-making context of the 
update. 
1.3 Is the system in which the study was 
conducted sufficiently similar to the current UK 
context? 
Partly It is likely the costs of the US 
health care system do not 
represent those incurred by the 
NHS 
1.4 Are the perspectives clearly stated and are 
they appropriate for the review question? 
No US societal perspective adopted 
1.5 Are all direct effects on individuals included, 
and are all other effects included where they are 
material? 
Yes  
1.6 Are all future costs and outcomes 
discounted appropriately? 
Partly 3% 
NICE reference case is 3.5% 
1.7 Is QALY used as an outcome, and was it 
derived using NICE’s preferred methods? If not, 
describe rationale and outcomes used in line 
with analytical perspectives taken (item 1.4 
above). 
Yes  
1.8 Are costs and outcomes from other sectors 
fully and appropriately measured and valued? 
n/a  
1.9 Overall judgement: Partially applicable 
There is no need to use section 2 of the checklist if the study is considered ‘not applicable’. 
Other comments: 
 
Two parameters in the model substantially limit the generalisability of this study to decision-making 
in the NHS. 
 The first year screening cost of US$5,528 far exceeds what would be incurred by the NHS. 
A sensitivity analysis found that genetic cascade screening was cost effective compared 
with lipid cascade screening for a first year screening cost of $1,830 and it is likely that the 
cost in the UK is less than this. 
 The 10mg dose of atorvastatin is less than the high potency treatment recommended by 
UK guidelines. 
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International Journal of Cardiology, 181, pp.417-24. 
 
Section 2: Study limitations (the level of 
methodological quality) 
This checklist should be used once it has been 
decided that the study is sufficiently applicable 
to the context of the guideline 
Yes/partl
y/no/uncl
ear/NA 
Comments 
2.1 Does the model structure adequately reflect 
the nature of the topic under evaluation? 
Partly The Markov model based on 3 
health states may oversimplify the 
health states relevant to the risks 
that lipid-modification hopes to 
address 
2.2 Is the time horizon sufficiently long to reflect 
all important differences in costs and outcomes? 
Yes  
2.3 Are all important and relevant outcomes 
included? 
Partly The Markov model based on 3 
health states may oversimplify the 
health states relevant to the risks 
that lipid-modification hopes to 
address 
2.4 Are the estimates of baseline outcomes from 
the best available source? 
Partly The Simon Broome register is a 
reasonable source for FH specific 
risk adjustments but it is unknown 
whether this is the best-available 
source 
2.5 Are the estimates of relative intervention 
effects from the best available source? 
Partly The reductions in cholesterol due 
to statins appear to be the same as 
the general population as per the 
Framingham study 
2.6 Are all important and relevant costs 
included? 
Yes However, the cost of genetic 
testing far exceeds what is incurred 
by the NHS 
2.7 Are the estimates of resource use from the 
best available source? 
Yes  
2.8 Are the unit costs of resources from the best 
available source? 
Yes  
2.9 Is an appropriate incremental analysis 
presented or can it be calculated from the data? 
Yes  
2.10 Are all important parameters whose values 
are uncertain subjected to appropriate sensitivity 
analysis? 
Partly Inappropriate distributions used. 
Normal distributions used for 
transition probabilities and utilities. 
Triangle distributions used for 
hazard ratio of death after CVD 
event and disutility from statin 
medication in the pre-CVD state. 
2.11 Is there any potential conflict of interest? No  
2.12 Overall assessment: Potentially serious limitations 
 
Other comments: 
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National Collaborating Centre for Primary Care. (2008). Familial Hypercholesterolaemia, 
appendix E, health economic modelling. , NICE Clinical Guideline 71, pp.. 
Nherera L, Marks D, Minhas R, Thorogood M, and Humphries S E. (2011). Probabilistic cost-
effectiveness analysis of cascade screening for familial hypercholesterolaemia using 
alternative diagnostic and identification strategies. Heart, 97, pp.1175-1181. 
Section 1: Applicability (relevance to specific 
review questions and the NICE reference case 
as described in section 7.5) 
This checklist should be used first to filter out 
irrelevant studies. 
Yes/par
tly/no/u
nclear/
NA 
Comments 
1.1 Is the study population appropriate for the 
review question? 
Yes  
1.2 Are the interventions appropriate for the 
review question? 
Yes  
1.3 Is the system in which the study was 
conducted sufficiently similar to the current UK 
context? 
Yes UK 
1.4 Are the perspectives clearly stated and are 
they appropriate for the review question? 
Yes NHS 
1.5 Are all direct effects on individuals included, 
and are all other effects included where they are 
material? 
Yes  
1.6 Are all future costs and outcomes 
discounted appropriately? 
Yes  
1.7 Is QALY used as an outcome, and was it 
derived using NICE’s preferred methods? If not, 
describe rationale and outcomes used in line 
with analytical perspectives taken (item 1.4 
above). 
Yes  
1.8 Are costs and outcomes from other sectors 
fully and appropriately measured and valued? 
n/a  
1.9 Overall judgement: Directly applicable 
There is no need to use section 2 of the checklist if the study is considered ‘not applicable’. 
Other comments: 
 
 
Section 2: Study limitations (the level of 
methodological quality) 
This checklist should be used once it has been 
decided that the study is sufficiently applicable 
to the context of the guideline 
Yes/par
tly/no/u
nclear/
NA 
Comments 
2.1 Does the model structure adequately reflect 
the nature of the topic under evaluation? 
Yes  
2.2 Is the time horizon sufficiently long to reflect 
all important differences in costs and outcomes? 
Yes  
2.3 Are all important and relevant outcomes 
included? 
Yes  
2.4 Are the estimates of baseline outcomes from 
the best available source? 
Yes Simon Broome register 
2.5 Are the estimates of relative intervention 
effects from the best available source? 
Yes TA94 
2.6 Are all important and relevant costs 
included? 
Yes  
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National Collaborating Centre for Primary Care. (2008). Familial Hypercholesterolaemia, 
appendix E, health economic modelling. , NICE Clinical Guideline 71, pp.. 
Nherera L, Marks D, Minhas R, Thorogood M, and Humphries S E. (2011). Probabilistic cost-
effectiveness analysis of cascade screening for familial hypercholesterolaemia using 
alternative diagnostic and identification strategies. Heart, 97, pp.1175-1181. 
2.7 Are the estimates of resource use from the 
best available source? 
Yes  
2.8 Are the unit costs of resources from the best 
available source? 
Yes  
2.9 Is an appropriate incremental analysis 
presented or can it be calculated from the data? 
Yes  
2.10 Are all important parameters whose values 
are uncertain subjected to appropriate sensitivity 
analysis? 
Partly PSA conducted for journal article but 
not full guideline 
2.11 Is there any potential conflict of interest? Unclear As per declarations of interest in full 
guideline for guideline committee 
2.12 Overall assessment: very serious limitations 
 
Other comments: 
 
 The diagnostic definitions change according to strategy. For example, a true positive can have 
elevated LDL-C levels or be a carrier of the family mutation. That is, a person with a family 
mutation would be a true positive in a DNA strategy but not in the cholesterol strategy if they do 
not have raised cholesterol. Therefore, the results are not necessarily comparable between 
strategies. 
 The cost and QALYs per person from treatment were used to estimate total cost and QALY gain 
for each strategy by multiplying the number of index cases recruited by the cost and QALY gain 
per patient. This fails to take into account the QALYs (and costs) that would have been accrued 
by these people had they not been identified, overinflating the QALY gain of these strategies (and 
potentially cost). 
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Appendix O: Cost-utility analysis of 
strategies to identify and diagnose familial 
hypercholesterolaemia 
O.1 Introduction 
Familial hypercholesterolaemia (FH) is characterised by an inherited genetic mutation which 
causes a high cholesterol concentration from birth. People with FH have a higher risk of 
coronary heart disease, particularly at younger ages (Nordestgaard 2013). Once diagnosed, 
treatement with statins substantially reduces the risk of coronary heart disease (Versmissen 
et al. 2008; Neil et al. 2008). 
It is estimated that between 115,770 (based on a prevalence of 1 in 500) (Nordestgaard et al. 
2013) and 266,272 (based on a prevalence of 1 in 217) (Benn et al. 2016) people in England 
and Wales have FH but only 15% of are currently diagnosed (Pedersen et al. 2010). 
Cascade testing, where the relatives of people currently diagnosed with FH are genetically 
tested to see if they carry the family mutation, is currently recommended in NICE CG71 but it 
has been estimated that only half of all carriers are likely to be identified using this strategy 
(Pedersen et al. 2010). Since the original guideline (NICE CG71) was published new 
evidence has been produced on the effectiveness of identifying FH in primary care and 
secondary care databases. It is the goal of this update and economic analysis to establish 
the clinical and cost effectiveness of these strategies compared with cascade testing. 
Strategies that involve case identification in primary and secondary care are in addition to 
cascade testing. That is, for example, once a person is diagnosed with FH in primary care, it 
is expected that their relatives are invited for cascade testing following identification of the 
family mutation in the new index case. This is supported by the existing literature on cascade 
testing included in the present economic systematic review, including the economic analysis 
conducted for the original guideline (NICE CG71; NCCPC 2008; Nherera 2011).  
The resource impact of cascade testing is influenced by the cost of contacting relatives, the 
cost of genetic testing, administrative and staffing costs involved in patient advice and 
support before and after testing, the number of relatives able to be approached (usually 
dependent on where they live), the probability an index case agrees to cascade testing, and 
the probability a relative takes up the offer of cascade testing. There are three types of 
cascade testing. Indirect cascade testing occurs when index cases take responsibility for 
contacting relatives and informing them of their risk of having FH. Direct cascade testing 
involves a healthcare professional, usually a specialist nurse, making direct contact with 
potentially affected relatives and informing them about FH and the potential benefits of 
genetic testing. Direct cascade testing requires more resources but is thought to be more 
effective at eliciting participation by relatives in genetic testing. The third type of cascade 
testing is a combination of direct and indirect methods. Combination direct and indirect 
cascade testing was found to be most effective in the clinical review and used to represent 
cascade testing in this economic analysis. 
The resource impact of new case identification in primary care is influenced by the cost of 
informatics setup and training in GP surgeries, contacting patients for further assessment, 
the likelihood those people identified actually have FH, the take up of further clinical 
assessment, the diagnostic performance of clinical assessment tools (particularly regarding 
their specificity and false positives that result in unnecessary genetic testing), the cost of 
referral to a lipid clinic and genetic testing, and the benefits gained from cascade testing the 
relatives of new index cases. 
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The resource impact of identifying new index cases that have already experienced an early 
myocardial infarction in secondary care databases is influenced by similar factors as those 
identified through GP surgeries except that this is usually conducted in the secondary care 
setting. 
The committee determined that de novo economic modelling was required for the update 
because: 
 The cost effectiveness of new index case identification in primary care and secondary 
care has not been investigated in any of the studies identified in the economic review. 
 The cost of treatment (with atorvastatin) has decreased since the original guideline. 
 The cost of genetic testing has decreased since the original guideline. 
 The ability to differentiate between monogenic FH and polygenic hypercholesterolaemia 
due to developments in genetic testing is now an important part of the cascade testing 
pathway and its relative cost effectiveness. 
O.2 Model overview 
O.2.1 Interventions 
The following strategies were compared in the analysis: 
1. No case identification and no cascade testing 
2. Genetic cascade testing of the relatives of people with a current clinical diagnosis of FH 
and a functional mutation in the LDLR, APOB or PCSK9 gene 
3. Primary care case identification, clinical assessment using the Simon Broome criteria, and 
cascade testing of the relatives of newly identified index cases; in addition to cascade 
testing from currently diagnosed index cases 
4. Primary care case identification, clinical assessment using the DLCN criteria, and cascade 
testing of the relatives of newly identified cases; in addition to cascade testing from 
currently diagnosed index cases 
5. Secondary care case identification, clinical assessment using the Simon Broome criteria, 
and cascade testing of the relatives of newly identified index cases; in addition to cascade 
testing from currently diagnosed index cases 
6. Secondary care case identification, clinical assessment using the DLCN criteria, and 
cascade testing of the relatives of new identified index cases; in addition to cascade 
testing from currently diagnosed index cases 
7. Primary care case identification, secondary care case identification, clinical assessment 
using the SB criteria, and cascade testing of the relatives of newly identified index cases; 
in addition to cascade testing from currently diagnosed index cases 
8. Primary care case identification, secondary care case identification, clinical assessment 
using the DLCN criteria, and cascade testing of the relatives of newly identified index 
cases; in addition to cascade testing from currently diagnosed index cases 
Two alternative cascade testing strategies are currently recommended by NICE. CG71 
recommends the use of genetic testing and lipid-based cascade testing in the event that a 
family mutation is not identified. The Quality Standard for FH recommends the use of 
cascade testing of monogenic FH index cases only, reflecting the development of the 
evidence-base since the clinical guideline was published. The lipid-based cascade testing 
strategy currently recommended by CG71 was not included in the analysis because only 
relatives of index cases with a monogenic mutation have a 50% chance of having FH. Topic 
experts advised that, where it is implemented, current practice is thought to follow the Quality 
Standard (genetic cascade testing from index cases with a monogenic mutation, not lipid-
based cascade testing). 
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Universal screening for FH in children was assessed by the UK National Screening 
Committee and not recommended (UK National Screening Committee 2016) and has not 
been included in this analysis. Reverse cascade testing, where parents and siblings of 
children in whom FH has been diagnosed are tested for FH, effectively relies on the 
existence of universal screening for FH in children and has been excluded from this analysis. 
The strategies compared in this analysis are not universal screening interventions. 
Economic analyses for NICE usually identify a strategy to represent current practice to serve 
as a comparator against which other strategies are compared. Topic experts advised that 
implementation of cascade testing in England is poor but has been taken up in some local 
areas. It is difficult to estimate whether strategy 1 or 2 best represents current practice so 
both have been included in this analysis. 
O.2.2 Population 
There are six subpopulations that have the potential to come in to contact with these 
strategies for which short term costs and long term health and cost consequences need to be 
accounted for: 
1. People with a current clinical diagnosis of FH 
2. Relatives of people with a current clinical diagnosis of FH 
3. People identified in a primary care database as requiring further investigation because 
they have a total cholesterol level higher than 7.5 mmol/L recorded (potential new index 
cases) 
4. Relatives of people identified in a primary care database who have FH 
5. People who have experienced an early myocardial infarction (potential new index cases in 
secondary care) 
6. Relatives of people who have experienced an early myocardial infarction who have FH 
O.2.3 Pathways 
This section provides a detailed description of the strategies and how each subpopulation is 
affected by the strategy. Figures representing each strategy in decision tree format can be 
found in the following section. 
O.2.3.1 Strategy 1: No cascade testing and no case identification 
There are no short term costs associated with this strategy. Long term costs and health 
outcomes will accrue according to the long term module people enter at the end of the 
diagnostic pathway. 
1. People with a current clinical diagnosis of FH: All receive treatment with statins, ezetimibe, 
or statins and ezetimibe, regardless of whether they have monogenic FH or actually have 
polygenic hypercholesterolaemia (in this model ‘polygenic hypercholesterolaemia’ is taken 
to mean people who have high cholesterol but in whom the monogenic mutation is not 
present. This group would include people who have elevated cholesterol for other reasons 
but their outcomes and treatment would not be appreciably different. They were therefore 
not modelled separately). 
2. Relatives of currently diagnosed: Relatives with FH remain untreated and have a higher 
risk of myocardial infarction, angina and coronary heart disease. Relatives without FH 
(healthy relatives) are not included in long term modelling because their numbers do not 
change between strategies. 
3. Primary care population with raised cholesterol: A proportion of people with and without 
FH will already be on statins regardless of intervention and these people are assigned to 
the treated polygenic hypercholesterolaemia module or treated FH module. All other 
people remain untreated in this strategy. 
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4. Relatives of new index cases in primary care: All people with FH remain untreated. People 
without FH (healthy people) are not included in long term modelling. 
5. Secondary care population with early myocardial infarction: All people with FH and 
polygenic hypercholesterolaemia are treated with high-intensity statins for secondary 
prevention. Therefore, this subpopulation has no impact on incremental differences in long 
term costs and QALYs. They will incur short term costs in strategies that aim to identify 
people with early MI and FH (not this strategy). 
6. Relatives of new index cases in secondary care: All people with FH remain untreated. 
People without FH are not included in long term modelling. 
O.2.3.2 Strategy 2: Cascade testing from monogenic FH index cases 
1. Currently clinically diagnosed FH: Most of this subpopulation incur a cost to undergo a 
genetic test to determine their family mutation. A proportion will have a functional mutation 
in the LDLR, APOB, or PCSK9 gene. The remainder are found to have a polygenic cause 
of their hypercholesterolaemia. All receive treatment with statins, ezetimibe, or statins and 
ezetimibe regardless of the outcome of the genetic test in the base case. 
2. Relatives of currently diagnosed: Relatives of index cases found to have monogenic FH 
are contacted and offered genetic counselling and testing. Some of the relatives will take 
up the offer. Some of the proportion (~50% in the base case) that take up the offer will 
have the family mutation and receive appropriate treatment. Relatives that do not have the 
mutation (healthy people) are not included in long term modelling. Genetic testing is 
assumed to have perfect diagnostic performance so there are no false positives or false 
negatives in this strategy. Relatives with FH who do not take up genetic testing remain 
untreated and have a higher risk of myocardial infarction, angina and mortality due to 
coronary heart disease. Relatives who do not take up genetic testing and do not have FH 
are not included in long term modelling. 
3. Primary care population with raised cholesterol: As per strategy1. 
4. Relatives of new index cases in primary care: As per strategy 1. 
5. Secondary care population with early myocardial infarction: As per strategy 1. 
6. Relatives of new index cases in secondary care: As per strategy 1. 
O.2.3.3 Strategy 3: Primary care case identification, clinical assessment using the Simon 
Broome criteria, and cascade testing of the relatives of newly identified index cases; 
in addition to cascade testing from currently diagnosed index cases 
1. Currently clinically diagnosed FH: As per strategy 2. 
2. Relatives of currently diagnosed: As per strategy 2. 
3. Primary care population with raised cholesterol: Resource is required to set up informatics 
in GP surgeries. Those identified by the database search have their medical records 
examined by a practice nurse and invited for clinical assessment. Those patients that take 
up the invitation and are identified as having possible or definite FH (in the base case) 
during a clinical assessment with a nurse specialist are referred to a lipid clinic for genetic 
testing. Those identified as possible or definite FH either have monogenic FH (true 
positives) or not (false positives). False positives undergo a genetic test, overturning their 
initial clinical diagnosis, and enter the treated hypercholesterolaemia module. That is, 
although they do not have FH, coming into contact with a healthcare professional means 
they moved fromm an untreated to treated state. True positives undergo a genetic test to 
confirm their diagnosis and enter the treated FH module. Out of the people that the Simon 
Broome criteria determines do not have possible or definite FH, some will have 
monogenic FH (false negatives) and the remainder will not (true negatives). False 
negatives enter the treated FH module. Although the clinical assessment found 
(incorrectly) they did not have FH, they still have high cholesterol and have come into 
contact with a healthcare professional. Following NICE CG181, these people would be 
prescribed a high-intensity statin in the base case. True negatives are not included in long 
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term modelling. There is a proportion of people with FH and polygenic 
hypercholesterolaemia that are already on statins and enter the treated modules even if 
they do not take up the offer of clinical assessment. 
4. Relatives of new index cases in primary care: Relatives of these new index cases are 
offered cascade testing and follow the same path as that specified for population 2 above. 
Whether they are offered cascade testing at all depends on the likelihood of potential new 
index cases being correctly identified as having FH. That is, the explanation for 
subpopulation 3 directly above. 
5. Secondary care population with early myocardial infarction: As per strategy 1. 
6. Relatives of new index cases in secondary care: As per strategy 1. 
O.2.3.4 Strategy 4: Primary care case identification, clinical assessment using the DLCN 
criteria, and cascade testing of the relatives of newly identified index cases; in 
addition to cascade testing from currently diagnosed index cases 
As per strategy 3 with the exception of using the DLCN criteria as the clinical assessment 
tool with referral to a lipid clinic if they have probable or definite FH (score >5) in the base 
case. 
O.2.3.5 Strategy 5: Secondary care case identification, clinical assessment using the Simon 
Broome criteria, and cascade testing of the relatives of newly identified index cases; 
in addition to cascade testing from currently diagnosed index cases 
1. Currently clinically diagnosed FH: As per strategy 2. 
2. Relatives of currently diagnosed: As per strategy 2. 
3. Primary care population with raised cholesterol: As per strategy 1. 
4. Relatives of new index cases in primary care: As per strategy 1. 
5. Secondary care population with raised cholesterol: People with early MI are invited to 
undergo further clinical assessment with the Simon Broome criteria. Those that take up 
the offer and are identified as having possible or definite FH are referred to a lipid clinic. 
Those identified as possible or definite FH will turn out to have monogenic FH (true 
positives) or not (false positives). Out of the people that the Simon Broome criteria 
determines do not have possible or definite FH, some will have monogenic FH (false 
negatives) and the remainder will not (true negatives). True positives undergo a genetic 
test to confirm their diagnosis and enter the treated FH model. False positives also 
undergo a genetic test, overturning their initial diagnosis but still entering a treated 
hypercholesterolaemia model due to their high cholesterol. All people receive treatment 
for secondary prevention. The long term outcomes for this subpopulation are actually the 
same and do not change between strategies because they are treated with statins 
regardless of diagnosis. What does change is the short term cost they incur in the process 
of being diagnosed with FH and then the long term health and cost outcomes their 
relatives benefit from (if diagnosed) who otherwise may have remained untreated. 
6. Relatives of new index cases in secondary care: Relatives of these new index cases are 
offered cascade testing and follow the same path as that specified for relatives in strategy 
2. Whether relatives are offered cascade testing at all depends on the potential new index 
cases above being correctly identified. 
O.2.3.6 Strategy 6: Secondary care case identification, clinical assessment using the DLCN 
criteria, and cascade testing of the relatives of newly identified index cases; in 
addition to cascade testing from currently diagnosed index cases 
The pathway here is the same as strategy 5 apart from using the DLCN criteria as the clinical 
assessment tool to determine referral to the lipid clinic (probable or definite FH, score >5). 
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O.2.3.7 Strategy 7: Primary care case identification, secondary care case identification, 
clinical assessment using the SB criteria, and cascade testing of the relatives of newly 
identified index cases; in addition to cascade testing from currently diagnosed index 
cases 
The pathways of strategy 7 and 8 follows what has already been specified in previous 
strategies but now in combination. 
1. Currently clinically diagnosed FH: As per strategy 2. 
2. Relatives of currently diagnosed: As per strategy 2. 
3. Primary care population with raised cholesterol: As per strategy 3. 
4. Relatives of new index cases in primary care: As per strategy 3. 
5. Secondary care population with early myocardial infarction: As per strategy 5. 
6. Relatives of new index cases in secondary care: As per strategy 5. 
O.2.3.8 Strategy 8: Primary care case identification, secondary care case identification, 
clinical assessment using the DLCN criteria, and cascade testing of the relatives of 
newly identified index cases; in addition to cascade testing from currently diagnosed 
index cases 
As per strategy 7 but with the DLCN criteria for clinical assessment (probable or definite FH, 
score >5 in the base case). 
O.2.4 Structure 
The structure of the economic model consists of five modules: 
1. The decision tree module captures short term identification, diagnosis and cost outcomes. 
There is one subtree for each strategy and a pathway for each subgroup within each 
subtree. 
2. The ‘Untreated FH’ module contains the summary payoffs from a Markov model to 
capture the long term consequences of untreated FH. People can enter this module if they 
are diagnosed as not having FH even though they actually do (false negative) or because 
they have not been identified and tested for FH simply because there is no opportunity to 
within that strategy. These payoffs were extracted from the cost-effectiveness analysis of 
low-intensity, medium-intensity and high-intensity statin treatment for the primary and 
secondary prevention of cardiovascular disease in NICE CG181 (lipid modification). This 
model has 8 alive health states (plus 7 transition states) and has been adjusted to account 
for the different risk profile of people with FH. Further detail can be found in the economic 
modelling report for CG181 and information how it was adjusted to account for the FH 
population can be found in the next section on input parameters. 
3. The ‘Treated FH’ module contains the summary payoffs from a Markov model that 
captures the long term consequences of treated FH. This is based on adjusted CG181 
module explained in module 2 above with treatment effects based on atorvastatin 80 mg 
and additional information is provided in the next section on input parameters. 
4. The ‘Untreated polygenic hypercholesterolaemia’ module contains the summary payoffs 
from the unadjusted CG181 Markov model. Reference costs have been updated to the 
most recent financial year for which reference costs are available (2014-15).  
5. As per module 4 with treatment effect based on atorvastatin 20 mg and updated costs. 
Atorvastatin 20 mg is recommended in NICE CG181. 
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The following diagrams present the structure of the short term identification and diagnosis module. 
Figure 12: Structure of case identification and diagnosis module 
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O.2.5 Time horizon, perspective and discount rate 
The analysis follows the NICE reference case by adopting a lifetime time horizon, the NHS & 
personal social services (PSS) perspective for costs and a discount rate of 3.5%. Some 
results are provided for the short term identification and diagnosis module only to aid 
decision-making. 
O.2.6 Outcomes 
The model calculates the following outcomes: 
 Expected cost per person per strategy 
 Total cost per strategy 
 Cost per newly treated FH 
 Cost per newly treated polygenic hypercholesterolaemia 
 Incremental cost-effectiveness ratio (ICER) in terms of cost per quality adjusted life year 
(QALY) 
 Net monetary benefit (NMB) 
The ICER is calculated by dividing the difference in costs associated with two alternatives by 
the difference in QALYs. The optimal strategy is the one with the highest ICER below NICE’s 
cost-effectiveness threshold of £20,000 to £30,000 per QALY after dominated and 
extendedly dominated options have been excluded because this is the strategy that 
maximises health benefits for an acceptable opportunity cost. A strategy is dominated and 
ruled out if another intervention is less costly and more effective. A strategy is extendedly 
dominated and ruled out if a combination of two other options is less costly and more 
effective.  
Net monetary benefit is calculated by multiplying the health benefit in terms of QALYs by the 
cost-effectiveness threshold and subtracting the cost of the strategy. The decision rule here 
is that the strategy with the greatest NMB should be recommended. A £20,000 per QALY 
threshold has been adopted to calculate NMB in this analysis. 
Both methods of calculating cost-effectiveness yield exactly the same optimal strategy. NMB 
is used as the main outcome measure due to the relative ease of computation and 
comparing results in sensitivity analysis. 
O.2.7 Assumptions 
The following assumptions were made in consultation with the committee: 
 Genetic testing has perfect sensitivity and specificity. The committee discussed the 
potential impact of variants of unknown clinical significance (VUS) and determined not to 
include this because VUS occur in only around 5% of genetic tests (and not at all in 
testing relatives of mutation positive cases) and the approach to management would be 
similar to someone with confirmed FH apart from cascade testing their relatives. 
Consequently, false positives are not possible by the end of the diagnostic pathway. A 
false positive clinical diagnosis is possible but this is corrected by subsequent genetic 
testing and converted to a true positive (this assumption was not the subject of sensitivity 
analysis but its effect is explored in the discussion section). A false negative clinical 
diagnosis is possible and this is not corrected by a subsequent genetic test because this 
cohort would not be referred for additional testing. 
 All people with early MI (potential new index cases in secondary care) receive treatment 
with high-intensity statins regardless of whether their FH status is known or not. 
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Therefore, any benefit (and cost) of strategies that involve case identification in secondary 
care stems from cascade testing and correctly diagnosis the relatives of new index cases. 
 A proportion of people with previously undiagnosed monogenic FH identified by a primary 
care database search who do not come into contact with a healthcare provider are 
assumed to be already appropriately treated with high intensity statins or ezetimibe due to 
having a high prior cholesterol reading. This proportion is assumed to be the same as the 
polygenic population, 19.3% in the base case based on an evaluation of the NHS Health 
Check (Robson et al. 2016).  
 If people with monogenic FH identified by a primary care database search take up clinical 
assessment, they receive appropriate treatment regardless of whether the clinical 
assessment diagnoses them with FH or not due to blood tests that show they have high 
cholesterol and additional contact with primary care. That is, false negatives are counted 
as treated FH in the long term module even though they do not have a genetic test.  
 A single probability of take up was used for each subgroup representing the acceptance of 
clinical assessment, referral to a lipid clinic and genetic testing. In reality, there is the 
potential for people to take up clinical assessment but not proceed to consultation at the 
lipid clinic or genetic testing following that. However, insufficient data was available to 
inform additional take up probabilities. The probability of take up adopted for each 
subgroup was taken from published literature included in the clinical review and agreed 
with the committee.  
 There is 100% adherence to the treatment once disease is diagnosed. This is consistent 
with the lipid modification model. The focus of the model is case identification and 
diagnosis and the committee advised that in their experience adherence is quite high in 
the population with FH. In practice, the committee advised that while people are likely to 
pick up their prescriptions (and thus incur costs), a proportion would not adhere to 
treatment. This limitation was assessed as minor as efficacy estimates for statins were 
drawn from trials that contained a proportion of non-adherents.  
 All relatives are assumed to not know their FH status, cholesterol level or be currently 
treated with statins. This is a strong assumption but was assessed as minor in the context 
of the conservativey small number of relatives assumed to be identified per index case. 
 Crossover has not been implemented in the model. In practice, a primary care database 
search may identify relatives of current index cases who have already been cascade 
tested, and vice versa. However, no data was identified in the published literature to 
inform an alternative approach. 
O.3 Input parameters 
O.3.1 Identification and diagnosis module 
The key input parameters and their sources are provided in Table 37. These parameters 
were informed as much as possible by the clinical review. 
O.3.1.1 Clinical parameters 
People with a current clinical diagnosis of FH 
The number of people with a current clinical diagnosis of FH, 18,000, was informed by an 
audit of lipid clinics in the United Kingdom in 2010 (Pedersen 2010). This is based on the 
actual number of FH patients reported to be under active management by the audited lipid 
clinics, and represents ~15% of the lower estimate of FH prevalence in the general 
population, 120,000. 
 242 
 
Out of the people with a current clinical diagnosis of FH, only a proportion will actually have 
monogenic FH. Kerr et al. (2017) provided an estimate based on the experiences of the 
Welsh, Scottish and Wessex FH services, 22.98%. 
The prevalence of FH in the general population is widely noted in the literature as 1/500 (for 
example, Nordestgaard 2013) and is thought to represent a low estimate of actual 
prevalence. A conservative approach was taken and this figure was used in the base case. 
Recent studies have reported prevalence in the general population up to 1 in 217 and this 
was used in sensitivity analysis (Benn 2016). A prevalence of FH-mutation carriers of 1/273 
in UK children has recently been reported (Wald et al NEJM 2016). This value was not used 
directly in the model but was used qualitatively to validate the prevalence of FH predicted by 
the different possible search criteria. 
People identified by a primary care database search 
The adult population of England and Wales was sourced from the Office of National Statistics 
(2015). This was used to represent the number of people registered in primary care 
databses.  
The proportion of people in primary care databases identified for further investigation by a 
search, and the prevalence of FH within this group, was informed by a single study. A single 
study was preferred because of the relationship that exists between the threshold of total 
cholesterol or LDL-C and the likelihood of having FH. Four main criteria were used when 
selecting the most appropriate study: 
1. population was representative of people registered with GP practices in England and 
Wales; 
2. diagnosis of FH was based on genetic testing; 
3. the study reported both the number or proportion of people with raised cholesterol and the 
proportion of those people that had FH; and 
4. resulted in general population prevalence of FH within expected limits when combined 
with other parameters of the model. 
Eleven studies were considered to inform these two parameters. Seven studies were those 
included in the clinical review (Bell 2014b, Gray 2008, Green 2016, Kirke 2015, Norsworthy 
2014, Qureshi 2016, Troeung 2016) and another four were identified by the topic experts as 
potentially useful for economic modelling (Weng 2015, Benn 2016, Khera 2016, Futema 
2015). Five studies were not appropriate for the model because diagnosis was based on 
clinical assessment rather than genetic testing (Weng 2015, Gray 2008, Qureshi 2016, 
Troeung 2016, Green 2016). Another two studies conducted genetic testing but only for 
people with positive clinical assessment findings so the prevalence of FH would not have 
taken account of false negative clinical assessment results (Kirke 2015, Bell 2014b). Four 
studies reported the results of genetic testing for the whole sample with raised cholesterol 
(Futema 2015, Norsworthy 2014, Benn 2016, Khera 2016). Norsworthy et al. (2014) provided 
insufficient detail on how the sample taken forward for testing was selected from the 
Generation Scotland: Sottish Family Health Study sample of 24,000 people to allow 
meaningful calculation of these parameters for the model. Khera et al. (2016) reported the 
proportion of FH mutations for several bands of LDL-C in an American population but the 
implied general population prevalence of FH was too high (1/120 to 1/80) to be 
representative of the UK general population. Benn et al. (2016) reported the prevalence of 
FH for various bands of LDL-C in a large Danish population but the implied general 
population prevalence was too low for some stratifications (for example, 1/930 to 1/3190). 
Futema et al. (2015) genetically tested samples from the Whitehall II cohort of UK public 
service employees, broadly (although somewhat older and based in one geographical area) 
representative of people registered in primary care databases that reported total cholesterol 
greater than 9.3 mmol/L. The implied general population prevalence based on this data and 
the relatives that would be found through cascade testing was 1/340, falling between the 
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commonly adopted estimates used in the literature of 1/200 to 1/500. Therefore, the study by 
Futema et al. (2015) was used to inform the proportion of people in a primary care database 
that require further investigation and the prevalence of FH in this group.  
Within any primary care database, only a certain portion of patients will actually have their 
cholesterol recorded. This was estimated to be 31% based on the finding by Futema et al. 
(2015) that 7.3% of adults with a cholesterol reading in the Whitehall II cohort had total 
cholesterol >7.5 mmol/L, combined with the finding by Qureshi et al. that 831 people out of 
~36,000 in a real-world primary care database required further investigation based on their 
total cholesterol level >7.5 mmol/L (831/(7.3% x ~36000) = approx. 31%). This estimate was 
acknowledged to be uncertain and was the subject of sensitivity analysis (although varying 
this parameter only materially affects the overall resource impact rather than the cost 
effectivenss of the different strategies as there are few fixed costs within the model). 
The take up of clinical assessment by people identified by a primary care database search 
was informed by the general practice and work place identification cohorts of an Australian 
study included in the clinical review (Kirke 2015), 26%, varied up to 50% in sensitivity 
analysis. 
A proportion of people in primary care databases will already be on statins regardless of 
intervention or take up. This proportion was informed by an evaluation of the NHS Health 
Check which found that 19.3% of people were prescribed lipid modification following the 
health check. This was varied down to 10% and up to 99% in sensitivity analysis. 
People with early MI 
The prevalence of FH in people with early MI is expected to be greater than the general 
population due to the higher risk of coronary heart disease. Wald et al. (2015) estimated this 
to be 1.3%. De Backer et al. (2015) provided an estimate of 8.3% but this was based on 
definite and probable scores from the DLCN criteria. Because this was not based on genetic 
diagnosis, it could not be used as the base case but was used to inform the upper limit for 
sensitivity analysis. 
The take up of clinical assessment and genetic testing by people with early MI was also 
informed by Wald et al. (2015), with 72.5% agreeing to be tested for FH. 
Relatives 
The number of relatives approached for cascade testing per index case was estimated to be 
2.22 based on the experience of the Welsh, Scottish and Wessex FH services as reported by 
Kerr et al. (2017). Although based on actual service experience, topic experts were 
concerned this was too low and this was increased to 12 first, second and third degree 
relatives per index case in sensitivity analysis based on the assumptions adopted in the 2009 
NICE CG71 costing report. 
The take up of clinical assessment by relatives was informed by a study included in the 
clinical review (Hadfield 2009). Although this study reported take up for relatives of people 
with a current clinical diagnosis, no data was identified for relatives of people with early MI or 
new index cases identified by a primary care database search so the same take up was used 
for all three groups of relatives. This was varied for each relative subpopulation 
independently in sensitivity analysis. 
Table 37: Input parameters for current index cases, potential new index cases and 
relatives 
Parameter Amount Source 
People with a current clinical 
diagnosis of FH (current index cases)     
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Parameter Amount Source 
Number of people with a current clinical 
diagnosis of possible or definite FH 
18,000 RCP 2010 (UK FH audit), 15% of 
120k (number under active 
management in UK lipid clinics) 
Proportion of current clinical diagnosis 
with definite FH with monogenic mutation 
22.98% Welsh, Scottish & Wessex FH 
services, cited in Kerr et al. 2017 
Prevalence monogenic FH in general 
population 
0.20% Nordestgaard 2013, 1 in 500, 
conservative lower limit found in 
literature 
Take up of genetic testing by people with 
a current clinical diagnosis of FH prior to 
cascade testing 
84.10% Median from clinical review 
People identified by primary care 
database search (potential new index 
cases)     
Population of England and Wales 45,579,669 Office of National Statistics 2015 
(age 18+) 
Proportion database search that warrant 
further investigation 
0.51% Futema 2015 TC >9.3 (base case) 
Number of people identified by primary 
care database search 
54,069 Calculated: population of England & 
Wales * proportion warranting further 
investigation * take up rate -currently 
diagnosed FH 
Prevalence of FH in people identified by 
primary care database search 
28.00% Futema 2015 TC >9.3 (base case) 
Proportion of people with high cholesterol 
already on statins 
19.30% Robson 2016, NHS Health Check 
Take up of clinical assessment and 
genetic testing by people identified by 
primary care database search 
26.03% Kirke et al. 2015, general practice 
database and work place 
assessment 
People with early myocardial infarction 
(potential new index cases in 
secondary care)     
Number of people with early MI 
(secondary care) 
104,833 Calculated: population of England & 
Wales x prevalence of MI 
Prevalence of FH in people with early MI 
(secondary care) 
1.30% Wald et al. 2015 
Take up of clinical assessment and 
genetic testing by people with early MI 
72.50% Wald et al. 2015 (% excluding 
declined and too unwell) 
Prevalence of MI in general population 0.23% Prevalence MI age<55 from 
Bhatnagar 2015, adjusted for age 
and sex from ONS 2015 
Relatives     
Number of relatives of index cases with 
FH 
8,438 Calculated: no. with current FH * 
relatives per index case * probability 
of FH among relatives 
Number of relatives of people with FH 
identified through primary care database 
search 
32,259 Calculated: number at risk in primary 
care * prevalence of FH in that 
population * no of relatives per index 
case 
Number of relatives of people with FH 
that have had an early MI (secondary 
care) 
2,780 Calculated: number at risk in 
secondary care * prevalence of FH 
in that population * no of relatives 
per index case 
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Parameter Amount Source 
Number of relatives invited for cascade 
testing per index case 
2.22 Calculated: 1.33 genetically tested 
(Kerr et al 2017) / 59.89% proportion 
take up that were invited (Hadfield 
2009). This is the number of 
relatives per (index case with 
genetically confirmed FH) that are 
invited for cascade testing 
regardless of whether they take up 
the offer or actually have FH. 
Probability tested relative has monogenic 
FH 
50.89% Welsh, Scottish & Wessex FH 
services, cited in Kerr et al. 2017  
Take up by relatives of cascade testing 
from currently diagnosed FH population 
59.89% Clinical review: Hadfield 2009 
Take up by relatives of clinical 
assessment and genetic testing from 
people identified in primary care 
59.89% Clinical review: Hadfield 2009 
Take up by relatives of clinical 
assessment and genetic testing from 
people with early MI (secondary care) 
59.89% Assume same as primary care 
relatives 
The results of the meta-analyses from the clinical review were used to inform the sensitivity 
and specificity of clinical assessment tools. In the base case analysis a ‘rule out’ profile was 
used for referral to a lipid clinic and genetic testing (Simon Broome possible and definite; 
DLCN probable and definite (score >5). By adopting a lower threshold, the clinical 
assessment tool was used to ‘rule out’ disease (high sensitivity) in the base case at the 
expense of referring many false positives (low specificity). This may be undesirable if the 
cost of correctly diagnosing the false positives outweighed the benefit of correctly diagnosing 
people that do have FH through minimising false negatives. 
In a sensitivity analysis, clinical assessment tools were used as ‘rule in’ test where only 
people with definite FH were referred for genetic testing. Increasing the threshold increases 
the level of confidence (due to higher specificity) that a person has FH before being referred 
to a lipid clinic at the expense of missing some people that do have FH (false negatives, 
lower sensitivity). This approach also reduces short term costs because less people are 
referred for genetic testing. This may be undesirable if the benefits gained by identifying and 
treating disease are likely to outweigh the cost of correcting false positive diagnoses. In other 
topics the health and cost consequences of inappropriate treatment provided to false 
positives also needs to be taken into account but in the present model there are no false 
positives by the end of the diagnostic module due to genetic testing that occurs following 
clinical assessment and the assumption that genetic testing has perfect diagnostic accuracy. 
Table 38: Sensitivity and specificity of clinical assessment tools 
Clinical assessment tool and threshold Sensitivity or specificity 
Sensitivity Simon Broome possible or definite FH  0.890 
Specificity Simon Broome possible or definite FH 0.287 
Sensitivity Simon Broome definite FH 0.360 
Specificity Simon Broome definite FH 0.940 
Sensitivity DLCN probable, definite FH (>=6) 0.861 
Specificity DLCN probable, definite FH (>=6) 0.457 
Sensitivity DLCN definite FH (>8) 0.567 
Specificity DLCN definite FH (>8) 0.802 
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O.3.1.2 Short term costs 
The cost of each strategy is provided in Table 43. Note the totals, or ‘expected cost’ for each 
subgroup are the total costs adjusted for the probability of the individual costs occurring.  
Most of the costs are listed for each individual resource (such as a genetic test or 15 minutes 
of specialist nurse time) with the exception of staff input that occurs directly before and after 
a genetic test. These estimates were sourced from Kerr et al. 2017 and are based on the 
resource use in the Welsh, Scottish and Wessex FH services with the latest costs from the 
PSSRU applied. There are four options for this cost that could be incurred depending on the 
subgroup and whether the genetic test is positive or negative. For index cases, the costs are 
higher due to the additional time and resource required for genetic counselling but less when 
the test is negative and treatment options and cascade testing do not need to be discussed. 
Genetic testing for relatives costs less than index cases because the family mutation is 
known, so it is a less time consuming process. 
Table 39: Cost of genetic testing, index cases 
Laboratory 
NHS 
Price Source 
Bristol RGC £287.00 Bristol, personal communication 07.02.2017 
London North East RGC 
GOSH 
£460.00 https://ukgtn.nhs.uk/, 07.02.2017  
Liverpool RGC £375.00 https://ukgtn.nhs.uk/, 07.02.2017  
Cardiff RGC £350.00 https://ukgtn.nhs.uk/, 07.02.2017  
Sheffield RGC £400.00 https://ukgtn.nhs.uk/, 07.02.2017  
Table 40: Cost of genetic testing, relatives 
Laboratory 
NHS 
Price Source 
London North East RGC GOSH £130.00 https://ukgtn.nhs.uk/, 07.02.2017  
Liverpool RGC £75.00 https://ukgtn.nhs.uk/, 07.02.2017  
Sheffield RGC £105.00 https://ukgtn.nhs.uk/, 07.02.2017  
Cardiff RGC £160.00 https://ukgtn.nhs.uk/, 07.02.2017  
Salisbury RGC £175.00 https://ukgtn.nhs.uk/, 07.02.2017  
Bristol RGC £77.00 https://ukgtn.nhs.uk/, 07.02.2017  
Table 41: Healthcare admin and staff support for genetic testing 
Action Resource Amount 
Polygenic index cases 
  
Consultation to plan genetic testing 20 minutes medical consultant £60.74 
Arrangement of DNA test 10 minutes admin assistant £4.00 
Take blood sample and send to DNA 
service 
1 hour specialist nurse band 7 £131.00 
Notification of test results 10 minutes admin assistant £4.00 
Total polygenic index cases   £199.74 
Additional costs for mutation-positive index cases 
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Action Resource Amount 
Follow-up consultation with test 
result 
30 minutes specialist nurse £65.50 
Draw family tree and discuss cascade 
testing 
1 hour genetic counsellor £131.00 
Total mutation-positive FH index 
cases 
  £396.24 
Mutation-negative relatives 
  
Take blood sample and send to DNA 
service 
1 hour specialist nurse £131.00 
Provide test result 20 minutes genetic counsellor £43.67 
Total mutation-negative relatives   £174.67 
Additional costs for mutation-positive relatives 
 
Follow-up consultation, prescribe 
statins 
40 minutes consultant or 
specialist nurse 
£104.40 
Total mutation-positive relatives   £279.07 
 
Table 42: Summary of unit costs 
Model Input Cost Source 
Genetic test, index case, family mutation 
unknown (each) 
£375.00 UK Genetic Testing Network website 
(median value used) 
Genetic test, relative of index case, family 
mutation known (each) 
£117.50 UK Genetic Testing Network website 
(median value used) 
Primary care nurse specialist £75.00 Curtis 2015 (PSSRU), 10.4 Nurse 
specialist (community), including quals.  
GP practice nurse - non-face-to-face contact 
(per hour) 
£43.00 Curtis 2015 (PSSRU), 10.6 Nurse (GP 
practice), including qualifications 
General practitioner (per hour) £225.00 Curtis 2015 (PSSRU), 10.8b GP, including 
direct care staff costs, with quals. 
Healthcare and admin staff inputs index case 
testing mutation positive cases (per person) 
£396.24 Kerr 2016 (resource use Welsh FH 
service, unit costs PSSRU) 
Healthcare and admin staff inputs index case 
testing mutation negative cases (per person) 
£199.74 Kerr 2016 (resource use Welsh FH 
service, unit costs PSSRU) 
Healthcare and admin staff inputs relative 
testing mutation positive cases (per person) 
£279.07 Kerr 2016 (resource use Welsh FH 
service, unit costs PSSRU) 
Healthcare and admin staff inputs relative 
testing mutation negative cases (per person) 
£174.67 Kerr 2016 (resource use Welsh FH 
service, unit costs PSSRU) 
Hospital nurse, band 7 (per hour) no patient 
contact 
£60.00 Curtis 2015 (PSSRU), hospital-based 
nurse band 7 
Hospital nurse, band 7 (per hour) patient 
contact 
£131.00 Curtis 2015 (PSSRU), hospital-based 
nurse band 7 
Consultant medical (per hour) £182.21 Curtis 2015 (PSSRU), Consultant: 
medical, including qualifications * 
inflation for non face-to-face time from 
Curtis 2008 (PSSRU) - no newer data 
were available 
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Model Input Cost Source 
Lipid clinic/hospital administration assistant £24.00 Curtis 2015(PSSRU), Allied health 
professional support worker 
Lipid profile £3.05 CG181 indexed to 2016 
 
When 2015 PSSRU staff costs are used it is because 2016 costs were not available in the 
correct format. Based on other comparable data, the 2015 costs were thought not to have 
meaningfully changed, however. 
When these unit costs are combined with the probability of those costs occurring (from the 
decision tree), we derive the expected cost per person for that strategy (Table 43). 
Table 43: Expected short term costs per person per subpopulation 
Total cost of each strategy, adjusted for the probability of individual resource use    
1. No case identification or cascade 
testing 
    
   
No cost incurred in identification and 
diagnosis module 
£0.00   
   
2. Cascade testing        
People with a current clinical 
diagnosis of FH 
  
Genetic test for index case £375.00 UK Genetic Testing Network website 
Healthcare and admin staff inputs 
index case testing mutation positive 
cases 
£396.24 Kerr 2016 (resource use Welsh FH service, 
unit costs PSSRU) 
Healthcare and admin staff inputs 
index case testing mutation negative 
cases 
£199.74 Kerr 2016 (resource use Welsh FH service, 
unit costs PSSRU) 
Expected cost £521.33 
 
   
Relatives of people with a current clinical 
diagnosis of FH 
 
Offer cascade testing regardless of 
acceptance (all contacted relatives) 
£18.75 15 minutes nurse specialist 
Genetic test for relative where FH 
mutation is known 
£117.50 UK Genetic Testing Network website 
Healthcare and admin staff inputs 
relative testing mutation positive 
cases 
£279.07 Kerr 2016 (resource use Welsh FH service, 
unit costs PSSRU) 
Healthcare and admin staff inputs 
relative testing mutation negative 
cases 
£174.67 Kerr 2016 (resource use Welsh FH service, 
unit costs PSSRU) 
Lipid profile for relatives that accept 
cascade testing 
£3.05 CG181 lipid modification model indexed to 
2015 
Expected cost £191.22 
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Total cost of each strategy, adjusted for the probability of individual resource use 
         
3. Primary care case identification and clinical assessment with SB    
People with a current clinical 
diagnosis of FH 
  
As per strategy 2 £521.33 
 
   
Relatives of people with a current clinical 
diagnosis of FH 
 
As per strategy 2 £191.22 
 
   
People identified by primary care database search (potential new index cases) 
Informatics setup and introduction 
session per at risk patient 
£17.13 1 hour of 2 GPs and 2 GP practice nurses ÷ 
31 (6127 patients per practice x 0.51% 
(Futema 2015 TC >9.3)) 
Information gathering (for all patients 
identified by search) 
£10.75 15 minutes GP practice nurse non-face-to-
face 
Clinical assessment for those that 
accept using Simon Broome criteria 
£18.75 15 minutes nurse specialist 
GP consultation for referral to lipid 
clinic 
£56.25 15 minutes GP 
Information pack for those that accept 
clinical assessment 
£2.00 assumed 
Genetic test for index case £375.00 UK Genetic Testing Network website 
Lipid clinic healthcare and admin staff 
inputs index case testing mutation 
positive cases 
£396.24 Kerr 2016 
Lipid clinic healthcare and admin staff 
inputs index case testing mutation 
negative cases 
£199.74 Kerr 2016 
Lipid profile (GP) for those that accept 
clinical assessment 
£3.05 CG181 lipid modification model indexed to 
2015 
Expected cost £172.07 
 
   
Relatives of people with FH identified through primary care database search 
Offer cascade testing regardless of 
acceptance (all contacted relatives) 
£18.75 15 minutes nurse specialist 
Genetic test for relative where FH 
mutation is known 
£117.50 UK Genetic Testing Network website 
Healthcare and admin staff inputs 
relative testing mutation positive 
cases 
£279.07 Kerr 2016 (resource use Welsh FH service, 
unit costs PSSRU) 
Healthcare and admin staff inputs 
relative testing mutation negative 
cases 
£174.67 Kerr 2016 (resource use Welsh FH service, 
unit costs PSSRU) 
Lipid profile for those that accept 
genetic testing 
£3.05 CG181 lipid modification model indexed to 
2015 
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Total cost of each strategy, adjusted for the probability of individual resource use 
Expected cost £52.68 
 
         
4. Primary care case identification and clinical assessment with DLCN    
People with a current clinical 
diagnosis of FH 
  
As per strategy 2 £521.33 
 
   
Relatives of people with a current clinical 
diagnosis of FH 
 
As per strategy 2 £191.22 
 
   
People identified by primary care database search (potential new index cases) 
Informatics setup and introduction 
session per at risk patient 
£17.13 1 hour of 2 GPs and 2 GP practice nurses ÷ 
31 (6127 patients per practice x 0.51% 
(Futema 2015 TC >9.3)) 
Information gathering (for all patients 
identified by search) 
£10.75 15 minutes GP practice nurse non-face-to-
face 
Clinical assessment for those that 
accept using DLCN criteria 
£37.50 30 minutes specialist nurse 
GP consultation for referral to lipid 
clinic 
£56.25 15 minutes GP 
Information pack for those that accept 
clinical assessment 
£2.00 assumed 
Genetic test for potential new index 
case 
£375.00 UK Genetic Testing Network website 
Healthcare and admin staff inputs 
index case testing mutation positive 
cases 
£396.24 Kerr 2016 
Healthcare and admin staff inputs 
index case testing mutation negative 
cases 
£199.74 Kerr 2016 
Lipid profile for those that accept 
clinical assessment 
£3.05 CG181 lipid modification model indexed to 
2015 
Expected cost £155.26 
 
   
Relatives of people with FH identified through primary care database search 
Offer cascade testing regardless of 
acceptance (all contacted relatives) 
£18.75 15 minutes nurse specialist 
Genetic test for relative where FH 
mutation is known 
£117.50 UK Genetic Testing Network website 
Healthcare and admin staff inputs 
relative testing mutation positive 
cases 
£279.07 Kerr 2016 (resource use Welsh FH service, 
unit costs PSSRU) 
Healthcare and admin staff inputs 
relative testing mutation negative 
cases 
£174.67 Kerr 2016 (resource use Welsh FH service, 
unit costs PSSRU) 
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Total cost of each strategy, adjusted for the probability of individual resource use 
Lipid profile for those that accept 
genetic testing 
£3.05 CG181 lipid modification model indexed to 
2015 
Expected cost £50.96 
 
         
5. Secondary care case identification and clinical assessment with SB    
People with a current clinical 
diagnosis of FH 
  
As per strategy 2 £521.33 
 
   
Relatives of people with a current clinical 
diagnosis of FH 
 
As per strategy 2 £191.22 
 
   
People with early MI (potential new 
index cases) 
  
Information gathering and invitation 
for further clinical assessment (all 
patients with early MI) 
£15.00 15 minutes hospital-based nurse band 7, 
no patient contact 
Clinical assessment using SB criteria £32.75 15 minutes hospital-based nurse band 7, 
patient contact 
Information pack with clinical 
assessment 
£2.00 assume 
Genetic test for potential new index 
case 
£375.00 UK Genetic Testing Network website 
Healthcare and admin staff inputs 
index case testing mutation positive 
cases 
£396.24 Kerr 2016 
Healthcare and admin staff inputs 
index case testing mutation negative 
cases 
£199.74 Kerr 2016 
Expected cost £339.90 
 
   
Relatives of people with FH who have had early 
MI 
 
Offer cascade testing regardless of 
acceptance (all contacted relatives) 
£32.75 15 minutes hospital-based nurse band 7, 
patient contact 
Genetic test for relative where FH 
mutation is known 
£117.50 UK Genetic Testing Network website 
Healthcare and admin staff inputs 
relative testing mutation positive 
cases 
£279.07 Kerr 2016 (resource use Welsh FH service, 
unit costs PSSRU) 
Healthcare and admin staff inputs 
relative testing mutation negative 
cases 
£174.67 Kerr 2016 (resource use Welsh FH service, 
unit costs PSSRU) 
Lipid profile for those that accept 
genetic testing 
£3.05 CG181 lipid modification model indexed to 
2015 
Expected cost £155.75 
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Total cost of each strategy, adjusted for the probability of individual resource use 
         
6. Secondary care case identification and clinical assessment with DLCN    
People with a current clinical 
diagnosis of FH 
  
As per strategy 2 £521.33 
 
   
Relatives of people with a current clinical 
diagnosis of FH 
 
As per strategy 2 £191.22 
 
   
People with early MI (potential new 
index cases) 
  
Information gathering and invitation 
for further clinical assessment (all 
patients with early MI) 
£15.00 15 minutes hospital-based nurse band 7, 
no patient contact 
Clinical assessment using DLCN 
criteria 
£65.50 30 minutes hospital-based nurse band 7, 
patient contact 
Information pack with clinical 
assessment 
£2.00 assume 
Genetic test for potential new index 
case 
£375.00 UK Genetic Testing Network website 
Healthcare and admin staff inputs 
index case testing mutation positive 
cases 
£396.24 Kerr 2016 
Healthcare and admin staff inputs 
index case testing mutation negative 
cases 
£199.74 Kerr 2016 
Expected cost £293.51 
 
   
Relatives of people with FH who have had early 
MI 
 
Offer cascade testing regardless of 
acceptance (all contacted relatives) 
£32.75 15 minutes hospital-based nurse band 7, 
patient contact 
Genetic test for relative where FH 
mutation is known 
£117.50 UK Genetic Testing Network website 
Healthcare and admin staff inputs 
relative testing mutation positive 
cases 
£279.07 Kerr 2016 (resource use Welsh FH service, 
unit costs PSSRU) 
Healthcare and admin staff inputs 
relative testing mutation negative 
cases 
£174.67 Kerr 2016 (resource use Welsh FH service, 
unit costs PSSRU) 
Lipid profile for those that accept 
genetic testing 
£3.05 CG181 lipid modification model indexed to 
2015 
Expected cost £150.67 
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Total cost of each strategy, adjusted for the probability of individual resource use 
7. Primary care and secondary care case identification with SB criteria    
People with a current clinical 
diagnosis of FH 
  
As per strategy 2 £521.33 
 
   
Relatives of people with a current clinical 
diagnosis of FH 
 
As per strategy 2 £191.22 
 
   
People identified by primary care database search (potential new index cases) 
As per strategy 3 £172.23 
 
   
Relatives of people with FH identified through primary care database search 
As per strategy 3 £52.68 
 
   
People with early MI (potential new 
index cases) 
  
As per strategy 5 £339.90 
 
   
Relatives of people with FH who have had early 
MI 
 
As per strategy 5 £155.75 
 
         
8. Primary care and secondary care case identification with DLCN criteria    
People with a current clinical 
diagnosis of FH 
  
As per strategy 2 £521.33 
 
   
Relatives of people with a current clinical 
diagnosis of FH 
 
As per strategy 2 £191.22 
 
   
People identified by primary care database search (potential new index cases) 
As per strategy 4 £155.26 
 
   
Relatives of people with FH identified through primary care database search 
As per strategy 4 £50.96 
 
   
People with early MI (potential new 
index cases) 
  
As per strategy 6 £293.51 
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Total cost of each strategy, adjusted for the probability of individual resource use 
Relatives of people with FH who have had early 
MI 
 
As per strategy 6 £150.67 
 
         
9. Primary care case identification with DLCN criteria, cascade testing currently diagnosed 
only (not relatives of new index cases) (used for sensitivity analysis only - see section O.4.3)    
People with a current clinical 
diagnosis of FH 
  
As per strategy 2 £521.33 
 
   
Relatives of people with a current clinical 
diagnosis of FH 
 
As per strategy 2 £191.22 
 
   
People identified by primary care database search (potential new index cases) 
Informatics setup and introduction 
session per at risk patient 
£17.13 1 hour of 2 GPs and 2 GP practice nurses ÷ 
31 (6127 patients per practice x 0.51% 
(Futema 2015 TC >9.3)) 
Information gathering (for all patients 
identified by search) 
£10.75 15 minutes GP practice nurse non-face-to-
face 
GP consultation for those that accept £56.25 15 minutes GP 
Lipid profile for those that accept £3.05 CG181 lipid modification model indexed to 
2015  
£43.48 
 
   
Relatives of people with FH identified through primary care database search 
No intervention £0.00 
 
   
People with early MI (potential new 
index cases) 
  
No intervention £0.00 
 
   
Relatives of people with FH who have had early 
MI 
 
No intervention £0.00 
 
      
 
O.3.2 Long term costs and QALYs for treated and untreated polygenic 
hypercholesterolaemia 
O.3.2.1 Long term clinical inputs 
On the advice of the committee, the lipid modification model (NICE CG181) was used to 
derive the risk of cardiac events, reduction in this risk due to treatment and how this 
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translates into improved survival and quality of life as accumulated through quality-adjusted 
life years. The CG181 model allows the user to specify underlying risk scores and the age 
and sex of patients who are then tracked over time and experience cardiovascular events 
(including myocardial infarction, stroke, transitory ishchaemic attack, heart failure, peripheral 
arterial disease, stable and unstable angina) that affect their HRQoL and mortality. The 
probabilities of these events happening are reduced by the use of statins. No changes were 
made to the clinical aspects of this model for the polygenic cohorts. Treatment was based on 
atorvastatin 20mg. A full description of the model can be found in the appendices of CG181. 
O.3.2.2 Long term costs 
The cost of cardiac events was updated to account for the latest NHS reference costs (2015-
16). For the polygenic cohort, the cost of atorvastatin 20 mg was £1.04 per pack (Drug Tariff 
November 2016) resulting in a first year cost with monitoring of £129.09 and £111.06 for 
subsequent years. 
Table 44: Cost of CVD events 
PROCEDURES Unit cost Source of cost Detail of source 
1x GP appointment  £    44.00  PSSRU 2015 (10.8b) 1 appointment: GP, 11.7 min, incl direct 
care staff costs and qualifications 
1x GP Nurse 
appointment 
 £    14.47  PSSRU 2015 (10.6) 1 appointment: GP practice nurse, 15.5 
min, £52 per hour of face-to-face contact 
including qualifications 
1x HCA 
appointment 
 £       5.17  PSSRU 2015 (10.5) 1 appointment: Clinical support worker 
nursing (community), 15.5 min (based on 
nurse appointment length), £25 per hour of 
patient-related work 
1x Cardiology initial 
appointment 
 £  156.00  NHS Ref Costs 2015-16 WF01B Consultant led 
1x Cardiology 
follow-up 
appointment 
 £  122.00  NHS Ref Costs 2015-16 WF01A Consultant led 
1x Cardiology 
follow-up non-
consultant led 
(nurse) 
 £    94.00  NHS Ref Costs 2015-16 WF01A Non-consultant led 
Angina 
hospitalisation 
£709.92 NHS Ref Costs 2015-16 Weighted average of EB13A-D 
MI (suspected) 
hospitalisation 
£1,497.47 NHS Ref Costs 2015-16 Weighted average of EB10A-E 
(50%) TIA 
hospitalisation 
£977.35 NHS Ref Costs 2015-16 Weighted average of AA29C-F 
Stroke 
hospitalisation 
£3,332.34 NHS Ref Costs 2015-16 Weighted average of AA35A-F 
HF hospitalisation £2,066.10 NHS Ref Costs 2015-16 Weighted average of EB03A-E 
(10%) PAD 
hospitalisation 
£1,808.69 NHS Ref Costs 2015-16 Weighted average of YQ50A-F 
(60%) PCI elective £2,320.92 NHS Ref Costs 2015-16 Weighted average of YR10A-C, YR11A-D: 
EI+EBD 
(5%) PCI elective £2,320.92 NHS Ref Costs 2015-16 Weighted average of YR10A-C, YR11A-D: 
EI+EBD 
PPCI emergency £7,396.07 NHS Ref Costs 2015-16 Weighted average of YR12Z, YR13Z, YR14A-
B, YR15A-C: NEI+NEEBD, NESS 
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PROCEDURES Unit cost Source of cost Detail of source 
(40%) Non-coronary 
PI 
£1,208.06 NHS Ref Costs 2015-16 Weighted average of YR23A-B, YR24C-D 
(10%) Non-coronary 
PI 
£1,208.06 NHS Ref Costs 2015-16 Weighted average of YR23A-B, YR24C-D 
(25%) Complex 
echocardiogram 
£253.04 NHS Ref Costs 2015-16 EY50Z 
(40%) CABG £10,875.62 NHS Ref Costs 2015-16 Weighted average of ED26A-C, ED27A-C, 
ED28A-C 
(5%) CABG £10,875.62 NHS Ref Costs 2015-16 Weighted average of ED26A-C, ED27A-C, 
ED28A-C 
Angiography £1,695.89 NHS Ref Costs 2015-16 Weighted average of EY43A-F 
(50%) CT scan, one 
area 
£138.75 NHS Ref Costs 2015-16 RD28Z Complex computerised tomography 
scan 
Stroke rehab 
programme 
£906.29 CG162 Stroke 
rehabilitation 
Appendix K.2.3.5 p705, indexed to 2016 
 
O.3.3 Long term costs and QALYs for treated and untreated familial 
hypercholesterolaemia 
The lipid modification model contained four health states that are at an increased risk of 
occurring in people with FH: 
 Stable angina 
 Unstable angina 
 Myocardial infarction 
 Death due to cardiovascular disease, of which coronary heart disease mortality is a 
component 
The risk of first events was adjusted in the model as well as the risk of these events 
occurring subsequent to other health states. 
The risk of the following events was left the same as the general population: 
 Transient ischaemic attack 
 Stroke 
 Heart failure 
 Peripheral artery disease 
Three sources were considered to inform the higher risk of cardiac events due to FH. Benn 
et al. (2016) provided a summary adjusted odds ratio of 3.3 (95% CI 1.7 to 6.4) for LDLR 
carriers and 1.3 (95% CI 0.6 to 2.5) for APOB carriers as well as odds ratios specifically for 
MI. However, this study was based on a Danish cohort and odds ratios are not reported 
separately by age and sex. Khera et al. (2016) provide a summary odds ratio for CAD of 3.8 
(95% CI 2.6 to 5.4). However, this study was based on an American cohort and odds ratios 
are not reported by age or sex. The Simon Broome Register Group (1999 and personal 
communication Humphries January 2017) provided data on the mortality of a UK cohort over 
multiple decades with standardised mortality ratios reported by age and sex. This data also 
provided results with males and females combined which was useful for the risk of 
subsequent events in the lipid modification model which used the same probabilities for 
males and females (subsequent events only). Therefore, the Simon Broome Register data 
was used to inform this parameter. One limitation of this data was it recorded mortality only. 
Therefore, the increased risk of mortality due to FH was extrapolated to represent non-fatal 
events as well. Extrapolating mortality data to represent non-fatal cardiac events was 
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consistent with prior economic analyses on FH (Kerr et al 2017; Chen 2015, Nherera 2011, 
NCCPC 2008). These baseline relative risks are provided inTables 45-47.The Simon Broome 
Register data was split into pre-1991 and post-1991 deaths, and all deaths combined, with 
the pre-1991 data representing untreated FH in an era before statins. There was less data 
for pre-1991 than post-1991. For example, there were only 2 deaths in males of 60-79 years 
of age. This lack of statistical power lead to a counter-intuitive finding of a relative risk 0.76. 
That is, FH had a protective effect for men in that age group. Although it may be plausible 
due to a survivor effect, it may have lead to anomalies in the model. The combined data 
provided more statistical power with relative risks in the right direction and this was used to 
inform the model. It was recognised this was a conservative approach with a large portion of 
this data subject to reduced risks due to statin treatment. But there was still a four-times 
greater and five-times greater risk for males and females respectively of coronary heart 
disease in the 40-59 age group based on this combined data. In males the relative risk of ~4 
was similar in pre and post 1991 data. In females the RR halved from ~10 to 5 after 1991 but 
the pre-1991 data was based on very few patients. The fact that most of the data came from 
patients with treated FH vs the general population was a limitation as what the long term 
model required was a relative risk of CVD in FH vs non-FH in people with a very high total 
cholesterol. If it can be inferred that people with treated high cholesterol have a similar risk to 
the general population then these data would be a reasonable proxy, however. It was 
recognised that although uncertain, these were the best data available but the RRs should 
be the subject of extreme sensitivity analysis (halving and doubling relative to 1). 
Table 45: Relative risk of coronary heart disease due to FH in males (first events) 
Age Relative risk 
40 4.0028 
45 4.0028 
55 4.0028 
65 1.6199 
75 1.6199 
85 1.6199 
 
Table 46: Relative risk of coronary heart disease due to FH in females (first events) 
Age Relative risk 
40 5.133 
45 5.133 
55 5.133 
65 2.2827 
75 2.2827 
85 2.2827 
Table 47: Relative risk of coronary heart disease due to FH in males and females 
(subsequent events) 
Age Relative risk 
40 4.179 
45 4.179 
55 4.179 
65 1.8842 
75 1.8842 
85 1.8842 
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The treatment effect in terms of relative risk of CVD events due to appropriate treatment with 
lipid modification is provided inTable 48. There has been no change to the figures used in 
CG181 for either the polygenic or familial hypercholesterolaemia populations due to a lack of 
evidence on the adult FH population identified in the clinical review. Placebo-controlled trials 
have not included people with FH because it is unethical to withhold treatment from patients 
with severe hypercholesterolaemia and high lifetime risk of CHD. Appropriate treatment with 
statins was assumed to result in the same relative reduction in CVD event risk whether that 
was achieved with statins or ezetimibe or a combination of both in the base case The 
committee suggested that relatively greater improvements might be seen in people with FH, 
however, so a sensitivity analysis was conducted where the treatment effect was assumed to 
bring CVD risk in people in FH down to the values in treated people with polygenic 
hypercholesterolaemia. 
Table 48: Treatment effect on CVD risk 
CVD event Relative risk 
Stable angina 0.46 
Unstable angina 0.46 
Myocardial infarction 0.46 
Transient ischaemic attack 0.8 
Stroke 0.8 
Heart failure 1 
Peripheral artery disease 0.46 
Cardiovascular mortality 0.73 
Non-cardiac mortality 0.96 
Note that although the relative treatment effect was the same as that used in the lipid 
modification model, the absolute risk of CHD for treated FH was still raised compared with 
the general and polygenic populations. Under treatment, the 10-year CVD risk for people 
with FH was typically similar to the untreated polygenic cohort of the same age and sex. 
Male sub populations are included in Table 48a below (the risks are broadly similar for 
females). Total CVD risks are higher than QRISK because they include the probability of 
developing Heart Failure and PAD:- 
Table 48a: Example 10 year CVD risks for sub populations within the model and 
alternatives explored in sensitivity analysis 
Age 
(Males) 
Equivilent 
polygenic 
QRISK 
Base 
Case 
 
Low RR with FH High RR with FH High RR + High 
Treatment 
Effect 
U
n
tr
ea
te
d
 
Tr
ea
te
d
 
U
n
tr
ea
te
d
 
Tr
ea
te
d
 
U
n
tr
ea
te
d
 
Tr
ea
te
d
 
U
n
tr
ea
te
d
 
Tr
ea
te
d
 
40 30% 78% 51% 62% 38% 94% 72% 94% 63% 
40 25% 70% 44% 54% 32% 89% 63% 89% 55% 
40 20% 60% 36% 45% 26% 81% 54% 81% 46% 
40 15% 49% 28% 35% 20% 69% 43% 69% 36% 
40 10% 35% 19% 25% 13% 53% 30% 53% 25% 
50 30% 77% 51% 61% 38% 93% 72% 93% 64% 
50 25% 69% 44% 53% 32% 88% 64% 88% 56% 
50 20% 59% 36% 44% 26% 80% 54% 80% 47% 
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Age 
(Males) 
Equivilent 
polygenic 
QRISK 
Base 
Case 
 
Low RR with FH High RR with FH High RR + High 
Treatment 
Effect 
U
n
tr
ea
te
d
 
Tr
ea
te
d
 
U
n
tr
ea
te
d
 
Tr
ea
te
d
 
U
n
tr
ea
te
d
 
Tr
ea
te
d
 
U
n
tr
ea
te
d
 
Tr
ea
te
d
 
50 15% 48% 28% 34% 20% 68% 43% 68% 37% 
50 10% 34% 19% 24% 13% 52% 30% 52% 25% 
60 30% 47% 31% 43% 29% 55% 36% 55% 31% 
60 25% 40% 26% 37% 24% 48% 30% 48% 26% 
60 20% 33% 21% 30% 19% 39% 24% 39% 21% 
60 15% 25% 16% 23% 14% 30% 18% 30% 16% 
60 10% 17% 10% 15% 10% 21% 12% 21% 10% 
70 30% 46% 32% 42% 30% 54% 36% 54% 32% 
70 25% 39% 26% 36% 25% 47% 30% 47% 26% 
70 20% 32% 21% 29% 20% 39% 24% 39% 21% 
70 15% 24% 16% 22% 15% 30% 18% 30% 16% 
70 10% 17% 11% 15% 10% 20% 12% 20% 11% 
The ‘high’ and ‘low’ risks here were calculated by arbitrarily doubling and halving the RR of 
FH relative to 1. The increased treatment effect was calculated using the lower confidence 
interval of the RRs associated with statin use for primary and secondary prevention. These 
are extreme values and not underpinned by an evidence base in the population with 
confirmed FH. The RRs are in Table 48b:- 
Table 48b: Relative CVD risks for Males and Females with FH 
Male Base Case SA Low RR SA High RR 
40 4.0028 2.5014 7.0056 
45 4.0028 2.5014 7.0056 
55 4.0028 2.5014 7.0056 
65 1.6199 1.30995 2.2398 
75 1.6199 1.30995 2.2398 
85 1.6199 1.30995 2.2398 
Female 
   
40 5.133 3.0665 9.266 
45 5.133 3.0665 9.266 
55 5.133 3.0665 9.266 
65 2.2827 1.64135 3.5654 
75 2.2827 1.64135 3.5654 
85 2.2827 1.64135 3.5654 
Both 
   
40 4.179 2.5895 7.358 
45 4.179 2.5895 7.358 
55 4.179 2.5895 7.358 
65 1.8842 1.4421 2.7684 
75 1.8842 1.4421 2.7684 
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Male Base Case SA Low RR SA High RR 
85 1.8842 1.4421 2.7684 
Two studies supported this continued increased absolute risk associated with FH despite 
treatment (Simon Broome Register Group 1999; Mohrschladt et al. 2004) but another two 
found this risk was reduced to the same level as the general population (Versmissen et al. 
2008; Neil et al. 2008). However, the cohorts compared by Versmissen et al. were older with 
a mean age of 61.6 years and contained only 24.5% men. Considering all 4 studies would 
have been based on a clinical diagnosis (rather than genetic) and, therefore, contained a 
large polygenic cohort, a conservative approach was taken and higher absolute risk of CHD 
(same relative risk due to treatment as the general population) retained with treatment. The 
treatment effects were heightened to the top of their observed confidences interval in all 
clinical domains in sensitivity analysis to move treated risk closer to that of the overall 
population. 
One limitation of this method is that it calculates costs and QALYs incorrectly for the very 
small subpopulation of this model who have already had an early MI. This limitation is minor, 
however, as this population is exactly the same among strategies so any error will cancel out 
and relative cost effectiveness results will be unaffected. 
O.3.3.1 Long term costs 
For the FH cohort, the cost of treatment was based on the proportion of people on high 
potency medicines from the Welsh, Scottish and Wessex FH services (Kerr et al., 2017) 
(Table 49). The proportion prescribed does not sum to 100% because some people take 
statins alone, some take ezetimibe alone, and some are prescribed both. 
Table 49: Cost of lipid modification for FH 
Dose 
Cost per 
pack 
Doses per 
pack 
Cost per 
dose 
Annual 
cost 
% 
prescribed 
Atorvastatin 80 mg £1.89 28 £0.07 £24.65 70.77% 
Rosuvastatin 40 
mg 
£29.69 28 £1.06 £387.30 15.53% 
Ezetimibe 10 mg £26.31 28 £0.94 £343.20 40.00% 
Weighted average       £214.89   
O.3.4 Expected long term costs and QALYs, FH and polygenic 
After adjusting for age, the Markov modules result in the following expected payoffs for the 
four cohorts (Table 49a). These figures represent the expected total, discounted cost and 
health outcomes experienced by each cohort over their lifetimes. That is, it is a summary of 
each of the four long term modules. Differences in QALYs and costs between males and 
females are predominantly due to different baseline risks of cardiovascular events and 
different adjustments in those risks due to FH. As might be expected, people with FH gain 
more costs and less QALYs from their significantly higher risk of experiencing cardiovascular 
events. These costs were weighted by age group within each sex and by possible baseline 
QRISK score of the polygenic population. In the absence of data on the prevalence of 
different QRISK scores among the population of interest, equal weight was given to QRISKs 
for 10%, 15%, 20%, 25% and 30%. This was varied from 100% having 10% to 100% having 
30% in sensitivity analysis. 
Table 49a – Expected lifetime costs and QALYs under base case assumptions 
Payoff Treated FH Untreated FH Treated 
polygenic 
Untreated 
polygenic 
Male - cost £12,045.05 £12,347.77 £6,270.82 £6,286.97 
 261 
 
Payoff Treated FH Untreated FH Treated 
polygenic 
Untreated 
polygenic 
Male - QALYs 12.13 11.22 12.97 12.35 
Females - cost £12,737.57 £13,237.78 £5,994.42 £5,765.35 
Females - QALYs 12.39 11.47 13.32 12.68 
Table 49a shows that if a case of FH can be found, it is highly cost effective to treat. Indeed it 
may be cost saving especially for women and men at younger ages due to the large 
reduction in CVD event costs outweighing the cost of high intensity statins. 
O.3.5 Sensitivity analysis 
One-way sensitivity analysis was conducted on several parameters (Table 50). 
The number of relatives approached for cascade testing in the base case was 2.22 based on 
the FH services in Wales, Scotland and Wessex as reported by Kerr et al. (2017). The 
committee viewed this figure as overly conservative as it was based on an incomplete 
national cascade testing service in England. Families are geographically spread and if most 
of the relatives for any given index case are in an area that does not have a FH service for 
screening relatives then the yield from the index cases is minimal. In the committee’s view, it 
should be possible to achieve a higher yield from cascade testing which is likely once the 
service is provided across England. Therefore, this parameter was testing in sensitivity 
analysis up to 12 relatives per patient based on the assumption used in a previous NICE 
costing report.  
The other parameters tested and their sources are listed below. 
Table 50: Parameters varied in sensitivity analysis 
Parameter Low value 
High 
value Source 
Prevalence monogenic FH in 
general population 
0.20% 0.46% Upper: Benn et al. 2016; lower 
same as base case 
Take up of genetic testing by people 
with a current clinical diagnosis of 
FH prior to cascade testing 
69.10% 98.9% Range from clinical review 
Proportion database search that 
warrant further investigation 
0.50% 2.36% Futema 2015, total cholesterol 
>9.3mmol/L 
Prevalence of FH in people 
identified by primary care database 
search 
15% 41.18% Futema 2015 range 
Proportion of people with high 
cholesterol already on statins 
10% 99.00% Expert advice 
Take up of clinical assessment and 
genetic testing by people identified 
by primary care database search 
26% 50% Expert advice 
Prevalence of FH in people with 
early MI (secondary care) 
0.30% 8.30% Lower: 95% CI Wald 2015; 
Higher: De Backer 2015 
Take up of clinical assessment and 
genetic testing by people with early 
MI 
54.38% 90.63% 25% higher and lower than 
expected 
Number of relatives invited for 
cascade testing per index case 
2 12 NICE CG71 Costing Report 
2009 
Take up by relatives of cascade 
testing from currently diagnosed FH 
population 
44.92% 74.86% 25% higher and lower than 
expected 
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Parameter Low value 
High 
value Source 
Take up by relatives of clinical 
assessment and genetic testing from 
people identified in primary care 
44.92% 74.86% 25% higher and lower than 
expected 
Take up by relatives of clinical 
assessment and genetic testing from 
people with early MI (secondary 
care) 
44.92% 74.86% 25% higher and lower than 
expected 
Cost of genetic testing index case £287.00 £460.00 UK genetic testing network 
Cost of genetic testing relative £75.00 £175.00 UK genetic testing network 
In addition, a ‘rule in’ profile was used in a sensitivity analysis for the clinical assessment 
tools where a higher threshold for referral to lipid clinics was adopted. In the base case, both 
possible and and definite findings using the Simon Broome criteria and DLCN criteria scores 
greater than 5 were referred for genetic testing. In this sensitivity analysis, only definite cases 
of FH using either criteria were referred for genetic testing. Additional detail on this can be 
found above Table 38. 
A scenario analysis was conducted with an additional strategy where all people with high 
cholesterol were identified and put onto statins regardless of their FH status or genetic 
testing to isolate the incremental benefit of simply ensuring anyone with high cholesterol is 
appropriately treated with high-intensity statins. 
Futema et al. (2015) provided alternative thresholds for primary care case identification and 
the proportion of people that require further investigation and prevalence associated with 
those alternative thresholds. The second threshold option (the first being the base case of 
total cholesterol greater than 9.3 mmol/L) was to exclude people with triglyceride levels 
above 2.3 mmol/L as these people are unlikely to have FH, enhancing the accuracy of the 
primary care database search.  
Table 51: Primary care search criteria at alternative thresholds 
Search algorithm 
Proportion 
requiring 
further 
investigation 
Prevalence of 
mutation 
positive FH in 
this proportion Notes 
Futema 2015 TC >9.3 
(base case) 
0.51% 28.00% Includes people with 
triglycerides > 2.3 mmol/L 
Futema 2015 TC >9.3 & 
TG <2.3 
0.35% 41.18% Excludes people with 
triglycerides > 2.3 mmol/L 
O.3.6 Probabilistic sensitivity anlaysis 
One way sensitivity analysis tests the robustness of results by varying one parameter at a 
time. Probabilistic sensitivity analysis tests the uncertainty in results by taking account of the 
joint uncertainty in several parameters at the same time by conducting Monte Carlo 
simulation. This is operationalised by establishing distributions around the means of these 
parameters. Sensitivity was correlated with specificity via Diagnostic Odds Ratios (DORs) 
rather than variance-covariance matrices as the clinical review did not identify enough data 
to power the latter. DORs were assumed to be fixed in the PSA rather than varied about their 
means. 
The following clinical parameters were varied in the short term. 
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Table 52: PSA short term clinical parameters 
Parameter Distribution alpha beta 
Proportion database search that warrant further 
investigation 
beta 831 34,607 
Prevalence of FH in people identified by primary care 
database search 
beta 24 1,362 
Take up of clinical assessment and genetic testing by 
people identified by primary care database search 
beta 719 2,042 
Prevalence of FH in people with early MI (secondary care) beta 2 158 
Take up of clinical assessment and genetic testing by 
people with early MI 
beta 167 63 
Take up by relatives of cascade testing from currently 
diagnosed FH population 
beta 768 515 
Take up by relatives of clinical assessment and genetic 
testing from people identified in primary care 
beta 768 515 
Take up by relatives of clinical assessment and genetic 
testing from people with early MI (secondary care) 
beta 768 515 
Sensitivity Simon Broome possible or definite FH  correlated to 
spec 
    
Specificity Simon Broome possible or definite FH beta 8.21 20.38 
Sensitivity Simon Broome definite FH correlated to 
spec 
    
Specificity Simon Broome definite FH beta 9.99 0.64 
Sensitivity DLCN probable, definite FH (>=6) correlated to 
spec 
    
Specificity DLCN probable, definite FH (>=6) beta 21.61 25.68 
Sensitivity DLCN definite FH (>8) correlated to 
spec 
    
Specificity DLCN definite FH (>8) beta 79.61 19.66 
The cost of genetic test was varied in PSA as follows. 
Table 53: Genetic testing PSA parameters 
Distribution alpha beta Mean se Source 
gamma 16.00 23.44 375 93.75 approximation 
gamma 16.00 7.34 117.5 29.375 approximation 
The 95% confidence intervals provided in the Simon Broome data were included as follows: 
Table 54: Relative risk of CHD due to FH PSA parameters 
Male Mean RR Lower CI Upper CI ln(RR) se(ln(RR)) 
40 4.0028 2.83 5.49 1.386994 0.169044 
45 4.0028 2.83 5.49 1.386994 0.169044 
55 4.0028 2.83 5.49 1.386994 0.169044 
65 1.6199 1.19 2.16 0.482364 0.15208 
75 1.6199 1.19 2.16 0.482364 0.15208 
85 1.6199 1.19 2.16 0.482364 0.15208 
Female 
     
40 5.133 2.35 9.74 1.63569 0.362711 
45 5.133 2.35 9.74 1.63569 0.362711 
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Male Mean RR Lower CI Upper CI ln(RR) se(ln(RR)) 
55 5.133 2.35 9.74 1.63569 0.362711 
65 2.2827 1.65 3.07 0.825359 0.158393 
75 2.2827 1.65 3.07 0.825359 0.158393 
85 2.2827 1.65 3.07 0.825359 0.158393 
The uncertainty around long term costs and QALYs was established by taking the simulation 
output from the lipid modification model for a broadly representative set of age and sex 
subpopulations and using the maximum observed standard error as a percentage of the 
mean for these samples to represent a normal distribution around the deterministic estimates 
from the model. Different estimates were taken for costs and QALYs for the FH and 
polygenic cohorts to ensure differences in relative uncertainy were accounted for. Due to the 
tightness of the observed distributions, the simplicity of this methodology (versus one that ran 
probabilistic sensitivity analysis for every single sub population and then averaged the 
results) was not expected to affect any conclusions drawn from the model. 
Table 55: Maximum SEs for Payoffs relative to the mean values 
  Max se as a % of 
mean Costs 
Max se as a % of 
mean QALYs 
Polygenic 2.58% 1.05% 
FH 5.44% 2.50% 
O.4 Results 
The identification and diagnosis decision tree module calculated the proportion of each 
subgroup allocated to the long term modules. This was converted into the number of actual 
people allocated using the estimates of each subpopulation that come into contact with the 
interventions. 
Under the base case settings of the model, the maximum number of people with FH that a 
perfectly sensitive strategy would have been able to diagnose was 43,963 (at 100% take up 
rates, sensitivity and specificity). This assumes a data availability rate of 31% in primary 
care, which crucially determines the number of people that are ‘able to be found’ by the case 
finding strategies and includes the relatives found through cascade testing strategies. 
Strategy 1 (no intervention) assumed that 20% of these people would already be receiving 
treatment with statins for high cholesterol, whether they had a clinical diagnosis of FH or not. 
Based on the assumptions in the model, only about 4,000 of the current 18,000 people with a 
clinical diagnosis of FH would have a monogenic mutation if diagnosed definitively via 
genetic testing.  
Cascade testing only, strategy 2, resulted in 2,355 relatives being diagnosed and treated, 
increasing the proportion of people with FH who were treated to 25%. 
The primary care case identification strategies resulted in 6,100 people in primary care with 
FH being diagnosed along with over 2000 of their relatives. This equated to 37% of people 
with FH in the model being identified. 
Due to the relatively small numbers of people with early MI, secondary care case 
identification strategies identified about 600 relatives with FH.  
The maximum number of people identified and diagnosed with FH was achieved by Strategy 
7, primary care and secondary care case identification with clinical assessment using the 
Simon Broome criteria in addition to cascade testing. 
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Table 50: Base case, number of people allocated to long term modules by 
subpopulation and strategy 
 
 
Treate
d FH  
 
Untreat
ed FH  
 Treated 
polygeni
c  
 
Untreat
ed 
polygen
ic  
 1. No cascade testing and no case identification  
 Current clinical diagnosis of FH           
4,136  
                  
-    
           
13,864  
                  
-    
 Relatives of people with a current clinical diagnosis of 
FH  
                
-    
           
4,675  
                    
-    
                  
-    
 People identified by a primary care database search           
2,922  
         
12,217  
             
7,513  
         
31,416  
 Relatives of people identified by a primary care 
database search  
                
-    
         
17,109  
                    
-    
                  
-    
 People with early MI           
1,363  
                  
-    
         
103,470  
                  
-    
 Relatives of people with early MI                  
-    
           
1,540  
                    
-    
                  
-    
 2. Cascade testing  
 Current clinical diagnosis of FH           
4,136  
                  
-    
           
13,864  
                  
-    
 Relatives of people with a current clinical diagnosis of 
FH  
         
2,355  
           
2,320  
                    
-    
                  
-    
 People identified by a primary care database search           
2,922  
         
12,217  
             
7,513  
         
31,416  
 Relatives of people identified by a primary care 
database search  
                
-    
         
17,109  
                    
-    
                  
-    
 People with early MI           
1,363  
                  
-    
         
103,470  
                  
-    
 Relatives of people with early MI                  
-    
           
1,540  
                    
-    
                  
-    
 3. Primary care case identification, clinical assessment with SB criteria  
 Current clinical diagnosis of FH           
4,136  
                  
-    
           
13,864  
                  
-    
 Relatives of people with a current clinical diagnosis of 
FH  
         
2,355  
           
2,320  
                    
-    
                  
-    
 People identified by a primary care database search           
6,102  
           
9,037  
           
15,691  
         
23,239  
 Relatives of people identified by a primary care 
database search  
         
2,374  
         
14,736  
                    
-    
                  
-    
 People with early MI           
1,363  
                  
-    
         
103,470  
                  
-    
 Relatives of people with early MI                  
-    
           
1,540  
                    
-    
                  
-    
 4. Primary care case identification, clinical assessment with DLCN criteria  
 Current clinical diagnosis of FH           
4,136  
                  
-    
           
13,864  
                  
-    
 Relatives of people with a current clinical diagnosis of 
FH  
         
2,355  
           
2,320  
                    
-    
                  
-    
 People identified by a primary care database search           
6,102  
           
9,037  
           
15,691  
         
23,239  
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Treate
d FH  
 
Untreat
ed FH  
 Treated 
polygeni
c  
 
Untreat
ed 
polygen
ic  
 Relatives of people identified by a primary care 
database search  
         
2,297  
         
14,813  
                    
-    
                  
-    
 People with early MI           
1,363  
                  
-    
         
103,470  
                  
-    
 Relatives of people with early MI                  
-    
           
1,540  
                    
-    
                  
-    
 5. Secondary care case identification, clinical assessment with SB criteria  
 Current clinical diagnosis of FH           
4,136  
                  
-    
           
13,864  
                  
-    
 Relatives of people with a current clinical diagnosis of 
FH  
         
2,355  
           
2,320  
                    
-    
                  
-    
 People identified by a primary care database search           
2,922  
         
12,217  
             
7,513  
         
31,416  
 Relatives of people identified by a primary care 
database search  
                
-    
         
17,109  
                    
-    
                  
-    
 People with early MI           
1,363  
                  
-    
         
103,470  
                  
-    
 Relatives of people with early MI              
595  
               
945  
                    
-    
                  
-    
 6. Secondary care case identification, clinical assessment with DLCN criteria  
 Current clinical diagnosis of FH           
4,136  
                  
-    
           
13,864  
                  
-    
 Relatives of people with a current clinical diagnosis of 
FH  
         
2,355  
           
2,320  
                    
-    
                  
-    
 People identified by a primary care database search           
2,922  
         
12,217  
             
7,513  
         
31,416  
 Relatives of people identified by a primary care 
database search  
                
-    
         
17,109  
                    
-    
                  
-    
 People with early MI           
1,363  
                  
-    
         
103,470  
                  
-    
 Relatives of people with early MI              
576  
               
964  
                    
-    
                  
-    
 7. Primary care and secondary care case identification with SB criteria  
 Current clinical diagnosis of FH           
4,136  
                  
-    
           
13,864  
                  
-    
 Relatives of people with a current clinical diagnosis of 
FH  
         
2,355  
           
2,320  
                    
-    
                  
-    
 People identified by a primary care database search           
6,102  
           
9,037  
           
15,691  
         
23,239  
 Relatives of people identified by a primary care 
database search  
         
2,374  
         
14,736  
                    
-    
                  
-    
 People with early MI           
1,363  
                  
-    
         
103,470  
                  
-    
 Relatives of people with early MI              
595  
               
945  
                    
-    
                  
-    
 8. Primary care and secondary care case identification with DLCN criteria  
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d FH  
 
Untreat
ed FH  
 Treated 
polygeni
c  
 
Untreat
ed 
polygen
ic  
 Current clinical diagnosis of FH           
4,136  
                  
-    
           
13,864  
                  
-    
 Relatives of people with a current clinical diagnosis of 
FH  
         
2,355  
           
2,320  
                    
-    
                  
-    
 People identified by a primary care database search           
6,102  
           
9,037  
           
15,691  
         
23,239  
 Relatives of people identified by a primary care 
database search  
         
2,297  
         
14,813  
                    
-    
                  
-    
 People with early MI           
1,363  
                  
-    
         
103,470  
                  
-    
 Relatives of people with early MI              
595  
               
945  
                    
-    
                  
-    
 
The overall results of the base case scenario produced when the proportion of people 
assigned to each module were combined with short term costs, long term costs and long 
term health benefits are reported in Table 49a. At a cost-effectivenes threshold of £20,000, 
Strategy 3, primary care case identification and clinical assessment with the Simon Broome 
criteria (in addition to cascade testing), was the most cost-effective strategy with the highest 
net monetary benefit. Table 58reports these results in terms of incremental analysis. Strategy 
3 was the most cost-effective strategy because it had the highest incremental cost-
effectiveness ratio up to the threshold of £20,000 per QALY. 
Table 51: Base case results, ranked by NMB, £20,000/QALY threshold 
Strategy Cost QALYs NMB Rank 
1. No cascade testing and no case identification £6,797.2
6 
11.408 221,355 8 
2. Cascade testing £6,843.0
3 
11.417 221,503 5 
3. Primary care case identification, clinical assessment 
with SB criteria 
£6,886.6
5 
11.463 222,379 1 
4. Primary care case identification, clinical assessment 
with DLCN criteria 
£6,882.4
1 
11.463 222,377 2 
5. Secondary care case identification, clinical 
assessment with SB criteria 
£7,004.0
5 
11.420 221,391 7 
6. Secondary care case identification, clinical 
assessment with DLCN criteria 
£6,982.1
9 
11.420 221,411 6 
7. Primary and secondary care case identification, 
clinical assessment with SB criteria 
£7,047.6
7 
11.466 222,267 4 
8. Primary and secondary care case identification, 
clinical assessment with DLCN criteria 
£7,021.5
3 
11.465 222,287 3 
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Table 52: Incremental base case results 
Strategy Cost 
QALY
s ICER 
1. No cascade testing and no case identification £6,797 11.408 £0 
2. Cascade testing £6,843 11.417 Ext.Dom 
4. Primary care case identification, clinical assessment with DLCN 
criteria 
£6,882 11.463 £1,538 
3. Primary care case identification, clinical assessment with SB 
criteria 
£6,887 11.463 £13,361 
6. Secondary care case identification, clinical assessment with 
DLCN criteria 
£6,982 11.420 Dominat
ed 
5. Secondary care case identification, clinical assessment with SB 
criteria 
£7,004 11.420 Dominat
ed 
8. Primary and secondary care case identification, clinical 
assessment with DLCN criteria 
£7,022 11.465 £63,492 
7. Primary and secondary care case identification, clinical 
assessment with SB criteria 
£7,048 11.466 £82,374 
 
Strategy 3 had an ICER of £13,361/QALY compared with strategy 4, which was associated 
with an ICER of £1,538 vs no genetic testing although the differences in costs and QALYs 
between strategies 3 and 4 were very small. Strategies 7 and 8 had an ICERs well above the 
threshold usually considered cost effective by NICE. 
Figure 13: Base case, cost-effectiveness plane 
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O.4.1 Base case, total short term economic cost 
The total short term economic cost is reported in Table 59. The table below reports short 
term opportunity cost only. It does not report long term treatment costs or, more importantly, 
health benefits gained over the lifetime of people who are properly diagnosed and treated. 
Long term costs were dependent on the assumptions underpinning the distribution of risk 
scores and age groups in the target populations and very small in net terms due to cost 
savings associated with the effectiveness of treating FH and polygenic 
hypercholesterolaemia. The short term cost has therefore been presented alone to allow 
comparisons of the main differences between the proposed strategies including where the 
resource impact is likely to fall. 
Table 53: Total short term economic cost by setting, strategy and subpopulation 
Summary table for report - short term costs only   
Strategy/subpopulation Cost to 
primary care 
Cost to 
secondary care 
Cost of genetic 
testing 
1. No cascade testing and no case 
identification 
- - - 
Current clinical diagnosis of FH - - - 
Relatives of people with a current clinical 
diagnosis of FH 
- - - 
People identified by a primary care database 
search 
- - - 
Relatives of people identified by a primary care 
database search 
- - - 
People with early MI - - - 
Relatives of people with early MI - - - 
Total £0 £0 £0 
2. Cascade testing       
Current clinical diagnosis of FH £0 £3,707,181 £5,676,750 
Relatives of people with a current clinical 
diagnosis of FH 
£0 £1,212,909 £543,636 
People identified by a primary care database 
search 
£0 £0 £0 
Relatives of people identified by a primary care 
database search 
£0 £0 £0 
People with early MI £0 £0 £0 
Relatives of people with early MI £0 £0 £0 
Total £0 £4,920,090 £6,220,386 
3. Primary care case identification, clinical assessment with SB criteria 
Current clinical diagnosis of FH £0 £3,707,181 £5,676,750 
Relatives of people with a current clinical 
diagnosis of FH 
£0 £1,212,909 £543,636 
People identified by a primary care database 
search 
£2,446,238 £2,832,836 £4,024,651 
Relatives of people identified by a primary care 
database search 
£0 £1,222,871 £548,101 
People with early MI £0 £0 £0 
Relatives of people with early MI £0 £0 £0 
Total £2,446,238 £8,975,796 £10,793,137 
4. Primary care case identification, clinical assessment with DLCN criteria 
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Summary table for report - short term costs only   
Current clinical diagnosis of FH £0 £3,707,181 £5,676,750 
Relatives of people with a current clinical 
diagnosis of FH 
£0 £1,212,909 £543,636 
People identified by a primary care database 
search 
£2,606,800 £2,443,471 £3,335,790 
Relatives of people identified by a primary care 
database search 
£0 £1,222,871 £530,241 
People with early MI £0 £0 £0 
Relatives of people with early MI £0 £0 £0 
Total £2,606,800 £8,586,431 £10,086,417 
5. Secondary care case identification, clinical assessment with SB criteria 
Current clinical diagnosis of FH £0 £3,707,181 £5,676,750 
Relatives of people with a current clinical 
diagnosis of FH 
£0 £1,212,909 £543,636 
People identified by a primary care database 
search 
£0 £0 £0 
Relatives of people identified by a primary care 
database search 
£0 £0 £0 
People with early MI £0 £15,245,282 £20,387,178 
Relatives of people with early MI £0 £333,945 £137,423 
Total £0 £20,499,317 £26,744,987 
6. Secondary care case identification, clinical assessment with DLCN criteria 
Current clinical diagnosis of FH £0 £3,707,181 £5,676,750 
Relatives of people with a current clinical 
diagnosis of FH 
£0 £1,212,909 £543,636 
People identified by a primary care database 
search 
£0 £0 £0 
Relatives of people identified by a primary care 
database search 
£0 £0 £0 
People with early MI £0 £15,175,875 £15,594,160 
Relatives of people with early MI £0 £333,945 £132,945 
Total £0 £20,429,910 £21,947,491 
7. Primary care and secondary care case identification with SB criteria 
Current clinical diagnosis of FH £0 £3,707,181 £5,676,750 
Relatives of people with a current clinical 
diagnosis of FH 
£0 £1,212,909 £543,636 
People identified by a primary care database 
search 
£2,446,238 £2,832,836 £4,024,651 
Relatives of people identified by a primary care 
database search 
£0 £1,222,871 £548,101 
People with early MI £0 £15,245,282 £20,387,178 
Relatives of people with early MI £0 £333,945 £137,423 
Total £2,446,238 £24,555,023 £31,317,738 
8. Primary care and secondary care case identification with DLCN criteria 
Current clinical diagnosis of FH £0 £3,707,181 £5,676,750 
Relatives of people with a current clinical 
diagnosis of FH 
£0 £1,212,909 £543,636 
 271 
 
Summary table for report - short term costs only   
People identified by a primary care database 
search 
£2,606,800 £2,443,471 £3,335,790 
Relatives of people identified by a primary care 
database search 
£0 £1,222,871 £530,241 
People with early MI £0 £15,175,875 £15,594,160 
Relatives of people with early MI £0 £333,945 £132,945 
Total £2,606,800 £24,096,251 £25,813,523 
 
The low specificities of clinical assessment tools result in people being referred for genetic 
testing even they they do not have FH. Table 60 reports the number of tests this resulted in 
for the entire population of England and Wales and the cost associated with this based on 
the base case median cost of genetic testing. The fourth and fifth columns encapsulate all 
other genetic testing (true positive clinical assessments, cascade testing for relatives that do 
and do not have FH). This table contains no information on the long term costs and health 
benefits of correctly diagnosing and treating people with FH or polygenic 
hypercholesterolaemia. 
Table 54: Base case, cost of genetic testing for false positive clinical assessments vs. 
others 
1. No cascade testing and no case identification     
Current clinical diagnosis of FH 0 £0 0 £0 
Relatives of people with a current clinical 
diagnosis of FH 
0 £0 0 £0 
People identified by a primary care database 
search 
0 £0 0 £0 
Relatives of people identified by a primary care 
database search 
0 £0 0 £0 
People with early MI 0 £0 0 £0 
Relatives of people with early MI 0 £0 0 £0 
Total 0 £0 0 £0 
2. Cascade testing       
Current clinical diagnosis of FH 0 £0 15,138 £5,676,75
0 
Relatives of people with a current clinical 
diagnosis of FH 
0 £0 4,627 £543,636 
People identified by a primary care database 
search 
0 £0 0 £0 
Relatives of people identified by a primary care 
database search 
0 £0 0 £0 
People with early MI 0 £0 0 £0 
Relatives of people with early MI 0 £0 0 £0 
Total 0 £0 19,765 £6,220,38
6 
3. Primary care case identification, clinical assessment with SB criteria   
Current clinical diagnosis of FH 0 £0 15,138 £5,676,75
0 
Relatives of people with a current clinical 
diagnosis of FH 
0 £0 4,627 £543,636 
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1. No cascade testing and no case identification     
People identified by a primary care database 
search 
7,2
25 
£2,709,419 3,507 £1,315,23
2 
Relatives of people identified by a primary care 
database search 
0 £0 4,665 £548,101 
People with early MI 0 £0 0 £0 
Relatives of people with early MI 0 £0 0 £0 
Total 7,2
25 
£2,709,419 27,937 £8,083,71
8 
4. Primary care case identification, clinical assessment with DLCN criteria   
Current clinical diagnosis of FH 0 £0 15,138 £5,676,75
0 
Relatives of people with a current clinical 
diagnosis of FH 
0 £0 4,627 £543,636 
People identified by a primary care database 
search 
5,5
02 
£2,063,415 3,393 £1,272,37
6 
Relatives of people identified by a primary care 
database search 
0 £0 4,513 £530,241 
People with early MI 0 £0 0 £0 
Relatives of people with early MI 0 £0 0 £0 
Total 5,5
02 
£2,063,415 27,670 £8,023,00
3 
5. Secondary care case identification, clinical assessment with SB criteria   
Current clinical diagnosis of FH 0 £0 15,138 £5,676,75
0 
Relatives of people with a current clinical 
diagnosis of FH 
0 £0 4,627 £543,636 
People identified by a primary care database 
search 
0 £0 0 £0 
Relatives of people identified by a primary care 
database search 
0 £0 0 £0 
People with early MI 53,
48
6 
£20,057,415 879 £329,763 
Relatives of people with early MI 0 £0 1,170 £137,423 
Total 53,
48
6 
£20,057,415 21,814 £6,687,57
2 
6. Secondary care case identification, clinical assessment with DLCN criteria   
Current clinical diagnosis of FH 0 £0 15,138 £5,676,75
0 
Relatives of people with a current clinical 
diagnosis of FH 
0 £0 4,627 £543,636 
People identified by a primary care database 
search 
0 £0 0 £0 
Relatives of people identified by a primary care 
database search 
0 £0 0 £0 
People with early MI 40,
73
4 
£15,275,142 851 £319,018 
Relatives of people with early MI 0 £0 1,131 £132,945 
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1. No cascade testing and no case identification     
Total 40,
73
4 
£15,275,142 21,747 £6,672,34
9 
7. Primary care and secondary care case identification with SB criteria   
Current clinical diagnosis of FH 0 £0 15,138 £5,676,75
0 
Relatives of people with a current clinical 
diagnosis of FH 
0 £0 4,627 £543,636 
People identified by a primary care database 
search 
7,2
25 
£2,709,419 3,507 £1,315,23
2 
Relatives of people identified by a primary care 
database search 
0 £0 4,665 £548,101 
People with early MI 53,
48
6 
£20,057,415 879 £329,763 
Relatives of people with early MI 0 £0 1,170 £137,423 
Total 60,
71
2 
£22,766,834 29,986 £8,550,90
4 
8. Primary care and secondary care case identification with DLCN criteria   
Current clinical diagnosis of FH 0 £0 15,138 £5,676,75
0 
Relatives of people with a current clinical 
diagnosis of FH 
0 £0 4,627 £543,636 
People identified by a primary care database 
search 
5,5
02 
£2,063,415 3,393 £1,272,37
6 
Relatives of people identified by a primary care 
database search 
0 £0 4,513 £530,241 
People with early MI 40,
73
4 
£15,275,142 851 £319,018 
Relatives of people with early MI 0 £0 1,131 £132,945 
Total 46,
23
6 
£17,338,557 29,653 £8,474,96
6 
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O.4.2 One way sensitivity analysis 
The results of the one way sensitivity analysis are reported in terms of rank based on net monetary benefit because of the large number of 
strategies and parameters varied as a simplified method of identifying when results change. The results are grouped as follows: 
 Prevalence of FH 
 Take up of interventions 
 Number of relatives and cost of genetic testing 
 Entire population assigned specific QRISK scores rather than spread evenly across scores 
All rankings are based on deterministic net monetary benefit using a cost-effectiveness threshold of £20,000 per QALY, where rank 1 is the 
most cost effective strategy. A discussion of the results appears below the tables. 
Table 55: One way sensitivity analysis, prevalence of FH 
  Base Case 
Analysis 
General 
population 
Identified by 
primary care 
database search 
People with 
early MI 
Strategy  Low High Low High Low High 
Amounts >  0.20% 0.46% 15.00% 41.18% 0.30% 8.30% 
1. No cascade testing and no case identification 8 8 8 8 8 8 8 
2. Cascade testing 5 5 5 5 5 5 7 
3. Primary care case identification, clinical assessment with SB criteria 1 1 1 2 1 1 3 
4. Primary care case identification, clinical assessment with DLCN criteria 2 2 2 1 2 2 4 
5. Secondary care case identification, clinical assessment with SB criteria 7 7 7 7 7 7 6 
6. Secondary care case identification, clinical assessment with DLCN criteria 6 6 6 6 6 6 5 
7. Primary and secondary care case identification, clinical assessment with SB criteria 4 4 4 4 4 4 2 
8. Primary and secondary care case identification, clinical assessment with DLCN 
criteria 
3 3 3 3 3 3 1 
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Table 56: One way sensitivity analysis, take up of interventions 
  Current clinical 
diagnosis of FH 
Identified by 
primary care 
database search 
Early MI Relatives of 
current clinical 
diagnosis 
Relatives of new 
primary care 
index cases 
Relatives of new 
secondary care 
index cases 
Strategy Low High Low High Low High Low High Low High Low High 
Amount > 69.10% 98.90% 13.00% 50.00% 54.38% 90.63% 44.92% 74.86% 44.92% 74.86% 44.92% 74.86% 
1. No cascade testing and no case 
identification 
7 8 8 8 8 7 6 8 8 8 8 8 
2. Cascade testing 5 5 5 5 5 5 5 5 5 5 5 5 
3. Primary care case identification, 
clinical assessment with SB criteria 
1 1 1 1 1 1 1 1 1 1 1 1 
4. Primary care case identification, 
clinical assessment with DLCN 
criteria 
2 2 2 2 2 2 2 2 2 2 2 2 
5. Secondary care case 
identification, clinical assessment 
with SB criteria 
8 7 7 7 7 8 8 7 7 7 7 7 
6. Secondary care case 
identification, clinical assessment 
with DLCN criteria 
6 6 6 6 6 6 7 6 6 6 6 6 
7. Primary and secondary care case 
identification, clinical assessment 
with SB criteria 
4 4 4 4 4 4 4 4 4 4 4 4 
8. Primary and secondary care case 
identification, clinical assessment 
with DLCN criteria 
3 3 3 3 3 3 3 3 3 3 3 3 
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Table 57: One way sensitivity analysis, number of relatives and cost of genetic testing 
  Base Case 
Analysis 
Number of 
relatives 
Cost of genetic 
testing 
Strategy  Low High Low High 
Amount >  1 12 £287.00 £460.00 
1. No cascade testing and no case identification 8 6 8 8 7 
2. Cascade testing 5 5 7 5 5 
3. Primary care case identification, clinical assessment with SB criteria 1 2 3 1 1 
4. Primary care case identification, clinical assessment with DLCN criteria 2 1 4 2 2 
5. Secondary care case identification, clinical assessment with SB criteria 7 8 6 7 8 
6. Secondary care case identification, clinical assessment with DLCN criteria 6 7 5 6 6 
7. Primary and secondary care case identification, clinical assessment with SB criteria 4 4 1 4 4 
8. Primary and secondary care case identification, clinical assessment with DLCN 
criteria 
3 3 2 3 3 
Table 58: One way sensitivity analysis, alternative QRISK scores 
  Proportion 
assigned to risk 
bands 
Strategy QRISK 
Amount > 30% 20% 10% 
1. No cascade testing and no case identification 8 8 6 
2. Cascade testing 5 5 5 
3. Primary care case identification, clinical assessment with SB criteria 1 1 1 
4. Primary care case identification, clinical assessment with DLCN criteria 2 2 2 
5. Secondary care case identification, clinical assessment with SB criteria 7 7 8 
6. Secondary care case identification, clinical assessment with DLCN criteria 6 6 7 
7. Primary and secondary care case identification, clinical assessment with SB criteria 4 4 4 
  
Clinical Guideline 71.1 (Familial Hypercholesterolaemia) 
Glossary and abbreviations 
 
277 
  Proportion 
assigned to risk 
bands 
8. Primary and secondary care case identification, clinical assessment with DLCN 
criteria 
3 3 3 
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Discussion of one-way sensitivity analysis 
When the prevalence of FH in people identified for further investigation in primary care was 
decreased to 20%, strategy 4, primary care case identification with clinical assessment using 
the DLCN criteria, became the most cost-effective strategy, with strategy 3 ranked second. 
Some exploratory threshold analysis was also conducted on this parameter and found that 
the prevalence of FH in the target group would have to decrease to 3.2% before primary care 
case-finding became cost-ineffective. There is no good reason to believe that the true value 
would be this low but this is also not hard evidence for a more inclusive case-finding strategy; 
it should be noted that low prevalence values in the target group would likely mean that such 
a strategy would not be robust to additional deterministic sensitivity analysis. 
When the prevalence of FH in people with early MI was increased to an upper estimate of 
8.3%, strategy 8, primary care and secondary care case identification with clinical 
assessment using the DLCN criteria, became the most cost-effective strategy. This was 
because a higher prevalence of FH in this subpopulation increased the yield of interventions 
designed to identify new cases in the secondary care setting. However, the upper estimate of 
8.3% was based on a study where diagnosis was based on clinical assessment alone (De 
Backer 2015). This contrasts with the base case of 1.3% which was based on genetic 
diagnosis (Wald 2015), a more certain estimate of the prevalence of FH in this population. 
Strategy 3 was 3rd placed in terms of net monetary benefit when the prevalence of FH in 
people with early MI was 8.3%. The threshold at which strategy 3 no longer had the 
maximum net monetary benefit at a £20,000 per QALY threshold was ~3.8%. That is, the 
prevalence of FH in people with early MI had to be over 3.8% for the conclusions of the 
model to change.  
A number of additional parameters were varied separately to those above: 
 When the proportion of people in primary care databases for who data is available was 
increased to 100% from the base case of 31%, strategy 3 remained the most cost-
effective option, although this has the expected consequence of very directly affecting the 
short term resource impact. 
 The proportion of people already taking high intensity statins was varied from 10% to 99% 
and made no difference to the order of preferred strategies. 
 The SB and DLCN referral algorithms were varied to their ‘definite only’ criteria but this 
resulted in lower net monetary benefits than the more inclusive criteria. 
Strategies 7 and 8 became preferred in the high scenario analysis for the number of relatives 
approached. Threshold analysis reveals that the preferred strategies change once 8 relatives 
are identified and contacted per index case. This is 3.5x the base case value. 
Overall, strategy 3 remained cost effective in most sensitivity analyses. Where results 
changed, primary care case identification was still often considered the most cost-effective 
intervention, but using the DLCN criteria for clinical assessment was preferred. Strategy 3 
consistently had the second-highest net monetary benefit when results changed. The results 
were robust to changes in the cost of genetic testing, and changes in most of the take up 
rates. The prevalence of FH within MI was the most notable exception to these trends. 
O.4.3 Detailed scenario analysis: Strategy 9, ensure everyone with high cholesterol 
in primary care are treated with lipid modification regardless of FH status (no 
genetic testing) 
An additional scenario was requested during internal quality assurance. Much of the health 
benefit produced by these interventions was due to the polygenic population with high 
cholesterol invited for further assessment and receiving appropriate treatment. Therefore, an 
additional strategy was requested that retained cascade testing for the relatives of people 
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with a current clinical diagnosis of FH, but only included searching primary care databases 
for people with high cholesterol and prescribing appropriate cases high-intensity statins with 
no genetic testing for them or their relatives, thereby isolating the incremental costs and 
benefits of simply prescribing people with high cholesterol lipid modification treatment 
regardless of whether they have FH or not. The impact of this group is reduced with higher 
total cholesterol thresholds for primary care database searching. 
Under this scenario, strategy 9 ranked well, with a very low incremental cost-effectiveness 
ratio, but strategy 3 remained the most cost-effective due to the additional health benefit of 
diagnosing relatives through genetic cascade testing. 
Total short term economic costs are provided for strategy 9 along with all other strategies in 
Table 67. It reflects the low cost of reviewing people with high cholesterol in primary care, 
albeit at the exclusion of assessment with one of the FH clinical tools. The costs that appear 
for secondary care and genetic testing are identical to strategy 2, due to the cascade testing 
from currently diagnosied index cases included in this strategy. 
 
Figure 14: Sensitivity analysis, strategy 9, structure of pathway 
 
Table 59: Sensitivity analysis, strategy 9, results ranked by net monetary benefit 
Strategy Cost QALYs NMB Rank 
3. Primary care case identification, clinical 
assessment with SB criteria 
£6,886.65 11.463 222,379 1 
4. Primary care case identification, clinical 
assessment with DLCN criteria 
£6,882.41 11.463 222,377 2 
8. Primary and secondary care case 
identification, clinical assessment with DLCN 
criteria 
£7,021.53 11.465 222,287 3 
7. Primary and secondary care case 
identification, clinical assessment with SB criteria 
£7,047.67 11.466 222,267 4 
9. Primary care case identification, no cascade 
testing from new index cases 
£6,851.76 11.454 222,220 5 
2. Cascade testing £6,843.03 11.417 221,503 6 
6. Secondary care case identification, clinical 
assessment with DLCN criteria 
£6,982.19 11.420 221,411 7 
5. Secondary care case identification, clinical 
assessment with SB criteria 
£7,004.05 11.420 221,391 8 
1. No cascade testing and no case identification £6,797.26 11.408 221,355 9 
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Table 60: Sensitivity analysis, strategy 9, incremental analysis  
Strategy Cost QALYs ICER 
1. No cascade testing and no case identification 6797.257 11.40763 £0 
2. Cascade testing 6843.03 11.41729 Ext.Dom 
9. Primary care case identification, no cascade testing 
from new index cases 
6851.76 11.45357 £1,186 
4. Primary care case identification, clinical assessment 
with DLCN criteria 
6882.41 11.46299 £3,253 
3. Primary care case identification, clinical assessment 
with SB criteria 
6886.649 11.4633 £13,361 
6. Secondary care case identification, clinical 
assessment with DLCN criteria 
6982.186 11.41965 Dominated 
5. Secondary care case identification, clinical 
assessment with SB criteria 
7004.05 11.41973 Dominated 
8. Primary and secondary care case identification, 
clinical assessment with DLCN criteria 
7021.53 11.46543 £63,492 
7. Primary and secondary care case identification, 
clinical assessment with SB criteria 
7047.67 11.46575 £82,374 
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Table 61: Summary total short term economic cost, detailed scenario analysis with strategy 9  
Total short term economic cost                 
Strategy Primary care Secondary 
care 
Genetic 
testing 
Total short 
term cost 
Number 
of 
unnece
ssary 
genetic 
tests 
Cost of 
unnecessary 
genetic tests 
Number 
of other 
genetic 
tests 
Cost of 
other 
genetic 
tests 
False 
negatives 
missed by 
clinical 
assessment 
1. No cascade testing and no case identification - - - £0 0 £0 0 £0 0 
2. Cascade testing £0 £4,920,090 £6,220,386 £11,140,475 0 £0 19,765 £6,220,386 0 
3. Primary care case identification, clinical assessment 
with SB criteria 
£2,446,238 £8,975,796 £10,793,137 £22,215,171 7,225 £2,709,419 27,937 £8,083,718 1,665 
4. Primary care case identification, clinical assessment 
with DLCN criteria 
£2,606,800 £8,586,431 £10,086,417 £21,279,648 5,502 £2,063,415 27,670 £8,023,003 2,104 
5. Secondary care case identification, clinical 
assessment with SB criteria 
£0 £20,499,317 £26,744,987 £47,244,303 53,486 £20,057,415 21,814 £6,687,572 150 
6. Secondary care case identification, clinical 
assessment with DLCN criteria 
£0 £20,429,910 £21,947,491 £42,377,401 40,734 £15,275,142 21,747 £6,672,349 189 
7. Primary and secondary care case identification, clinical 
assessment with SB criteria 
£2,446,238 £24,555,023 £31,317,738 £58,318,999 60,712 £22,766,834 29,986 £8,550,904 1,815 
8. Primary and secondary care case identification, clinical 
assessment with DLCN criteria 
£2,606,800 £24,096,251 £25,813,523 £52,516,574 46,236 £17,338,557 29,653 £8,474,966 2,294 
9. Primary care case identification, no cascade testing 
from new index cases 
£2,350,712 £4,920,090 £6,220,386 £13,491,187 0 £0 19,765 £6,220,386 0 
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O.4.4 Detailed scenario analysis: ‘Definite’ clinical assessments only referred for 
genetic testing 
As explained in section O.3.5, only referring people with definite FH based on clinical 
assessment ensures that the genetic testing resources are focussed on people most likely to 
have FH. The goal of this scenario analysis was to establish whether the cost savings 
achieved by the definite strategies were worth the health benefits lost due to the increase in 
false negative clinical assessments. 
Under this scenario, the strategies based on referral of definite FH cases only ranked well 
with low ICERs but strategy 4, primary care case identification and clinical assessment using 
the DLCN criteria, was the most cost-effective strategy with an ICER of £3,987 per QALY 
(Table 68). The committee noted that due to the uniform assumption that clinical assessment 
would be done by a specialist nurse, when in reality the level of training needed to assess 
the ‘definite’ criteria would be higher, may have undervalued the benefit of the ‘rule out’ 
strategies over the ‘rule in’ ones. This limitation did not affect the conclusions of the model as 
it favoured the diagnostic criteria that were already shown to be more cost effective. 
The total short term economic cost for all strategies was reduced by roughly a quarter under 
this scenario (Table 69). 
Table 62: Sensitivity analysis, definite vs. probable referral criteria, ranked by Net 
Monetary Benefit (NMB), deterministic 
Strategy Costs QALYs NMB 
Prob 3. £6,887 11.4633 £222,379 
Prob 4. £6,882 11.4630 £222,377 
Def 4. £6,867 11.4598 £222,328 
Def 3. £6,858 11.4575 £222,292 
Prob 8. £7,022 11.4654 £222,287 
Def 7. £6,890 11.4585 £222,280 
Def 8. £6,938 11.4608 £222,277 
Prob 7. £7,048 11.4657 £222,267 
9. £6,852 11.4536 £222,220 
2. £6,843 11.4173 £221,503 
Def 5. £6,875 11.4183 £221,490 
Def 6. £6,914 11.4188 £221,463 
Prob 6. £6,982 11.4197 £221,411 
Prob 5. £7,004 11.4197 £221,391 
1. £6,797 11.4076 £221,355 
 
Strategies based on referring possible and definite Simon Broome and probable and definite DLCN results 
marked with “Prob” in strategy number. Strategies based on referring definite Simon Broome and definite DLCN 
indicated with a “Def” in the strategy name. 
  
Clinical Guideline 71.1 (Familial Hypercholesterolaemia) 
Glossary and abbreviations 
 
283 
Table 63: Summary total economic cost, all strategies definite referral criteria only 
Total short term economic cost                 
Strategy Prima
ry 
care 
Second
ary care 
Genetic 
testing 
Total 
short 
term 
cost 
Number 
of 
unneces
sary 
genetic 
tests 
Cost of 
unneces
sary 
genetic 
tests 
Number 
of other 
genetic 
tests 
Cost of 
other 
genetic 
tests 
False 
negatives 
missed by 
clinical 
assessmen
t 
1. No cascade testing and no case identification - - - £0 0 £0 0 £0 0 
2. Cascade testing £0 £4,920,090 £6,220,386 £11,140,47
5 
0 £0 19,765 £6,220,386 0 
3. Primary care case identification, clinical assessment 
with SB criteria 
£1,956,
541 
£6,098,306 £7,202,095 £15,256,94
3 
608 £228,002 23,070 £6,974,093 9,689 
4. Primary care case identification, clinical assessment 
with DLCN criteria 
£2,344,
978 
£6,700,846 £8,159,880 £17,205,70
4 
2,006 £752,405 24,971 £7,407,475 6,555 
5. Secondary care case identification, clinical 
assessment with SB criteria 
£0 £10,308,758 £8,097,221 £18,405,97
9 
4,501 £1,687,861 20,593 £6,409,360 872 
6. Secondary care case identification, clinical 
assessment with DLCN criteria 
£0 £14,946,650 £12,087,96
1 
£27,034,61
1 
14,853 £5,569,941 21,070 £6,518,020 590 
7. Primary and secondary care case identification, 
clinical assessment with SB criteria 
£1,956,
541 
£11,486,975 £9,078,930 £22,522,44
6 
5,109 £1,915,863 23,899 £7,163,067 10,561 
8. Primary and secondary care case identification, 
clinical assessment with DLCN criteria 
£2,344,
978 
£16,727,406 £14,027,45
6 
£33,099,84
0 
16,860 £6,322,347 26,276 £7,705,109 7,145 
9. Primary care case identification, no cascade testing 
from new index cases 
£2,350,
712 
£4,920,090 £6,220,386 £13,491,18
7 
0 £0 19,765 £6,220,386 0 
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O.4.5 Detailed scenario analysis: Alternative thresholds for searching primary care 
databases 
We considered configuring the economic model to explicitly compare a variety of of database 
search criteria, such as the possible TC>8.6 and TG<2.3 discussed in Futema et a 2015 and 
those discussed in section O.3.1 above but decided that the evidence underpinning these 
criteria would not be strong enough to justify the resource impact that would result from any 
positive recommendations that might arise. In the case of those criteria discussed in section 
O.3.1 this was either due to the implausibility of the implied total prevalence of FH or due to 
the unimplementability of having criteria too broad. It was felt that the estimated prevalence 
of FH in lower TC thesholds discussed in Futema et al was calculated from a trend drawn 
from too few individuals to be robust. 
The Futema criteria of TC>9.3 and TG<2.3, within which the prevalence of FH was confirmed 
by genetic testing, would obviously be cost-effective compared to TC>9.3 only as all the 
individuals identified in the study had TG<2.3. If these data can be believed then all 
individuals with a TC>9.3 who have FH would have TG<2.3. Due to small numbers in the 
study, we asked the committee for clinical opinion on which of these criteria should be used 
in the base case analysis. The ranking of strategies does not change under these 
assumptions but the overall resource impact decreases as expected. 
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Table 64: Incremental results, scenario analysis, primary care search total cholesterol > 9.3 mmol/L & triglycerides < 2.3 mmol/L 
Incremental Results (incl Strategy 9) 
Strategy Costs QALYs ICER 
1. No cascade testing and no case identification £6,813 11.428 £0 
2. Cascade testing £6,865 11.439 Ext.Dom 
9. Primary care case identification, no cascade testing from new index cases £6,869 11.464 £1,548 
4. Primary care case identification, clinical assessment with DLCN criteria £6,893 11.473 £2,696 
3. Primary care case identification, clinical assessment with SB criteria £6,896 11.474 £7,720 
6. Secondary care case identification, clinical assessment with DLCN criteria £7,025 11.442 Dominated 
5. Secondary care case identification, clinical assessment with SB criteria £7,050 11.442 Dominated 
8. Primary and secondary care case identification, clinical assessment with DLCN criteria £7,053 11.476 £63,040 
7. Primary and secondary care case identification, clinical assessment with SB criteria £7,080 11.477 £89,554 
 
 
Table 65: Total short term economic cost, scenario analysis, primary care search total cholesterol > 9.3 mmol/L & triglycerides < 2.3 
mmol/L 
Total short term economic cost                 
Strategy Primary 
care 
Secondary 
care 
Genetic 
testing 
Total short 
term cost 
Number of 
unnecessary 
genetic tests 
Cost of 
unnecessary 
genetic tests 
Number of 
other genetic 
tests 
Cost of other 
genetic tests 
False negatives 
missed by clinical 
assessment 
1. No cascade testing and no case identification - - - £0 0 £0 0 £0 0 
2. Cascade testing £0 £4,920,090 £6,220,386 £11,140,475 0 £0 19,765 £6,220,386 0 
3. Primary care case identification, clinical assessment with SB criteria £1,663,4
19 
£7,799,513 £9,061,223 £18,524,156 3,385 £1,269,419 26,656 £7,791,804 1,404 
4. Primary care case identification, clinical assessment with DLCN criteria £1,763,9
31 
£7,600,115 £8,707,353 £18,071,399 2,578 £966,753 26,432 £7,740,600 1,775 
5. Secondary care case identification, clinical assessment with SB criteria £0 £20,499,317 £26,744,987 £47,244,303 53,486 £20,057,415 21,814 £6,687,572 150 
6. Secondary care case identification, clinical assessment with DLCN criteria £0 £20,429,910 £21,947,491 £42,377,401 40,734 £15,275,142 21,747 £6,672,349 189 
7. Primary and secondary care case identification, clinical assessment with SB criteria £1,663,4
19 
£23,378,741 £29,585,824 £54,627,984 56,872 £21,326,834 28,705 £8,258,990 1,554 
8. Primary and secondary care case identification, clinical assessment with DLCN criteria £1,763,9
31 
£23,109,935 £24,434,458 £49,308,325 43,312 £16,241,895 28,414 £8,192,563 1,964 
9. Primary care case identification, no cascade testing from new index cases £1,348,0
62 
£4,920,090 £6,220,386 £12,488,537 0 £0 19,765 £6,220,386 0 
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Detailed scenario analysis: Alternative Relative Risks 
The relative risk associated with FH over and above polygenic hypercholesterolaemia was uncertain. The Guideline Committee believed that 
the relative risks could be higher than those used in the base case analysis (the Simon Broome register data). They also believed that the 
relative treatment effect could be greater than in the polygenic population. Scenario analyses were therefore performed to investigate extreme 
changes in these parameters. The overall CVD risks associated with various types of patients within these scenario analyses are detailed in 
section O.3.4 above. 
Table 66: ICERs of strategies under different scenario analyses 
Strategy Low RR  Strategy High RR  Strategy 
High RR + High 
Treatment 
Effect 
1. £0 1. £0 1. £0 
2. Ext.Dom 
 
9. £535 
 
9. £94 
9. £2,017 
 
2. Dominated 
 
4. £745 
4. £5,361 
 
4. £1,785 
 
3. £7,685 
3. £16,949 
 
3. £10,811 
 
2. Dominated 
6. Dominated 
 
6. Dominated 
 
8. £42,109 
5. Dominated 
 
8. £55,577 
 
6. Dominated 
8. £74,424 
 
5. Dominated 
 
7. £55,074 
7. £96,072 
 
7. £72,439 
 
5. Dominated 
Table 66 shows that the ICERs move in the directions expected but the decision is insensitive to even the extreme variations in risk related 
parameters shown here. Furthermore, these risk profiles were then combined with the one-way sensitivity analyses detailed in section O.4.2. in 
multi-way sensitivity analyses and rankings of treatments were found not to materially alter. 
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O.4.6 Detailed scenario analysis: SAFEHEART Data 
A study predicting risks in the general treated-FH population (Perez de Isla et al 2017) was 
highlighted by a stakeholder during consultation. This study was published after the cutoff 
date for searches and after any committee meetings where the design of the economic 
model developed for this guideline was discussed. It was not possible to configure the 
economic model to match the specific distribution of CVD events predicted by the 
SAFEHEART statistical model. This is mostly because the economic model structure was a 
cohort model and the correlation data necessary to predict cohort level effects were not 
available in the SAFEHEART paper. Nevertheless, we conducted a sensitivity analysis 
where we calibrated the long term module for the FH cohort to predict the overall 10-year 
risks reported in the SAFEHEART paper as closely as possible. The SAFEHEART data 
predict a 10-year CVD risk of 7.53% for patients with treated FH whereas the 10-year CVD 
risk in the guideline model ranged between 15%-44%. 
Table 67: Adjusted risks calibrating treated-FH arm to SAFEHEART data 
Statins Base Effectiveness High Effectiveness 
Patients Untreated Treated Untreated Treated 
Male 40 20.1% 10.4% 17.7% 7.5% 
Male 50 19.5% 10.4% 17.1% 7.5% 
Female 40 17.5% 7.5% 20.9% 7.5% 
Female 50 17.4% 7.5% 21.0% 7.5% 
Table 67 shows that we were able to match the risks of the female cohort quite closely but 
were unable to reduce the male risks any further than 10.4% in the base case. This is 
because the risk equations used in the model would have begun to predict negative risks 
below this level. This is a limitation of this sensitivity analysis. Calibrating the treated-FH 
cohort in this way allowed the back-calculation of costs and QALYs for the untreated cohort 
(those who would have had a similar risk profile were it not for statin treatment). The results 
are in Table 68. 
Table 68: Long Term Costs and QALYs for SAFEHEART calibrated cohorts 
  M Cost M QALYs F Cost F QALYs T ICER M T ICER F 
Implied No Treatment £7,217 14.93 £5,988 15.79     
Treatment £9,822 15.67 £9,308 16.49 £3,537 £4,775 
High Effectiveness 
Implied No Treatment 
£6,648 15.23 £7,033 15.63     
High Effectiveness 
Treatment 
£9,318 16.10 £9,384 16.62 £3,069 £2,379 
Table 68 shows that under these assumptions it is not as cost effective to treat FH as under 
the base case assumptions (where it may have been cost saving). The resulting implications 
for the case finding strategies are shown in Table 69. 
Table 69: Incremental cost-effectiveness ratios (SAFEHEART calibrated model) 
Incremental Results (incl Strategy 9) 
Strategy Costs QALYs ICER 
1. No cascade testing and no case identification £5,703 12.193 £0 
2. Cascade testing £5,784 12.201 Ext.Dom 
9. Primary care case identification, no cascade testing from 
new index cases 
£5,841 12.234 £3,367 
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Incremental Results (incl Strategy 9) 
4. Primary care case identification, clinical assessment with 
DLCN criteria 
£5,906 12.241 £8,850 
3. Primary care case identification, clinical assessment with SB 
criteria 
£5,911 12.242 £21,749 
6. Secondary care case identification, clinical assessment with 
DLCN criteria 
£5,932 12.202 Dominated 
5. Secondary care case identification, clinical assessment with 
SB criteria 
£5,954 12.203 Dominated 
8. Primary and secondary care case identification, clinical 
assessment with DLCN criteria 
£6,054 12.243 £85,724 
7. Primary and secondary care case identification, clinical 
assessment with SB criteria 
£6,081 12.244 £109,820 
These data suggest that primary care case finding with the DLCN remains cost effective but 
that primary care case finding with the SB may not be, with an ICER of £21.7k per QALY. 
This is because sensitivity is relatively less valuable than under the base case assumptions. 
When the upper effectiveness estimate for statin treatment is used, the results return to 
similar values to those under the base case. Primary care case finding remains cost effective 
when subjected to one-way sensitivity analysis even under the SAFEHEART assumptions. 
Table 70: Incremental cost-effectiveness ratios (SAFEHEART Calibrated + high 
effectiveness of statins) 
Incremental Results (incl Strategy 9) 
Strategy Costs QALYs ICER 
1. No cascade testing and no case identification £5,732 12.214 £0 
2. Cascade testing £5,809 12.224 Ext.Dom 
9. Primary care case identification, no cascade testing from 
new index cases 
£5,859 12.261 £2,739 
4. Primary care case identification, clinical assessment with 
DLCN criteria 
£5,920 12.270 £6,333 
3. Primary care case identification, clinical assessment with 
SB criteria 
£5,925 12.271 £16,272 
6. Secondary care case identification, clinical assessment 
with DLCN criteria 
£5,956 12.227 Dominated 
5. Secondary care case identification, clinical assessment 
with SB criteria 
£5,978 12.227 Dominated 
8. Primary and secondary care case identification, clinical 
assessment with DLCN criteria 
£6,067 12.273 £65,568 
7. Primary and secondary care case identification, clinical 
assessment with SB criteria 
£6,094 12.273 £84,135 
There are several reasons why these data should not be relied upon to concretely prefer the 
DLCN to the SB criteria:- 
 The Guideline Committee believe that a diagnosis of FH is more effective than the 
mean estimate of statin treatment for people with polygenic hypercholesterolaemia 
and may even reduce risks down to normal population levels. In the high 
effectiveness sensitivity analysis, which does not take risks down this far, the results 
were largely unchanged. 
 The population in the SAFEHEART study does not reflect the population in the case 
finding model as only the patients with the very highest cholesterol and therefore 
higher absolute risk will be found (plus their relatives, for whom the SAFEHEART 
data would likely be more representative). 
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 The results of the PSA (O.4.7) show that the confidence intervals of strategies 3 and 
4 overlap almost exactly and the mean result only differs by £1 of NMB 
 Unlike the base case analysis, the results produced by the model using the 
SAFEHEART data are dissimilar from other models evaluating the cost effectiveness 
of cascade testing, notably Kerr 2016. The use of the high-effectiveness data reduces 
the disparity.  
 NICE’s cost effectiveness threshold is £20-30k per QALY and the SB would be the 
most cost effective at the upper limit. This finding is robust to one-way sensitivity 
analysis. 
O.4.7 Probabilistic sensitivity analysis (base case and SAFEHEART analysis) 
Probabilistic sensitivity analysis indicated that strategy 3 had a 53.7% probability of being the 
most cost-effective option at a threshold of £20,000 per QALY. Strategy 4 had a 43.5% 
probability of being the most cost effective option (Table 72) although their confidence 
intervals overlapped almost exactly. 
The cost-effectiveness acceptability curve is presented below. This shows the probability of 
selected strategies being cost effective at different thresholds relative to other selected 
thresholds. Four strategies were selected for this analysis based on their deterministic 
results. Strategy 9 had the highest probability of being cost effective up to a threshold ICER 
of ~£3,500/QALY, above which, primary care case finding became the most cost effective 
option. Strategy 4 has the highest probability of being cost effective between approximately 
£3,500 and £16,600 per QALY. Strategy 3 is more likely to be cost effective for thresholds 
greater than £16,600 per QALY. 
Figure 15: Cost-effectiveness acceptability curve, base case assumptions 
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Table 71: Probabilistic results, base case 
Strategy 
NMB Probability 
most cost 
effective Mean Lower 95% CI Upper 95% CI 
1. No cascade testing and no case identification 222,081 207,026 234,106 0.00% 
2. Cascade testing 222,231 207,137 234,277 0.00% 
3. Primary care case identification, clinical assessment with SB criteria 223,088 208,285 234,905 53.70% 
4. Primary care case identification, clinical assessment with DLCN criteria 223,086 208,277 234,903 43.50% 
5. Secondary care case identification, clinical assessment with SB criteria 222,117 207,024 234,125 0.00% 
6. Secondary care case identification, clinical assessment with DLCN criteria 222,137 207,044 234,148 0.00% 
7. Primary and secondary care case identification, clinical assessment with SB criteria 222,974 208,172 234,747 0.30% 
8. Primary and secondary care case identification, clinical assessment with DLCN criteria 222,995 208,184 234,767 2.50% 
9. Primary care case identification, no cascade testing from new index cases 222,935 208,004 234,822 0.00% 
 
Table 72: Probabilistic results, SAFEHEART Analysis 
Strategy 
NMB Probability 
most cost 
effective Mean Lower 95% CI Upper 95% CI 
1. No cascade testing and no case identification 238,442 229,895 245,108 9.80% 
2. Cascade testing 238,508 230,117 245,137 0.00% 
3. Primary care case identification, clinical assessment with SB criteria 239,188 231,134 245,711 31.48% 
4. Primary care case identification, clinical assessment with DLCN criteria 239,189 231,123 245,712 55.12% 
5. Secondary care case identification, clinical assessment with SB criteria 238,374 230,036 244,951 0.00% 
6. Secondary care case identification, clinical assessment with DLCN criteria 238,394 230,044 244,955 0.00% 
7. Primary and secondary care case identification, clinical assessment with SB criteria 239,054 231,034 245,559 0.48% 
8. Primary and secondary care case identification, clinical assessment with DLCN criteria 239,075 231,059 245,586 3.12% 
9. Primary care case identification, no cascade testing from new index cases 239,111 230,947 245,665 27.80% 
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Figure 16: Cost Effectiveness Acceptability Curve, SAFEHEART Analysis 
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O.5 Discussion 
This analysis found that primary care case identification with clinical assessment using the 
Simon Broome criteria in addition to cascade testing was cost effective with an ICER of 
£13,361 per QALY and a 54% probability of being cost effective. Primary care case 
identification using the DLCN criteria had a 43% probability of being the most cost-effective 
strategy and deterministic costs and QALYs that were very close to the Simon Broome 
option. The main cost driver, accounting for around 50% of short term costs, was the 
increase in genetic tests. 
These results were robust to the cost of genetic testing, the number of relatives approached 
for cascade testing and most take up rates. Where results changed, strategy 4, primary care 
case identification using the DLCN criteria for clinical assessment usually became the most 
cost-effective option, highlighting how close these two strategies were and how primary care 
case identification with either clinical assessment tool was likely to be a cost-effective 
intervention. This finding was supported by the probabilistic sensitivity analysis, where the 
confidence intervals around the NMB of either intervention overlapped almost exactly. 
Primary care case identification remained cost effective when compared with a strategy of 
treating everyone with lipid modification regardless of their FH status and without genetic or 
cascade testing. 
Referring both possible and definite cases of FH for genetic testing based on the Simon 
Broome criteria from primary care (strategy 3) remained cost effective compared with 
referring definite cases only, despite the short term cost savings offered by the latter.  
It is possible that more accurate and/or cost-effective search criteria exist in the literature but 
could not be used to inform the model due to diagnosis of FH in the studies being based on 
clinical assessment rather than genetic testing, leaving the true prevalence of FH within 
these populations uncertain. Further research in this area has the potential to ensure primary 
care resources are focussed on those people most likely to have FH by establishing the 
accuracy of database search algorithms based on genetically confirmed diagnoses. This 
research could also be used to clarify which clinical assessment tool is the most appropriate 
for use in primary care in England and Wales. 
There are a number of advantages to this analysis. It is the first time case identification in 
addition to cascade testing has been compared with cascade testing alone. In addition, a 
novel meta-analysis based on the latest data using genetic testing as the reference test, was 
used to inform a comparison of the two main clinical assessment tools, the Simon Broome 
criteria and DLCN criteria. Another advantage of this analysis is that the prevalence for each 
specific subpopulation was taken from recent, peer-reviewed literature. Long term impacts of 
treating FH and polygenic hypercholesterolaemia were based on the economic analysis 
conducted for the NICE lipid modification guideline. 
Interpretation of these results needs to take into consideration that cost effectiveness of the 
primary care case identification strategies in this model was influenced by the number of 
people with polygenic hypercholesterolaemia that come into contact with primary care as a 
result of the interventions. Although the guideline is focused on familial 
hypercholesterolaemia, the committee took the view that the polygenic population would be 
impacted by the interventions and should continue to be included in the model. 
This analysis confirmed the cost effectiveness of cascade testing compared with no cascade 
testing with an ICER of £4,740 per QALY and 100% likelihood the strategy is cost effective 
compared with no cascade testing at a threshold of £20,000 per QALY. However, additional 
health benefits are achieved at an acceptable cost with primary care case identification 
strategies. The ICER for cascade testing alone, although cost effective and comparable to 
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another recently published UK CUA, was greater than those reported by some other studies. 
This was potentially due to: 
 the adoption of a stricter definition of FH in the present analysis based on LDLR, apoB or 
PCSK9 mutations; 
 the proportion of people with a current clinical diagnosis of FH who actually have one of 
these mutations set at 23% based on the experiences of services in the UK;  
 a conservative approach to the number of relatives approached for cascade testing based 
on the experiences of services in the UK set at 2.22 per index case; and 
 inclusion of take up rates for both index cases and relatives (set at 84% and 60% 
respectively), limiting the effectiveness of cascade testing. 
The analysis has a number of limitations, mainly related to the assumptions required to 
operationalise the model. Genetic testing was assumed to have perfect sensitivity and 
specificitya single probability of take up was used to represent take up across the entire care 
pathway, and all people were assumed to accept and adhere to lipid modification treatment 
once diagnosed. Assuming 100% accuracy in genetic testing was a limitation common to all 
strategies so was thought not to affect the overall conclusions of the model but was noted to 
marginally favour strategies implying the SB criteria due to undervaluing the costs of its lower 
specificity, which strengthened the committee’s conclusions not to overinterpret the 
consistently higher rank of the SB over the DLCN criteria and recommend that either be used 
in practice. The assumptions related to statin use may have overestimated the cost 
effectiveness of all interventions compared with no case identification and no cascade 
testing, although given that ranking of the strategies was completely insensitive to the 
number of people already taking statins within the model, this limitiation was assessed as 
minor. The minimum starting age was 40 as this was the lowest used in the lipid modification 
model. This limitation likely led to an underestimation of the cost effectiveness of all 
strategies due to the increased risk of coronary heart disease at younger ages due to FH. 
There was uncertainty as to the true relative risk of CVD and relative treatment effect 
between people with and without FH among those with a total cholesterol of >9.3mmol/L, 
various theoretical data were tested in sensitivity analysis but did not affect conclusions. 
There were also no data to inform the distribution of risk scores in the target population but 
the rankings were insensitive to extreme high and low values so this limitation was 
considered minor. Another limitation is that crossover has not been accounted for. It is likely 
that an intervention of primary care case identification will identify people that have already 
been diagnosed with FH through cascade testing, and vice versa. However, no data was 
identified in the literature to inform the inclusion of this into the model. 
O.6 Conclusion 
The identification of FH by analysing primary care databases in addition to cascade testing is 
likely to be a cost effective strategy. The Simon Broome criteria is likely to be more cost-
effective than the DLCN although the results for both clinical assessment tools are very 
close. Strategies that involve case identification in people with early MI are unlikely to be cost 
effective. The model confirmed that cascade testing (alone) is cost effective compared with 
no cascade testing and no case identification, a finding consistent with previous published 
results. 
O.6.1 Alternative thresholds for case-finding 
Since the distribution of total cholesterol is known to vary by age and sex, it is possible that 
setting the case-finding threshold at the whole study population level value of 9.3 from 
Futema et al. 2015 would lead to over and under representation in some groups. Alternative 
data was therefore sought to determine the distribution of total cholesterol in different 
age/sex groups at the national level. The best available evidence came from the Health 
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Survey for England (HSE) data, a large sample of the UK general population collected 
across 7 individual years between 2003 and 2014. All the total cholesterol data in this section 
were provided by colleagues at the NIHR Diagnostic Evidence Co-operative Newcastle.  
Figure 17 Total Cholesterol Distribution by Age and Sex (Curve Fitted) 
 
Figure 17 shows the differences in TC distribution by age and sex, with women typically 
having higher TC under the age of 30, men having higher TC between the ages of 30 and 55 
and women having higher TC at age 55+. A blanket whole population TC case-finding 
threshold may therefore not be appropriate as it would clearly lead to under and over 
representation from different groups. Based on these distributions, the committee requested 
the age/sex data shown in Table 73: Total Cholesterol Thresholds by Age/Sex Group (HSE 
2003-2013)Table 73 be extracted from the HSE data. The 99.5th percentile data have been 
highlighted. The percentile equivalent limits of the confidence intervals were calculated via 
the binomial approximate method. For example, the confidence interval for the 99.5th 
percentile in the 16-29 ‘all people’ group runs from the value observed at the 99.27th 
percentile to the value observed at the 99.73rd percentile. Reading from the table, it can be 
inferred that these values would be slightly higher than 7.36 and slightly lower than 7.95.  
Table 73: Total Cholesterol Thresholds by Age/Sex Group (HSE 2003-2013) 
  
Age 
Group 97.50% 99% 
99.25
% 
99.50
% 
99.75
% N LCL UCL 
All 
people 
16-29 6.70 7.20 7.36 7.60 7.95 3,783 99.27% 99.73% 
  >30 8.10 8.60 8.80 9.00 9.30 22,897 99.41% 99.59% 
Men 16-29 6.60 7.10 7.40 7.70 8.07 1,737 99.16% 99.84% 
  >30 7.90 8.40 8.60 8.80 9.16 9,758 99.36% 99.64% 
Women 16-29 6.79 7.20 7.30 7.48 7.88 2,046 99.19% 99.81% 
  >30 8.10 8.70 8.90 9.03 9.50 13,139 99.38% 99.62% 
All 
people 
16-24 6.40 6.80 6.97 7.11 7.40 2,174 99.20% 99.80% 
  25-34 7.10 7.70 8.00 8.20 8.58 3,698 99.27% 99.73% 
  >35 8.10 8.60 8.80 9.00 9.40 20,808 99.40% 99.60% 
Men 16-24 6.30 6.60 6.62 6.78 6.90 1,040 99.07% 99.93% 
  25-34 7.40 8.10 8.22 8.50 8.81 1,568 99.15% 99.85% 
  >35 7.90 8.40 8.60 8.80 9.18 8,887 99.35% 99.65% 
Women 16-24 6.50 7.00 7.25 7.40 7.62 1,134 99.09% 99.91% 
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Age 
Group 97.50% 99% 
99.25
% 
99.50
% 
99.75
% N LCL UCL 
  25-34 6.98 7.30 7.40 7.77 8.17 2,130 99.20% 99.80% 
  >35 8.20 8.70 8.90 9.10 9.60 11,921 99.37% 99.63% 
All 
people 
<34 7.00 7.40 7.60 8.00 8.43 5,872 99.32% 99.68% 
  >55 8.30 8.80 8.90 9.10 9.60 10,162 99.36% 99.64% 
  35-54 7.80 8.40 8.50 8.80 9.20 10,646 99.36% 99.64% 
Men <34 7.10 7.69 8.00 8.20 8.55 2,608 99.23% 99.77% 
  >55 7.80 8.30 8.40 8.60 8.80 4,326 99.29% 99.71% 
  35-54 8.00 8.50 8.80 9.00 9.36 4,561 99.29% 99.71% 
Women <34 6.80 7.30 7.40 7.60 8.07 3,264 99.26% 99.74% 
  >55 8.50 9.00 9.10 9.38 10.14 5,836 99.32% 99.68% 
  35-54 7.80 8.20 8.40 8.60 9.08 6,085 99.32% 99.68% 
Regardless of how the top 0.05% of the population is defined, the absolute number of people 
affected by the primary care case finding strategies in the economic model would be similar if 
the prevalence of FH within these subdivided groups does not greatly differ. Given that FH is 
strongly associated with high TC, this is perhaps a defensible assumption and one the 
Guideline Committee found plausible although no relevant data more nuanced than that used 
in the economic model could be found. Sensitivity analysis on the age/sex distribution of 
those found in the case finding strategies in the model was not undertaken due to lack of 
suitable data. However, it is obvious from the outputs of the long term treatment model 
(Table 74) in different age/sex groups that any case finding strategy that increases the 
proportion of young people among those found will increase the cost-effectiveness of case 
finding. As noted in O.3.4, treating FH may even be cost saving in younger people and those 
at the highest risk of CVD events. As shown in the results of the sensitivity analysis (O.4.2), 
the prevalence of FH would have to be extremely low (~3.5%) before primary care case 
finding becomes cost-ineffective. 
Table 74: Long Term Difference in Costs and QALYs between Treated and Untreated 
FH 
Age QRISK2 
Males Inc. 
Costs 
Males Inc. 
QALYs 
Females Inc. 
Costs 
Females Inc. 
QALYs 
40 30% -£3,365 1.47 -£2,717 1.32 
40 25% -£3,185 1.57 -£2,721 1.47 
40 20% -£2,750 1.63 -£2,546 1.59 
40 15% -£1,897 1.60 -£2,001 1.65 
40 10% -£375 1.43 -£729 1.55 
50 30% -£3,226 1.32 -£3,021 1.25 
50 25% -£2,801 1.38 -£2,879 1.36 
50 20% -£2,114 1.38 -£2,480 1.42 
50 15% -£1,060 1.31 -£1,659 1.41 
50 10% £506 1.12 -£168 1.26 
60 30% -£1,495 1.09 -£2,351 1.08 
60 25% -£919 1.07 -£1,845 1.11 
60 20% -£176 1.01 -£1,115 1.10 
60 15% £768 0.91 -£96 1.02 
60 10% £1,951 0.75 £1,292 0.87 
70 30% £771 0.68 £254 0.79 
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Age QRISK2 
Males Inc. 
Costs 
Males Inc. 
QALYs 
Females Inc. 
Costs 
Females Inc. 
QALYs 
70 25% £1,142 0.64 £658 0.76 
70 20% £1,579 0.60 £1,160 0.70 
70 15% £2,090 0.53 £1,775 0.63 
70 10% £2,684 0.46 £2,521 0.53 
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